

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request cder\_mpl1r\_wp225

**Request ID:** cder\_mpl1r\_wp225\_nsdp\_v01

**Request Description:** This report contains the estimates of utilization of hydrochlorothiazide (HCTZ)-containing diuretics, non HCTZ-containing diuretics, and antihypertensives in the Sentinel Distributed Database (SDD) to understand the impact of labeling changes that were made on August 8, 2020.

**Sentinel Routine Querying Module:** Cohort Identification and Descriptive Analysis (CIDA) module, version 11.2.4

**Data Source:** We distributed this query to five Sentinel Data Partners on December 12, 2022. The study period included data from January 1, 2017 through June 30, 2022. Please see Appendix A for a list of dates of available data for each Data Partner.

**Study Design:** The analyses were conducted in two runs. We assessed the prevalence of outpatient dispensings of HCTZ-containing diuretics, non HCTZ-containing diuretics, and antihypertensives among individuals within the SDD, overall and by calendar year-month. Results were reported overall and stratified by age group, sex, race, and strength of HCTZ containing products (where applicable). Separately, we assessed the prevalence of outpatient dispensings of HCTZ-containing diuretics, non HCTZ-containing diuretics, and antihypertensives, separately among individuals with and without a history of skin cancer. Results were reported overall and stratified by age group. This was a Type 2 analysis in the Query Request Package (QRP) documentation.

**Exposure(s) of Interest:** The exposures of interest were any HCTZ-containing product (including HCTZ monotherapy, any HCTZ combination product, HCTZ-angiotensin converting enzyme inhibitor [ACEi] combination product, HCTZ-angiotensin receptor blocker [ARB] combination product, HCTZ-potassium sparing diuretic combination product, HCTZ-beta blocker combination product, HCTZ-ARB-calcium channel blocker [CCB] combination product, HCTZ-direct renin inhibitor combination product, and HCTZ-central alpha 2 agonist combination product), any non HCTZ-containing diuretic (including chlorothiazide, bendroflumethiazide, and thiazide-like diuretics), ACEi, CCB, potassium sparing diuretic, and loop diuretic. Additionally, two groups of exposures were defined as denominators for calculating proportions by calendar year-month: limited denominator (any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic) and full denominator (any HCTZ-containing product, any thiazide diuretic, or any antihypertensive). All qualifying exposures during the study period were evaluated. The exposures of interest were defined using both dispensing data and National Drug Code (NDCs). For a list of generic names used to define the exposures of interest, please see Appendices B and C.

**Cohort Eligibility Criteria:** We identified cohorts which included patients of all ages. The following age groups were defined: 0-40, 41-54, 55-64, 65-74, 75-84, and  $\geq 85$  years. No pre-index enrollment requirement was applied.

**Inclusion/Exclusion Criteria:** In the second run, individuals with and without a skin cancer history were identified based on any International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code for skin cancer in the entire pre-index enrollment history. Please see Appendix D for the lists of ICD-9-CM and ICD-10-CM diagnosis codes used to define skin cancer.

**Please see the Appendices E and F for the specifications of parameters used in the analyses for this request.**

**Limitations:** Algorithms to define exposures, inclusion, and exclusion criteria are imperfect and may result in misclassification. Therefore, data should be interpreted with this limitation in mind.

**Notes:** Please contact the Sentinel Operations Center ([info@sentinelssystem.org](mailto:info@sentinelssystem.org)) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

**Table of Contents**

<b>Glossary</b>	List of terms found in this report and their definitions
<b>Table 1a</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022
<b>Table 1b</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month
<b>Figure 1</b>	Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month
<b>Table 2a</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years)
<b>Table 2b</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month
<b>Figure 2</b>	Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month
<b>Table 3a</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex
<b>Table 3b</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month
<b>Figure 3</b>	Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month
<b>Table 4a</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race
<b>Table 4b</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month
<b>Figure 4</b>	Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month
<b>Table 5</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month
<b>Figure 5</b>	Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month
<b>Table 6a</b>	Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength
<b>Table 6b</b>	Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month
<b>Figure 6</b>	Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month
<b>Table 7a</b>	Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and race
<b>Table 7b</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month
<b>Figure 7</b>	Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month
<b>Table 8a</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer
<b>Table 8b</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

**Table of Contents**

<b>Figure 8</b>	Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month
<b>Table 9a</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and age group (years)
<b>Table 9b</b>	Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month
<b>Figure 9</b>	Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month
<b>Appendix A</b>	Query period end dates for each Data Partner
<b>Appendix B</b>	List of generic and brand names of medical products used to define hydrochlorothiazide (HCTZ)-containing products
<b>Appendix C</b>	List of generic and brand names of medical products used to define non-hydrochlorothiazide (HCTZ)-containing products
<b>Appendix D</b>	List of international Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes used to define skin cancer
<b>Appendix E</b>	Specifications Defining Parameters for this Request
<b>Appendix F</b>	Specifications Defining Parameters for this Request, Part II

**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms

**Ambulatory Visit (AV)** - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

**Emergency Department (ED)** - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

**Inpatient Hospital Stay (IP)** - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

**Non-Acute Institutional Stay (IS)** - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

**Other Ambulatory Visit (OA)** - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

**Charlson/Elixhauser Combined Comorbidity Score** - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

**Code Days** - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

**Cohort Definition (drug/exposure)** - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

**Computed Start Marketing Date** - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

**Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Event Deduplication** - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Lookback Period** - number of days wherein a member is required to have evidence of pre-existing condition

**Maximum Episode Duration** - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Member-Years** - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

**Switch Gap Inclusion Indicator** - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

**Switch Pattern Cohort Inclusion Date** - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

**Switch Pattern Cohort Inclusion Strategy** - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

**Treatment Episode Truncation Indicator** - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

**Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

\*all terms may not be used in this report

Table 1a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b><i>HCTZ-containing</i></b>					
Any HCTZ-containing products	15,059,254	171,270,903	172,414,010	130,785,425	115.1
HCTZ single ingredient/monotherapy	8,241,599	75,458,081	75,700,223	130,785,425	63.0
HCTZ combination products	8,605,294	96,154,068	96,713,799	130,785,425	65.8
ACEI + HCTZ	3,179,520	33,330,647	33,440,990	130,785,425	24.3
ARB + HCTZ	3,801,004	41,137,736	41,397,079	130,785,425	29.1
Potassium-sparing diuretic + HCTZ	1,620,804	17,159,416	17,220,589	130,785,425	12.4
Beta blocker + HCTZ	291,857	3,556,514	3,573,456	130,785,425	2.2
ARB + CCB + HCTZ	103,046	1,017,547	1,022,901	130,785,425	0.8
Direct renin inhibitor + HCTZ	4,699	55,294	55,886	130,785,425	0.0
Central alpha 2 agonist + HCTZ	387	2,871	2,901	130,785,425	0.0
<b><i>Non-HCTZ-containing</i></b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	1,923,737	14,314,807	14,378,837	130,785,425	14.7
Chlorothiazide	6,705	41,519	41,972	130,785,425	0.1
Bendroflumethiazide	581	5,075	5,121	130,785,425	0.0
Thiazide-like diuretics	1,917,889	14,268,343	14,331,744	130,785,425	14.7
ACEIs	16,926,825	196,184,161	197,229,388	130,785,425	129.4
CCBs	17,737,988	213,095,625	214,624,200	130,785,425	135.6
Potassium-sparing diuretics	3,567,012	30,564,688	30,785,242	130,785,425	27.3
Loop diuretics	10,083,212	105,228,087	106,417,739	130,785,425	77.1

Table 1a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b>Denominators</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	16,490,059	185,496,008	186,792,846	130,785,425	126.1
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	38,912,004	642,506,777	735,847,902	130,785,425	297.5

<sup>1</sup>Eligible members includes those who have at least one day of enrollment during the query period.



Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products	3,089,409	2,846,047	3,121,296	2,943,314	3,106,727	3,032,006	3,008,685	3,046,749
HCTZ single ingredient/monotherapy	1,206,429	1,110,911	1,220,532	1,154,470	1,222,157	1,195,255	1,190,314	1,206,048
HCTZ combination products	1,898,171	1,748,455	1,916,262	1,802,635	1,899,766	1,851,517	1,832,596	1,855,518
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	208,616	191,020	214,202	203,468	214,133	212,701	209,733	213,313
ACEIs	3,525,160	3,247,229	3,543,043	3,334,105	3,510,635	3,414,668	3,390,978	3,440,087
CCBs	3,429,848	3,169,360	3,466,192	3,275,289	3,444,155	3,365,672	3,344,945	3,398,764
Potassium-sparing diuretics	447,455	415,310	457,817	434,724	461,291	455,126	452,149	463,285
Loop diuretics	1,632,695	1,514,502	1,649,522	1,575,001	1,666,085	1,649,651	1,638,684	1,659,984
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	3,293,731	3,033,129	3,331,003	3,142,868	3,316,476	3,240,417	3,214,349	3,255,807
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	9,698,328	9,031,488	9,802,908	9,318,748	9,779,832	9,584,347	9,531,174	9,662,696
	<b>Eligible members per month</b>							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
Enrollees with at least one day of coverage	62,229,431	62,191,560	62,228,731	62,164,229	62,111,028	62,123,634	62,130,040	62,204,794

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products	49.6	45.8	50.2	47.3	50.0	48.8	48.4	49.0
HCTZ single ingredient/monotherapy	19.4	17.9	19.6	18.6	19.7	19.2	19.2	19.4
HCTZ combination products	30.5	28.1	30.8	29.0	30.6	29.8	29.5	29.8
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.4	3.1	3.4	3.3	3.4	3.4	3.4	3.4
ACEIs	56.6	52.2	56.9	53.6	56.5	55.0	54.6	55.3
CCBs	55.1	51.0	55.7	52.7	55.5	54.2	53.8	54.6
Potassium-sparing diuretics	7.2	6.7	7.4	7.0	7.4	7.3	7.3	7.4
Loop diuretics	26.2	24.4	26.5	25.3	26.8	26.6	26.4	26.7
<b>Denominators</b>								
Limited denominator	52.9	48.8	53.5	50.6	53.4	52.2	51.7	52.3
Full denominator	155.8	145.2	157.5	149.9	157.5	154.3	153.4	155.3
	Proportion of numerators / denominators							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
Numerator: HCTZ-containing products; Limited denominator	0.938	0.938	0.937	0.937	0.937	0.936	0.936	0.936
Numerator: HCTZ single ingredient; Limited denominator	0.366	0.366	0.366	0.367	0.369	0.369	0.370	0.370
Numerator: HCTZ combination products; Limited denominator	0.576	0.576	0.575	0.574	0.573	0.571	0.570	0.570
Numerator: HCTZ-containing products; Full denominator	0.319	0.315	0.318	0.316	0.318	0.316	0.316	0.315
Numerator: HCTZ single ingredient; Full denominator	0.124	0.123	0.125	0.124	0.125	0.125	0.125	0.125
Numerator: HCTZ combination products; Full denominator	0.196	0.194	0.195	0.193	0.194	0.193	0.192	0.192

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products	2,889,951	3,015,206	2,903,025	2,913,453	2,943,707	2,683,759	2,888,984	2,853,304
HCTZ single ingredient/monotherapy	1,144,699	1,196,085	1,150,394	1,152,393	1,171,306	1,067,259	1,149,400	1,138,833
HCTZ combination products	1,758,614	1,833,496	1,766,331	1,774,395	1,786,404	1,628,763	1,753,465	1,727,665
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	204,315	213,181	208,489	210,987	215,601	200,086	219,318	218,694
ACEIs	3,272,647	3,413,833	3,290,632	3,294,557	3,343,159	3,049,012	3,266,256	3,207,638
CCBs	3,251,642	3,397,962	3,299,561	3,314,333	3,389,623	3,109,771	3,345,560	3,304,416
Potassium-sparing diuretics	442,629	462,604	450,567	451,523	457,802	422,653	456,215	452,280
Loop diuretics	1,584,436	1,630,452	1,571,622	1,567,821	1,579,438	1,460,982	1,560,284	1,551,337
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	3,090,447	3,224,284	3,107,540	3,120,532	3,155,168	2,880,155	3,104,118	3,067,953
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	9,248,120	9,611,456	9,316,181	9,339,202	9,445,301	8,729,334	9,319,678	9,224,104
<b>Eligible members per month</b>								
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
Enrollees with at least one day of coverage	61,836,252	61,845,502	61,869,177	61,873,272	61,213,863	61,123,877	61,109,989	61,024,866

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products	46.7	48.8	46.9	47.1	48.1	43.9	47.3	46.8
HCTZ single ingredient/monotherapy	18.5	19.3	18.6	18.6	19.1	17.5	18.8	18.7
HCTZ combination products	28.4	29.6	28.5	28.7	29.2	26.6	28.7	28.3
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.3	3.4	3.4	3.4	3.5	3.3	3.6	3.6
ACEIs	52.9	55.2	53.2	53.2	54.6	49.9	53.4	52.6
CCBs	52.6	54.9	53.3	53.6	55.4	50.9	54.7	54.1
Potassium-sparing diuretics	7.2	7.5	7.3	7.3	7.5	6.9	7.5	7.4
Loop diuretics	25.6	26.4	25.4	25.3	25.8	23.9	25.5	25.4
<b>Denominators</b>								
Limited denominator	50.0	52.1	50.2	50.4	51.5	47.1	50.8	50.3
Full denominator	149.6	155.4	150.6	150.9	154.3	142.8	152.5	151.2
	Proportion of numerators / denominators							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
Numerator: HCTZ-containing products; Limited denominator	0.935	0.935	0.934	0.934	0.933	0.932	0.931	0.930
Numerator: HCTZ single ingredient; Limited denominator	0.370	0.371	0.370	0.369	0.371	0.371	0.370	0.371
Numerator: HCTZ combination products; Limited denominator	0.569	0.569	0.568	0.569	0.566	0.566	0.565	0.563
Numerator: HCTZ-containing products; Full denominator	0.312	0.314	0.312	0.312	0.312	0.307	0.310	0.309
Numerator: HCTZ single ingredient; Full denominator	0.124	0.124	0.123	0.123	0.124	0.122	0.123	0.123
Numerator: HCTZ combination products; Full denominator	0.190	0.191	0.190	0.190	0.189	0.187	0.188	0.187

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing products	2,878,791	2,773,003	2,868,199	2,869,158	2,642,702	2,881,450	2,701,895	2,690,652
HCTZ single ingredient/monotherapy	1,156,573	1,115,994	1,146,739	1,153,502	1,072,175	1,154,439	1,093,049	1,092,373
HCTZ combination products	1,736,257	1,670,057	1,737,191	1,731,011	1,583,042	1,740,879	1,621,725	1,610,886
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	224,607	218,327	221,146	224,114	210,908	227,414	217,966	220,020
ACEIs	3,217,660	3,098,056	3,161,112	3,180,136	2,967,994	3,189,176	3,033,374	3,022,554
CCBs	3,329,639	3,218,763	3,285,140	3,309,325	3,112,140	3,352,909	3,204,961	3,206,340
Potassium-sparing diuretics	464,209	448,799	463,191	468,190	440,556	474,744	455,364	456,221
Loop diuretics	1,597,686	1,550,425	1,581,904	1,586,221	1,481,055	1,563,732	1,489,520	1,491,655
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	3,099,112	2,987,443	3,085,262	3,088,896	2,849,878	3,104,559	2,915,867	2,906,925
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	9,313,900	9,023,594	9,237,341	9,281,835	8,716,822	9,337,240	8,907,050	8,895,377
	<b>Eligible members per month</b>							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
Enrollees with at least one day of coverage	60,985,306	61,006,669	60,989,906	61,092,592	61,161,878	61,189,962	61,179,325	61,155,027

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing products	47.2	45.5	47.0	47.0	43.2	47.1	44.2	44.0
HCTZ single ingredient/monotherapy	19.0	18.3	18.8	18.9	17.5	18.9	17.9	17.9
HCTZ combination products	28.5	27.4	28.5	28.3	25.9	28.5	26.5	26.3
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.7	3.6	3.6	3.7	3.4	3.7	3.6	3.6
ACEIs	52.8	50.8	51.8	52.1	48.5	52.1	49.6	49.4
CCBs	54.6	52.8	53.9	54.2	50.9	54.8	52.4	52.4
Potassium-sparing diuretics	7.6	7.4	7.6	7.7	7.2	7.8	7.4	7.5
Loop diuretics	26.2	25.4	25.9	26.0	24.2	25.6	24.3	24.4
<b>Denominators</b>								
Limited denominator	50.8	49.0	50.6	50.6	46.6	50.7	47.7	47.5
Full denominator	152.7	147.9	151.5	151.9	142.5	152.6	145.6	145.5
	Proportion of numerators / denominators							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
Numerator: HCTZ-containing products; Limited denominator	0.929	0.928	0.930	0.929	0.927	0.928	0.927	0.926
Numerator: HCTZ single ingredient; Limited denominator	0.373	0.374	0.372	0.373	0.376	0.372	0.375	0.376
Numerator: HCTZ combination products; Limited denominator	0.560	0.559	0.563	0.560	0.555	0.561	0.556	0.554
Numerator: HCTZ-containing products; Full denominator	0.309	0.307	0.311	0.309	0.303	0.309	0.303	0.302
Numerator: HCTZ single ingredient; Full denominator	0.124	0.124	0.124	0.124	0.123	0.124	0.123	0.123
Numerator: HCTZ combination products; Full denominator	0.186	0.185	0.188	0.186	0.182	0.186	0.182	0.181

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products	2,788,575	2,514,065	2,669,759	2,724,887	2,697,983	2,550,474	2,699,077	2,612,431
HCTZ single ingredient/monotherapy	1,141,419	1,040,549	1,112,027	1,141,500	1,138,261	1,084,645	1,147,354	1,134,592
HCTZ combination products	1,662,482	1,486,976	1,572,380	1,598,264	1,574,380	1,479,354	1,566,192	1,492,886
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	225,707	206,841	222,431	226,079	227,499	215,704	227,005	223,583
ACEIs	3,126,881	2,842,312	3,036,876	3,079,120	3,054,208	2,890,212	3,042,478	2,971,993
CCBs	3,327,886	3,042,972	3,239,146	3,286,807	3,264,979	3,101,120	3,271,289	3,201,281
Potassium-sparing diuretics	468,094	429,800	459,842	469,024	471,561	451,174	476,416	469,746
Loop diuretics	1,526,283	1,402,197	1,483,048	1,513,981	1,528,079	1,464,455	1,544,022	1,504,040
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	3,010,129	2,717,243	2,888,211	2,946,915	2,921,424	2,762,621	2,922,239	2,832,282
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	9,162,749	8,418,375	8,919,483	9,065,171	9,024,971	8,609,505	9,041,808	8,842,292
	<b>Eligible members per month</b>							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
Enrollees with at least one day of coverage	60,886,631	60,813,142	60,826,591	60,746,637	60,686,962	60,624,928	60,662,237	60,651,542

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products	45.8	41.3	43.9	44.9	44.5	42.1	44.5	43.1
HCTZ single ingredient/monotherapy	18.7	17.1	18.3	18.8	18.8	17.9	18.9	18.7
HCTZ combination products	27.3	24.5	25.9	26.3	25.9	24.4	25.8	24.6
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.7	3.4	3.7	3.7	3.7	3.6	3.7	3.7
ACEIs	51.4	46.7	49.9	50.7	50.3	47.7	50.2	49.0
CCBs	54.7	50.0	53.3	54.1	53.8	51.2	53.9	52.8
Potassium-sparing diuretics	7.7	7.1	7.6	7.7	7.8	7.4	7.9	7.7
Loop diuretics	25.1	23.1	24.4	24.9	25.2	24.2	25.5	24.8
<b>Denominators</b>								
Limited denominator	49.4	44.7	47.5	48.5	48.1	45.6	48.2	46.7
Full denominator	150.5	138.4	146.6	149.2	148.7	142.0	149.1	145.8
	<b>Proportion of numerators / denominators</b>							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
Numerator: HCTZ-containing products; Limited denominator	0.926	0.925	0.924	0.925	0.924	0.923	0.924	0.922
Numerator: HCTZ single ingredient; Limited denominator	0.379	0.383	0.385	0.387	0.390	0.393	0.393	0.401
Numerator: HCTZ combination products; Limited denominator	0.552	0.547	0.544	0.542	0.539	0.535	0.536	0.527
Numerator: HCTZ-containing products; Full denominator	0.304	0.299	0.299	0.301	0.299	0.296	0.299	0.295
Numerator: HCTZ single ingredient; Full denominator	0.125	0.124	0.125	0.126	0.126	0.126	0.127	0.128
Numerator: HCTZ combination products; Full denominator	0.181	0.177	0.176	0.176	0.174	0.172	0.173	0.169



Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing products	2,518,928	2,658,479	2,450,650	2,580,400	2,644,856	2,427,829	2,786,455	2,477,060
HCTZ single ingredient/monotherapy	1,124,682	1,234,263	1,176,622	1,272,621	1,315,566	1,212,734	1,389,601	1,233,880
HCTZ combination products	1,410,376	1,446,220	1,293,659	1,327,850	1,348,859	1,230,564	1,415,952	1,258,159
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	215,745	228,624	213,915	225,651	232,484	217,154	243,713	218,180
ACEIs	2,884,592	3,038,792	2,815,579	2,954,403	3,026,261	2,790,499	3,162,320	2,818,744
CCBs	3,109,236	3,285,152	3,073,392	3,243,860	3,334,301	3,103,755	3,508,717	3,140,288
Potassium-sparing diuretics	455,614	480,170	449,417	471,383	484,844	453,218	507,517	457,421
Loop diuretics	1,451,770	1,506,621	1,402,150	1,480,767	1,493,816	1,391,716	1,546,057	1,416,185
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,731,218	2,883,104	2,661,217	2,802,322	2,873,440	2,641,656	3,026,542	2,692,045
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,596,102	9,016,167	8,427,278	8,832,097	9,015,163	8,416,032	9,438,044	8,502,032
	<b>Eligible members per month</b>							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
Enrollees with at least one day of coverage	60,683,951	60,706,276	60,703,605	60,686,255	61,089,472	60,949,008	60,913,111	60,771,289

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing products	41.5	43.8	40.4	42.5	43.3	39.8	45.7	40.8
HCTZ single ingredient/monotherapy	18.5	20.3	19.4	21.0	21.5	19.9	22.8	20.3
HCTZ combination products	23.2	23.8	21.3	21.9	22.1	20.2	23.2	20.7
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.6	3.8	3.5	3.7	3.8	3.6	4.0	3.6
ACEIs	47.5	50.1	46.4	48.7	49.5	45.8	51.9	46.4
CCBs	51.2	54.1	50.6	53.5	54.6	50.9	57.6	51.7
Potassium-sparing diuretics	7.5	7.9	7.4	7.8	7.9	7.4	8.3	7.5
Loop diuretics	23.9	24.8	23.1	24.4	24.5	22.8	25.4	23.3
<b>Denominators</b>								
Limited denominator	45.0	47.5	43.8	46.2	47.0	43.3	49.7	44.3
Full denominator	141.7	148.5	138.8	145.5	147.6	138.1	154.9	139.9
	Proportion of numerators / denominators							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
Numerator: HCTZ-containing products; Limited denominator	0.922	0.922	0.921	0.921	0.920	0.919	0.921	0.920
Numerator: HCTZ single ingredient; Limited denominator	0.412	0.428	0.442	0.454	0.458	0.459	0.459	0.458
Numerator: HCTZ combination products; Limited denominator	0.516	0.502	0.486	0.474	0.469	0.466	0.468	0.467
Numerator: HCTZ-containing products; Full denominator	0.293	0.295	0.291	0.292	0.293	0.288	0.295	0.291
Numerator: HCTZ single ingredient; Full denominator	0.131	0.137	0.140	0.144	0.146	0.144	0.147	0.145
Numerator: HCTZ combination products; Full denominator	0.164	0.160	0.154	0.150	0.150	0.146	0.150	0.148

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products	2,432,620	2,594,615	2,508,863	2,477,675	2,461,378	2,466,157	2,367,351	2,521,361
HCTZ single ingredient/monotherapy	1,210,759	1,295,462	1,252,583	1,232,325	1,216,095	1,211,306	1,160,187	1,231,174
HCTZ combination products	1,235,294	1,314,666	1,271,413	1,258,825	1,257,536	1,266,770	1,217,635	1,301,585
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	216,391	228,932	222,673	219,118	218,274	219,260	212,463	225,998
ACEIs	2,763,876	2,944,132	2,855,644	2,830,732	2,822,481	2,831,560	2,721,038	2,890,339
CCBs	3,084,829	3,265,285	3,171,018	3,145,756	3,151,303	3,176,876	3,073,959	3,271,823
Potassium-sparing diuretics	451,588	480,131	469,684	464,642	465,279	469,266	453,951	482,263
Loop diuretics	1,404,833	1,495,284	1,461,937	1,430,295	1,417,453	1,407,771	1,351,072	1,414,220
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,645,912	2,820,073	2,728,239	2,693,626	2,676,449	2,682,264	2,576,897	2,744,154
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,385,217	8,871,474	8,633,695	8,554,757	8,534,061	8,569,272	8,282,124	8,748,406
	<b>Eligible members per month</b>							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
Enrollees with at least one day of coverage	60,620,412	60,527,157	60,414,419	60,300,149	60,017,165	59,954,097	59,949,698	59,918,233

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products	40.1	42.9	41.5	41.1	41.0	41.1	39.5	42.1
HCTZ single ingredient/monotherapy	20.0	21.4	20.7	20.4	20.3	20.2	19.4	20.5
HCTZ combination products	20.4	21.7	21.0	20.9	21.0	21.1	20.3	21.7
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.6	3.8	3.7	3.6	3.6	3.7	3.5	3.8
ACEIs	45.6	48.6	47.3	46.9	47.0	47.2	45.4	48.2
CCBs	50.9	53.9	52.5	52.2	52.5	53.0	51.3	54.6
Potassium-sparing diuretics	7.4	7.9	7.8	7.7	7.8	7.8	7.6	8.0
Loop diuretics	23.2	24.7	24.2	23.7	23.6	23.5	22.5	23.6
<b>Denominators</b>								
Limited denominator	43.6	46.6	45.2	44.7	44.6	44.7	43.0	45.8
Full denominator	138.3	146.6	142.9	141.9	142.2	142.9	138.2	146.0
	Proportion of numerators / denominators							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
Numerator: HCTZ-containing products; Limited denominator	0.919	0.920	0.920	0.920	0.920	0.919	0.919	0.919
Numerator: HCTZ single ingredient; Limited denominator	0.458	0.459	0.459	0.457	0.454	0.452	0.450	0.449
Numerator: HCTZ combination products; Limited denominator	0.467	0.466	0.466	0.467	0.470	0.472	0.473	0.474
Numerator: HCTZ-containing products; Full denominator	0.290	0.292	0.291	0.290	0.288	0.288	0.286	0.288
Numerator: HCTZ single ingredient; Full denominator	0.144	0.146	0.145	0.144	0.142	0.141	0.140	0.141
Numerator: HCTZ combination products; Full denominator	0.147	0.148	0.147	0.147	0.147	0.148	0.147	0.149

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products	2,394,166	2,201,735	2,498,860	2,396,301	2,317,001	2,423,433	2,372,469	2,359,961
HCTZ single ingredient/monotherapy	1,170,097	1,073,552	1,215,559	1,165,713	1,128,648	1,178,545	1,153,192	1,144,912
HCTZ combination products	1,234,445	1,137,329	1,294,442	1,240,802	1,197,827	1,254,950	1,228,891	1,224,398
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	215,073	200,618	228,238	219,493	213,655	221,362	217,119	215,935
ACEIs	2,734,178	2,528,212	2,853,181	2,734,096	2,640,165	2,754,904	2,698,557	2,686,062
CCBs	3,131,622	2,901,902	3,275,363	3,151,074	3,056,830	3,182,832	3,128,475	3,121,990
Potassium-sparing diuretics	462,083	431,247	490,142	476,190	465,659	486,748	480,348	480,077
Loop diuretics	1,335,594	1,244,072	1,408,028	1,367,934	1,343,354	1,408,766	1,385,434	1,369,778
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,606,231	2,399,843	2,723,919	2,612,740	2,527,754	2,641,772	2,586,794	2,573,098
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,344,132	7,772,439	8,707,477	8,406,963	8,180,714	8,509,932	8,371,573	8,342,967
	<b>Eligible members per month</b>							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
Enrollees with at least one day of coverage	59,781,113	59,645,359	59,627,640	59,563,961	59,525,867	59,558,070	59,609,299	59,732,038

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products	40.0	36.9	41.9	40.2	38.9	40.7	39.8	39.5
HCTZ single ingredient/monotherapy	19.6	18.0	20.4	19.6	19.0	19.8	19.3	19.2
HCTZ combination products	20.6	19.1	21.7	20.8	20.1	21.1	20.6	20.5
<b>Non-HCTZ-containing</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.6	3.4	3.8	3.7	3.6	3.7	3.6	3.6
ACEIs	45.7	42.4	47.8	45.9	44.4	46.3	45.3	45.0
CCBs	52.4	48.7	54.9	52.9	51.4	53.4	52.5	52.3
Potassium-sparing diuretics	7.7	7.2	8.2	8.0	7.8	8.2	8.1	8.0
Loop diuretics	22.3	20.9	23.6	23.0	22.6	23.7	23.2	22.9
<b>Denominators</b>								
Limited denominator	43.6	40.2	45.7	43.9	42.5	44.4	43.4	43.1
Full denominator	139.6	130.3	146.0	141.1	137.4	142.9	140.4	139.7
<b>Proportion of numerators / denominators</b>								
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
Numerator: HCTZ-containing products; Limited denominator	0.919	0.917	0.917	0.917	0.917	0.917	0.917	0.917
Numerator: HCTZ single ingredient; Limited denominator	0.449	0.447	0.446	0.446	0.447	0.446	0.446	0.445
Numerator: HCTZ combination products; Limited denominator	0.474	0.474	0.475	0.475	0.474	0.475	0.475	0.476
Numerator: HCTZ-containing products; Full denominator	0.287	0.283	0.287	0.285	0.283	0.285	0.283	0.283
Numerator: HCTZ single ingredient; Full denominator	0.140	0.138	0.140	0.139	0.138	0.138	0.138	0.137
Numerator: HCTZ combination products; Full denominator	0.148	0.146	0.149	0.148	0.146	0.147	0.147	0.147

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>HCTZ-containing</b>							
HCTZ-containing products	2,311,066	2,307,142	2,270,736	2,306,815	2,026,016	1,575,872	1,415,916
HCTZ single ingredient/monotherapy	1,119,820	1,113,965	1,097,741	1,126,197	1,009,379	789,595	717,743
HCTZ combination products	1,200,217	1,202,091	1,181,636	1,190,388	1,025,024	792,579	703,999
<b>Non-HCTZ-containing</b>							
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	211,356	211,149	210,358	215,320	193,288	152,551	143,121
ACEIs	2,633,809	2,635,951	2,599,920	2,646,781	2,333,772	1,830,003	1,675,419
CCBs	3,068,011	3,082,185	3,073,331	3,133,668	2,863,861	2,236,149	2,119,646
Potassium-sparing diuretics	470,105	471,947	471,446	480,911	419,824	338,529	301,425
Loop diuretics	1,331,991	1,317,875	1,305,703	1,334,049	1,230,548	971,002	976,299
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,519,877	2,515,582	2,478,493	2,519,437	2,216,898	1,726,573	1,557,013
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,186,746	8,194,599	8,123,489	8,256,130	7,385,493	5,834,273	5,380,829
	<b>Eligible members per month</b>						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
Enrollees with at least one day of coverage	59,762,995	59,765,302	59,810,685	59,853,545	49,088,999	43,774,291	29,085,316

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>HCTZ-containing</b>							
HCTZ-containing products	38.7	38.6	38.0	38.5	41.3	36.0	48.7
HCTZ single ingredient/monotherapy	18.7	18.6	18.4	18.8	20.6	18.0	24.7
HCTZ combination products	20.1	20.1	19.8	19.9	20.9	18.1	24.2
<b>Non-HCTZ-containing</b>							
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.5	3.5	3.5	3.6	3.9	3.5	4.9
ACEIs	44.1	44.1	43.5	44.2	47.5	41.8	57.6
CCBs	51.3	51.6	51.4	52.4	58.3	51.1	72.9
Potassium-sparing diuretics	7.9	7.9	7.9	8.0	8.6	7.7	10.4
Loop diuretics	22.3	22.1	21.8	22.3	25.1	22.2	33.6
<b>Denominators</b>							
Limited denominator	42.2	42.1	41.4	42.1	45.2	39.4	53.5
Full denominator	137.0	137.1	135.8	137.9	150.5	133.3	185.0
	Proportion of numerators / denominators						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
Numerator: HCTZ-containing products; Limited denominator	0.917	0.917	0.916	0.916	0.914	0.913	0.909
Numerator: HCTZ single ingredient; Limited denominator	0.444	0.443	0.443	0.447	0.455	0.457	0.461
Numerator: HCTZ combination products; Limited denominator	0.476	0.478	0.477	0.472	0.462	0.459	0.452
Numerator: HCTZ-containing products; Full denominator	0.282	0.282	0.280	0.279	0.274	0.270	0.263
Numerator: HCTZ single ingredient; Full denominator	0.137	0.136	0.135	0.136	0.137	0.135	0.133
Numerator: HCTZ combination products; Full denominator	0.147	0.147	0.145	0.144	0.139	0.136	0.131



Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Patients with dispensing per month		
	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>			
HCTZ-containing products	166,678	168,976	165,075
HCTZ single ingredient/monotherapy	78,508	79,546	77,738
HCTZ combination products	88,808	90,063	87,946
<b>Non-HCTZ-containing</b>			
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	14,234	14,453	14,279
ACEIs	180,295	182,846	178,079
CCBs	195,795	199,724	194,882
Potassium-sparing diuretics	38,538	39,697	38,987
Loop diuretics	61,295	63,175	62,449
<b>Denominators</b>			
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	180,724	183,252	179,195
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	544,750	554,590	543,130
	<b>Eligible members per month</b>		
	Apr-22	May-22	Jun-22
Enrollees with at least one day of coverage	8,254,494	8,291,948	8,319,950

Table 1b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month

	Number of patients with dispensing per 1,000 eligible members		
	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>			
HCTZ-containing products	20.2	20.4	19.8
HCTZ single ingredient/monotherapy	9.5	9.6	9.3
HCTZ combination products	10.8	10.9	10.6
<b>Non-HCTZ-containing</b>			
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	1.7	1.7	1.7
ACEIs	21.8	22.1	21.4
CCBs	23.7	24.1	23.4
Potassium-sparing diuretics	4.7	4.8	4.7
Loop diuretics	7.4	7.6	7.5
<b>Denominators</b>			
Limited denominator	21.9	22.1	21.5
Full denominator	66.0	66.9	65.3
<b>Proportion of numerators / denominators</b>			
	Apr-22	May-22	Jun-22
Numerator: HCTZ-containing products; Limited denominator	0.922	0.922	0.921
Numerator: HCTZ single ingredient; Limited denominator	0.434	0.434	0.434
Numerator: HCTZ combination products; Limited denominator	0.491	0.491	0.491
Numerator: HCTZ-containing products; Full denominator	0.306	0.305	0.304
Numerator: HCTZ single ingredient; Full denominator	0.144	0.143	0.143
Numerator: HCTZ combination products; Full denominator	0.163	0.162	0.162

Figure 1. Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Figure 1 (Continued). Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Figure 1 (Continued). Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Figure 1 (Continued). Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Figure 1 (Continued). Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Figure 1 (Continued). Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month






Figure 1 (Continued). Use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Table 2a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years)

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b>HCTZ-containing</b>					
<b>HCTZ-containing products</b>					
0-40	651,656	4,736,728	4,799,327	55,406,349	11.8
41-64	5,038,915	51,585,463	52,218,039	42,301,935	119.1
65-74	6,615,519	66,270,335	66,540,423	30,031,167	220.3
75-84	3,652,528	36,473,918	36,604,187	15,443,595	236.5
85+	1,199,950	12,204,459	12,252,034	6,358,823	188.7
<b>HCTZ single ingredient/monotherapy</b>					
0-40	362,902	2,160,609	2,179,391	55,406,349	6.5
41-64	2,543,629	21,237,762	21,383,349	42,301,935	60.1
65-74	3,524,276	29,027,572	29,069,812	30,031,167	117.4
75-84	2,038,348	16,827,778	16,850,574	15,443,595	132.0
85+	707,579	6,204,360	6,217,097	6,358,823	111.3
<b>HCTZ combination products</b>					
0-40	346,728	2,586,943	2,619,934	55,406,349	6.3
41-64	2,990,829	30,477,272	30,834,691	42,301,935	70.7
65-74	3,812,207	37,362,620	37,470,621	30,031,167	126.9
75-84	2,006,736	19,707,119	19,753,613	15,443,595	129.9
85+	605,775	6,020,114	6,034,940	6,358,823	95.3

Table 2a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years)

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b>Non-HCTZ-containing</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics					
0-40	59,011	338,302	342,345	55,406,349	1.1
41-64	491,887	3,550,775	3,582,210	42,301,935	11.6
65-74	757,046	5,257,063	5,268,961	30,031,167	25.2
75-84	539,553	3,565,360	3,574,594	15,443,595	34.9
85+	246,720	1,603,307	1,610,727	6,358,823	38.8
ACEIs					
0-40	808,492	6,051,005	6,116,967	55,406,349	14.6
41-64	5,582,631	56,502,368	56,981,076	42,301,935	132.0
65-74	7,144,453	71,765,175	72,008,277	30,031,167	237.9
75-84	4,135,658	43,327,078	43,487,223	15,443,595	267.8
85+	1,599,962	18,538,535	18,635,845	6,358,823	251.6
CCBs					
0-40	682,246	4,610,296	4,673,082	55,406,349	12.3
41-64	4,709,302	46,719,190	47,209,813	42,301,935	111.3
65-74	7,371,485	74,832,716	75,237,179	30,031,167	245.5
75-84	5,203,201	56,625,778	56,961,859	15,443,595	336.9
85+	2,410,086	30,307,645	30,542,267	6,358,823	379.0
Potassium-sparing diuretics					
0-40	610,921	3,764,913	3,853,485	55,406,349	11.0
41-64	913,201	7,590,433	7,673,611	42,301,935	21.6
65-74	1,137,837	9,114,949	9,139,121	30,031,167	37.9
75-84	832,122	6,645,306	6,660,362	15,443,595	53.9
85+	393,969	3,449,087	3,458,663	6,358,823	62.0

Table 2a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years)

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b>Non-HCTZ-containing</b>					
Loop diuretics					
0-40	196,324	1,097,694	1,109,999	55,406,349	3.5
41-64	2,070,638	17,786,543	17,981,494	42,301,935	48.9
65-74	3,532,705	29,765,006	30,015,717	30,031,167	117.6
75-84	3,300,840	30,554,821	30,868,117	15,443,595	213.7
85+	2,203,114	26,024,023	26,442,412	6,358,823	346.5
<b>Denominators</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
0-40	698,120	5,073,432	5,141,672	55,406,349	12.6
41-64	5,416,327	55,109,274	55,800,249	42,301,935	128.0
65-74	7,188,572	71,497,183	71,809,384	30,031,167	239.4
75-84	4,068,646	40,018,642	40,178,781	15,443,595	263.5
85+	1,403,257	13,797,477	13,862,760	6,358,823	220.7
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
0-40	2,361,921	18,917,647	20,895,243	55,406,349	42.6
41-64	12,350,667	160,998,964	185,646,560	42,301,935	292.0
65-74	16,075,678	226,188,738	258,209,195	30,031,167	535.3
75-84	10,022,744	156,166,051	178,155,642	15,443,595	649.0
85+	4,473,588	80,235,377	92,941,262	6,358,823	703.5

<sup>1</sup>Eligible members includes those who have at least one day of enrollment during the query period.

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products								
0-40	92,298	88,145	96,649	90,257	94,429	92,730	90,160	91,897
41-64	1,003,059	951,535	1,035,979	977,716	1,023,330	1,003,120	987,913	1,004,403
65-74	1,149,870	1,042,638	1,149,264	1,082,389	1,148,520	1,117,929	1,114,785	1,128,658
75-84	621,333	560,890	618,984	583,934	620,609	604,259	602,134	607,244
85+	223,457	203,122	221,111	209,411	220,546	214,498	214,214	215,308
HCTZ single ingredient/monotherapy								
0-40	37,331	35,745	39,520	37,148	38,891	38,411	37,501	38,184
41-64	365,211	346,087	378,407	358,128	376,175	369,533	365,374	372,022
65-74	446,052	404,720	445,860	421,712	448,064	437,188	437,327	443,035
75-84	255,277	230,654	255,234	240,613	256,933	250,420	250,394	252,779
85+	102,798	93,802	101,790	97,015	102,375	99,914	99,915	100,323
HCTZ combination products								
0-40	55,468	52,837	57,639	53,584	56,063	54,825	53,110	54,241
41-64	643,302	610,385	663,284	624,768	652,814	638,981	627,881	637,851
65-74	709,237	642,555	708,809	665,449	705,729	685,910	682,382	690,785
75-84	368,899	332,641	366,640	345,830	366,479	356,531	354,296	357,162
85+	121,616	110,206	120,290	113,230	119,084	115,568	115,234	115,923

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	97,115	92,665	101,832	95,202	99,462	97,791	95,136	96,938
41-64	1,055,608	1,000,642	1,090,818	1,030,069	1,078,111	1,057,707	1,041,653	1,059,580
65-74	1,222,584	1,108,338	1,223,257	1,152,820	1,222,722	1,191,611	1,187,915	1,202,706
75-84	671,461	606,343	670,253	632,409	671,832	655,211	652,102	657,983
85+	247,625	225,461	245,602	232,798	245,128	238,684	238,131	239,445
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	304,932	291,511	319,343	300,527	314,371	309,013	302,844	310,740
41-64	2,700,375	2,572,426	2,782,631	2,638,285	2,754,770	2,704,964	2,669,304	2,716,988
65-74	3,334,943	3,066,151	3,347,651	3,178,743	3,351,644	3,277,405	3,272,118	3,316,219
75-84	2,210,482	2,033,507	2,213,447	2,106,921	2,219,675	2,175,291	2,170,014	2,193,688
85+	1,152,393	1,071,202	1,144,932	1,097,829	1,144,522	1,122,158	1,121,543	1,130,668
<b>Eligible members per month</b>								
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
Enrollees with at least one day of coverage								
0-40	21,458,747	21,414,934	21,413,389	21,367,201	21,344,614	21,329,780	21,257,150	21,274,967
41-64	17,468,832	17,436,389	17,442,620	17,396,639	17,357,916	17,345,289	17,299,728	17,293,063
65-74	13,369,235	13,392,196	13,422,886	13,433,239	13,439,448	13,466,965	13,565,282	13,603,974
75-84	7,104,457	7,112,943	7,133,366	7,141,128	7,153,647	7,169,275	7,209,867	7,238,149
85+	3,103,222	3,094,619	3,093,641	3,084,691	3,081,547	3,082,078	3,090,573	3,095,582

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing								
0-40: HCTZ-containing	4.3	4.1	4.5	4.2	4.4	4.3	4.2	4.3
41-64: HCTZ-containing	57.4	54.6	59.4	56.2	59.0	57.8	57.1	58.1
65-74: HCTZ-containing	86.0	77.9	85.6	80.6	85.5	83.0	82.2	83.0
75-84: HCTZ-containing	87.5	78.9	86.8	81.8	86.8	84.3	83.5	83.9
85+: HCTZ-containing	72.0	65.6	71.5	67.9	71.6	69.6	69.3	69.6
HCTZ single ingredient								
0-40: HCTZ single ingredient	1.7	1.7	1.8	1.7	1.8	1.8	1.8	1.8
41-64: HCTZ single ingredient	20.9	19.8	21.7	20.6	21.7	21.3	21.1	21.5
65-74: HCTZ single ingredient	33.4	30.2	33.2	31.4	33.3	32.5	32.2	32.6
75-84: HCTZ single ingredient	35.9	32.4	35.8	33.7	35.9	34.9	34.7	34.9
85+: HCTZ single ingredient	33.1	30.3	32.9	31.5	33.2	32.4	32.3	32.4
HCTZ combination								
0-40: HCTZ combination	2.6	2.5	2.7	2.5	2.6	2.6	2.5	2.5
41-64: HCTZ combination	36.8	35.0	38.0	35.9	37.6	36.8	36.3	36.9
65-74: HCTZ combination	53.0	48.0	52.8	49.5	52.5	50.9	50.3	50.8
75-84: HCTZ combination	51.9	46.8	51.4	48.4	51.2	49.7	49.1	49.3
85+: HCTZ combination	39.2	35.6	38.9	36.7	38.6	37.5	37.3	37.4

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>0-40: Limited denominator</i>	4.5	4.3	4.8	4.5	4.7	4.6	4.5	4.6
<i>41-64: Limited denominator</i>	60.4	57.4	62.5	59.2	62.1	61.0	60.2	61.3
<i>65-74: Limited denominator</i>	91.4	82.8	91.1	85.8	91.0	88.5	87.6	88.4
<i>75-84: Limited denominator</i>	94.5	85.2	94.0	88.6	93.9	91.4	90.4	90.9
<i>85+: Limited denominator</i>	79.8	72.9	79.4	75.5	79.5	77.4	77.1	77.4
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>0-40: Full denominator</i>	14.2	13.6	14.9	14.1	14.7	14.5	14.2	14.6
<i>41-64: Full denominator</i>	154.6	147.5	159.5	151.7	158.7	155.9	154.3	157.1
<i>65-74: Full denominator</i>	249.4	229.0	249.4	236.6	249.4	243.4	241.2	243.8
<i>75-84: Full denominator</i>	311.1	285.9	310.3	295.0	310.3	303.4	301.0	303.1
<i>85+: Full denominator</i>	371.4	346.1	370.1	355.9	371.4	364.1	362.9	365.3



Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
0-40: HCTZ-containing products	0.950	0.951	0.949	0.948	0.949	0.948	0.948	0.948
41-64: HCTZ-containing products	0.950	0.951	0.950	0.949	0.949	0.948	0.948	0.948
65-74: HCTZ-containing products	0.941	0.941	0.940	0.939	0.939	0.938	0.938	0.938
75-84: HCTZ-containing products	0.925	0.925	0.924	0.923	0.924	0.922	0.923	0.923
85+: HCTZ-containing products	0.902	0.901	0.900	0.900	0.900	0.899	0.900	0.899
HCTZ single ingredient numerator, limited denominator								
0-40: HCTZ single ingredient	0.384	0.386	0.388	0.390	0.391	0.393	0.394	0.394
41-64: HCTZ single ingredient	0.346	0.346	0.347	0.348	0.349	0.349	0.351	0.351
65-74: HCTZ single ingredient	0.365	0.365	0.364	0.366	0.366	0.367	0.368	0.368
75-84: HCTZ single ingredient	0.380	0.380	0.381	0.380	0.382	0.382	0.384	0.384
85+: HCTZ single ingredient	0.415	0.416	0.414	0.417	0.418	0.419	0.420	0.419
HCTZ combination products numerator, limited denominator								
0-40: HCTZ combination products	0.571	0.570	0.566	0.563	0.564	0.561	0.558	0.560
41-64: HCTZ combination products	0.609	0.610	0.608	0.607	0.606	0.604	0.603	0.602
65-74: HCTZ combination products	0.580	0.580	0.579	0.577	0.577	0.576	0.574	0.574
75-84: HCTZ combination products	0.549	0.549	0.547	0.547	0.545	0.544	0.543	0.543
85+: HCTZ combination products	0.491	0.489	0.490	0.486	0.486	0.484	0.484	0.484

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40: HCTZ-containing products</i>	0.303	0.302	0.303	0.300	0.300	0.300	0.298	0.296
<i>41-64: HCTZ-containing products</i>	0.371	0.370	0.372	0.371	0.371	0.371	0.370	0.370
<i>65-74: HCTZ-containing products</i>	0.345	0.340	0.343	0.341	0.343	0.341	0.341	0.340
<i>75-84: HCTZ-containing products</i>	0.281	0.276	0.280	0.277	0.280	0.278	0.277	0.277
<i>85+: HCTZ-containing products</i>	0.194	0.190	0.193	0.191	0.193	0.191	0.191	0.190
HCTZ single ingredient numerator, limited denominator								
<i>0-40: HCTZ single ingredient</i>	0.122	0.123	0.124	0.124	0.124	0.124	0.124	0.123
<i>41-64: HCTZ single ingredient</i>	0.135	0.135	0.136	0.136	0.137	0.137	0.137	0.137
<i>65-74: HCTZ single ingredient</i>	0.134	0.132	0.133	0.133	0.134	0.133	0.134	0.134
<i>75-84: HCTZ single ingredient</i>	0.115	0.113	0.115	0.114	0.116	0.115	0.115	0.115
<i>85+: HCTZ single ingredient</i>	0.089	0.088	0.089	0.088	0.089	0.089	0.089	0.089
HCTZ combination products numerator, limited denominator								
<i>0-40: HCTZ combination products</i>	0.182	0.181	0.180	0.178	0.178	0.177	0.175	0.175
<i>41-64: HCTZ combination products</i>	0.238	0.237	0.238	0.237	0.237	0.236	0.235	0.235
<i>65-74: HCTZ combination products</i>	0.213	0.210	0.212	0.209	0.211	0.209	0.209	0.208
<i>75-84: HCTZ combination products</i>	0.167	0.164	0.166	0.164	0.165	0.164	0.163	0.163
<i>85+: HCTZ combination products</i>	0.106	0.103	0.105	0.103	0.104	0.103	0.103	0.103

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
0-40	86,087	87,951	85,831	85,271	84,269	80,740	86,586	83,982
41-64	946,108	976,895	949,046	951,704	919,173	865,006	923,287	897,523
65-74	1,072,187	1,127,052	1,078,099	1,084,061	1,120,823	1,004,457	1,086,405	1,080,719
75-84	580,453	609,950	585,297	589,852	610,802	544,993	592,141	590,907
85+	205,528	213,957	205,187	203,035	209,279	188,850	201,152	200,604
HCTZ single ingredient/monotherapy								
0-40	35,756	36,749	35,707	35,274	35,188	33,878	36,298	35,249
41-64	351,015	363,235	352,409	352,141	341,788	321,361	344,103	334,616
65-74	420,665	442,936	423,051	425,525	441,445	395,467	427,872	427,304
75-84	241,404	253,828	243,675	244,655	255,393	228,074	247,145	247,644
85+	96,034	99,559	95,732	94,969	97,749	88,577	94,205	94,176
HCTZ combination products								
0-40	50,802	51,674	50,599	50,435	49,536	47,316	50,758	49,185
41-64	600,035	619,058	601,837	604,572	582,362	548,056	584,171	567,667
65-74	656,174	689,189	659,803	663,122	684,432	613,297	663,492	658,123
75-84	341,445	358,658	344,063	347,656	358,052	319,243	347,623	345,726
85+	110,379	115,271	110,271	108,897	112,386	101,028	107,773	107,219

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	90,929	92,819	90,654	90,189	89,186	85,538	91,926	89,131
41-64	998,448	1,031,043	1,002,477	1,005,931	971,994	915,814	978,367	952,252
65-74	1,143,460	1,202,170	1,151,134	1,158,229	1,197,982	1,075,234	1,164,103	1,158,750
75-84	629,411	660,878	635,406	640,343	663,213	592,811	645,104	643,664
85+	228,659	238,040	228,347	226,364	233,496	211,075	225,263	224,626
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	292,645	301,791	296,456	295,691	295,028	282,168	301,704	293,612
41-64	2,576,628	2,658,353	2,595,774	2,599,289	2,528,617	2,394,850	2,541,001	2,479,776
65-74	3,176,162	3,320,901	3,200,596	3,213,506	3,309,892	3,015,435	3,238,228	3,221,343
75-84	2,115,177	2,206,540	2,134,457	2,146,870	2,207,712	2,015,808	2,162,708	2,159,518
85+	1,091,666	1,128,974	1,093,111	1,088,031	1,109,286	1,024,362	1,080,689	1,073,861
<b>Eligible members per month</b>								
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
Enrollees with at least one day of coverage								
0-40	21,044,291	21,019,807	21,015,632	21,002,218	20,731,748	20,659,536	20,630,005	20,575,695
41-64	17,098,475	17,069,931	17,052,126	17,033,309	16,624,662	16,573,457	16,556,749	16,500,878
65-74	13,628,496	13,650,277	13,651,937	13,659,414	13,734,317	13,743,701	13,766,839	13,762,411
75-84	7,266,957	7,303,093	7,327,549	7,359,884	7,342,630	7,356,083	7,387,139	7,402,829
85+	3,098,470	3,102,555	3,100,132	3,099,460	3,072,367	3,055,221	3,053,209	3,046,144

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing								
0-40: HCTZ-containing	4.1	4.2	4.1	4.1	4.1	3.9	4.2	4.1
41-64: HCTZ-containing	55.3	57.2	55.7	55.9	55.3	52.2	55.8	54.4
65-74: HCTZ-containing	78.7	82.6	79.0	79.4	81.6	73.1	78.9	78.5
75-84: HCTZ-containing	79.9	83.5	79.9	80.1	83.2	74.1	80.2	79.8
85+: HCTZ-containing	66.3	69.0	66.2	65.5	68.1	61.8	65.9	65.9
HCTZ single ingredient								
0-40: HCTZ single ingredient	1.7	1.7	1.7	1.7	1.7	1.6	1.8	1.7
41-64: HCTZ single ingredient	20.5	21.3	20.7	20.7	20.6	19.4	20.8	20.3
65-74: HCTZ single ingredient	30.9	32.4	31.0	31.2	32.1	28.8	31.1	31.0
75-84: HCTZ single ingredient	33.2	34.8	33.3	33.2	34.8	31.0	33.5	33.5
85+: HCTZ single ingredient	31.0	32.1	30.9	30.6	31.8	29.0	30.9	30.9
HCTZ combination								
0-40: HCTZ combination	2.4	2.5	2.4	2.4	2.4	2.3	2.5	2.4
41-64: HCTZ combination	35.1	36.3	35.3	35.5	35.0	33.1	35.3	34.4
65-74: HCTZ combination	48.1	50.5	48.3	48.5	49.8	44.6	48.2	47.8
75-84: HCTZ combination	47.0	49.1	47.0	47.2	48.8	43.4	47.1	46.7
85+: HCTZ combination	35.6	37.2	35.6	35.1	36.6	33.1	35.3	35.2

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>0-40: Limited denominator</i>	4.3	4.4	4.3	4.3	4.3	4.1	4.5	4.3
<i>41-64: Limited denominator</i>	58.4	60.4	58.8	59.1	58.5	55.3	59.1	57.7
<i>65-74: Limited denominator</i>	83.9	88.1	84.3	84.8	87.2	78.2	84.6	84.2
<i>75-84: Limited denominator</i>	86.6	90.5	86.7	87.0	90.3	80.6	87.3	86.9
<i>85+: Limited denominator</i>	73.8	76.7	73.7	73.0	76.0	69.1	73.8	73.7
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>0-40: Full denominator</i>	13.9	14.4	14.1	14.1	14.2	13.7	14.6	14.3
<i>41-64: Full denominator</i>	150.7	155.7	152.2	152.6	152.1	144.5	153.5	150.3
<i>65-74: Full denominator</i>	233.1	243.3	234.4	235.3	241.0	219.4	235.2	234.1
<i>75-84: Full denominator</i>	291.1	302.1	291.3	291.7	300.7	274.0	292.8	291.7
<i>85+: Full denominator</i>	352.3	363.9	352.6	351.0	361.1	335.3	354.0	352.5

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
0-40: HCTZ-containing products	0.947	0.948	0.947	0.945	0.945	0.944	0.942	0.942
41-64: HCTZ-containing products	0.948	0.947	0.947	0.946	0.946	0.945	0.944	0.943
65-74: HCTZ-containing products	0.938	0.938	0.937	0.936	0.936	0.934	0.933	0.933
75-84: HCTZ-containing products	0.922	0.923	0.921	0.921	0.921	0.919	0.918	0.918
85+: HCTZ-containing products	0.899	0.899	0.899	0.897	0.896	0.895	0.893	0.893
HCTZ single ingredient numerator, limited denominator								
0-40: HCTZ single ingredient	0.393	0.396	0.394	0.391	0.395	0.396	0.395	0.395
41-64: HCTZ single ingredient	0.352	0.352	0.352	0.350	0.352	0.351	0.352	0.351
65-74: HCTZ single ingredient	0.368	0.368	0.368	0.367	0.368	0.368	0.368	0.369
75-84: HCTZ single ingredient	0.384	0.384	0.383	0.382	0.385	0.385	0.383	0.385
85+: HCTZ single ingredient	0.420	0.418	0.419	0.420	0.419	0.420	0.418	0.419
HCTZ combination products numerator, limited denominator								
0-40: HCTZ combination products	0.559	0.557	0.558	0.559	0.555	0.553	0.552	0.552
41-64: HCTZ combination products	0.601	0.600	0.600	0.601	0.599	0.598	0.597	0.596
65-74: HCTZ combination products	0.574	0.573	0.573	0.573	0.571	0.570	0.570	0.568
75-84: HCTZ combination products	0.542	0.543	0.541	0.543	0.540	0.539	0.539	0.537
85+: HCTZ combination products	0.483	0.484	0.483	0.481	0.481	0.479	0.478	0.477

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40: HCTZ-containing products</i>	0.294	0.291	0.290	0.288	0.286	0.286	0.287	0.286
<i>41-64: HCTZ-containing products</i>	0.367	0.367	0.366	0.366	0.364	0.361	0.363	0.362
<i>65-74: HCTZ-containing products</i>	0.338	0.339	0.337	0.337	0.339	0.333	0.335	0.335
<i>75-84: HCTZ-containing products</i>	0.274	0.276	0.274	0.275	0.277	0.270	0.274	0.274
<i>85+: HCTZ-containing products</i>	0.188	0.190	0.188	0.187	0.189	0.184	0.186	0.187
HCTZ single ingredient numerator, limited denominator								
<i>0-40: HCTZ single ingredient</i>	0.122	0.122	0.120	0.119	0.119	0.120	0.120	0.120
<i>41-64: HCTZ single ingredient</i>	0.136	0.137	0.136	0.135	0.135	0.134	0.135	0.135
<i>65-74: HCTZ single ingredient</i>	0.132	0.133	0.132	0.132	0.133	0.131	0.132	0.133
<i>75-84: HCTZ single ingredient</i>	0.114	0.115	0.114	0.114	0.116	0.113	0.114	0.115
<i>85+: HCTZ single ingredient</i>	0.088	0.088	0.088	0.087	0.088	0.086	0.087	0.088
HCTZ combination products numerator, limited denominator								
<i>0-40: HCTZ combination products</i>	0.174	0.171	0.171	0.171	0.168	0.168	0.168	0.168
<i>41-64: HCTZ combination products</i>	0.233	0.233	0.232	0.233	0.230	0.229	0.230	0.229
<i>65-74: HCTZ combination products</i>	0.207	0.208	0.206	0.206	0.207	0.203	0.205	0.204
<i>75-84: HCTZ combination products</i>	0.161	0.163	0.161	0.162	0.162	0.158	0.161	0.160
<i>85+: HCTZ combination products</i>	0.101	0.102	0.101	0.100	0.101	0.099	0.100	0.100



Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b><i>HCTZ-containing</i></b>								
HCTZ-containing products								
0-40	85,113	81,547	80,988	82,613	76,730	80,852	76,847	75,274
41-64	911,136	877,344	884,922	896,008	832,415	885,355	843,190	837,150
65-74	1,085,523	1,045,435	1,095,633	1,090,849	999,364	1,103,946	1,027,998	1,025,504
75-84	595,401	574,595	604,274	599,835	550,183	611,030	566,545	566,736
85+	202,203	194,498	203,040	200,569	184,373	200,926	187,724	186,435
HCTZ single ingredient/monotherapy								
0-40	36,033	34,432	34,508	35,031	32,656	34,425	32,841	32,070
41-64	342,134	330,265	333,045	338,298	315,500	333,647	319,000	317,179
65-74	431,936	417,078	431,889	433,446	401,236	436,537	412,398	412,257
75-84	251,000	242,494	252,159	252,355	234,845	255,568	240,089	241,772
85+	95,717	91,889	95,365	94,624	88,063	94,532	88,870	89,248
HCTZ combination products								
0-40	49,592	47,561	46,947	48,057	44,482	46,881	44,457	43,627
41-64	573,948	551,706	557,196	563,002	521,325	556,463	528,745	524,489
65-74	658,627	632,987	669,433	662,980	602,657	672,500	620,267	617,749
75-84	347,042	334,690	355,350	350,541	317,725	358,181	328,904	327,372
85+	107,368	103,351	108,659	106,870	97,074	107,230	99,590	97,921

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	90,473	86,741	86,229	87,942	81,693	86,211	82,087	80,415
41-64	967,218	932,325	939,855	952,239	885,595	941,960	897,992	892,097
65-74	1,165,180	1,123,052	1,174,784	1,170,528	1,074,500	1,185,094	1,105,488	1,104,404
75-84	649,790	627,513	657,944	653,922	601,082	666,469	619,390	620,242
85+	227,082	218,262	227,177	225,053	207,412	225,553	211,378	210,294
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	298,512	286,971	288,285	293,996	274,957	291,379	280,526	276,844
41-64	2,515,585	2,431,279	2,451,763	2,484,258	2,327,031	2,462,900	2,366,790	2,354,076
65-74	3,240,391	3,137,810	3,241,108	3,245,332	3,037,518	3,282,964	3,115,610	3,117,878
75-84	2,180,431	2,118,392	2,183,716	2,186,160	2,059,983	2,223,467	2,112,491	2,118,348
85+	1,083,714	1,053,010	1,077,324	1,077,397	1,020,897	1,081,457	1,035,426	1,032,205
<b>Eligible members per month</b>								
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
Enrollees with at least one day of coverage								
0-40	20,554,537	20,539,482	20,492,392	20,530,339	20,537,040	20,521,946	20,492,536	20,459,807
41-64	16,472,891	16,464,304	16,435,008	16,427,009	16,412,506	16,389,533	16,363,440	16,336,530
65-74	13,768,118	13,793,818	13,846,086	13,886,594	13,925,975	13,955,228	13,970,631	13,988,947
75-84	7,421,594	7,444,393	7,472,759	7,504,037	7,531,189	7,560,024	7,577,343	7,599,191
85+	3,042,467	3,041,045	3,042,002	3,045,160	3,045,642	3,046,769	3,043,556	3,042,322

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing								
0-40: HCTZ-containing	4.1	4.0	4.0	4.0	3.7	3.9	3.7	3.7
41-64: HCTZ-containing	55.3	53.3	53.8	54.5	50.7	54.0	51.5	51.2
65-74: HCTZ-containing	78.8	75.8	79.1	78.6	71.8	79.1	73.6	73.3
75-84: HCTZ-containing	80.2	77.2	80.9	79.9	73.1	80.8	74.8	74.6
85+: HCTZ-containing	66.5	64.0	66.7	65.9	60.5	65.9	61.7	61.3
HCTZ single ingredient								
0-40: HCTZ single ingredient	1.8	1.7	1.7	1.7	1.6	1.7	1.6	1.6
41-64: HCTZ single ingredient	20.8	20.1	20.3	20.6	19.2	20.4	19.5	19.4
65-74: HCTZ single ingredient	31.4	30.2	31.2	31.2	28.8	31.3	29.5	29.5
75-84: HCTZ single ingredient	33.8	32.6	33.7	33.6	31.2	33.8	31.7	31.8
85+: HCTZ single ingredient	31.5	30.2	31.3	31.1	28.9	31.0	29.2	29.3
HCTZ combination								
0-40: HCTZ combination	2.4	2.3	2.3	2.3	2.2	2.3	2.2	2.1
41-64: HCTZ combination	34.8	33.5	33.9	34.3	31.8	34.0	32.3	32.1
65-74: HCTZ combination	47.8	45.9	48.3	47.7	43.3	48.2	44.4	44.2
75-84: HCTZ combination	46.8	45.0	47.6	46.7	42.2	47.4	43.4	43.1
85+: HCTZ combination	35.3	34.0	35.7	35.1	31.9	35.2	32.7	32.2

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>0-40: Limited denominator</i>	4.4	4.2	4.2	4.3	4.0	4.2	4.0	3.9
<i>41-64: Limited denominator</i>	58.7	56.6	57.2	58.0	54.0	57.5	54.9	54.6
<i>65-74: Limited denominator</i>	84.6	81.4	84.8	84.3	77.2	84.9	79.1	78.9
<i>75-84: Limited denominator</i>	87.6	84.3	88.0	87.1	79.8	88.2	81.7	81.6
<i>85+: Limited denominator</i>	74.6	71.8	74.7	73.9	68.1	74.0	69.5	69.1
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>0-40: Full denominator</i>	14.5	14.0	14.1	14.3	13.4	14.2	13.7	13.5
<i>41-64: Full denominator</i>	152.7	147.7	149.2	151.2	141.8	150.3	144.6	144.1
<i>65-74: Full denominator</i>	235.4	227.5	234.1	233.7	218.1	235.2	223.0	222.9
<i>75-84: Full denominator</i>	293.8	284.6	292.2	291.3	273.5	294.1	278.8	278.8
<i>85+: Full denominator</i>	356.2	346.3	354.1	353.8	335.2	355.0	340.2	339.3

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
0-40: HCTZ-containing products	0.941	0.940	0.939	0.939	0.939	0.938	0.936	0.936
41-64: HCTZ-containing products	0.942	0.941	0.942	0.941	0.940	0.940	0.939	0.938
65-74: HCTZ-containing products	0.932	0.931	0.933	0.932	0.930	0.932	0.930	0.929
75-84: HCTZ-containing products	0.916	0.916	0.918	0.917	0.915	0.917	0.915	0.914
85+: HCTZ-containing products	0.890	0.891	0.894	0.891	0.889	0.891	0.888	0.887
HCTZ single ingredient numerator, limited denominator								
0-40: HCTZ single ingredient	0.398	0.397	0.400	0.398	0.400	0.399	0.400	0.399
41-64: HCTZ single ingredient	0.354	0.354	0.354	0.355	0.356	0.354	0.355	0.356
65-74: HCTZ single ingredient	0.371	0.371	0.368	0.370	0.373	0.368	0.373	0.373
75-84: HCTZ single ingredient	0.386	0.386	0.383	0.386	0.391	0.383	0.388	0.390
85+: HCTZ single ingredient	0.422	0.421	0.420	0.420	0.425	0.419	0.420	0.424
HCTZ combination products numerator, limited denominator								
0-40: HCTZ combination products	0.548	0.548	0.544	0.546	0.545	0.544	0.542	0.543
41-64: HCTZ combination products	0.593	0.592	0.593	0.591	0.589	0.591	0.589	0.588
65-74: HCTZ combination products	0.565	0.564	0.570	0.566	0.561	0.567	0.561	0.559
75-84: HCTZ combination products	0.534	0.533	0.540	0.536	0.529	0.537	0.531	0.528
85+: HCTZ combination products	0.473	0.474	0.478	0.475	0.468	0.475	0.471	0.466

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40: HCTZ-containing products</i>	0.285	0.284	0.281	0.281	0.279	0.277	0.274	0.272
<i>41-64: HCTZ-containing products</i>	0.362	0.361	0.361	0.361	0.358	0.359	0.356	0.356
<i>65-74: HCTZ-containing products</i>	0.335	0.333	0.338	0.336	0.329	0.336	0.330	0.329
<i>75-84: HCTZ-containing products</i>	0.273	0.271	0.277	0.274	0.267	0.275	0.268	0.268
<i>85+: HCTZ-containing products</i>	0.187	0.185	0.188	0.186	0.181	0.186	0.181	0.181
HCTZ single ingredient numerator, limited denominator								
<i>0-40: HCTZ single ingredient</i>	0.121	0.120	0.120	0.119	0.119	0.118	0.117	0.116
<i>41-64: HCTZ single ingredient</i>	0.136	0.136	0.136	0.136	0.136	0.135	0.135	0.135
<i>65-74: HCTZ single ingredient</i>	0.133	0.133	0.133	0.134	0.132	0.133	0.132	0.132
<i>75-84: HCTZ single ingredient</i>	0.115	0.114	0.115	0.115	0.114	0.115	0.114	0.114
<i>85+: HCTZ single ingredient</i>	0.088	0.087	0.089	0.088	0.086	0.087	0.086	0.086
HCTZ combination products numerator, limited denominator								
<i>0-40: HCTZ combination products</i>	0.166	0.166	0.163	0.163	0.162	0.161	0.158	0.158
<i>41-64: HCTZ combination products</i>	0.228	0.227	0.227	0.227	0.224	0.226	0.223	0.223
<i>65-74: HCTZ combination products</i>	0.203	0.202	0.207	0.204	0.198	0.205	0.199	0.198
<i>75-84: HCTZ combination products</i>	0.159	0.158	0.163	0.160	0.154	0.161	0.156	0.155
<i>85+: HCTZ combination products</i>	0.099	0.098	0.101	0.099	0.095	0.099	0.096	0.095

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products								
0-40	76,160	71,152	75,779	75,469	75,255	71,001	73,289	72,045
41-64	831,086	772,814	815,883	815,593	812,811	770,805	795,273	781,363
65-74	1,086,108	963,428	1,028,684	1,059,645	1,046,247	987,693	1,057,208	1,018,001
75-84	600,473	531,358	565,744	585,289	576,601	544,735	585,229	560,539
85+	195,324	175,563	184,122	189,326	187,584	176,556	188,703	180,980
HCTZ single ingredient/monotherapy								
0-40	32,905	30,817	33,315	33,539	33,458	31,707	32,967	33,089
41-64	318,100	299,288	318,789	321,087	321,753	307,854	318,934	319,442
65-74	440,629	395,618	424,092	439,588	437,151	416,075	444,464	438,105
75-84	256,975	230,368	246,527	255,703	254,414	242,174	258,608	253,926
85+	93,049	84,550	89,470	91,757	91,713	86,962	92,637	90,245
HCTZ combination products								
0-40	43,754	40,791	42,979	42,400	42,290	39,754	40,779	39,536
41-64	518,249	478,430	502,309	499,697	496,340	467,963	481,592	467,847
65-74	651,204	572,607	609,796	625,546	614,316	576,260	617,863	584,833
75-84	346,426	303,513	322,042	332,443	324,997	305,140	329,404	309,372
85+	103,160	91,777	95,516	98,423	96,710	90,403	96,895	91,560

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	81,428	75,967	81,190	80,819	80,619	76,267	78,644	77,342
41-64	885,687	824,101	870,716	870,857	868,796	824,134	850,366	836,420
65-74	1,167,758	1,037,790	1,108,871	1,141,407	1,128,638	1,065,561	1,140,227	1,099,175
75-84	656,369	581,703	620,105	641,021	632,341	597,658	641,148	615,319
85+	219,529	197,983	207,840	213,301	211,609	199,367	212,559	204,579
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	280,545	264,484	282,826	282,003	281,947	269,156	276,754	274,708
41-64	2,343,931	2,197,309	2,319,337	2,321,252	2,318,982	2,210,033	2,279,035	2,250,432
65-74	3,267,301	2,964,162	3,156,562	3,233,174	3,212,265	3,059,519	3,243,702	3,159,789
75-84	2,211,205	2,011,993	2,135,147	2,187,193	2,173,360	2,075,458	2,199,563	2,138,744
85+	1,064,262	983,346	1,029,469	1,045,387	1,042,693	998,660	1,047,629	1,022,926
<b>Eligible members per month</b>								
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
Enrollees with at least one day of coverage								
0-40	20,120,535	20,050,040	20,031,259	19,973,728	19,940,484	19,870,826	19,836,309	19,779,142
41-64	16,115,662	16,060,556	16,046,795	15,990,192	15,948,964	15,908,165	15,886,180	15,854,399
65-74	14,216,654	14,242,160	14,280,817	14,297,933	14,316,594	14,350,724	14,429,631	14,479,156
75-84	7,668,012	7,679,134	7,702,202	7,710,499	7,722,139	7,739,132	7,772,375	7,799,933
85+	3,047,688	3,039,679	3,039,728	3,032,447	3,030,563	3,029,868	3,035,178	3,041,844



Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing								
0-40: HCTZ-containing	3.8	3.5	3.8	3.8	3.8	3.6	3.7	3.6
41-64: HCTZ-containing	51.6	48.1	50.8	51.0	51.0	48.5	50.1	49.3
65-74: HCTZ-containing	76.4	67.6	72.0	74.1	73.1	68.8	73.3	70.3
75-84: HCTZ-containing	78.3	69.2	73.5	75.9	74.7	70.4	75.3	71.9
85+: HCTZ-containing	64.1	57.8	60.6	62.4	61.9	58.3	62.2	59.5
HCTZ single ingredient								
0-40: HCTZ single ingredient	1.6	1.5	1.7	1.7	1.7	1.6	1.7	1.7
41-64: HCTZ single ingredient	19.7	18.6	19.9	20.1	20.2	19.4	20.1	20.1
65-74: HCTZ single ingredient	31.0	27.8	29.7	30.7	30.5	29.0	30.8	30.3
75-84: HCTZ single ingredient	33.5	30.0	32.0	33.2	32.9	31.3	33.3	32.6
85+: HCTZ single ingredient	30.5	27.8	29.4	30.3	30.3	28.7	30.5	29.7
HCTZ combination								
0-40: HCTZ combination	2.2	2.0	2.1	2.1	2.1	2.0	2.1	2.0
41-64: HCTZ combination	32.2	29.8	31.3	31.3	31.1	29.4	30.3	29.5
65-74: HCTZ combination	45.8	40.2	42.7	43.8	42.9	40.2	42.8	40.4
75-84: HCTZ combination	45.2	39.5	41.8	43.1	42.1	39.4	42.4	39.7
85+: HCTZ combination	33.8	30.2	31.4	32.5	31.9	29.8	31.9	30.1

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>0-40: Limited denominator</i>	4.0	3.8	4.1	4.0	4.0	3.8	4.0	3.9
<i>41-64: Limited denominator</i>	55.0	51.3	54.3	54.5	54.5	51.8	53.5	52.8
<i>65-74: Limited denominator</i>	82.1	72.9	77.6	79.8	78.8	74.3	79.0	75.9
<i>75-84: Limited denominator</i>	85.6	75.8	80.5	83.1	81.9	77.2	82.5	78.9
<i>85+: Limited denominator</i>	72.0	65.1	68.4	70.3	69.8	65.8	70.0	67.3
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>0-40: Full denominator</i>	13.9	13.2	14.1	14.1	14.1	13.5	14.0	13.9
<i>41-64: Full denominator</i>	145.4	136.8	144.5	145.2	145.4	138.9	143.5	141.9
<i>65-74: Full denominator</i>	229.8	208.1	221.0	226.1	224.4	213.2	224.8	218.2
<i>75-84: Full denominator</i>	288.4	262.0	277.2	283.7	281.4	268.2	283.0	274.2
<i>85+: Full denominator</i>	349.2	323.5	338.7	344.7	344.1	329.6	345.2	336.3

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
0-40: HCTZ-containing products	0.935	0.937	0.933	0.934	0.933	0.931	0.932	0.932
41-64: HCTZ-containing products	0.938	0.938	0.937	0.937	0.936	0.935	0.935	0.934
65-74: HCTZ-containing products	0.930	0.928	0.928	0.928	0.927	0.927	0.927	0.926
75-84: HCTZ-containing products	0.915	0.913	0.912	0.913	0.912	0.911	0.913	0.911
85+: HCTZ-containing products	0.890	0.887	0.886	0.888	0.886	0.886	0.888	0.885
HCTZ single ingredient numerator, limited denominator								
0-40: HCTZ single ingredient	0.404	0.406	0.410	0.415	0.415	0.416	0.419	0.428
41-64: HCTZ single ingredient	0.359	0.363	0.366	0.369	0.370	0.374	0.375	0.382
65-74: HCTZ single ingredient	0.377	0.381	0.382	0.385	0.387	0.390	0.390	0.399
75-84: HCTZ single ingredient	0.392	0.396	0.398	0.399	0.402	0.405	0.403	0.413
85+: HCTZ single ingredient	0.424	0.427	0.430	0.430	0.433	0.436	0.436	0.441
HCTZ combination products numerator, limited denominator								
0-40: HCTZ combination products	0.537	0.537	0.529	0.525	0.525	0.521	0.519	0.511
41-64: HCTZ combination products	0.585	0.581	0.577	0.574	0.571	0.568	0.566	0.559
65-74: HCTZ combination products	0.558	0.552	0.550	0.548	0.544	0.541	0.542	0.532
75-84: HCTZ combination products	0.528	0.522	0.519	0.519	0.514	0.511	0.514	0.503
85+: HCTZ combination products	0.470	0.464	0.460	0.461	0.457	0.453	0.456	0.448

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40: HCTZ-containing products</i>	0.271	0.269	0.268	0.268	0.267	0.264	0.265	0.262
<i>41-64: HCTZ-containing products</i>	0.355	0.352	0.352	0.351	0.351	0.349	0.349	0.347
<i>65-74: HCTZ-containing products</i>	0.332	0.325	0.326	0.328	0.326	0.323	0.326	0.322
<i>75-84: HCTZ-containing products</i>	0.272	0.264	0.265	0.268	0.265	0.262	0.266	0.262
<i>85+: HCTZ-containing products</i>	0.184	0.179	0.179	0.181	0.180	0.177	0.180	0.177
HCTZ single ingredient numerator, limited denominator								
<i>0-40: HCTZ single ingredient</i>	0.117	0.117	0.118	0.119	0.119	0.118	0.119	0.120
<i>41-64: HCTZ single ingredient</i>	0.136	0.136	0.137	0.138	0.139	0.139	0.140	0.142
<i>65-74: HCTZ single ingredient</i>	0.135	0.133	0.134	0.136	0.136	0.136	0.137	0.139
<i>75-84: HCTZ single ingredient</i>	0.116	0.114	0.115	0.117	0.117	0.117	0.118	0.119
<i>85+: HCTZ single ingredient</i>	0.087	0.086	0.087	0.088	0.088	0.087	0.088	0.088
HCTZ combination products numerator, limited denominator								
<i>0-40: HCTZ combination products</i>	0.156	0.154	0.152	0.150	0.150	0.148	0.147	0.144
<i>41-64: HCTZ combination products</i>	0.221	0.218	0.217	0.215	0.214	0.212	0.211	0.208
<i>65-74: HCTZ combination products</i>	0.199	0.193	0.193	0.193	0.191	0.188	0.190	0.185
<i>75-84: HCTZ combination products</i>	0.157	0.151	0.151	0.152	0.150	0.147	0.150	0.145
<i>85+: HCTZ combination products</i>	0.097	0.093	0.093	0.094	0.093	0.091	0.092	0.090

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b><i>HCTZ-containing</i></b>								
HCTZ-containing products								
0-40	68,910	71,559	67,060	65,762	70,635	66,832	74,156	66,845
41-64	751,815	782,607	729,422	734,935	757,875	712,701	795,400	720,905
65-74	981,728	1,043,430	957,517	1,029,086	1,054,062	955,576	1,115,409	980,387
75-84	541,804	576,734	527,202	570,394	578,573	524,844	612,196	537,281
85+	175,055	184,690	169,756	180,712	184,168	168,148	189,906	172,029
HCTZ single ingredient/monotherapy								
0-40	32,126	34,458	33,094	33,252	36,245	34,328	38,180	34,600
41-64	315,819	343,807	331,209	343,704	358,069	338,023	377,490	342,228
65-74	435,391	481,863	457,660	505,132	520,703	474,166	552,308	484,483
75-84	252,294	277,659	262,861	290,949	298,092	271,968	315,832	276,526
85+	89,212	96,713	91,942	99,817	102,668	94,377	106,091	96,248
HCTZ combination products								
0-40	37,374	37,911	34,715	33,164	35,069	33,058	36,600	32,713
41-64	442,646	448,105	406,989	399,251	407,465	380,692	425,178	384,235
65-74	551,538	568,616	505,842	530,652	540,111	486,743	569,847	501,253
75-84	292,297	302,695	267,462	282,959	283,905	255,588	299,824	263,580
85+	86,721	89,167	78,791	82,046	82,520	74,601	84,789	76,542

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	74,058	77,007	72,260	70,844	76,196	72,095	79,959	72,216
41-64	804,993	838,566	781,872	788,957	813,442	765,743	854,374	774,646
65-74	1,060,125	1,127,228	1,035,756	1,112,686	1,140,168	1,035,225	1,206,135	1,060,937
75-84	594,840	632,584	579,466	626,267	636,035	578,249	672,476	590,219
85+	197,626	208,317	192,213	204,112	208,116	190,652	214,282	194,448
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	266,026	278,344	262,745	261,533	280,128	267,058	294,478	265,120
41-64	2,179,812	2,268,065	2,130,555	2,159,720	2,218,020	2,106,007	2,322,122	2,124,750
65-74	3,070,478	3,242,046	3,015,555	3,213,510	3,276,595	3,025,468	3,449,112	3,075,257
75-84	2,084,442	2,192,496	2,041,075	2,175,936	2,204,248	2,043,904	2,310,437	2,064,416
85+	999,017	1,039,714	980,468	1,025,499	1,040,248	976,655	1,066,453	975,734
<b>Eligible members per month</b>								
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
Enrollees with at least one day of coverage								
0-40	19,753,352	19,726,063	19,688,073	19,655,630	19,720,084	19,631,393	19,599,316	19,476,737
41-64	15,833,940	15,802,941	15,774,471	15,745,009	15,678,482	15,605,234	15,579,282	15,506,949
65-74	14,523,941	14,571,549	14,602,413	14,625,618	14,916,876	14,918,585	14,946,847	14,975,438
75-84	7,818,587	7,842,206	7,857,931	7,879,052	7,979,274	7,978,487	7,995,164	8,005,406
85+	3,047,599	3,054,573	3,054,603	3,055,866	3,081,540	3,074,714	3,074,853	3,070,850

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b><i>HCTZ-containing</i></b>								
HCTZ-containing								
0-40: HCTZ-containing	3.5	3.6	3.4	3.3	3.6	3.4	3.8	3.4
41-64: HCTZ-containing	47.5	49.5	46.2	46.7	48.3	45.7	51.1	46.5
65-74: HCTZ-containing	67.6	71.6	65.6	70.4	70.7	64.1	74.6	65.5
75-84: HCTZ-containing	69.3	73.5	67.1	72.4	72.5	65.8	76.6	67.1
85+: HCTZ-containing	57.4	60.5	55.6	59.1	59.8	54.7	61.8	56.0
HCTZ single ingredient								
0-40: HCTZ single ingredient	1.6	1.7	1.7	1.7	1.8	1.7	1.9	1.8
41-64: HCTZ single ingredient	19.9	21.8	21.0	21.8	22.8	21.7	24.2	22.1
65-74: HCTZ single ingredient	30.0	33.1	31.3	34.5	34.9	31.8	37.0	32.4
75-84: HCTZ single ingredient	32.3	35.4	33.5	36.9	37.4	34.1	39.5	34.5
85+: HCTZ single ingredient	29.3	31.7	30.1	32.7	33.3	30.7	34.5	31.3
HCTZ combination								
0-40: HCTZ combination	1.9	1.9	1.8	1.7	1.8	1.7	1.9	1.7
41-64: HCTZ combination	28.0	28.4	25.8	25.4	26.0	24.4	27.3	24.8
65-74: HCTZ combination	38.0	39.0	34.6	36.3	36.2	32.6	38.1	33.5
75-84: HCTZ combination	37.4	38.6	34.0	35.9	35.6	32.0	37.5	32.9
85+: HCTZ combination	28.5	29.2	25.8	26.8	26.8	24.3	27.6	24.9

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>0-40: Limited denominator</i>	3.7	3.9	3.7	3.6	3.9	3.7	4.1	3.7
<i>41-64: Limited denominator</i>	50.8	53.1	49.6	50.1	51.9	49.1	54.8	50.0
<i>65-74: Limited denominator</i>	73.0	77.4	70.9	76.1	76.4	69.4	80.7	70.8
<i>75-84: Limited denominator</i>	76.1	80.7	73.7	79.5	79.7	72.5	84.1	73.7
<i>85+: Limited denominator</i>	64.8	68.2	62.9	66.8	67.5	62.0	69.7	63.3
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>0-40: Full denominator</i>	13.5	14.1	13.3	13.3	14.2	13.6	15.0	13.6
<i>41-64: Full denominator</i>	137.7	143.5	135.1	137.2	141.5	135.0	149.1	137.0
<i>65-74: Full denominator</i>	211.4	222.5	206.5	219.7	219.7	202.8	230.8	205.4
<i>75-84: Full denominator</i>	266.6	279.6	259.7	276.2	276.2	256.2	289.0	257.9
<i>85+: Full denominator</i>	327.8	340.4	321.0	335.6	337.6	317.6	346.8	317.7



Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
0-40: HCTZ-containing products	0.930	0.929	0.928	0.928	0.927	0.927	0.927	0.926
41-64: HCTZ-containing products	0.934	0.933	0.933	0.932	0.932	0.931	0.931	0.931
65-74: HCTZ-containing products	0.926	0.926	0.924	0.925	0.924	0.923	0.925	0.924
75-84: HCTZ-containing products	0.911	0.912	0.910	0.911	0.910	0.908	0.910	0.910
85+: HCTZ-containing products	0.886	0.887	0.883	0.885	0.885	0.882	0.886	0.885
HCTZ single ingredient numerator, limited denominator								
0-40: HCTZ single ingredient	0.434	0.447	0.458	0.469	0.476	0.476	0.477	0.479
41-64: HCTZ single ingredient	0.392	0.410	0.424	0.436	0.440	0.441	0.442	0.442
65-74: HCTZ single ingredient	0.411	0.427	0.442	0.454	0.457	0.458	0.458	0.457
75-84: HCTZ single ingredient	0.424	0.439	0.454	0.465	0.469	0.470	0.470	0.469
85+: HCTZ single ingredient	0.451	0.464	0.478	0.489	0.493	0.495	0.495	0.495
HCTZ combination products numerator, limited denominator								
0-40: HCTZ combination products	0.505	0.492	0.480	0.468	0.460	0.459	0.458	0.453
41-64: HCTZ combination products	0.550	0.534	0.521	0.506	0.501	0.497	0.498	0.496
65-74: HCTZ combination products	0.520	0.504	0.488	0.477	0.474	0.470	0.472	0.472
75-84: HCTZ combination products	0.491	0.479	0.462	0.452	0.446	0.442	0.446	0.447
85+: HCTZ combination products	0.439	0.428	0.410	0.402	0.397	0.391	0.396	0.394

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40: HCTZ-containing products</i>	0.259	0.257	0.255	0.251	0.252	0.250	0.252	0.252
<i>41-64: HCTZ-containing products</i>	0.345	0.345	0.342	0.340	0.342	0.338	0.343	0.339
<i>65-74: HCTZ-containing products</i>	0.320	0.322	0.318	0.320	0.322	0.316	0.323	0.319
<i>75-84: HCTZ-containing products</i>	0.260	0.263	0.258	0.262	0.262	0.257	0.265	0.260
<i>85+: HCTZ-containing products</i>	0.175	0.178	0.173	0.176	0.177	0.172	0.178	0.176
HCTZ single ingredient numerator, limited denominator								
<i>0-40: HCTZ single ingredient</i>	0.121	0.124	0.126	0.127	0.129	0.129	0.130	0.131
<i>41-64: HCTZ single ingredient</i>	0.145	0.152	0.155	0.159	0.161	0.161	0.163	0.161
<i>65-74: HCTZ single ingredient</i>	0.142	0.149	0.152	0.157	0.159	0.157	0.160	0.158
<i>75-84: HCTZ single ingredient</i>	0.121	0.127	0.129	0.134	0.135	0.133	0.137	0.134
<i>85+: HCTZ single ingredient</i>	0.089	0.093	0.094	0.097	0.099	0.097	0.099	0.099
HCTZ combination products numerator, limited denominator								
<i>0-40: HCTZ combination products</i>	0.140	0.136	0.132	0.127	0.125	0.124	0.124	0.123
<i>41-64: HCTZ combination products</i>	0.203	0.198	0.191	0.185	0.184	0.181	0.183	0.181
<i>65-74: HCTZ combination products</i>	0.180	0.175	0.168	0.165	0.165	0.161	0.165	0.163
<i>75-84: HCTZ combination products</i>	0.140	0.138	0.131	0.130	0.129	0.125	0.130	0.128
<i>85+: HCTZ combination products</i>	0.087	0.086	0.080	0.080	0.079	0.076	0.080	0.078

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
0-40	64,721	66,501	65,704	63,670	61,913	61,928	58,760	60,843
41-64	702,533	728,077	711,853	697,040	687,786	686,779	654,428	686,588
65-74	965,388	1,044,600	1,005,788	997,460	994,539	999,954	962,291	1,034,800
75-84	531,710	575,767	551,451	548,302	546,589	547,071	528,089	566,472
85+	168,617	180,077	174,486	171,578	170,891	170,814	164,049	173,084
HCTZ single ingredient/monotherapy								
0-40	33,292	34,756	34,698	33,414	32,302	32,090	30,288	31,172
41-64	332,956	347,281	340,529	332,394	325,713	323,183	306,852	320,869
65-74	476,103	517,112	496,247	490,486	485,824	484,939	465,971	499,550
75-84	274,393	296,360	283,873	280,742	278,052	277,419	266,992	285,111
85+	94,187	100,142	97,435	95,469	94,353	93,869	90,208	94,686
HCTZ combination products								
0-40	31,827	32,257	31,578	30,721	30,022	30,226	28,770	30,014
41-64	374,560	386,422	376,992	369,624	366,227	367,573	351,044	369,369
65-74	494,133	533,107	514,907	511,770	513,295	519,570	500,351	539,723
75-84	259,794	282,316	270,249	270,046	270,879	271,922	263,139	283,588
85+	75,139	80,768	77,882	76,843	77,285	77,652	74,455	79,086

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	69,999	71,928	70,963	68,806	66,968	67,038	63,655	65,863
41-64	755,541	782,790	765,660	749,745	740,188	739,239	704,799	739,890
65-74	1,045,316	1,130,417	1,089,037	1,079,789	1,076,966	1,082,687	1,042,827	1,121,351
75-84	584,895	632,458	606,104	602,424	600,274	601,165	581,075	622,707
85+	190,572	202,938	196,948	193,282	192,429	192,573	184,849	194,815
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	259,868	268,405	265,510	259,925	256,496	258,925	248,407	259,785
41-64	2,076,499	2,152,490	2,110,292	2,071,770	2,052,571	2,055,053	1,970,099	2,064,882
65-74	3,044,420	3,259,944	3,161,303	3,145,284	3,150,628	3,171,116	3,074,009	3,276,159
75-84	2,048,259	2,188,881	2,116,935	2,109,879	2,109,129	2,115,885	2,053,781	2,178,054
85+	959,382	1,005,457	983,695	971,604	968,813	971,796	938,852	973,156
<b>Eligible members per month</b>								
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
Enrollees with at least one day of coverage								
0-40	19,370,973	19,282,828	19,143,240	19,043,005	18,810,702	18,750,337	18,723,916	18,699,595
41-64	15,453,559	15,406,725	15,350,343	15,300,386	15,194,333	15,142,842	15,117,826	15,093,930
65-74	15,004,010	15,035,053	15,109,331	15,138,724	15,176,384	15,208,059	15,233,909	15,251,594
75-84	8,011,498	8,024,429	8,050,600	8,062,528	8,074,546	8,087,069	8,095,369	8,104,545
85+	3,056,207	3,051,147	3,056,149	3,056,211	3,055,238	3,054,357	3,048,698	3,039,371

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing								
0-40: HCTZ-containing	3.3	3.4	3.4	3.3	3.3	3.3	3.1	3.3
41-64: HCTZ-containing	45.5	47.3	46.4	45.6	45.3	45.4	43.3	45.5
65-74: HCTZ-containing	64.3	69.5	66.6	65.9	65.5	65.8	63.2	67.8
75-84: HCTZ-containing	66.4	71.8	68.5	68.0	67.7	67.6	65.2	69.9
85+: HCTZ-containing	55.2	59.0	57.1	56.1	55.9	55.9	53.8	56.9
HCTZ single ingredient								
0-40: HCTZ single ingredient	1.7	1.8	1.8	1.8	1.7	1.7	1.6	1.7
41-64: HCTZ single ingredient	21.5	22.5	22.2	21.7	21.4	21.3	20.3	21.3
65-74: HCTZ single ingredient	31.7	34.4	32.8	32.4	32.0	31.9	30.6	32.8
75-84: HCTZ single ingredient	34.2	36.9	35.3	34.8	34.4	34.3	33.0	35.2
85+: HCTZ single ingredient	30.8	32.8	31.9	31.2	30.9	30.7	29.6	31.2
HCTZ combination								
0-40: HCTZ combination	1.6	1.7	1.6	1.6	1.6	1.6	1.5	1.6
41-64: HCTZ combination	24.2	25.1	24.6	24.2	24.1	24.3	23.2	24.5
65-74: HCTZ combination	32.9	35.5	34.1	33.8	33.8	34.2	32.8	35.4
75-84: HCTZ combination	32.4	35.2	33.6	33.5	33.5	33.6	32.5	35.0
85+: HCTZ combination	24.6	26.5	25.5	25.1	25.3	25.4	24.4	26.0

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>0-40: Limited denominator</i>	3.6	3.7	3.7	3.6	3.6	3.6	3.4	3.5
<i>41-64: Limited denominator</i>	48.9	50.8	49.9	49.0	48.7	48.8	46.6	49.0
<i>65-74: Limited denominator</i>	69.7	75.2	72.1	71.3	71.0	71.2	68.5	73.5
<i>75-84: Limited denominator</i>	73.0	78.8	75.3	74.7	74.3	74.3	71.8	76.8
<i>85+: Limited denominator</i>	62.4	66.5	64.4	63.2	63.0	63.0	60.6	64.1
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>0-40: Full denominator</i>	13.4	13.9	13.9	13.6	13.6	13.8	13.3	13.9
<i>41-64: Full denominator</i>	134.4	139.7	137.5	135.4	135.1	135.7	130.3	136.8
<i>65-74: Full denominator</i>	202.9	216.8	209.2	207.8	207.6	208.5	201.8	214.8
<i>75-84: Full denominator</i>	255.7	272.8	263.0	261.7	261.2	261.6	253.7	268.7
<i>85+: Full denominator</i>	313.9	329.5	321.9	317.9	317.1	318.2	308.0	320.2

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
0-40: HCTZ-containing products	0.925	0.925	0.926	0.925	0.925	0.924	0.923	0.924
41-64: HCTZ-containing products	0.930	0.930	0.930	0.930	0.929	0.929	0.929	0.928
65-74: HCTZ-containing products	0.924	0.924	0.924	0.924	0.923	0.924	0.923	0.923
75-84: HCTZ-containing products	0.909	0.910	0.910	0.910	0.911	0.910	0.909	0.910
85+: HCTZ-containing products	0.885	0.887	0.886	0.888	0.888	0.887	0.887	0.888
HCTZ single ingredient numerator, limited denominator								
0-40: HCTZ single ingredient	0.476	0.483	0.489	0.486	0.482	0.479	0.476	0.473
41-64: HCTZ single ingredient	0.441	0.444	0.445	0.443	0.440	0.437	0.435	0.434
65-74: HCTZ single ingredient	0.455	0.457	0.456	0.454	0.451	0.448	0.447	0.445
75-84: HCTZ single ingredient	0.469	0.469	0.468	0.466	0.463	0.461	0.459	0.458
85+: HCTZ single ingredient	0.494	0.493	0.495	0.494	0.490	0.487	0.488	0.486
HCTZ combination products numerator, limited denominator								
0-40: HCTZ combination products	0.455	0.448	0.445	0.446	0.448	0.451	0.452	0.456
41-64: HCTZ combination products	0.496	0.494	0.492	0.493	0.495	0.497	0.498	0.499
65-74: HCTZ combination products	0.473	0.472	0.473	0.474	0.477	0.480	0.480	0.481
75-84: HCTZ combination products	0.444	0.446	0.446	0.448	0.451	0.452	0.453	0.455
85+: HCTZ combination products	0.394	0.398	0.395	0.398	0.402	0.403	0.403	0.406

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40: HCTZ-containing products</i>	0.249	0.248	0.247	0.245	0.241	0.239	0.237	0.234
<i>41-64: HCTZ-containing products</i>	0.338	0.338	0.337	0.336	0.335	0.334	0.332	0.333
<i>65-74: HCTZ-containing products</i>	0.317	0.320	0.318	0.317	0.316	0.315	0.313	0.316
<i>75-84: HCTZ-containing products</i>	0.260	0.263	0.260	0.260	0.259	0.259	0.257	0.260
<i>85+: HCTZ-containing products</i>	0.176	0.179	0.177	0.177	0.176	0.176	0.175	0.178
HCTZ single ingredient numerator, limited denominator								
<i>0-40: HCTZ single ingredient</i>	0.128	0.129	0.131	0.129	0.126	0.124	0.122	0.120
<i>41-64: HCTZ single ingredient</i>	0.160	0.161	0.161	0.160	0.159	0.157	0.156	0.155
<i>65-74: HCTZ single ingredient</i>	0.156	0.159	0.157	0.156	0.154	0.153	0.152	0.152
<i>75-84: HCTZ single ingredient</i>	0.134	0.135	0.134	0.133	0.132	0.131	0.130	0.131
<i>85+: HCTZ single ingredient</i>	0.098	0.100	0.099	0.098	0.097	0.097	0.096	0.097
HCTZ combination products numerator, limited denominator								
<i>0-40: HCTZ combination products</i>	0.122	0.120	0.119	0.118	0.117	0.117	0.116	0.116
<i>41-64: HCTZ combination products</i>	0.180	0.180	0.179	0.178	0.178	0.179	0.178	0.179
<i>65-74: HCTZ combination products</i>	0.162	0.164	0.163	0.163	0.163	0.164	0.163	0.165
<i>75-84: HCTZ combination products</i>	0.127	0.129	0.128	0.128	0.128	0.129	0.128	0.130
<i>85+: HCTZ combination products</i>	0.078	0.080	0.079	0.079	0.080	0.080	0.079	0.081



Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month						
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21
<b><i>HCTZ-containing</i></b>							
HCTZ-containing products							
0-40	59,875	55,911	62,430	60,062	57,984	59,199	58,245
41-64	657,902	613,114	683,605	655,141	635,895	654,850	640,422
65-74	979,053	894,351	1,023,187	983,053	945,971	996,392	976,484
75-84	533,342	487,383	558,979	533,752	517,828	546,245	533,314
85+	164,266	151,158	171,151	164,585	159,594	167,121	164,328
HCTZ single ingredient/monotherapy							
0-40	30,762	28,393	31,717	30,543	29,457	30,105	29,607
41-64	306,403	284,957	317,435	304,121	294,477	303,483	296,261
65-74	473,409	431,327	492,148	472,581	455,986	478,869	469,671
75-84	269,869	245,981	280,906	268,842	261,357	274,866	268,307
85+	89,773	82,980	93,590	89,760	87,505	91,404	89,501
HCTZ combination products							
0-40	29,452	27,854	31,086	29,886	28,823	29,397	28,943
41-64	354,843	331,098	369,737	354,410	344,541	354,625	347,269
65-74	509,738	466,595	535,343	514,367	493,586	521,380	510,550
75-84	265,482	243,168	280,322	266,863	258,331	273,368	266,876
85+	75,069	68,701	78,188	75,422	72,670	76,350	75,408

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
0-40	64,879	60,625	67,840	65,191	62,873	64,256	63,188
41-64	708,821	661,257	737,647	707,104	686,513	706,983	691,581
65-74	1,061,206	970,811	1,110,165	1,067,041	1,027,602	1,081,210	1,059,732
75-84	586,483	536,820	615,666	587,834	570,817	601,314	587,045
85+	185,158	170,527	193,151	185,898	180,257	188,426	185,625
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
0-40	257,662	241,904	270,284	260,167	252,614	259,392	255,332
41-64	1,979,474	1,858,322	2,056,706	1,980,599	1,924,985	1,979,832	1,945,150
65-74	3,114,014	2,887,143	3,258,102	3,150,123	3,054,572	3,191,911	3,143,881
75-84	2,066,090	1,916,001	2,159,258	2,082,254	2,032,105	2,127,521	2,090,214
85+	930,039	871,351	967,243	936,760	919,290	954,718	940,512
<b>Eligible members per month</b>							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21
Enrollees with at least one day of coverage							
0-40	18,784,001	18,727,054	18,715,571	18,671,769	18,634,331	18,633,051	18,606,524
41-64	15,081,972	15,025,958	15,005,842	14,965,961	14,943,015	14,935,272	14,924,518
65-74	15,191,537	15,190,863	15,214,069	15,215,773	15,227,610	15,250,880	15,319,049
75-84	8,006,290	7,987,818	7,997,985	8,002,081	8,018,890	8,041,874	8,084,968
85+	2,995,026	2,973,643	2,973,088	2,970,850	2,971,963	2,975,111	2,983,833

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members						
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21
<b>HCTZ-containing</b>							
HCTZ-containing							
0-40: HCTZ-containing	3.2	3.0	3.3	3.2	3.1	3.2	3.1
41-64: HCTZ-containing	43.6	40.8	45.6	43.8	42.6	43.8	42.9
65-74: HCTZ-containing	64.4	58.9	67.3	64.6	62.1	65.3	63.7
75-84: HCTZ-containing	66.6	61.0	69.9	66.7	64.6	67.9	66.0
85+: HCTZ-containing	54.8	50.8	57.6	55.4	53.7	56.2	55.1
HCTZ single ingredient							
0-40: HCTZ single ingredient	1.6	1.5	1.7	1.6	1.6	1.6	1.6
41-64: HCTZ single ingredient	20.3	19.0	21.2	20.3	19.7	20.3	19.9
65-74: HCTZ single ingredient	31.2	28.4	32.3	31.1	29.9	31.4	30.7
75-84: HCTZ single ingredient	33.7	30.8	35.1	33.6	32.6	34.2	33.2
85+: HCTZ single ingredient	30.0	27.9	31.5	30.2	29.4	30.7	30.0
HCTZ combination							
0-40: HCTZ combination	1.6	1.5	1.7	1.6	1.5	1.6	1.6
41-64: HCTZ combination	23.5	22.0	24.6	23.7	23.1	23.7	23.3
65-74: HCTZ combination	33.6	30.7	35.2	33.8	32.4	34.2	33.3
75-84: HCTZ combination	33.2	30.4	35.0	33.3	32.2	34.0	33.0
85+: HCTZ combination	25.1	23.1	26.3	25.4	24.5	25.7	25.3

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>0-40: Limited denominator</i>	3.5	3.2	3.6	3.5	3.4	3.4	3.4
<i>41-64: Limited denominator</i>	47.0	44.0	49.2	47.2	45.9	47.3	46.3
<i>65-74: Limited denominator</i>	69.9	63.9	73.0	70.1	67.5	70.9	69.2
<i>75-84: Limited denominator</i>	73.3	67.2	77.0	73.5	71.2	74.8	72.6
<i>85+: Limited denominator</i>	61.8	57.3	65.0	62.6	60.7	63.3	62.2
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<i>0-40: Full denominator</i>	13.7	12.9	14.4	13.9	13.6	13.9	13.7
<i>41-64: Full denominator</i>	131.2	123.7	137.1	132.3	128.8	132.6	130.3
<i>65-74: Full denominator</i>	205.0	190.1	214.2	207.0	200.6	209.3	205.2
<i>75-84: Full denominator</i>	258.1	239.9	270.0	260.2	253.4	264.6	258.5
<i>85+: Full denominator</i>	310.5	293.0	325.3	315.3	309.3	320.9	315.2

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators						
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
0-40: HCTZ-containing products	0.923	0.922	0.920	0.921	0.922	0.921	0.922
41-64: HCTZ-containing products	0.928	0.927	0.927	0.927	0.926	0.926	0.926
65-74: HCTZ-containing products	0.923	0.921	0.922	0.921	0.921	0.922	0.921
75-84: HCTZ-containing products	0.909	0.908	0.908	0.908	0.907	0.908	0.908
85+: HCTZ-containing products	0.887	0.886	0.886	0.885	0.885	0.887	0.885
HCTZ single ingredient numerator, limited denominator							
0-40: HCTZ single ingredient	0.474	0.468	0.468	0.469	0.469	0.469	0.469
41-64: HCTZ single ingredient	0.432	0.431	0.430	0.430	0.429	0.429	0.428
65-74: HCTZ single ingredient	0.446	0.444	0.443	0.443	0.444	0.443	0.443
75-84: HCTZ single ingredient	0.460	0.458	0.456	0.457	0.458	0.457	0.457
85+: HCTZ single ingredient	0.485	0.487	0.485	0.483	0.485	0.485	0.482
HCTZ combination products numerator, limited denominator							
0-40: HCTZ combination products	0.454	0.459	0.458	0.458	0.458	0.457	0.458
41-64: HCTZ combination products	0.501	0.501	0.501	0.501	0.502	0.502	0.502
65-74: HCTZ combination products	0.480	0.481	0.482	0.482	0.480	0.482	0.482
75-84: HCTZ combination products	0.453	0.453	0.455	0.454	0.453	0.455	0.455
85+: HCTZ combination products	0.405	0.403	0.405	0.406	0.403	0.405	0.406

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40: HCTZ-containing products</i>	0.232	0.231	0.231	0.231	0.230	0.228	0.228
<i>41-64: HCTZ-containing products</i>	0.332	0.330	0.332	0.331	0.330	0.331	0.329
<i>65-74: HCTZ-containing products</i>	0.314	0.310	0.314	0.312	0.310	0.312	0.311
<i>75-84: HCTZ-containing products</i>	0.258	0.254	0.259	0.256	0.255	0.257	0.255
<i>85+: HCTZ-containing products</i>	0.177	0.173	0.177	0.176	0.174	0.175	0.175
HCTZ single ingredient numerator, limited denominator							
<i>0-40: HCTZ single ingredient</i>	0.119	0.117	0.117	0.117	0.117	0.116	0.116
<i>41-64: HCTZ single ingredient</i>	0.155	0.153	0.154	0.154	0.153	0.153	0.152
<i>65-74: HCTZ single ingredient</i>	0.152	0.149	0.151	0.150	0.149	0.150	0.149
<i>75-84: HCTZ single ingredient</i>	0.131	0.128	0.130	0.129	0.129	0.129	0.128
<i>85+: HCTZ single ingredient</i>	0.097	0.095	0.097	0.096	0.095	0.096	0.095
HCTZ combination products numerator, limited denominator							
<i>0-40: HCTZ combination products</i>	0.114	0.115	0.115	0.115	0.114	0.113	0.113
<i>41-64: HCTZ combination products</i>	0.179	0.178	0.180	0.179	0.179	0.179	0.179
<i>65-74: HCTZ combination products</i>	0.164	0.162	0.164	0.163	0.162	0.163	0.162
<i>75-84: HCTZ combination products</i>	0.128	0.127	0.130	0.128	0.127	0.128	0.128
<i>85+: HCTZ combination products</i>	0.081	0.079	0.081	0.081	0.079	0.080	0.080

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month							
	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b><i>HCTZ-containing</i></b>								
HCTZ-containing products								
0-40	56,784	55,140	54,486	53,237	52,410	36,375	32,775	14,958
41-64	632,856	619,834	614,451	597,886	596,318	431,714	357,969	175,209
65-74	972,138	951,724	951,333	936,543	956,907	892,527	669,961	685,088
75-84	535,297	525,057	527,652	525,348	541,394	512,183	392,552	413,923
85+	163,301	159,630	159,538	158,038	160,134	153,468	122,765	127,027
HCTZ single ingredient/monotherapy								
0-40	28,701	27,794	27,322	26,647	26,227	18,889	17,084	8,245
41-64	291,795	285,891	282,265	274,389	277,111	206,844	171,729	89,607
65-74	466,760	455,902	454,562	447,901	462,370	437,056	330,784	337,113
75-84	268,657	263,297	263,457	262,873	273,230	261,812	201,796	212,542
85+	89,207	87,103	86,508	86,075	87,426	84,889	68,276	70,375
HCTZ combination products								
0-40	28,398	27,633	27,436	26,862	26,478	17,668	15,848	6,782
41-64	344,024	336,806	335,018	326,221	322,421	226,901	187,857	86,433
65-74	508,975	499,270	500,191	491,977	498,185	459,082	341,785	350,674
75-84	268,556	263,599	266,034	264,259	270,175	252,349	192,198	203,083
85+	74,636	73,047	73,563	72,477	73,289	69,146	54,958	57,164

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	61,546	59,918	59,188	57,982	57,086	39,752	35,802	16,625
41-64	683,490	669,487	664,185	646,429	645,502	469,505	388,664	193,536
65-74	1,054,919	1,032,887	1,032,354	1,017,186	1,039,924	970,091	729,107	745,776
75-84	589,575	577,910	580,254	579,124	596,647	564,562	434,147	457,514
85+	184,038	180,044	179,955	178,139	180,667	173,283	139,020	143,891
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	250,868	246,039	243,126	241,125	238,813	169,253	152,563	77,768
41-64	1,923,416	1,886,682	1,874,616	1,839,822	1,842,528	1,398,704	1,146,093	658,468
65-74	3,135,275	3,072,612	3,081,785	3,050,004	3,115,975	2,908,482	2,224,260	2,255,079
75-84	2,096,927	2,062,549	2,074,617	2,076,470	2,130,740	2,020,061	1,580,363	1,639,017
85+	940,414	922,434	923,826	919,513	931,612	892,179	732,914	753,293
<b>Eligible members per month</b>								
	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
Enrollees with at least one day of coverage								
0-40	18,672,200	18,682,305	18,678,106	18,696,263	18,709,982	12,405,056	12,032,589	4,256,313
41-64	14,920,685	14,893,066	14,860,568	14,847,130	14,846,448	10,781,942	9,763,420	4,401,154
65-74	15,345,164	15,353,585	15,346,751	15,326,728	15,313,134	14,992,417	12,648,182	11,660,962
75-84	8,127,517	8,170,362	8,216,686	8,259,967	8,311,881	8,248,350	6,990,657	6,575,617
85+	2,989,818	2,990,043	2,989,669	2,986,248	2,984,200	2,954,442	2,566,696	2,400,900



Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>HCTZ-containing</b>								
HCTZ-containing								
0-40: HCTZ-containing	3.0	3.0	2.9	2.8	2.8	2.9	2.7	3.5
41-64: HCTZ-containing	42.4	41.6	41.3	40.3	40.2	40.0	36.7	39.8
65-74: HCTZ-containing	63.4	62.0	62.0	61.1	62.5	59.5	53.0	58.8
75-84: HCTZ-containing	65.9	64.3	64.2	63.6	65.1	62.1	56.2	62.9
85+: HCTZ-containing	54.6	53.4	53.4	52.9	53.7	51.9	47.8	52.9
HCTZ single ingredient								
0-40: HCTZ single ingredient	1.5	1.5	1.5	1.4	1.4	1.5	1.4	1.9
41-64: HCTZ single ingredient	19.6	19.2	19.0	18.5	18.7	19.2	17.6	20.4
65-74: HCTZ single ingredient	30.4	29.7	29.6	29.2	30.2	29.2	26.2	28.9
75-84: HCTZ single ingredient	33.1	32.2	32.1	31.8	32.9	31.7	28.9	32.3
85+: HCTZ single ingredient	29.8	29.1	28.9	28.8	29.3	28.7	26.6	29.3
HCTZ combination								
0-40: HCTZ combination	1.5	1.5	1.5	1.4	1.4	1.4	1.3	1.6
41-64: HCTZ combination	23.1	22.6	22.5	22.0	21.7	21.0	19.2	19.6
65-74: HCTZ combination	33.2	32.5	32.6	32.1	32.5	30.6	27.0	30.1
75-84: HCTZ combination	33.0	32.3	32.4	32.0	32.5	30.6	27.5	30.9
85+: HCTZ combination	25.0	24.4	24.6	24.3	24.6	23.4	21.4	23.8

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>0-40: Limited denominator</i>	3.3	3.2	3.2	3.1	3.1	3.2	3.0	3.9
<i>41-64: Limited denominator</i>	45.8	45.0	44.7	43.5	43.5	43.5	39.8	44.0
<i>65-74: Limited denominator</i>	68.7	67.3	67.3	66.4	67.9	64.7	57.6	64.0
<i>75-84: Limited denominator</i>	72.5	70.7	70.6	70.1	71.8	68.4	62.1	69.6
<i>85+: Limited denominator</i>	61.6	60.2	60.2	59.7	60.5	58.7	54.2	59.9
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>0-40: Full denominator</i>	13.4	13.2	13.0	12.9	12.8	13.6	12.7	18.3
<i>41-64: Full denominator</i>	128.9	126.7	126.1	123.9	124.1	129.7	117.4	149.6
<i>65-74: Full denominator</i>	204.3	200.1	200.8	199.0	203.5	194.0	175.9	193.4
<i>75-84: Full denominator</i>	258.0	252.4	252.5	251.4	256.3	244.9	226.1	249.3
<i>85+: Full denominator</i>	314.5	308.5	309.0	307.9	312.2	302.0	285.5	313.8

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators							
	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
0-40: HCTZ-containing products	0.923	0.920	0.921	0.918	0.918	0.915	0.915	0.900
41-64: HCTZ-containing products	0.926	0.926	0.925	0.925	0.924	0.920	0.921	0.905
65-74: HCTZ-containing products	0.922	0.921	0.922	0.921	0.920	0.920	0.919	0.919
75-84: HCTZ-containing products	0.908	0.909	0.909	0.907	0.907	0.907	0.904	0.905
85+: HCTZ-containing products	0.887	0.887	0.887	0.887	0.886	0.886	0.883	0.883
HCTZ single ingredient numerator, limited denominator								
0-40: HCTZ single ingredient	0.466	0.464	0.462	0.460	0.459	0.475	0.477	0.496
41-64: HCTZ single ingredient	0.427	0.427	0.425	0.424	0.429	0.441	0.442	0.463
65-74: HCTZ single ingredient	0.442	0.441	0.440	0.440	0.445	0.451	0.454	0.452
75-84: HCTZ single ingredient	0.456	0.456	0.454	0.454	0.458	0.464	0.465	0.465
85+: HCTZ single ingredient	0.485	0.484	0.481	0.483	0.484	0.490	0.491	0.489
HCTZ combination products numerator, limited denominator								
0-40: HCTZ combination products	0.461	0.461	0.464	0.463	0.464	0.444	0.443	0.408
41-64: HCTZ combination products	0.503	0.503	0.504	0.505	0.499	0.483	0.483	0.447
65-74: HCTZ combination products	0.482	0.483	0.485	0.484	0.479	0.473	0.469	0.470
75-84: HCTZ combination products	0.456	0.456	0.458	0.456	0.453	0.447	0.443	0.444
85+: HCTZ combination products	0.406	0.406	0.409	0.407	0.406	0.399	0.395	0.397

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40: HCTZ-containing products</i>	0.226	0.224	0.224	0.221	0.219	0.215	0.215	0.192
<i>41-64: HCTZ-containing products</i>	0.329	0.329	0.328	0.325	0.324	0.309	0.312	0.266
<i>65-74: HCTZ-containing products</i>	0.310	0.310	0.309	0.307	0.307	0.307	0.301	0.304
<i>75-84: HCTZ-containing products</i>	0.255	0.255	0.254	0.253	0.254	0.254	0.248	0.253
<i>85+: HCTZ-containing products</i>	0.174	0.173	0.173	0.172	0.172	0.172	0.168	0.169
HCTZ single ingredient numerator, limited denominator								
<i>0-40: HCTZ single ingredient</i>	0.114	0.113	0.112	0.111	0.110	0.112	0.112	0.106
<i>41-64: HCTZ single ingredient</i>	0.152	0.152	0.151	0.149	0.150	0.148	0.150	0.136
<i>65-74: HCTZ single ingredient</i>	0.149	0.148	0.147	0.147	0.148	0.150	0.149	0.149
<i>75-84: HCTZ single ingredient</i>	0.128	0.128	0.127	0.127	0.128	0.130	0.128	0.130
<i>85+: HCTZ single ingredient</i>	0.095	0.094	0.094	0.094	0.094	0.095	0.093	0.093
HCTZ combination products numerator, limited denominator								
<i>0-40: HCTZ combination products</i>	0.113	0.112	0.113	0.111	0.111	0.104	0.104	0.087
<i>41-64: HCTZ combination products</i>	0.179	0.179	0.179	0.177	0.175	0.162	0.164	0.131
<i>65-74: HCTZ combination products</i>	0.162	0.162	0.162	0.161	0.160	0.158	0.154	0.156
<i>75-84: HCTZ combination products</i>	0.128	0.128	0.128	0.127	0.127	0.125	0.122	0.124
<i>85+: HCTZ combination products</i>	0.079	0.079	0.080	0.079	0.079	0.078	0.075	0.076

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Patients with dispensing per month		
	Apr-22	May-22	Jun-22
<b><i>HCTZ-containing</i></b>			
HCTZ-containing products			
0-40	6,975	7,003	6,975
41-64	78,411	79,208	77,611
65-74	51,842	52,766	51,390
75-84	23,612	24,129	23,424
85+	5,855	5,895	5,696
HCTZ single ingredient/monotherapy			
0-40	3,388	3,461	3,428
41-64	35,214	35,549	34,770
65-74	24,726	25,159	24,553
75-84	11,955	12,174	11,908
85+	3,236	3,219	3,089
HCTZ combination products			
0-40	3,615	3,567	3,579
41-64	43,515	44,003	43,171
65-74	27,306	27,788	26,988
75-84	11,737	12,026	11,594
85+	2,639	2,688	2,625

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>			
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic			
0-40	7,613	7,646	7,633
41-64	84,456	85,378	83,706
65-74	56,226	57,193	55,747
75-84	25,895	26,445	25,757
85+	6,552	6,618	6,375
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive			
0-40	35,450	36,057	35,235
41-64	220,698	223,827	220,396
65-74	164,293	167,881	164,147
75-84	91,700	93,647	90,871
85+	32,767	33,386	32,665
<b>Eligible members per month</b>			
	Apr-22	May-22	Jun-22
Enrollees with at least one day of coverage			
0-40	3,663,747	3,682,008	3,691,431
41-64	2,349,473	2,359,952	2,367,067
65-74	1,399,260	1,404,139	1,409,857
75-84	666,667	670,887	675,573
85+	205,767	206,515	207,281

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Number of patients with dispensing per 1,000 eligible members		
	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>			
HCTZ-containing			
0-40: HCTZ-containing	1.9	1.9	1.9
41-64: HCTZ-containing	33.4	33.6	32.8
65-74: HCTZ-containing	37.0	37.6	36.5
75-84: HCTZ-containing	35.4	36.0	34.7
85+: HCTZ-containing	28.5	28.5	27.5
HCTZ single ingredient			
0-40: HCTZ single ingredient	0.9	0.9	0.9
41-64: HCTZ single ingredient	15.0	15.1	14.7
65-74: HCTZ single ingredient	17.7	17.9	17.4
75-84: HCTZ single ingredient	17.9	18.1	17.6
85+: HCTZ single ingredient	15.7	15.6	14.9
HCTZ combination			
0-40: HCTZ combination	1.0	1.0	1.0
41-64: HCTZ combination	18.5	18.6	18.2
65-74: HCTZ combination	19.5	19.8	19.1
75-84: HCTZ combination	17.6	17.9	17.2
85+: HCTZ combination	12.8	13.0	12.7

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Denominators</b>			
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic			
<i>0-40: Limited denominator</i>	2.1	2.1	2.1
<i>41-64: Limited denominator</i>	35.9	36.2	35.4
<i>65-74: Limited denominator</i>	40.2	40.7	39.5
<i>75-84: Limited denominator</i>	38.8	39.4	38.1
<i>85+: Limited denominator</i>	31.8	32.0	30.8
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive			
<i>0-40: Full denominator</i>	9.7	9.8	9.5
<i>41-64: Full denominator</i>	93.9	94.8	93.1
<i>65-74: Full denominator</i>	117.4	119.6	116.4
<i>75-84: Full denominator</i>	137.5	139.6	134.5
<i>85+: Full denominator</i>	159.2	161.7	157.6



Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

	Proportion of numerators / denominators		
	Apr-22	May-22	Jun-22
<b>Proportions, limited denominator</b>			
HCTZ-containing numerator, limited denominator			
0-40: HCTZ-containing products	0.916	0.916	0.914
41-64: HCTZ-containing products	0.928	0.928	0.927
65-74: HCTZ-containing products	0.922	0.923	0.922
75-84: HCTZ-containing products	0.912	0.912	0.909
85+: HCTZ-containing products	0.894	0.891	0.893
HCTZ single ingredient numerator, limited denominator			
0-40: HCTZ single ingredient	0.445	0.453	0.449
41-64: HCTZ single ingredient	0.417	0.416	0.415
65-74: HCTZ single ingredient	0.440	0.440	0.440
75-84: HCTZ single ingredient	0.462	0.460	0.462
85+: HCTZ single ingredient	0.494	0.486	0.485
HCTZ combination products numerator, limited denominator			
0-40: HCTZ combination products	0.475	0.467	0.469
41-64: HCTZ combination products	0.515	0.515	0.516
65-74: HCTZ combination products	0.486	0.486	0.484
75-84: HCTZ combination products	0.453	0.455	0.450
85+: HCTZ combination products	0.403	0.406	0.412

Table 2b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month

<b>Proportions, full denominator</b>			
HCTZ-containing numerator, limited denominator			
<i>0-40: HCTZ-containing products</i>	0.197	0.194	0.198
<i>41-64: HCTZ-containing products</i>	0.355	0.354	0.352
<i>65-74: HCTZ-containing products</i>	0.316	0.314	0.313
<i>75-84: HCTZ-containing products</i>	0.257	0.258	0.258
<i>85+: HCTZ-containing products</i>	0.179	0.177	0.174
HCTZ single ingredient numerator, limited denominator			
<i>0-40: HCTZ single ingredient</i>	0.096	0.096	0.097
<i>41-64: HCTZ single ingredient</i>	0.160	0.159	0.158
<i>65-74: HCTZ single ingredient</i>	0.150	0.150	0.150
<i>75-84: HCTZ single ingredient</i>	0.130	0.130	0.131
<i>85+: HCTZ single ingredient</i>	0.099	0.096	0.095
HCTZ combination products numerator, limited denominator			
<i>0-40: HCTZ combination products</i>	0.102	0.099	0.102
<i>41-64: HCTZ combination products</i>	0.197	0.197	0.196
<i>65-74: HCTZ combination products</i>	0.166	0.166	0.164
<i>75-84: HCTZ combination products</i>	0.128	0.128	0.128
<i>85+: HCTZ combination products</i>	0.081	0.081	0.080

Figure 2. Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month




Figure 2 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month




Figure 2 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month




Figure 2 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month




Figure 2 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month




Figure 2 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years) and calendar year/month






Table 3a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members	Number of Exposed Patients per 1,000 Eligible Members
<b>HCTZ-containing</b>					
HCTZ-containing products					
<i>Female</i>	8,878,785	102,534,814	103,193,979	67,875,517	130.8
<i>Male</i>	6,180,469	68,736,089	69,220,031	62,909,908	98.2
HCTZ single ingredient/monotherapy					
<i>Female</i>	5,011,720	46,360,317	46,502,279	67,875,517	73.8
<i>Male</i>	3,229,879	29,097,764	29,197,944	62,909,908	51.3
HCTZ combination products					
<i>Female</i>	4,959,042	56,390,093	56,691,708	67,875,517	73.1
<i>Male</i>	3,646,252	39,763,975	40,022,091	62,909,908	58.0
<b>Non-HCTZ-containing</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics					
<i>Female</i>	1,024,562	7,752,200	7,784,900	67,875,517	15.1
<i>Male</i>	899,175	6,562,607	6,593,937	62,909,908	14.3
ACEIs					
<i>Female</i>	8,051,316	94,189,530	94,667,421	67,875,517	118.6
<i>Male</i>	8,875,509	101,994,631	102,561,967	62,909,908	141.1
CCBs					
<i>Female</i>	9,734,411	120,238,489	121,101,134	67,875,517	143.4
<i>Male</i>	8,003,577	92,857,136	93,523,066	62,909,908	127.2
Potassium-sparing diuretics					
<i>Female</i>	2,290,631	19,547,710	19,718,782	67,875,517	33.7
<i>Male</i>	1,276,381	11,016,978	11,066,460	62,909,908	20.3
Loop diuretics					
<i>Female</i>	5,841,066	63,706,075	64,464,053	67,875,517	86.1
<i>Male</i>	4,242,146	41,522,012	41,953,686	62,909,908	67.4

Table 3a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members	Number of Exposed Patients per 1,000 Eligible Members
<b>Denominators</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
<i>Female</i>	9,620,050	110,233,461	110,978,878	67,875,517	141.7
<i>Male</i>	6,870,009	75,262,547	75,813,968	62,909,908	109.2
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
<i>Female</i>	21,337,580	360,050,285	410,929,306	67,875,517	314.4
<i>Male</i>	17,574,424	282,456,492	324,918,596	62,909,908	279.4

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>Female</i>	1,872,134	1,725,015	1,892,556	1,783,425	1,885,097	1,841,923	1,826,019	1,848,923
<i>Male</i>	1,217,275	1,121,032	1,228,740	1,159,889	1,221,630	1,190,083	1,182,666	1,197,826
HCTZ single ingredient/monotherapy								
<i>Female</i>	749,382	690,617	758,972	717,754	761,688	745,944	742,395	752,271
<i>Male</i>	457,047	420,294	461,560	436,716	460,469	449,311	447,919	453,777
HCTZ combination products								
<i>Female</i>	1,132,661	1,043,056	1,143,761	1,074,713	1,133,381	1,105,770	1,093,038	1,106,576
<i>Male</i>	765,510	705,399	772,501	727,922	766,385	745,747	739,558	748,942
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female</i>	1,984,966	1,828,413	2,008,238	1,893,920	2,001,339	1,957,317	1,940,262	1,964,943
<i>Male</i>	1,308,765	1,204,716	1,322,765	1,248,948	1,315,137	1,283,100	1,274,087	1,290,864
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female</i>	5,466,324	5,098,947	5,526,787	5,252,295	5,517,343	5,413,659	5,374,573	5,452,104
<i>Male</i>	4,232,004	3,932,541	4,276,121	4,066,453	4,262,489	4,170,688	4,156,601	4,210,592
	Eligible members per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
Enrollees with at least one day of coverage								
<i>Female</i>	33,041,335	33,023,388	33,042,913	33,009,662	32,986,786	32,990,265	32,987,296	33,026,003
<i>Male</i>	29,188,096	29,168,172	29,185,818	29,154,567	29,124,242	29,133,369	29,142,744	29,178,791

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>Female: HCTZ-containing</i>	56.7	52.2	57.3	54.0	57.1	55.8	55.4	56.0
<i>Male: HCTZ-containing</i>	41.7	38.4	42.1	39.8	41.9	40.8	40.6	41.1
HCTZ single ingredient								
<i>Female: HCTZ single ingredient</i>	22.7	20.9	23.0	21.7	23.1	22.6	22.5	22.8
<i>Male: HCTZ single ingredient</i>	15.7	14.4	15.8	15.0	15.8	15.4	15.4	15.6
HCTZ combination								
<i>Female: HCTZ combination</i>	34.3	31.6	34.6	32.6	34.4	33.5	33.1	33.5
<i>Male: HCTZ combination</i>	26.2	24.2	26.5	25.0	26.3	25.6	25.4	25.7
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female: Limited denominator</i>	60.1	55.4	60.8	57.4	60.7	59.3	58.8	59.5
<i>Male: Limited denominator</i>	44.8	41.3	45.3	42.8	45.2	44.0	43.7	44.2
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female: Full denominator</i>	165.4	154.4	167.3	159.1	167.3	164.1	162.9	165.1
<i>Male: Full denominator</i>	145.0	134.8	146.5	139.5	146.4	143.2	142.6	144.3

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>Female: HCTZ-containing products</i>	0.943	0.943	0.942	0.942	0.942	0.941	0.941	0.941
<i>Male: HCTZ-containing products</i>	0.930	0.931	0.929	0.929	0.929	0.928	0.928	0.928
HCTZ single ingredient numerator, limited denominator								
<i>Female: HCTZ single ingredient</i>	0.378	0.378	0.378	0.379	0.381	0.381	0.383	0.383
<i>Male: HCTZ single ingredient</i>	0.349	0.349	0.349	0.350	0.350	0.350	0.352	0.352
HCTZ combination products numerator, limited denominator								
<i>Female: HCTZ combination products</i>	0.571	0.570	0.570	0.567	0.566	0.565	0.563	0.563
<i>Male: HCTZ combination products</i>	0.585	0.586	0.584	0.583	0.583	0.581	0.580	0.580
<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>Female: HCTZ-containing products</i>	0.342	0.338	0.342	0.340	0.342	0.340	0.340	0.339
<i>Male: HCTZ-containing products</i>	0.288	0.285	0.287	0.285	0.287	0.285	0.285	0.284
HCTZ single ingredient numerator, full denominator								
<i>Female: HCTZ single ingredient</i>	0.137	0.135	0.137	0.137	0.138	0.138	0.138	0.138
<i>Male: HCTZ single ingredient</i>	0.108	0.107	0.108	0.107	0.108	0.108	0.108	0.108
HCTZ combination products numerator, full denominator								
<i>Female: HCTZ combination products</i>	0.207	0.205	0.207	0.205	0.205	0.204	0.203	0.203
<i>Male: HCTZ combination products</i>	0.181	0.179	0.181	0.179	0.180	0.179	0.178	0.178

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>Female</i>	1,750,921	1,823,205	1,754,268	1,753,592	1,769,078	1,614,374	1,734,067	1,715,508
<i>Male</i>	1,139,030	1,192,001	1,148,757	1,159,861	1,174,629	1,069,385	1,154,917	1,137,796
HCTZ single ingredient/monotherapy								
<i>Female</i>	713,228	742,964	715,057	712,993	722,443	659,941	708,557	703,915
<i>Male</i>	431,471	453,121	435,337	439,400	448,863	407,318	440,843	434,918
HCTZ combination products								
<i>Female</i>	1,046,474	1,089,538	1,048,159	1,049,105	1,055,609	962,374	1,034,355	1,020,106
<i>Male</i>	712,140	743,958	718,172	725,290	730,795	666,389	719,110	707,559
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female</i>	1,861,644	1,938,617	1,866,663	1,866,749	1,884,115	1,721,125	1,851,112	1,832,115
<i>Male</i>	1,228,803	1,285,667	1,240,877	1,253,783	1,271,053	1,159,030	1,253,006	1,235,838
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female</i>	5,212,989	5,406,383	5,240,453	5,235,793	5,287,315	4,894,205	5,215,661	5,168,015
<i>Male</i>	4,035,131	4,205,073	4,075,728	4,103,409	4,157,986	3,835,129	4,104,017	4,056,089
<b>Eligible members per month</b>								
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
Enrollees with at least one day of coverage								
<i>Female</i>	32,823,780	32,828,378	32,843,034	32,838,775	32,465,159	32,416,844	32,409,319	32,366,713
<i>Male</i>	29,012,472	29,017,124	29,026,143	29,034,497	28,748,704	28,707,033	28,700,670	28,658,153

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>Female: HCTZ-containing</i>	53.3	55.5	53.4	53.4	54.5	49.8	53.5	53.0
<i>Male: HCTZ-containing</i>	39.3	41.1	39.6	39.9	40.9	37.3	40.2	39.7
HCTZ single ingredient								
<i>Female: HCTZ single ingredient</i>	21.7	22.6	21.8	21.7	22.3	20.4	21.9	21.7
<i>Male: HCTZ single ingredient</i>	14.9	15.6	15.0	15.1	15.6	14.2	15.4	15.2
HCTZ combination								
<i>Female: HCTZ combination</i>	31.9	33.2	31.9	31.9	32.5	29.7	31.9	31.5
<i>Male: HCTZ combination</i>	24.5	25.6	24.7	25.0	25.4	23.2	25.1	24.7
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female: Limited denominator</i>	56.7	59.1	56.8	56.8	58.0	53.1	57.1	56.6
<i>Male: Limited denominator</i>	42.4	44.3	42.8	43.2	44.2	40.4	43.7	43.1
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female: Full denominator</i>	158.8	164.7	159.6	159.4	162.9	151.0	160.9	159.7
<i>Male: Full denominator</i>	139.1	144.9	140.4	141.3	144.6	133.6	143.0	141.5

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>Female: HCTZ-containing products</i>	0.941	0.940	0.940	0.939	0.939	0.938	0.937	0.936
<i>Male: HCTZ-containing products</i>	0.927	0.927	0.926	0.925	0.924	0.923	0.922	0.921
HCTZ single ingredient numerator, limited denominator								
<i>Female: HCTZ single ingredient</i>	0.383	0.383	0.383	0.382	0.383	0.383	0.383	0.384
<i>Male: HCTZ single ingredient</i>	0.351	0.352	0.351	0.350	0.353	0.351	0.352	0.352
HCTZ combination products numerator, limited denominator								
<i>Female: HCTZ combination products</i>	0.562	0.562	0.562	0.562	0.560	0.559	0.559	0.557
<i>Male: HCTZ combination products</i>	0.580	0.579	0.579	0.578	0.575	0.575	0.574	0.573
<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>Female: HCTZ-containing products</i>	0.336	0.337	0.335	0.335	0.335	0.330	0.332	0.332
<i>Male: HCTZ-containing products</i>	0.282	0.283	0.282	0.283	0.282	0.279	0.281	0.281
HCTZ single ingredient numerator, full denominator								
<i>Female: HCTZ single ingredient</i>	0.137	0.137	0.136	0.136	0.137	0.135	0.136	0.136
<i>Male: HCTZ single ingredient</i>	0.107	0.108	0.107	0.107	0.108	0.106	0.107	0.107
HCTZ combination products numerator, full denominator								
<i>Female: HCTZ combination products</i>	0.201	0.202	0.200	0.200	0.200	0.197	0.198	0.197
<i>Male: HCTZ combination products</i>	0.176	0.177	0.176	0.177	0.176	0.174	0.175	0.174



Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>Female</i>	1,736,026	1,670,837	1,728,775	1,729,159	1,589,524	1,729,755	1,618,741	1,607,200
<i>Male</i>	1,142,765	1,102,166	1,139,424	1,139,999	1,053,178	1,151,695	1,083,154	1,083,452
HCTZ single ingredient/monotherapy								
<i>Female</i>	718,361	692,574	711,233	715,993	664,750	713,368	674,516	671,840
<i>Male</i>	438,212	423,420	435,506	437,509	407,425	441,071	418,533	420,533
HCTZ combination products								
<i>Female</i>	1,026,966	986,726	1,027,784	1,023,100	932,926	1,025,412	952,425	943,492
<i>Male</i>	709,291	683,331	709,407	707,911	650,116	715,467	669,300	667,394
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female</i>	1,856,037	1,787,774	1,847,269	1,849,235	1,702,227	1,851,225	1,734,450	1,723,996
<i>Male</i>	1,243,075	1,199,669	1,237,993	1,239,661	1,147,651	1,253,334	1,181,417	1,182,929
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female</i>	5,227,198	5,062,126	5,183,282	5,208,311	4,883,658	5,226,924	4,979,680	4,959,890
<i>Male</i>	4,086,702	3,961,468	4,054,059	4,073,524	3,833,164	4,110,316	3,927,370	3,935,487
	Eligible members per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
Enrollees with at least one day of coverage								
<i>Female</i>	32,348,688	32,356,820	32,340,099	32,393,645	32,432,285	32,445,023	32,440,377	32,425,302
<i>Male</i>	28,636,618	28,649,849	28,649,807	28,698,947	28,729,593	28,744,939	28,738,948	28,729,725

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>Female: HCTZ-containing</i>	53.7	51.6	53.5	53.4	49.0	53.3	49.9	49.6
<i>Male: HCTZ-containing</i>	39.9	38.5	39.8	39.7	36.7	40.1	37.7	37.7
HCTZ single ingredient								
<i>Female: HCTZ single ingredient</i>	22.2	21.4	22.0	22.1	20.5	22.0	20.8	20.7
<i>Male: HCTZ single ingredient</i>	15.3	14.8	15.2	15.2	14.2	15.3	14.6	14.6
HCTZ combination								
<i>Female: HCTZ combination</i>	31.7	30.5	31.8	31.6	28.8	31.6	29.4	29.1
<i>Male: HCTZ combination</i>	24.8	23.9	24.8	24.7	22.6	24.9	23.3	23.2
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female: Limited denominator</i>	57.4	55.3	57.1	57.1	52.5	57.1	53.5	53.2
<i>Male: Limited denominator</i>	43.4	41.9	43.2	43.2	39.9	43.6	41.1	41.2
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female: Full denominator</i>	161.6	156.4	160.3	160.8	150.6	161.1	153.5	153.0
<i>Male: Full denominator</i>	142.7	138.3	141.5	141.9	133.4	143.0	136.7	137.0

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>Female: HCTZ-containing products</i>	0.935	0.935	0.936	0.935	0.934	0.934	0.933	0.932
<i>Male: HCTZ-containing products</i>	0.919	0.919	0.920	0.920	0.918	0.919	0.917	0.916
HCTZ single ingredient numerator, limited denominator								
<i>Female: HCTZ single ingredient</i>	0.387	0.387	0.385	0.387	0.391	0.385	0.389	0.390
<i>Male: HCTZ single ingredient</i>	0.353	0.353	0.352	0.353	0.355	0.352	0.354	0.356
HCTZ combination products numerator, limited denominator								
<i>Female: HCTZ combination products</i>	0.553	0.552	0.556	0.553	0.548	0.554	0.549	0.547
<i>Male: HCTZ combination products</i>	0.571	0.570	0.573	0.571	0.566	0.571	0.567	0.564
<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>Female: HCTZ-containing products</i>	0.332	0.330	0.334	0.332	0.325	0.331	0.325	0.324
<i>Male: HCTZ-containing products</i>	0.280	0.278	0.281	0.280	0.275	0.280	0.276	0.275
HCTZ single ingredient numerator, full denominator								
<i>Female: HCTZ single ingredient</i>	0.137	0.137	0.137	0.137	0.136	0.136	0.135	0.135
<i>Male: HCTZ single ingredient</i>	0.107	0.107	0.107	0.107	0.106	0.107	0.107	0.107
HCTZ combination products numerator, full denominator								
<i>Female: HCTZ combination products</i>	0.196	0.195	0.198	0.196	0.191	0.196	0.191	0.190
<i>Male: HCTZ combination products</i>	0.174	0.172	0.175	0.174	0.170	0.174	0.170	0.170

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>Female</i>	1,665,780	1,502,431	1,592,363	1,627,030	1,613,310	1,525,391	1,615,188	1,563,159
<i>Male</i>	1,122,795	1,011,634	1,077,396	1,097,857	1,084,673	1,025,083	1,083,889	1,049,272
HCTZ single ingredient/monotherapy								
<i>Female</i>	700,936	639,833	682,635	702,280	701,737	669,675	708,431	699,331
<i>Male</i>	440,483	400,716	429,392	439,220	436,524	414,970	438,923	435,261
HCTZ combination products								
<i>Female</i>	974,400	871,122	918,912	934,189	920,916	864,274	915,922	873,155
<i>Male</i>	688,082	615,854	653,468	664,075	653,464	615,080	650,270	619,731
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female</i>	1,785,140	1,612,036	1,709,654	1,746,886	1,734,016	1,640,165	1,736,207	1,682,304
<i>Male</i>	1,224,989	1,105,207	1,178,557	1,200,029	1,187,408	1,122,456	1,186,032	1,149,978
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female</i>	5,105,700	4,697,289	4,968,796	5,052,112	5,036,250	4,803,992	5,045,936	4,933,424
<i>Male</i>	4,057,049	3,721,086	3,950,687	4,013,059	3,988,721	3,805,513	3,995,872	3,908,868
	Eligible members per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
Enrollees with at least one day of coverage								
<i>Female</i>	32,291,407	32,252,057	32,259,617	32,220,671	32,192,831	32,162,214	32,174,946	32,173,280
<i>Male</i>	28,595,224	28,561,085	28,566,974	28,525,966	28,494,131	28,462,714	28,487,291	28,478,262

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>Female: HCTZ-containing</i>	51.6	46.6	49.4	50.5	50.1	47.4	50.2	48.6
<i>Male: HCTZ-containing</i>	39.3	35.4	37.7	38.5	38.1	36.0	38.0	36.8
HCTZ single ingredient								
<i>Female: HCTZ single ingredient</i>	21.7	19.8	21.2	21.8	21.8	20.8	22.0	21.7
<i>Male: HCTZ single ingredient</i>	15.4	14.0	15.0	15.4	15.3	14.6	15.4	15.3
HCTZ combination								
<i>Female: HCTZ combination</i>	30.2	27.0	28.5	29.0	28.6	26.9	28.5	27.1
<i>Male: HCTZ combination</i>	24.1	21.6	22.9	23.3	22.9	21.6	22.8	21.8
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female: Limited denominator</i>	55.3	50.0	53.0	54.2	53.9	51.0	54.0	52.3
<i>Male: Limited denominator</i>	42.8	38.7	41.3	42.1	41.7	39.4	41.6	40.4
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female: Full denominator</i>	158.1	145.6	154.0	156.8	156.4	149.4	156.8	153.3
<i>Male: Full denominator</i>	141.9	130.3	138.3	140.7	140.0	133.7	140.3	137.3

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>Female: HCTZ-containing products</i>	0.933	0.932	0.931	0.931	0.930	0.930	0.930	0.929
<i>Male: HCTZ-containing products</i>	0.917	0.915	0.914	0.915	0.913	0.913	0.914	0.912
HCTZ single ingredient numerator, limited denominator								
<i>Female: HCTZ single ingredient</i>	0.393	0.397	0.399	0.402	0.405	0.408	0.408	0.416
<i>Male: HCTZ single ingredient</i>	0.360	0.363	0.364	0.366	0.368	0.370	0.370	0.378
HCTZ combination products numerator, limited denominator								
<i>Female: HCTZ combination products</i>	0.546	0.540	0.537	0.535	0.531	0.527	0.528	0.519
<i>Male: HCTZ combination products</i>	0.562	0.557	0.554	0.553	0.550	0.548	0.548	0.539
<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>Female: HCTZ-containing products</i>	0.326	0.320	0.320	0.322	0.320	0.318	0.320	0.317
<i>Male: HCTZ-containing products</i>	0.277	0.272	0.273	0.274	0.272	0.269	0.271	0.268
HCTZ single ingredient numerator, full denominator								
<i>Female: HCTZ single ingredient</i>	0.137	0.136	0.137	0.139	0.139	0.139	0.140	0.142
<i>Male: HCTZ single ingredient</i>	0.109	0.108	0.109	0.109	0.109	0.109	0.110	0.111
HCTZ combination products numerator, full denominator								
<i>Female: HCTZ combination products</i>	0.191	0.185	0.185	0.185	0.183	0.180	0.182	0.177
<i>Male: HCTZ combination products</i>	0.170	0.166	0.165	0.165	0.164	0.162	0.163	0.159

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>Female</i>	1,504,905	1,586,401	1,460,063	1,538,642	1,571,151	1,442,481	1,667,466	1,466,227
<i>Male</i>	1,014,023	1,072,078	990,587	1,041,758	1,073,705	985,348	1,118,989	1,010,833
HCTZ single ingredient/monotherapy								
<i>Female</i>	691,164	756,464	717,946	775,963	799,830	737,250	850,709	747,929
<i>Male</i>	433,518	477,799	458,676	496,658	515,736	475,484	538,892	485,951
HCTZ combination products								
<i>Female</i>	823,518	842,979	753,563	774,419	782,795	714,348	828,280	727,200
<i>Male</i>	586,858	603,241	540,096	553,431	566,064	516,216	587,672	530,959
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female</i>	1,619,483	1,707,585	1,573,123	1,657,583	1,692,863	1,556,399	1,796,103	1,580,477
<i>Male</i>	1,111,735	1,175,519	1,088,094	1,144,739	1,180,577	1,085,257	1,230,439	1,111,568
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female</i>	4,789,649	5,018,884	4,686,869	4,910,645	4,996,838	4,669,084	5,255,618	4,696,829
<i>Male</i>	3,806,453	3,997,283	3,740,409	3,921,452	4,018,325	3,746,948	4,182,426	3,805,203
	<b>Eligible members per month</b>							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
Enrollees with at least one day of coverage								
<i>Female</i>	32,194,195	32,207,488	32,209,146	32,201,114	32,390,972	32,318,072	32,302,938	32,236,673
<i>Male</i>	28,489,756	28,498,788	28,494,459	28,485,141	28,698,500	28,630,936	28,610,173	28,534,616

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>Female: HCTZ-containing</i>	46.7	49.3	45.3	47.8	48.5	44.6	51.6	45.5
<i>Male: HCTZ-containing</i>	35.6	37.6	34.8	36.6	37.4	34.4	39.1	35.4
HCTZ single ingredient								
<i>Female: HCTZ single ingredient</i>	21.5	23.5	22.3	24.1	24.7	22.8	26.3	23.2
<i>Male: HCTZ single ingredient</i>	15.2	16.8	16.1	17.4	18.0	16.6	18.8	17.0
HCTZ combination								
<i>Female: HCTZ combination</i>	25.6	26.2	23.4	24.0	24.2	22.1	25.6	22.6
<i>Male: HCTZ combination</i>	20.6	21.2	19.0	19.4	19.7	18.0	20.5	18.6
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female: Limited denominator</i>	50.3	53.0	48.8	51.5	52.3	48.2	55.6	49.0
<i>Male: Limited denominator</i>	39.0	41.2	38.2	40.2	41.1	37.9	43.0	39.0
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female: Full denominator</i>	148.8	155.8	145.5	152.5	154.3	144.5	162.7	145.7
<i>Male: Full denominator</i>	133.6	140.3	131.3	137.7	140.0	130.9	146.2	133.4



Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>Female: HCTZ-containing products</i>	0.929	0.929	0.928	0.928	0.928	0.927	0.928	0.928
<i>Male: HCTZ-containing products</i>	0.912	0.912	0.910	0.910	0.909	0.908	0.909	0.909
HCTZ single ingredient numerator, limited denominator								
<i>Female: HCTZ single ingredient</i>	0.427	0.443	0.456	0.468	0.472	0.474	0.474	0.473
<i>Male: HCTZ single ingredient</i>	0.390	0.406	0.422	0.434	0.437	0.438	0.438	0.437
HCTZ combination products numerator, limited denominator								
<i>Female: HCTZ combination products</i>	0.509	0.494	0.479	0.467	0.462	0.459	0.461	0.460
<i>Male: HCTZ combination products</i>	0.528	0.513	0.496	0.483	0.479	0.476	0.478	0.478
<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>Female: HCTZ-containing products</i>	0.314	0.316	0.312	0.313	0.314	0.309	0.317	0.312
<i>Male: HCTZ-containing products</i>	0.266	0.268	0.265	0.266	0.267	0.263	0.268	0.266
HCTZ single ingredient numerator, full denominator								
<i>Female: HCTZ single ingredient</i>	0.144	0.151	0.153	0.158	0.160	0.158	0.162	0.159
<i>Male: HCTZ single ingredient</i>	0.114	0.120	0.123	0.127	0.128	0.127	0.129	0.128
HCTZ combination products numerator, full denominator								
<i>Female: HCTZ combination products</i>	0.172	0.168	0.161	0.158	0.157	0.153	0.158	0.155
<i>Male: HCTZ combination products</i>	0.154	0.151	0.144	0.141	0.141	0.138	0.141	0.140

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>Female</i>	1,444,625	1,548,413	1,492,061	1,475,468	1,465,998	1,464,897	1,406,130	1,498,679
<i>Male</i>	987,995	1,046,202	1,016,802	1,002,207	995,380	1,001,260	961,221	1,022,682
HCTZ single ingredient/monotherapy								
<i>Female</i>	736,812	791,299	762,934	751,779	741,844	736,914	706,078	749,396
<i>Male</i>	473,947	504,163	489,649	480,546	474,251	474,392	454,109	481,778
HCTZ combination products								
<i>Female</i>	715,879	766,504	738,253	731,877	731,620	735,209	706,443	756,213
<i>Male</i>	519,415	548,162	533,160	526,948	525,916	531,561	511,192	545,372
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female</i>	1,558,280	1,668,665	1,609,237	1,590,455	1,580,348	1,579,711	1,517,426	1,616,085
<i>Male</i>	1,087,632	1,151,408	1,119,002	1,103,171	1,096,101	1,102,553	1,059,471	1,128,069
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female</i>	4,642,461	4,929,080	4,782,821	4,742,482	4,732,499	4,742,402	4,583,606	4,839,899
<i>Male</i>	3,742,756	3,942,394	3,850,874	3,812,275	3,801,562	3,826,870	3,698,518	3,908,507
	Eligible members per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
Enrollees with at least one day of coverage								
<i>Female</i>	32,163,577	32,120,085	32,070,653	32,019,243	31,889,886	31,858,596	31,859,346	31,847,412
<i>Male</i>	28,456,835	28,407,072	28,343,766	28,280,906	28,127,279	28,095,501	28,090,352	28,070,821

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>Female: HCTZ-containing</i>	44.9	48.2	46.5	46.1	46.0	46.0	44.1	47.1
<i>Male: HCTZ-containing</i>	34.7	36.8	35.9	35.4	35.4	35.6	34.2	36.4
HCTZ single ingredient								
<i>Female: HCTZ single ingredient</i>	22.9	24.6	23.8	23.5	23.3	23.1	22.2	23.5
<i>Male: HCTZ single ingredient</i>	16.7	17.7	17.3	17.0	16.9	16.9	16.2	17.2
HCTZ combination								
<i>Female: HCTZ combination</i>	22.3	23.9	23.0	22.9	22.9	23.1	22.2	23.7
<i>Male: HCTZ combination</i>	18.3	19.3	18.8	18.6	18.7	18.9	18.2	19.4
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female: Limited denominator</i>	48.4	52.0	50.2	49.7	49.6	49.6	47.6	50.7
<i>Male: Limited denominator</i>	38.2	40.5	39.5	39.0	39.0	39.2	37.7	40.2
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female: Full denominator</i>	144.3	153.5	149.1	148.1	148.4	148.9	143.9	152.0
<i>Male: Full denominator</i>	131.5	138.8	135.9	134.8	135.2	136.2	131.7	139.2

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>Female: HCTZ-containing products</i>	0.927	0.928	0.927	0.928	0.928	0.927	0.927	0.927
<i>Male: HCTZ-containing products</i>	0.908	0.909	0.909	0.908	0.908	0.908	0.907	0.907
HCTZ single ingredient numerator, limited denominator								
<i>Female: HCTZ single ingredient</i>	0.473	0.474	0.474	0.473	0.469	0.466	0.465	0.464
<i>Male: HCTZ single ingredient</i>	0.436	0.438	0.438	0.436	0.433	0.430	0.429	0.427
HCTZ combination products numerator, limited denominator								
<i>Female: HCTZ combination products</i>	0.459	0.459	0.459	0.460	0.463	0.465	0.466	0.468
<i>Male: HCTZ combination products</i>	0.478	0.476	0.476	0.478	0.480	0.482	0.482	0.483
<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>Female: HCTZ-containing products</i>	0.311	0.314	0.312	0.311	0.310	0.309	0.307	0.310
<i>Male: HCTZ-containing products</i>	0.264	0.265	0.264	0.263	0.262	0.262	0.260	0.262
HCTZ single ingredient numerator, full denominator								
<i>Female: HCTZ single ingredient</i>	0.159	0.161	0.160	0.159	0.157	0.155	0.154	0.155
<i>Male: HCTZ single ingredient</i>	0.127	0.128	0.127	0.126	0.125	0.124	0.123	0.123
HCTZ combination products numerator, full denominator								
<i>Female: HCTZ combination products</i>	0.154	0.156	0.154	0.154	0.155	0.155	0.154	0.156
<i>Male: HCTZ combination products</i>	0.139	0.139	0.138	0.138	0.138	0.139	0.138	0.140

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>Female</i>	1,415,073	1,301,940	1,479,014	1,417,557	1,372,592	1,436,721	1,405,560	1,398,993
<i>Male</i>	979,093	899,795	1,019,846	978,744	944,409	986,712	966,909	960,968
HCTZ single ingredient/monotherapy								
<i>Female</i>	709,272	650,958	738,067	707,847	686,917	717,010	702,058	697,644
<i>Male</i>	460,825	422,594	477,492	457,866	441,731	461,535	451,134	447,268
HCTZ combination products								
<i>Female</i>	712,023	656,618	747,745	715,939	691,519	725,813	709,521	707,129
<i>Male</i>	522,422	480,711	546,697	524,863	506,308	529,137	519,370	517,269
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female</i>	1,527,109	1,406,119	1,597,466	1,531,957	1,483,764	1,552,037	1,518,861	1,511,714
<i>Male</i>	1,079,122	993,724	1,126,453	1,080,783	1,043,990	1,089,735	1,067,933	1,061,384
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female</i>	4,602,842	4,290,777	4,807,210	4,642,554	4,522,854	4,706,627	4,625,818	4,611,123
<i>Male</i>	3,741,290	3,481,662	3,900,267	3,764,409	3,657,860	3,803,305	3,745,755	3,731,844
	Eligible members per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
Enrollees with at least one day of coverage								
<i>Female</i>	31,741,934	31,670,004	31,661,179	31,634,678	31,615,183	31,626,724	31,651,555	31,712,935
<i>Male</i>	28,039,179	27,975,355	27,966,461	27,929,283	27,910,684	27,931,346	27,957,744	28,019,103

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>Female: HCTZ-containing</i>	44.6	41.1	46.7	44.8	43.4	45.4	44.4	44.1
<i>Male: HCTZ-containing</i>	34.9	32.2	36.5	35.0	33.8	35.3	34.6	34.3
HCTZ single ingredient								
<i>Female: HCTZ single ingredient</i>	22.3	20.6	23.3	22.4	21.7	22.7	22.2	22.0
<i>Male: HCTZ single ingredient</i>	16.4	15.1	17.1	16.4	15.8	16.5	16.1	16.0
HCTZ combination								
<i>Female: HCTZ combination</i>	22.4	20.7	23.6	22.6	21.9	22.9	22.4	22.3
<i>Male: HCTZ combination</i>	18.6	17.2	19.5	18.8	18.1	18.9	18.6	18.5
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>Female: Limited denominator</i>	48.1	44.4	50.5	48.4	46.9	49.1	48.0	47.7
<i>Male: Limited denominator</i>	38.5	35.5	40.3	38.7	37.4	39.0	38.2	37.9
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>Female: Full denominator</i>	145.0	135.5	151.8	146.8	143.1	148.8	146.1	145.4
<i>Male: Full denominator</i>	133.4	124.5	139.5	134.8	131.1	136.2	134.0	133.2

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>Female: HCTZ-containing products</i>	0.927	0.926	0.926	0.925	0.925	0.926	0.925	0.925
<i>Male: HCTZ-containing products</i>	0.907	0.905	0.905	0.906	0.905	0.905	0.905	0.905
HCTZ single ingredient numerator, limited denominator								
<i>Female: HCTZ single ingredient</i>	0.464	0.463	0.462	0.462	0.463	0.462	0.462	0.461
<i>Male: HCTZ single ingredient</i>	0.427	0.425	0.424	0.424	0.423	0.424	0.422	0.421
HCTZ combination products numerator, limited denominator								
<i>Female: HCTZ combination products</i>	0.466	0.467	0.468	0.467	0.466	0.468	0.467	0.468
<i>Male: HCTZ combination products</i>	0.484	0.484	0.485	0.486	0.485	0.486	0.486	0.487
<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>Female: HCTZ-containing products</i>	0.307	0.303	0.308	0.305	0.303	0.305	0.304	0.303
<i>Male: HCTZ-containing products</i>	0.262	0.258	0.261	0.260	0.258	0.259	0.258	0.258
HCTZ single ingredient numerator, full denominator								
<i>Female: HCTZ single ingredient</i>	0.154	0.152	0.154	0.152	0.152	0.152	0.152	0.151
<i>Male: HCTZ single ingredient</i>	0.123	0.121	0.122	0.122	0.121	0.121	0.120	0.120
HCTZ combination products numerator, full denominator								
<i>Female: HCTZ combination products</i>	0.155	0.153	0.156	0.154	0.153	0.154	0.153	0.153
<i>Male: HCTZ combination products</i>	0.140	0.138	0.140	0.139	0.138	0.139	0.139	0.139

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>HCTZ-containing</b>							
HCTZ-containing products							
<i>Female</i>	1,368,397	1,364,188	1,340,797	1,361,249	1,209,084	934,248	856,535
<i>Male</i>	942,669	942,954	929,939	945,566	816,932	641,624	559,381
HCTZ single ingredient/monotherapy							
<i>Female</i>	680,781	677,512	665,720	681,913	615,175	478,841	439,675
<i>Male</i>	439,039	436,453	432,021	444,284	394,204	310,754	278,068
HCTZ combination products							
<i>Female</i>	693,066	692,143	680,326	685,188	599,044	459,237	420,571
<i>Male</i>	507,151	509,948	501,310	505,200	425,980	333,342	283,428
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>Female</i>	1,478,703	1,474,223	1,450,050	1,472,732	1,309,906	1,013,661	931,810
<i>Male</i>	1,041,174	1,041,359	1,028,443	1,046,705	906,992	712,912	625,203
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<i>Female</i>	4,523,125	4,521,384	4,481,346	4,550,601	4,108,655	3,240,204	3,035,914
<i>Male</i>	3,663,621	3,673,215	3,642,143	3,705,529	3,276,838	2,594,069	2,344,915
	<b>Eligible members per month</b>						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
Enrollees with at least one day of coverage							
<i>Female</i>	31,732,844	31,732,192	31,755,234	31,776,775	26,460,016	23,568,097	16,137,970
<i>Male</i>	28,030,151	28,033,110	28,055,451	28,076,770	22,628,983	20,206,194	12,947,346



Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>HCTZ-containing</b>							
HCTZ-containing							
<i>Female: HCTZ-containing</i>	43.1	43.0	42.2	42.8	45.7	39.6	53.1
<i>Male: HCTZ-containing</i>	33.6	33.6	33.1	33.7	36.1	31.8	43.2
HCTZ single ingredient							
<i>Female: HCTZ single ingredient</i>	21.5	21.4	21.0	21.5	23.2	20.3	27.2
<i>Male: HCTZ single ingredient</i>	15.7	15.6	15.4	15.8	17.4	15.4	21.5
HCTZ combination							
<i>Female: HCTZ combination</i>	21.8	21.8	21.4	21.6	22.6	19.5	26.1
<i>Male: HCTZ combination</i>	18.1	18.2	17.9	18.0	18.8	16.5	21.9
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>Female: Limited denominator</i>	46.6	46.5	45.7	46.3	49.5	43.0	57.7
<i>Male: Limited denominator</i>	37.1	37.1	36.7	37.3	40.1	35.3	48.3
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<i>Female: Full denominator</i>	142.5	142.5	141.1	143.2	155.3	137.5	188.1
<i>Male: Full denominator</i>	130.7	131.0	129.8	132.0	144.8	128.4	181.1

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>Female: HCTZ-containing products</i>	0.925	0.925	0.925	0.924	0.923	0.922	0.919
<i>Male: HCTZ-containing products</i>	0.905	0.906	0.904	0.903	0.901	0.900	0.895
HCTZ single ingredient numerator, limited denominator							
<i>Female: HCTZ single ingredient</i>	0.460	0.460	0.459	0.463	0.470	0.472	0.472
<i>Male: HCTZ single ingredient</i>	0.422	0.419	0.420	0.424	0.435	0.436	0.445
HCTZ combination products numerator, limited denominator							
<i>Female: HCTZ combination products</i>	0.469	0.469	0.469	0.465	0.457	0.453	0.451
<i>Male: HCTZ combination products</i>	0.487	0.490	0.487	0.483	0.470	0.468	0.453
<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>Female: HCTZ-containing products</i>	0.303	0.302	0.299	0.299	0.294	0.288	0.282
<i>Male: HCTZ-containing products</i>	0.257	0.257	0.255	0.255	0.249	0.247	0.239
HCTZ single ingredient numerator, full denominator							
<i>Female: HCTZ single ingredient</i>	0.151	0.150	0.149	0.150	0.150	0.148	0.145
<i>Male: HCTZ single ingredient</i>	0.120	0.119	0.119	0.120	0.120	0.120	0.119
HCTZ combination products numerator, full denominator							
<i>Female: HCTZ combination products</i>	0.153	0.153	0.152	0.151	0.146	0.142	0.139
<i>Male: HCTZ combination products</i>	0.138	0.139	0.138	0.136	0.130	0.129	0.121

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Patients with dispensing per month		
	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>			
HCTZ-containing products			
<i>Female</i>	93,949	95,369	93,494
<i>Male</i>	72,729	73,607	71,581
HCTZ single ingredient/monotherapy			
<i>Female</i>	46,700	47,309	46,478
<i>Male</i>	31,808	32,237	31,260
HCTZ combination products			
<i>Female</i>	47,596	48,452	47,363
<i>Male</i>	41,212	41,611	40,583
<b>Denominators</b>			
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic			
<i>Female</i>	101,044	102,680	100,752
<i>Male</i>	79,680	80,572	78,443
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive			
<i>Female</i>	288,067	294,236	288,406
<i>Male</i>	256,683	260,354	254,724
	<b>Eligible members per month</b>		
	Apr-22	May-22	Jun-22
Enrollees with at least one day of coverage			
<i>Female</i>	4,308,462	4,326,540	4,340,778
<i>Male</i>	3,946,032	3,965,408	3,979,172

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Number of patients with dispensing per 1,000 eligible members		
	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>			
HCTZ-containing			
<i>Female: HCTZ-containing</i>	21.8	22.0	21.5
<i>Male: HCTZ-containing</i>	18.4	18.6	18.0
HCTZ single ingredient			
<i>Female: HCTZ single ingredient</i>	10.8	10.9	10.7
<i>Male: HCTZ single ingredient</i>	8.1	8.1	7.9
HCTZ combination			
<i>Female: HCTZ combination</i>	11.0	11.2	10.9
<i>Male: HCTZ combination</i>	10.4	10.5	10.2
<b>Denominators</b>			
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic			
<i>Female: Limited denominator</i>	23.5	23.7	23.2
<i>Male: Limited denominator</i>	20.2	20.3	19.7
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive			
<i>Female: Full denominator</i>	66.9	68.0	66.4
<i>Male: Full denominator</i>	65.0	65.7	64.0

Table 3b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month

	Proportion of numerators / denominators		
	Apr-22	May-22	Jun-22
<b>Proportions, limited denominator</b>			
HCTZ-containing numerator, limited denominator			
<i>Female: HCTZ-containing products</i>	0.930	0.929	0.928
<i>Male: HCTZ-containing products</i>	0.913	0.914	0.913
HCTZ single ingredient numerator, limited denominator			
<i>Female: HCTZ single ingredient</i>	0.462	0.461	0.461
<i>Male: HCTZ single ingredient</i>	0.399	0.400	0.399
HCTZ combination products numerator, limited denominator			
<i>Female: HCTZ combination products</i>	0.471	0.472	0.470
<i>Male: HCTZ combination products</i>	0.517	0.516	0.517
<b>Proportions, full denominator</b>			
HCTZ-containing numerator, full denominator			
<i>Female: HCTZ-containing products</i>	0.326	0.324	0.324
<i>Male: HCTZ-containing products</i>	0.283	0.283	0.281
HCTZ single ingredient numerator, full denominator			
<i>Female: HCTZ single ingredient</i>	0.162	0.161	0.161
<i>Male: HCTZ single ingredient</i>	0.124	0.124	0.123
HCTZ combination products numerator, full denominator			
<i>Female: HCTZ combination products</i>	0.165	0.165	0.164
<i>Male: HCTZ combination products</i>	0.161	0.160	0.159

Figure 3. Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month




Figure 3 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by sex and calendar year/month




Table 4a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b>HCTZ-containing</b>					
HCTZ-containing products					
White	8,036,456	96,828,639	97,167,915	38,778,668	207.2
Non-white <sup>2</sup>	1,890,516	20,819,464	20,896,064	8,104,621	233.3
Unknown	5,132,282	53,622,800	54,350,031	83,902,136	61.2
HCTZ single ingredient/monotherapy					
White	4,578,542	44,555,911	44,611,208	38,778,668	118.1
Non-white <sup>2</sup>	1,065,787	9,506,698	9,519,322	8,104,621	131.5
Unknown	2,597,270	21,395,472	21,569,693	83,902,136	31.0
HCTZ combination products					
White	4,462,862	52,446,252	52,556,713	38,778,668	115.1
Non-white <sup>2</sup>	1,065,745	11,350,811	11,376,744	8,104,621	131.5
Unknown	3,076,687	32,357,005	32,780,342	83,902,136	36.7
<b>Non-HCTZ-containing</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics					
White	1,171,713	8,755,699	8,778,003	38,778,668	30.2
Non-white <sup>2</sup>	280,537	2,088,483	2,093,010	8,104,621	34.6
Unknown	471,487	3,470,625	3,507,824	83,902,136	5.6
ACEIs					
White	9,801,036	122,848,933	123,275,946	38,778,668	252.7
Non-white <sup>2</sup>	1,687,583	18,889,068	18,957,601	8,104,621	208.2
Unknown	5,438,206	54,446,160	54,995,841	83,902,136	64.8
CCBs					
White	10,099,025	130,404,379	131,172,918	38,778,668	260.4
Non-white <sup>2</sup>	2,798,240	34,699,119	34,910,250	8,104,621	345.3
Unknown	4,840,723	47,992,127	48,541,032	83,902,136	57.7



Table 4a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race

<b>Non-HCTZ-containing</b>					
Potassium-sparing diuretics					
<i>White</i>	1,957,845	18,322,008	18,371,180	38,778,668	50.5
<i>Non-white</i> <sup>2</sup>	384,365	3,265,206	3,272,924	8,104,621	47.4
<i>Unknown</i>	1,224,802	8,977,474	9,141,138	83,902,136	14.6
Loop diuretics					
<i>White</i>	7,107,369	78,999,094	79,921,215	38,778,668	183.3
<i>Non-white</i> <sup>2</sup>	1,249,096	12,970,329	13,089,253	8,104,621	154.1
<i>Unknown</i>	1,726,747	13,258,664	13,407,271	83,902,136	20.6
<b>Denominators</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
<i>White</i>	8,910,272	105,533,707	105,945,917	38,778,668	229.8
<i>Non-white</i> <sup>2</sup>	2,092,267	22,889,522	22,989,074	8,104,621	258.2
<i>Unknown</i>	5,487,520	57,072,779	57,857,855	83,902,136	65.4
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
<i>White</i>	21,665,409	402,254,940	458,686,262	38,778,668	558.7
<i>Non-white</i> <sup>2</sup>	4,511,396	78,446,265	93,218,796	8,104,621	556.6
<i>Unknown</i>	12,735,199	161,805,572	183,942,844	83,902,136	151.8

<sup>1</sup>Eligible members includes those who have at least one day of enrollment during the query period.

<sup>2</sup>Non-white racial category includes American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and Multi-racial.

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products								
White	1,713,809	1,548,820	1,703,817	1,605,164	1,701,957	1,656,417	1,649,361	1,665,978
Non-white	387,608	361,029	395,405	366,323	389,362	379,914	376,273	383,570
Unknown	987,992	936,198	1,022,074	971,827	1,015,408	995,675	983,051	997,201
HCTZ single ingredient/monotherapy								
White	705,588	638,642	702,967	664,292	705,882	688,860	687,191	694,983
Non-white	159,158	148,655	162,043	150,444	160,275	156,723	155,654	158,849
Unknown	341,683	323,614	355,522	339,734	356,000	349,672	347,469	352,216
HCTZ combination products								
White	1,016,312	917,058	1,008,899	948,017	1,003,976	975,277	969,486	978,619
Non-white	230,476	214,167	235,412	217,597	231,044	225,108	222,448	226,684
Unknown	651,383	617,230	671,951	637,021	664,746	651,132	640,662	650,215
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
White	1,840,043	1,663,171	1,832,295	1,727,095	1,830,074	1,783,418	1,774,651	1,793,032
Non-white	417,663	388,702	426,334	395,597	420,383	410,877	406,541	414,589
Unknown	1,036,025	981,256	1,072,374	1,020,176	1,066,019	1,046,122	1,033,157	1,048,186
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
White	5,957,091	5,483,875	5,953,406	5,662,310	5,955,581	5,828,426	5,811,453	5,879,251
Non-white	1,192,652	1,121,085	1,213,644	1,140,839	1,199,720	1,179,740	1,168,373	1,189,722
Unknown	2,548,585	2,426,528	2,635,858	2,515,599	2,624,531	2,576,181	2,551,348	2,593,723

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
Enrollees with at least one day of coverage								
<i>White</i>	22,824,758	22,837,050	22,857,466	22,850,534	22,834,257	22,863,667	22,973,864	23,025,283
<i>Non-white</i>	3,995,414	3,996,883	4,000,539	3,995,068	3,984,309	3,988,519	4,008,767	4,020,966
<i>Unknown</i>	35,409,259	35,357,627	35,370,726	35,318,627	35,292,462	35,271,448	35,147,409	35,158,545
	Number of patients with dispensing per 1,000 eligible members							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>White: HCTZ-containing</i>	75.1	67.8	74.5	70.2	74.5	72.4	71.8	72.4
<i>Non-white: HCTZ-containing</i>	97.0	90.3	98.8	91.7	97.7	95.3	93.9	95.4
<i>Unknown: HCTZ-containing</i>	27.9	26.5	28.9	27.5	28.8	28.2	28.0	28.4
HCTZ single ingredient								
<i>White: HCTZ single ingredient</i>	30.9	28.0	30.8	29.1	30.9	30.1	29.9	30.2
<i>Non-white: HCTZ single ingredient</i>	39.8	37.2	40.5	37.7	40.2	39.3	38.8	39.5
<i>Unknown: HCTZ single ingredient</i>	9.6	9.2	10.1	9.6	10.1	9.9	9.9	10.0
HCTZ combination								
<i>White: HCTZ combination</i>	44.5	40.2	44.1	41.5	44.0	42.7	42.2	42.5
<i>Non-white: HCTZ combination</i>	57.7	53.6	58.8	54.5	58.0	56.4	55.5	56.4
<i>Unknown: HCTZ combination</i>	18.4	17.5	19.0	18.0	18.8	18.5	18.2	18.5

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White: Limited denominator</i>	80.6	72.8	80.2	75.6	80.1	78.0	77.2	77.9
<i>Non-white: Limited denominator</i>	104.5	97.3	106.6	99.0	105.5	103.0	101.4	103.1
<i>Unknown: Limited denominator</i>	29.3	27.8	30.3	28.9	30.2	29.7	29.4	29.8
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White: Full denominator</i>	261.0	240.1	260.5	247.8	260.8	254.9	253.0	255.3
<i>Non-white: Full denominator</i>	298.5	280.5	303.4	285.6	301.1	295.8	291.5	295.9
<i>Unknown: Full denominator</i>	72.0	68.6	74.5	71.2	74.4	73.0	72.6	73.8
<b>Proportion of numerators / denominators</b>								
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>White: HCTZ-containing products</i>	0.931	0.931	0.930	0.929	0.930	0.929	0.929	0.929
<i>Non-white: HCTZ-containing products</i>	0.928	0.929	0.927	0.926	0.926	0.925	0.926	0.925
<i>Unknown: HCTZ-containing products</i>	0.954	0.954	0.953	0.953	0.953	0.952	0.952	0.951
HCTZ single ingredient numerator, limited denominator								
<i>White: HCTZ single ingredient</i>	0.383	0.384	0.384	0.385	0.386	0.386	0.387	0.388
<i>Non-white: HCTZ single ingredient</i>	0.381	0.382	0.380	0.380	0.381	0.381	0.383	0.383
<i>Unknown: HCTZ single ingredient</i>	0.330	0.330	0.332	0.333	0.334	0.334	0.336	0.336
HCTZ combination products numerator, limited denominator								
<i>White: HCTZ combination products</i>	0.552	0.551	0.551	0.549	0.549	0.547	0.546	0.546
<i>Non-white: HCTZ combination products</i>	0.552	0.551	0.552	0.550	0.550	0.548	0.547	0.547
<i>Unknown: HCTZ combination products</i>	0.629	0.629	0.627	0.624	0.624	0.622	0.620	0.620

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>White: HCTZ-containing products</i>	0.288	0.282	0.286	0.283	0.286	0.284	0.284	0.283
<i>Non-white: HCTZ-containing products</i>	0.325	0.322	0.326	0.321	0.325	0.322	0.322	0.322
<i>Unknown: HCTZ-containing products</i>	0.388	0.386	0.388	0.386	0.387	0.386	0.385	0.384
HCTZ single ingredient numerator, full denominator								
<i>White: HCTZ single ingredient</i>	0.118	0.116	0.118	0.117	0.119	0.118	0.118	0.118
<i>Non-white: HCTZ single ingredient</i>	0.133	0.133	0.134	0.132	0.134	0.133	0.133	0.134
<i>Unknown: HCTZ single ingredient</i>	0.134	0.133	0.135	0.135	0.136	0.136	0.136	0.136
HCTZ combination products numerator, full denominator								
<i>White: HCTZ combination products</i>	0.171	0.167	0.169	0.167	0.169	0.167	0.167	0.166
<i>Non-white: HCTZ combination products</i>	0.193	0.191	0.194	0.191	0.193	0.191	0.190	0.191
<i>Unknown: HCTZ combination products</i>	0.256	0.254	0.255	0.253	0.253	0.253	0.251	0.251

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
White	1,585,710	1,664,624	1,596,011	1,600,872	1,659,716	1,483,792	1,602,878	1,596,186
Non-white	363,417	377,528	362,668	360,110	366,938	337,026	361,025	353,589
Unknown	940,824	973,054	944,346	952,471	917,053	862,941	925,081	903,529
HCTZ single ingredient/monotherapy								
White	661,565	694,660	665,583	666,960	694,019	620,716	670,755	669,700
Non-white	150,382	156,360	150,186	148,869	152,290	140,024	149,593	147,266
Unknown	332,752	345,065	334,625	336,564	324,997	306,519	329,052	321,867
HCTZ combination products								
White	931,113	977,367	937,462	940,801	973,246	869,499	939,485	933,417
Non-white	214,787	223,050	214,228	212,883	216,413	198,578	213,189	207,993
Unknown	612,714	633,079	614,641	620,711	596,745	560,686	600,791	586,255
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
White	1,707,783	1,792,248	1,720,512	1,727,058	1,790,940	1,603,504	1,734,476	1,727,926
Non-white	393,114	408,405	393,007	390,305	397,972	366,175	392,905	385,216
Unknown	989,550	1,023,631	994,021	1,003,169	966,256	910,476	976,737	954,811
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
White	5,647,832	5,884,879	5,688,214	5,699,403	5,860,626	5,352,231	5,720,968	5,692,893
Non-white	1,141,454	1,179,954	1,142,559	1,136,406	1,156,093	1,075,762	1,145,640	1,124,827
Unknown	2,458,834	2,546,623	2,485,408	2,503,393	2,428,582	2,301,341	2,453,070	2,406,384

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
Enrollees with at least one day of coverage								
<i>White</i>	23,074,999	23,112,009	23,138,361	23,163,012	23,161,604	23,169,891	23,189,890	23,181,331
<i>Non-white</i>	4,031,434	4,040,463	4,044,741	4,054,825	4,044,706	4,042,942	4,045,149	4,033,490
<i>Unknown</i>	34,729,819	34,693,030	34,686,075	34,655,435	34,007,553	33,911,044	33,874,950	33,810,045
	Number of patients with dispensing per 1,000 eligible members							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>White: HCTZ-containing</i>	68.7	72.0	69.0	69.1	71.7	64.0	69.1	68.9
<i>Non-white: HCTZ-containing</i>	90.1	93.4	89.7	88.8	90.7	83.4	89.2	87.7
<i>Unknown: HCTZ-containing</i>	27.1	28.0	27.2	27.5	27.0	25.4	27.3	26.7
HCTZ single ingredient								
<i>White: HCTZ single ingredient</i>	28.7	30.1	28.8	28.8	30.0	26.8	28.9	28.9
<i>Non-white: HCTZ single ingredient</i>	37.3	38.7	37.1	36.7	37.7	34.6	37.0	36.5
<i>Unknown: HCTZ single ingredient</i>	9.6	9.9	9.6	9.7	9.6	9.0	9.7	9.5
HCTZ combination								
<i>White: HCTZ combination</i>	40.4	42.3	40.5	40.6	42.0	37.5	40.5	40.3
<i>Non-white: HCTZ combination</i>	53.3	55.2	53.0	52.5	53.5	49.1	52.7	51.6
<i>Unknown: HCTZ combination</i>	17.6	18.2	17.7	17.9	17.5	16.5	17.7	17.3

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White: Limited denominator</i>	74.0	77.5	74.4	74.6	77.3	69.2	74.8	74.5
<i>Non-white: Limited denominator</i>	97.5	101.1	97.2	96.3	98.4	90.6	97.1	95.5
<i>Unknown: Limited denominator</i>	28.5	29.5	28.7	28.9	28.4	26.8	28.8	28.2
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White: Full denominator</i>	244.8	254.6	245.8	246.1	253.0	231.0	246.7	245.6
<i>Non-white: Full denominator</i>	283.1	292.0	282.5	280.3	285.8	266.1	283.2	278.9
<i>Unknown: Full denominator</i>	70.8	73.4	71.7	72.2	71.4	67.9	72.4	71.2
<b>Proportion of numerators / denominators</b>								
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>White: HCTZ-containing products</i>	0.929	0.929	0.928	0.927	0.927	0.925	0.924	0.924
<i>Non-white: HCTZ-containing products</i>	0.924	0.924	0.923	0.923	0.922	0.920	0.919	0.918
<i>Unknown: HCTZ-containing products</i>	0.951	0.951	0.950	0.949	0.949	0.948	0.947	0.946
HCTZ single ingredient numerator, limited denominator								
<i>White: HCTZ single ingredient</i>	0.387	0.388	0.387	0.386	0.388	0.387	0.387	0.388
<i>Non-white: HCTZ single ingredient</i>	0.383	0.383	0.382	0.381	0.383	0.382	0.381	0.382
<i>Unknown: HCTZ single ingredient</i>	0.336	0.337	0.337	0.336	0.336	0.337	0.337	0.337
HCTZ combination products numerator, limited denominator								
<i>White: HCTZ combination products</i>	0.545	0.545	0.545	0.545	0.543	0.542	0.542	0.540
<i>Non-white: HCTZ combination products</i>	0.546	0.546	0.545	0.545	0.544	0.542	0.543	0.540
<i>Unknown: HCTZ combination products</i>	0.619	0.618	0.618	0.619	0.618	0.616	0.615	0.614



Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>White: HCTZ-containing products</i>	0.281	0.283	0.281	0.281	0.283	0.277	0.280	0.280
<i>Non-white: HCTZ-containing products</i>	0.318	0.320	0.317	0.317	0.317	0.313	0.315	0.314
<i>Unknown: HCTZ-containing products</i>	0.383	0.382	0.380	0.380	0.378	0.375	0.377	0.375
HCTZ single ingredient numerator, full denominator								
<i>White: HCTZ single ingredient</i>	0.117	0.118	0.117	0.117	0.118	0.116	0.117	0.118
<i>Non-white: HCTZ single ingredient</i>	0.132	0.133	0.131	0.131	0.132	0.130	0.131	0.131
<i>Unknown: HCTZ single ingredient</i>	0.135	0.135	0.135	0.134	0.134	0.133	0.134	0.134
HCTZ combination products numerator, full denominator								
<i>White: HCTZ combination products</i>	0.165	0.166	0.165	0.165	0.166	0.162	0.164	0.164
<i>Non-white: HCTZ combination products</i>	0.188	0.189	0.187	0.187	0.187	0.185	0.186	0.185
<i>Unknown: HCTZ combination products</i>	0.249	0.249	0.247	0.248	0.246	0.244	0.245	0.244

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
White	1,604,327	1,545,591	1,618,103	1,606,993	1,472,008	1,625,140	1,512,727	1,510,449
Non-white	356,775	343,632	354,697	357,926	324,544	353,842	330,064	325,443
Unknown	917,689	883,780	895,399	904,239	846,150	902,468	859,104	854,760
HCTZ single ingredient/monotherapy								
White	677,342	654,224	677,363	677,262	628,731	681,398	643,028	645,133
Non-white	149,559	143,937	148,029	149,904	137,023	147,719	138,648	137,266
Unknown	329,672	317,833	321,347	326,336	306,421	325,322	311,373	309,974
HCTZ combination products								
White	934,371	898,306	949,276	937,912	849,894	951,212	876,430	871,918
Non-white	209,032	201,315	208,607	209,964	189,119	207,807	192,982	189,670
Unknown	592,854	570,436	579,308	583,135	544,029	581,860	552,313	549,298
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
White	1,739,364	1,676,641	1,751,555	1,741,454	1,598,118	1,761,456	1,643,473	1,642,817
Non-white	389,172	375,380	386,628	390,281	355,075	386,600	361,108	356,605
Unknown	970,576	935,422	947,079	957,161	896,685	956,503	911,286	907,503
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
White	5,733,995	5,559,521	5,722,170	5,726,348	5,371,835	5,779,284	5,500,029	5,503,644
Non-white	1,135,455	1,102,353	1,127,356	1,137,070	1,059,288	1,132,025	1,074,852	1,066,371
Unknown	2,444,450	2,361,720	2,387,815	2,418,417	2,285,699	2,425,931	2,332,169	2,325,362

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
Enrollees with at least one day of coverage								
White	23,174,114	23,207,276	23,250,999	23,307,434	23,357,403	23,390,771	23,406,300	23,414,813
Non-white	4,019,865	4,022,834	4,037,138	4,050,287	4,056,144	4,059,831	4,061,294	4,063,774
Unknown	33,791,327	33,776,559	33,701,769	33,734,871	33,748,331	33,739,360	33,711,731	33,676,440
	Number of patients with dispensing per 1,000 eligible members							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing								
White: HCTZ-containing	69.2	66.6	69.6	68.9	63.0	69.5	64.6	64.5
Non-white: HCTZ-containing	88.8	85.4	87.9	88.4	80.0	87.2	81.3	80.1
Unknown: HCTZ-containing	27.2	26.2	26.6	26.8	25.1	26.7	25.5	25.4
HCTZ single ingredient								
White: HCTZ single ingredient	29.2	28.2	29.1	29.1	26.9	29.1	27.5	27.6
Non-white: HCTZ single ingredient	37.2	35.8	36.7	37.0	33.8	36.4	34.1	33.8
Unknown: HCTZ single ingredient	9.8	9.4	9.5	9.7	9.1	9.6	9.2	9.2
HCTZ combination								
White: HCTZ combination	40.3	38.7	40.8	40.2	36.4	40.7	37.4	37.2
Non-white: HCTZ combination	52.0	50.0	51.7	51.8	46.6	51.2	47.5	46.7
Unknown: HCTZ combination	17.5	16.9	17.2	17.3	16.1	17.2	16.4	16.3

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White: Limited denominator</i>	75.1	72.2	75.3	74.7	68.4	75.3	70.2	70.2
<i>Non-white: Limited denominator</i>	96.8	93.3	95.8	96.4	87.5	95.2	88.9	87.8
<i>Unknown: Limited denominator</i>	28.7	27.7	28.1	28.4	26.6	28.3	27.0	26.9
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White: Full denominator</i>	247.4	239.6	246.1	245.7	230.0	247.1	235.0	235.0
<i>Non-white: Full denominator</i>	282.5	274.0	279.2	280.7	261.2	278.8	264.7	262.4
<i>Unknown: Full denominator</i>	72.3	69.9	70.9	71.7	67.7	71.9	69.2	69.1
	<b>Proportion of numerators / denominators</b>							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>White: HCTZ-containing products</i>	0.922	0.922	0.924	0.923	0.921	0.923	0.920	0.919
<i>Non-white: HCTZ-containing products</i>	0.917	0.915	0.917	0.917	0.914	0.915	0.914	0.913
<i>Unknown: HCTZ-containing products</i>	0.946	0.945	0.945	0.945	0.944	0.944	0.943	0.942
HCTZ single ingredient numerator, limited denominator								
<i>White: HCTZ single ingredient</i>	0.389	0.390	0.387	0.389	0.393	0.387	0.391	0.393
<i>Non-white: HCTZ single ingredient</i>	0.384	0.383	0.383	0.384	0.386	0.382	0.384	0.385
<i>Unknown: HCTZ single ingredient</i>	0.340	0.340	0.339	0.341	0.342	0.340	0.342	0.342
HCTZ combination products numerator, limited denominator								
<i>White: HCTZ combination products</i>	0.537	0.536	0.542	0.539	0.532	0.540	0.533	0.531
<i>Non-white: HCTZ combination products</i>	0.537	0.536	0.540	0.538	0.533	0.538	0.534	0.532
<i>Unknown: HCTZ combination products</i>	0.611	0.610	0.612	0.609	0.607	0.608	0.606	0.605

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>White: HCTZ-containing products</i>	0.280	0.278	0.283	0.281	0.274	0.281	0.275	0.274
<i>Non-white: HCTZ-containing products</i>	0.314	0.312	0.315	0.315	0.306	0.313	0.307	0.305
<i>Unknown: HCTZ-containing products</i>	0.375	0.374	0.375	0.374	0.370	0.372	0.368	0.368
HCTZ single ingredient numerator, full denominator								
<i>White: HCTZ single ingredient</i>	0.118	0.118	0.118	0.118	0.117	0.118	0.117	0.117
<i>Non-white: HCTZ single ingredient</i>	0.132	0.131	0.131	0.132	0.129	0.130	0.129	0.129
<i>Unknown: HCTZ single ingredient</i>	0.135	0.135	0.135	0.135	0.134	0.134	0.134	0.133
HCTZ combination products numerator, full denominator								
<i>White: HCTZ combination products</i>	0.163	0.162	0.166	0.164	0.158	0.165	0.159	0.158
<i>Non-white: HCTZ combination products</i>	0.184	0.183	0.185	0.185	0.179	0.184	0.180	0.178
<i>Unknown: HCTZ combination products</i>	0.243	0.242	0.243	0.241	0.238	0.240	0.237	0.236

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products								
White	1,598,944	1,417,974	1,506,503	1,554,165	1,531,539	1,443,854	1,547,475	1,483,558
Non-white	339,854	307,548	324,734	329,682	327,150	307,843	327,359	316,624
Unknown	849,777	788,543	838,522	841,040	839,294	798,777	824,243	812,249
HCTZ single ingredient/monotherapy								
White	685,087	615,008	655,788	679,322	674,715	641,069	684,277	671,108
Non-white	144,667	133,100	141,121	143,958	143,871	136,369	144,804	142,460
Unknown	311,665	292,441	315,118	318,220	319,675	307,207	318,273	321,024
HCTZ combination products								
White	921,870	809,638	858,067	882,581	864,303	809,568	870,583	819,639
Non-white	197,020	176,123	185,412	187,539	185,084	172,975	184,299	175,806
Unknown	543,592	501,215	528,901	528,144	524,993	496,811	511,310	497,441
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
White	1,735,741	1,542,293	1,639,894	1,690,258	1,668,170	1,572,859	1,684,000	1,617,161
Non-white	372,448	337,364	356,513	362,066	359,531	338,875	360,126	348,976
Unknown	901,940	837,586	891,804	894,591	893,723	850,887	878,113	866,145
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
White	5,738,583	5,225,833	5,530,703	5,655,903	5,617,295	5,353,804	5,662,595	5,506,613
Non-white	1,108,251	1,021,260	1,077,053	1,088,651	1,084,429	1,033,046	1,088,195	1,063,039
Unknown	2,315,915	2,171,282	2,311,727	2,320,617	2,323,247	2,222,655	2,291,018	2,272,640

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
Enrollees with at least one day of coverage								
<i>White</i>	23,644,803	23,661,488	23,686,385	23,683,169	23,673,706	23,696,794	23,756,609	23,803,936
<i>Non-white</i>	4,060,858	4,060,926	4,065,766	4,060,155	4,048,132	4,047,633	4,058,435	4,068,816
<i>Unknown</i>	33,180,970	33,090,728	33,074,440	33,003,313	32,965,124	32,880,501	32,847,193	32,778,790
	Number of patients with dispensing per 1,000 eligible members							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>White: HCTZ-containing</i>	67.6	59.9	63.6	65.6	64.7	60.9	65.1	62.3
<i>Non-white: HCTZ-containing</i>	83.7	75.7	79.9	81.2	80.8	76.1	80.7	77.8
<i>Unknown: HCTZ-containing</i>	25.6	23.8	25.4	25.5	25.5	24.3	25.1	24.8
HCTZ single ingredient								
<i>White: HCTZ single ingredient</i>	29.0	26.0	27.7	28.7	28.5	27.1	28.8	28.2
<i>Non-white: HCTZ single ingredient</i>	35.6	32.8	34.7	35.5	35.5	33.7	35.7	35.0
<i>Unknown: HCTZ single ingredient</i>	9.4	8.8	9.5	9.6	9.7	9.3	9.7	9.8
HCTZ combination								
<i>White: HCTZ combination</i>	39.0	34.2	36.2	37.3	36.5	34.2	36.6	34.4
<i>Non-white: HCTZ combination</i>	48.5	43.4	45.6	46.2	45.7	42.7	45.4	43.2
<i>Unknown: HCTZ combination</i>	16.4	15.1	16.0	16.0	15.9	15.1	15.6	15.2

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White: Limited denominator</i>	73.4	65.2	69.2	71.4	70.5	66.4	70.9	67.9
<i>Non-white: Limited denominator</i>	91.7	83.1	87.7	89.2	88.8	83.7	88.7	85.8
<i>Unknown: Limited denominator</i>	27.2	25.3	27.0	27.1	27.1	25.9	26.7	26.4
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White: Full denominator</i>	242.7	220.9	233.5	238.8	237.3	225.9	238.4	231.3
<i>Non-white: Full denominator</i>	272.9	251.5	264.9	268.1	267.9	255.2	268.1	261.3
<i>Unknown: Full denominator</i>	69.8	65.6	69.9	70.3	70.5	67.6	69.7	69.3
<b>Proportion of numerators / denominators</b>								
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>White: HCTZ-containing products</i>	0.921	0.919	0.919	0.919	0.918	0.918	0.919	0.917
<i>Non-white: HCTZ-containing products</i>	0.912	0.912	0.911	0.911	0.910	0.908	0.909	0.907
<i>Unknown: HCTZ-containing products</i>	0.942	0.941	0.940	0.940	0.939	0.939	0.939	0.938
HCTZ single ingredient numerator, limited denominator								
<i>White: HCTZ single ingredient</i>	0.395	0.399	0.400	0.402	0.404	0.408	0.406	0.415
<i>Non-white: HCTZ single ingredient</i>	0.388	0.395	0.396	0.398	0.400	0.402	0.402	0.408
<i>Unknown: HCTZ single ingredient</i>	0.346	0.349	0.353	0.356	0.358	0.361	0.362	0.371
HCTZ combination products numerator, limited denominator								
<i>White: HCTZ combination products</i>	0.531	0.525	0.523	0.522	0.518	0.515	0.517	0.507
<i>Non-white: HCTZ combination products</i>	0.529	0.522	0.520	0.518	0.515	0.510	0.512	0.504
<i>Unknown: HCTZ combination products</i>	0.603	0.598	0.593	0.590	0.587	0.584	0.582	0.574



Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>White: HCTZ-containing products</i>	0.279	0.271	0.272	0.275	0.273	0.270	0.273	0.269
<i>Non-white: HCTZ-containing products</i>	0.307	0.301	0.302	0.303	0.302	0.298	0.301	0.298
<i>Unknown: HCTZ-containing products</i>	0.367	0.363	0.363	0.362	0.361	0.359	0.360	0.357
HCTZ single ingredient numerator, full denominator								
<i>White: HCTZ single ingredient</i>	0.119	0.118	0.119	0.120	0.120	0.120	0.121	0.122
<i>Non-white: HCTZ single ingredient</i>	0.131	0.130	0.131	0.132	0.133	0.132	0.133	0.134
<i>Unknown: HCTZ single ingredient</i>	0.135	0.135	0.136	0.137	0.138	0.138	0.139	0.141
HCTZ combination products numerator, full denominator								
<i>White: HCTZ combination products</i>	0.161	0.155	0.155	0.156	0.154	0.151	0.154	0.149
<i>Non-white: HCTZ combination products</i>	0.178	0.172	0.172	0.172	0.171	0.167	0.169	0.165
<i>Unknown: HCTZ combination products</i>	0.235	0.231	0.229	0.228	0.226	0.224	0.223	0.219

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>White</i>	1,431,636	1,518,924	1,391,210	1,501,905	1,525,269	1,379,671	1,603,577	1,413,559
<i>Non-white</i>	301,927	318,615	292,392	309,314	313,840	288,116	329,747	295,317
<i>Unknown</i>	785,365	820,940	767,048	769,181	805,747	760,042	853,131	768,184
HCTZ single ingredient/monotherapy								
<i>White</i>	665,128	728,898	689,907	762,688	779,821	710,055	822,597	723,890
<i>Non-white</i>	139,665	153,370	146,204	158,351	162,507	148,733	169,561	152,142
<i>Unknown</i>	319,889	351,995	340,511	351,582	373,238	353,946	397,443	357,848
HCTZ combination products								
<i>White</i>	773,729	799,561	709,292	748,420	754,547	676,791	790,034	697,014
<i>Non-white</i>	163,884	167,374	148,033	152,994	153,354	141,067	162,301	144,904
<i>Unknown</i>	472,763	479,285	436,334	426,436	440,958	412,706	463,617	416,241
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White</i>	1,560,664	1,655,313	1,518,872	1,638,610	1,664,842	1,508,832	1,749,241	1,543,261
<i>Non-white</i>	332,894	351,598	323,086	341,673	346,731	318,914	364,239	326,352
<i>Unknown</i>	837,660	876,193	819,259	822,039	861,867	813,910	913,062	822,432
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White</i>	5,356,430	5,622,405	5,243,121	5,578,982	5,641,019	5,219,919	5,887,027	5,282,193
<i>Non-white</i>	1,026,904	1,079,135	1,004,246	1,056,323	1,064,313	996,784	1,108,392	1,008,490
<i>Unknown</i>	2,212,768	2,314,627	2,179,911	2,196,792	2,309,831	2,199,329	2,442,625	2,211,349

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>Enrollees with at least one day of coverage</b>								
<i>White</i>	23,842,815	23,876,952	23,903,253	23,915,695	24,164,029	24,163,256	24,171,767	24,195,739
<i>Non-white</i>	4,073,163	4,084,216	4,093,209	4,102,147	4,098,487	4,094,647	4,093,419	4,093,223
<i>Unknown</i>	32,767,973	32,745,108	32,707,143	32,668,413	32,826,956	32,691,105	32,647,925	32,482,327
	Number of patients with dispensing per 1,000 eligible members							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>White: HCTZ-containing</i>	60.0	63.6	58.2	62.8	63.1	57.1	66.3	58.4
<i>Non-white: HCTZ-containing</i>	74.1	78.0	71.4	75.4	76.6	70.4	80.6	72.1
<i>Unknown: HCTZ-containing</i>	24.0	25.1	23.5	23.5	24.5	23.2	26.1	23.6
<b>HCTZ single ingredient</b>								
<i>White: HCTZ single ingredient</i>	27.9	30.5	28.9	31.9	32.3	29.4	34.0	29.9
<i>Non-white: HCTZ single ingredient</i>	34.3	37.6	35.7	38.6	39.7	36.3	41.4	37.2
<i>Unknown: HCTZ single ingredient</i>	9.8	10.7	10.4	10.8	11.4	10.8	12.2	11.0
<b>HCTZ combination</b>								
<i>White: HCTZ combination</i>	32.5	33.5	29.7	31.3	31.2	28.0	32.7	28.8
<i>Non-white: HCTZ combination</i>	40.2	41.0	36.2	37.3	37.4	34.5	39.6	35.4
<i>Unknown: HCTZ combination</i>	14.4	14.6	13.3	13.1	13.4	12.6	14.2	12.8

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White: Limited denominator</i>	65.5	69.3	63.5	68.5	68.9	62.4	72.4	63.8
<i>Non-white: Limited denominator</i>	81.7	86.1	78.9	83.3	84.6	77.9	89.0	79.7
<i>Unknown: Limited denominator</i>	25.6	26.8	25.0	25.2	26.3	24.9	28.0	25.3
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White: Full denominator</i>	224.7	235.5	219.3	233.3	233.4	216.0	243.5	218.3
<i>Non-white: Full denominator</i>	252.1	264.2	245.3	257.5	259.7	243.4	270.8	246.4
<i>Unknown: Full denominator</i>	67.5	70.7	66.6	67.2	70.4	67.3	74.8	68.1
<b>Proportion of numerators / denominators</b>								
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>White: HCTZ-containing products</i>	0.917	0.918	0.916	0.917	0.916	0.914	0.917	0.916
<i>Non-white: HCTZ-containing products</i>	0.907	0.906	0.905	0.905	0.905	0.903	0.905	0.905
<i>Unknown: HCTZ-containing products</i>	0.938	0.937	0.936	0.936	0.935	0.934	0.934	0.934
HCTZ single ingredient numerator, limited denominator								
<i>White: HCTZ single ingredient</i>	0.426	0.440	0.454	0.465	0.468	0.471	0.470	0.469
<i>Non-white: HCTZ single ingredient</i>	0.420	0.436	0.453	0.463	0.469	0.466	0.466	0.466
<i>Unknown: HCTZ single ingredient</i>	0.382	0.402	0.416	0.428	0.433	0.435	0.435	0.435
HCTZ combination products numerator, limited denominator								
<i>White: HCTZ combination products</i>	0.496	0.483	0.467	0.457	0.453	0.449	0.452	0.452
<i>Non-white: HCTZ combination products</i>	0.492	0.476	0.458	0.448	0.442	0.442	0.446	0.444
<i>Unknown: HCTZ combination products</i>	0.564	0.547	0.533	0.519	0.512	0.507	0.508	0.506

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>White: HCTZ-containing products</i>	0.267	0.270	0.265	0.269	0.270	0.264	0.272	0.268
<i>Non-white: HCTZ-containing products</i>	0.294	0.295	0.291	0.293	0.295	0.289	0.298	0.293
<i>Unknown: HCTZ-containing products</i>	0.355	0.355	0.352	0.350	0.349	0.346	0.349	0.347
HCTZ single ingredient numerator, full denominator								
<i>White: HCTZ single ingredient</i>	0.124	0.130	0.132	0.137	0.138	0.136	0.140	0.137
<i>Non-white: HCTZ single ingredient</i>	0.136	0.142	0.146	0.150	0.153	0.149	0.153	0.151
<i>Unknown: HCTZ single ingredient</i>	0.145	0.152	0.156	0.160	0.162	0.161	0.163	0.162
HCTZ combination products numerator, full denominator								
<i>White: HCTZ combination products</i>	0.144	0.142	0.135	0.134	0.134	0.130	0.134	0.132
<i>Non-white: HCTZ combination products</i>	0.160	0.155	0.147	0.145	0.144	0.142	0.146	0.144
<i>Unknown: HCTZ combination products</i>	0.214	0.207	0.200	0.194	0.191	0.188	0.190	0.188

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
White	1,392,329	1,503,803	1,444,774	1,432,325	1,426,204	1,429,235	1,378,372	1,473,424
Non-white	286,273	308,843	298,648	294,438	294,434	295,038	281,145	302,767
Unknown	754,018	781,969	765,441	750,912	740,740	741,884	707,834	745,170
HCTZ single ingredient/monotherapy								
White	714,369	771,903	741,012	732,185	724,052	722,114	694,931	740,264
Non-white	146,635	158,357	152,698	149,781	148,714	147,770	140,903	150,727
Unknown	349,755	365,202	358,873	350,359	343,329	341,422	324,353	340,183
HCTZ combination products								
White	684,551	739,582	711,089	706,770	708,503	713,354	689,073	739,288
Non-white	141,185	152,216	147,611	146,197	147,173	148,706	141,501	153,452
Unknown	409,558	422,868	412,713	405,858	401,860	404,710	387,061	408,845
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
White	1,521,293	1,641,617	1,577,878	1,563,599	1,557,259	1,560,432	1,506,219	1,609,739
Non-white	316,701	341,159	330,411	325,460	325,422	326,394	311,310	334,883
Unknown	807,918	837,297	819,950	804,567	793,768	795,438	759,368	799,532
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
White	5,224,501	5,569,987	5,398,262	5,366,456	5,360,782	5,378,637	5,220,977	5,518,093
Non-white	980,262	1,042,084	1,017,949	1,003,239	1,005,781	1,010,866	970,673	1,030,159
Unknown	2,180,454	2,259,403	2,217,484	2,185,062	2,167,498	2,179,769	2,090,474	2,200,154

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
Enrollees with at least one day of coverage								
<i>White</i>	24,199,398	24,220,699	24,280,794	24,297,872	24,331,161	24,343,613	24,356,375	24,349,632
<i>Non-white</i>	4,086,354	4,087,344	4,096,302	4,091,338	4,094,046	4,094,364	4,099,164	4,106,604
<i>Unknown</i>	32,334,660	32,219,114	32,037,323	31,910,939	31,591,958	31,516,120	31,494,159	31,461,997
	Number of patients with dispensing per 1,000 eligible members							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b><i>HCTZ-containing</i></b>								
HCTZ-containing								
<i>White: HCTZ-containing</i>	57.5	62.1	59.5	58.9	58.6	58.7	56.6	60.5
<i>Non-white: HCTZ-containing</i>	70.1	75.6	72.9	72.0	71.9	72.1	68.6	73.7
<i>Unknown: HCTZ-containing</i>	23.3	24.3	23.9	23.5	23.4	23.5	22.5	23.7
HCTZ single ingredient								
<i>White: HCTZ single ingredient</i>	29.5	31.9	30.5	30.1	29.8	29.7	28.5	30.4
<i>Non-white: HCTZ single ingredient</i>	35.9	38.7	37.3	36.6	36.3	36.1	34.4	36.7
<i>Unknown: HCTZ single ingredient</i>	10.8	11.3	11.2	11.0	10.9	10.8	10.3	10.8
HCTZ combination								
<i>White: HCTZ combination</i>	28.3	30.5	29.3	29.1	29.1	29.3	28.3	30.4
<i>Non-white: HCTZ combination</i>	34.6	37.2	36.0	35.7	35.9	36.3	34.5	37.4
<i>Unknown: HCTZ combination</i>	12.7	13.1	12.9	12.7	12.7	12.8	12.3	13.0

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White: Limited denominator</i>	62.9	67.8	65.0	64.4	64.0	64.1	61.8	66.1
<i>Non-white: Limited denominator</i>	77.5	83.5	80.7	79.5	79.5	79.7	75.9	81.5
<i>Unknown: Limited denominator</i>	25.0	26.0	25.6	25.2	25.1	25.2	24.1	25.4
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White: Full denominator</i>	215.9	230.0	222.3	220.9	220.3	220.9	214.4	226.6
<i>Non-white: Full denominator</i>	239.9	255.0	248.5	245.2	245.7	246.9	236.8	250.9
<i>Unknown: Full denominator</i>	67.4	70.1	69.2	68.5	68.6	69.2	66.4	69.9
<b>Proportion of numerators / denominators</b>								
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>White: HCTZ-containing products</i>	0.915	0.916	0.916	0.916	0.916	0.916	0.915	0.915
<i>Non-white: HCTZ-containing products</i>	0.904	0.905	0.904	0.905	0.905	0.904	0.903	0.904
<i>Unknown: HCTZ-containing products</i>	0.933	0.934	0.934	0.933	0.933	0.933	0.932	0.932
HCTZ single ingredient numerator, limited denominator								
<i>White: HCTZ single ingredient</i>	0.470	0.470	0.470	0.468	0.465	0.463	0.461	0.460
<i>Non-white: HCTZ single ingredient</i>	0.463	0.464	0.462	0.460	0.457	0.453	0.453	0.450
<i>Unknown: HCTZ single ingredient</i>	0.433	0.436	0.438	0.435	0.433	0.429	0.427	0.425
HCTZ combination products numerator, limited denominator								
<i>White: HCTZ combination products</i>	0.450	0.451	0.451	0.452	0.455	0.457	0.457	0.459
<i>Non-white: HCTZ combination products</i>	0.446	0.446	0.447	0.449	0.452	0.456	0.455	0.458
<i>Unknown: HCTZ combination products</i>	0.507	0.505	0.503	0.504	0.506	0.509	0.510	0.511



Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>White: HCTZ-containing products</i>	0.266	0.270	0.268	0.267	0.266	0.266	0.264	0.267
<i>Non-white: HCTZ-containing products</i>	0.292	0.296	0.293	0.293	0.293	0.292	0.290	0.294
<i>Unknown: HCTZ-containing products</i>	0.346	0.346	0.345	0.344	0.342	0.340	0.339	0.339
HCTZ single ingredient numerator, full denominator								
<i>White: HCTZ single ingredient</i>	0.137	0.139	0.137	0.136	0.135	0.134	0.133	0.134
<i>Non-white: HCTZ single ingredient</i>	0.150	0.152	0.150	0.149	0.148	0.146	0.145	0.146
<i>Unknown: HCTZ single ingredient</i>	0.160	0.162	0.162	0.160	0.158	0.157	0.155	0.155
HCTZ combination products numerator, full denominator								
<i>White: HCTZ combination products</i>	0.131	0.133	0.132	0.132	0.132	0.133	0.132	0.134
<i>Non-white: HCTZ combination products</i>	0.144	0.146	0.145	0.146	0.146	0.147	0.146	0.149
<i>Unknown: HCTZ combination products</i>	0.188	0.187	0.186	0.186	0.185	0.186	0.185	0.186

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products								
White	1,389,820	1,262,516	1,441,558	1,382,047	1,329,838	1,398,437	1,366,899	1,361,245
Non-white	281,731	256,350	290,676	277,418	265,334	278,811	271,895	268,849
Unknown	722,615	682,869	766,626	736,836	721,829	746,185	733,675	729,867
HCTZ single ingredient/monotherapy								
White	699,538	635,435	722,912	693,010	669,037	701,376	685,375	681,686
Non-white	141,225	128,007	144,276	137,590	132,222	138,175	134,863	132,941
Unknown	329,334	310,110	348,371	335,113	327,389	338,994	332,954	330,285
HCTZ combination products								
White	695,833	631,921	724,591	694,350	665,782	702,392	686,625	684,481
Non-white	141,705	129,394	147,654	141,038	134,193	141,798	138,141	136,987
Unknown	396,907	376,014	422,197	405,414	397,852	410,760	404,125	402,930
<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
White	1,518,404	1,381,900	1,577,557	1,512,367	1,456,681	1,530,076	1,495,275	1,489,536
Non-white	312,262	284,229	322,477	308,106	294,637	309,159	302,054	298,531
Unknown	775,565	733,714	823,885	792,267	776,436	802,537	789,465	785,031
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
White	5,227,617	4,835,557	5,428,442	5,238,870	5,089,635	5,307,471	5,212,410	5,202,288
Non-white	966,993	892,959	996,161	959,041	924,253	962,582	944,014	934,728
Unknown	2,149,522	2,043,923	2,282,874	2,209,052	2,166,826	2,239,879	2,215,149	2,205,951

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
Enrollees with at least one day of coverage								
<i>White</i>	23,964,473	23,898,411	23,865,241	23,825,399	23,804,948	23,805,278	23,844,559	23,861,039
<i>Non-white</i>	4,021,627	3,995,598	3,977,665	3,958,063	3,942,666	3,936,866	3,940,526	3,946,434
<i>Unknown</i>	31,795,013	31,751,350	31,784,734	31,780,499	31,778,253	31,815,926	31,824,214	31,924,565
	Number of patients with dispensing per 1,000 eligible members							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing								
<i>White: HCTZ-containing</i>	58.0	52.8	60.4	58.0	55.9	58.7	57.3	57.0
<i>Non-white: HCTZ-containing</i>	70.1	64.2	73.1	70.1	67.3	70.8	69.0	68.1
<i>Unknown: HCTZ-containing</i>	22.7	21.5	24.1	23.2	22.7	23.5	23.1	22.9
HCTZ single ingredient								
<i>White: HCTZ single ingredient</i>	29.2	26.6	30.3	29.1	28.1	29.5	28.7	28.6
<i>Non-white: HCTZ single ingredient</i>	35.1	32.0	36.3	34.8	33.5	35.1	34.2	33.7
<i>Unknown: HCTZ single ingredient</i>	10.4	9.8	11.0	10.5	10.3	10.7	10.5	10.3
HCTZ combination								
<i>White: HCTZ combination</i>	29.0	26.4	30.4	29.1	28.0	29.5	28.8	28.7
<i>Non-white: HCTZ combination</i>	35.2	32.4	37.1	35.6	34.0	36.0	35.1	34.7
<i>Unknown: HCTZ combination</i>	12.5	11.8	13.3	12.8	12.5	12.9	12.7	12.6

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
<i>White: Limited denominator</i>	63.4	57.8	66.1	63.5	61.2	64.3	62.7	62.4
<i>Non-white: Limited denominator</i>	77.6	71.1	81.1	77.8	74.7	78.5	76.7	75.6
<i>Unknown: Limited denominator</i>	24.4	23.1	25.9	24.9	24.4	25.2	24.8	24.6
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
<i>White: Full denominator</i>	218.1	202.3	227.5	219.9	213.8	223.0	218.6	218.0
<i>Non-white: Full denominator</i>	240.4	223.5	250.4	242.3	234.4	244.5	239.6	236.9
<i>Unknown: Full denominator</i>	67.6	64.4	71.8	69.5	68.2	70.4	69.6	69.1
<b>Proportion of numerators / denominators</b>								
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>White: HCTZ-containing products</i>	0.915	0.914	0.914	0.914	0.913	0.914	0.914	0.914
<i>Non-white: HCTZ-containing products</i>	0.902	0.902	0.901	0.900	0.901	0.902	0.900	0.901
<i>Unknown: HCTZ-containing products</i>	0.932	0.931	0.931	0.930	0.930	0.930	0.929	0.930
HCTZ single ingredient numerator, limited denominator								
<i>White: HCTZ single ingredient</i>	0.461	0.460	0.458	0.458	0.459	0.458	0.458	0.458
<i>Non-white: HCTZ single ingredient</i>	0.452	0.450	0.447	0.447	0.449	0.447	0.446	0.445
<i>Unknown: HCTZ single ingredient</i>	0.425	0.423	0.423	0.423	0.422	0.422	0.422	0.421
HCTZ combination products numerator, limited denominator								
<i>White: HCTZ combination products</i>	0.458	0.457	0.459	0.459	0.457	0.459	0.459	0.460
<i>Non-white: HCTZ combination products</i>	0.454	0.455	0.458	0.458	0.455	0.459	0.457	0.459
<i>Unknown: HCTZ combination products</i>	0.512	0.512	0.512	0.512	0.512	0.512	0.512	0.513

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>White: HCTZ-containing products</i>	0.266	0.261	0.266	0.264	0.261	0.263	0.262	0.262
<i>Non-white: HCTZ-containing products</i>	0.291	0.287	0.292	0.289	0.287	0.290	0.288	0.288
<i>Unknown: HCTZ-containing products</i>	0.336	0.334	0.336	0.334	0.333	0.333	0.331	0.331
HCTZ single ingredient numerator, full denominator								
<i>White: HCTZ single ingredient</i>	0.134	0.131	0.133	0.132	0.131	0.132	0.131	0.131
<i>Non-white: HCTZ single ingredient</i>	0.146	0.143	0.145	0.143	0.143	0.144	0.143	0.142
<i>Unknown: HCTZ single ingredient</i>	0.153	0.152	0.153	0.152	0.151	0.151	0.150	0.150
HCTZ combination products numerator, full denominator								
<i>White: HCTZ combination products</i>	0.133	0.131	0.133	0.133	0.131	0.132	0.132	0.132
<i>Non-white: HCTZ combination products</i>	0.147	0.145	0.148	0.147	0.145	0.147	0.146	0.147
<i>Unknown: HCTZ combination products</i>	0.185	0.184	0.185	0.184	0.184	0.183	0.182	0.183

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>HCTZ-containing</b>							
HCTZ-containing products							
White	1,328,441	1,329,380	1,312,579	1,344,166	1,270,298	997,831	1,111,524
Non-white	263,989	261,249	256,545	260,984	238,132	158,569	174,425
Unknown	718,636	716,513	701,612	701,665	517,586	419,472	129,967
HCTZ single ingredient/monotherapy							
White	664,634	662,334	655,942	676,689	647,117	511,387	566,226
Non-white	130,201	128,528	126,213	130,026	120,486	81,805	89,013
Unknown	324,985	323,103	315,586	319,482	241,776	196,403	62,504
HCTZ combination products							
White	668,577	671,795	661,243	672,613	628,135	490,281	549,727
Non-white	134,822	133,719	131,290	131,975	118,680	77,420	86,201
Unknown	396,818	396,577	389,103	385,800	278,209	224,878	68,071
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
White	1,453,479	1,453,769	1,437,121	1,472,470	1,391,628	1,095,309	1,220,142
Non-white	292,999	290,162	285,227	290,277	265,078	177,111	194,841
Unknown	773,399	771,651	756,145	756,690	560,192	454,153	142,030
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
White	5,088,460	5,100,166	5,067,637	5,175,035	4,891,240	3,904,504	4,287,408
Non-white	918,055	913,923	901,768	919,279	845,024	588,088	637,961
Unknown	2,180,231	2,180,510	2,154,084	2,161,816	1,649,229	1,341,681	455,460

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
Enrollees with at least one day of coverage							
<i>White</i>	23,856,274	23,843,589	23,837,115	23,830,034	23,421,808	20,524,330	20,520,459
<i>Non-white</i>	3,940,901	3,931,041	3,933,780	3,938,655	3,829,051	3,039,061	3,032,922
<i>Unknown</i>	31,965,820	31,990,672	32,039,790	32,084,856	21,838,140	20,210,900	5,531,935
	Number of patients with dispensing per 1,000 eligible members						
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b><i>HCTZ-containing</i></b>							
HCTZ-containing							
<i>White: HCTZ-containing</i>	55.7	55.8	55.1	56.4	54.2	48.6	54.2
<i>Non-white: HCTZ-containing</i>	67.0	66.5	65.2	66.3	62.2	52.2	57.5
<i>Unknown: HCTZ-containing</i>	22.5	22.4	21.9	21.9	23.7	20.8	23.5
HCTZ single ingredient							
<i>White: HCTZ single ingredient</i>	27.9	27.8	27.5	28.4	27.6	24.9	27.6
<i>Non-white: HCTZ single ingredient</i>	33.0	32.7	32.1	33.0	31.5	26.9	29.3
<i>Unknown: HCTZ single ingredient</i>	10.2	10.1	9.8	10.0	11.1	9.7	11.3
HCTZ combination							
<i>White: HCTZ combination</i>	28.0	28.2	27.7	28.2	26.8	23.9	26.8
<i>Non-white: HCTZ combination</i>	34.2	34.0	33.4	33.5	31.0	25.5	28.4
<i>Unknown: HCTZ combination</i>	12.4	12.4	12.1	12.0	12.7	11.1	12.3

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>White: Limited denominator</i>	60.9	61.0	60.3	61.8	59.4	53.4	59.5
<i>Non-white: Limited denominator</i>	74.3	73.8	72.5	73.7	69.2	58.3	64.2
<i>Unknown: Limited denominator</i>	24.2	24.1	23.6	23.6	25.7	22.5	25.7
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<i>White: Full denominator</i>	213.3	213.9	212.6	217.2	208.8	190.2	208.9
<i>Non-white: Full denominator</i>	233.0	232.5	229.2	233.4	220.7	193.5	210.3
<i>Unknown: Full denominator</i>	68.2	68.2	67.2	67.4	75.5	66.4	82.3
<b>Proportion of numerators / denominators</b>							
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>White: HCTZ-containing products</i>	0.914	0.914	0.913	0.913	0.913	0.911	0.911
<i>Non-white: HCTZ-containing products</i>	0.901	0.900	0.899	0.899	0.898	0.895	0.895
<i>Unknown: HCTZ-containing products</i>	0.929	0.929	0.928	0.927	0.924	0.924	0.915
HCTZ single ingredient numerator, limited denominator							
<i>White: HCTZ single ingredient</i>	0.457	0.456	0.456	0.460	0.465	0.467	0.464
<i>Non-white: HCTZ single ingredient</i>	0.444	0.443	0.443	0.448	0.455	0.462	0.457
<i>Unknown: HCTZ single ingredient</i>	0.420	0.419	0.417	0.422	0.432	0.432	0.440
HCTZ combination products numerator, limited denominator							
<i>White: HCTZ combination products</i>	0.460	0.462	0.460	0.457	0.451	0.448	0.451
<i>Non-white: HCTZ combination products</i>	0.460	0.461	0.460	0.455	0.448	0.437	0.442
<i>Unknown: HCTZ combination products</i>	0.513	0.514	0.515	0.510	0.497	0.495	0.479



Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>White: HCTZ-containing products</i>	0.261	0.261	0.259	0.260	0.260	0.256	0.259
<i>Non-white: HCTZ-containing products</i>	0.288	0.286	0.284	0.284	0.282	0.270	0.273
<i>Unknown: HCTZ-containing products</i>	0.330	0.329	0.326	0.325	0.314	0.313	0.285
HCTZ single ingredient numerator, full denominator							
<i>White: HCTZ single ingredient</i>	0.131	0.130	0.129	0.131	0.132	0.131	0.132
<i>Non-white: HCTZ single ingredient</i>	0.142	0.141	0.140	0.141	0.143	0.139	0.140
<i>Unknown: HCTZ single ingredient</i>	0.149	0.148	0.147	0.148	0.147	0.146	0.137
HCTZ combination products numerator, full denominator							
<i>White: HCTZ combination products</i>	0.131	0.132	0.130	0.130	0.128	0.126	0.128
<i>Non-white: HCTZ combination products</i>	0.147	0.146	0.146	0.144	0.140	0.132	0.135
<i>Unknown: HCTZ combination products</i>	0.182	0.182	0.181	0.178	0.169	0.168	0.149

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Patients with dispensing per month		
	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>			
HCTZ-containing products			
<i>White</i>	82,402	83,492	81,390
<i>Non-white</i>	26,679	27,167	26,724
<i>Unknown</i>	57,597	58,317	56,961
HCTZ single ingredient/monotherapy			
<i>White</i>	40,029	40,658	39,493
<i>Non-white</i>	12,674	12,835	12,671
<i>Unknown</i>	25,805	26,053	25,574
HCTZ combination products			
<i>White</i>	42,649	43,112	42,166
<i>Non-white</i>	14,118	14,426	14,160
<i>Unknown</i>	32,041	32,525	31,620
<b>Denominators</b>			
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic			
<i>White</i>	89,201	90,420	88,322
<i>Non-white</i>	29,294	29,850	29,300
<i>Unknown</i>	62,229	62,982	61,573
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive			
<i>White</i>	290,156	296,213	289,128
<i>Non-white</i>	80,144	81,846	80,585
<i>Unknown</i>	174,450	176,531	173,417

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

	Eligible members per month		
	Apr-22	May-22	Jun-22
Enrollees with at least one day of coverage			
<i>White</i>	3,106,042	3,117,618	3,123,734
<i>Non-white</i>	1,008,885	1,012,666	1,015,707
<i>Unknown</i>	4,139,567	4,161,664	4,180,509
	Number of patients with dispensing per 1,000 eligible members		
	Apr-22	May-22	Jun-22
<b><i>HCTZ-containing</i></b>			
HCTZ-containing			
<i>White: HCTZ-containing</i>	26.5	26.8	26.1
<i>Non-white: HCTZ-containing</i>	26.4	26.8	26.3
<i>Unknown: HCTZ-containing</i>	13.9	14.0	13.6
HCTZ single ingredient			
<i>White: HCTZ single ingredient</i>	12.9	13.0	12.6
<i>Non-white: HCTZ single ingredient</i>	12.6	12.7	12.5
<i>Unknown: HCTZ single ingredient</i>	6.2	6.3	6.1
HCTZ combination			
<i>White: HCTZ combination</i>	13.7	13.8	13.5
<i>Non-white: HCTZ combination</i>	14.0	14.2	13.9
<i>Unknown: HCTZ combination</i>	7.7	7.8	7.6

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Denominators</b>			
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic			
<i>White: Limited denominator</i>	28.7	29.0	28.3
<i>Non-white: Limited denominator</i>	29.0	29.5	28.8
<i>Unknown: Limited denominator</i>	15.0	15.1	14.7
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive			
<i>White: Full denominator</i>	93.4	95.0	92.6
<i>Non-white: Full denominator</i>	79.4	80.8	79.3
<i>Unknown: Full denominator</i>	42.1	42.4	41.5
<b>Proportion of numerators / denominators</b>			
	Apr-22	May-22	Jun-22
<b>Proportions, limited denominator</b>			
HCTZ-containing numerator, limited denominator			
<i>White: HCTZ-containing products</i>	0.924	0.923	0.922
<i>Non-white: HCTZ-containing products</i>	0.911	0.910	0.912
<i>Unknown: HCTZ-containing products</i>	0.926	0.926	0.925
HCTZ single ingredient numerator, limited denominator			
<i>White: HCTZ single ingredient</i>	0.449	0.450	0.447
<i>Non-white: HCTZ single ingredient</i>	0.433	0.430	0.432
<i>Unknown: HCTZ single ingredient</i>	0.415	0.414	0.415
HCTZ combination products numerator, limited denominator			
<i>White: HCTZ combination products</i>	0.478	0.477	0.477
<i>Non-white: HCTZ combination products</i>	0.482	0.483	0.483
<i>Unknown: HCTZ combination products</i>	0.515	0.516	0.514

Table 4b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month

<b>Proportions, full denominator</b>			
HCTZ-containing numerator, full denominator			
<i>White: HCTZ-containing products</i>	0.284	0.282	0.282
<i>Non-white: HCTZ-containing products</i>	0.333	0.332	0.332
<i>Unknown: HCTZ-containing products</i>	0.330	0.330	0.328
HCTZ single ingredient numerator, full denominator			
<i>White: HCTZ single ingredient</i>	0.138	0.137	0.137
<i>Non-white: HCTZ single ingredient</i>	0.158	0.157	0.157
<i>Unknown: HCTZ single ingredient</i>	0.148	0.148	0.147
HCTZ combination products numerator, full denominator			
<i>White: HCTZ combination products</i>	0.147	0.146	0.146
<i>Non-white: HCTZ combination products</i>	0.176	0.176	0.176
<i>Unknown: HCTZ combination products</i>	0.184	0.184	0.182

Figure 4. Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month




Figure 4 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by race and calendar year/month




Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17
<b>HCTZ-containing</b>							
HCTZ-containing products							
<i>0-40</i>							
White	13,576	12,844	13,698	12,875	13,402	13,235	12,924
Non-white	8,901	8,492	9,059	8,500	8,843	8,684	8,419
Unknown	69,821	66,809	73,892	68,882	72,184	70,811	68,817
<i>41-64</i>							
White	216,574	202,313	219,870	204,725	216,319	211,484	207,879
Non-white	109,525	103,018	111,766	103,175	109,048	106,551	104,574
Unknown	676,960	646,204	704,343	669,816	697,963	685,085	675,460
<i>65-74</i>							
White	827,555	743,347	820,438	773,415	820,871	797,884	796,299
Non-white	164,140	152,183	168,206	155,339	165,750	161,757	160,966
Unknown	158,175	147,108	160,620	153,635	161,899	158,288	157,520
<i>75-84</i>							
White	480,659	431,389	477,018	450,309	478,701	466,362	464,805
Non-white	79,350	73,405	80,493	74,868	80,121	77,640	77,234
Unknown	61,324	56,096	61,473	58,757	61,787	60,257	60,095
<i>85+</i>							
White	175,819	159,108	173,214	164,078	173,087	167,783	167,776
Non-white	25,790	23,976	25,994	24,504	25,725	25,366	25,170
Unknown	21,848	20,038	21,903	20,829	21,734	21,349	21,268
HCTZ single ingredient/monotherapy							
<i>0-40</i>							
White	6,476	6,119	6,571	6,190	6,457	6,443	6,284
Non-white	4,285	4,098	4,385	4,188	4,299	4,228	4,108
Unknown	26,570	25,528	28,564	26,770	28,135	27,740	27,109



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<i>41-64</i>							
<i>White</i>	93,990	87,778	95,546	89,299	94,465	92,762	91,187
<i>Non-white</i>	48,688	45,674	49,383	45,830	48,478	47,190	46,711
<i>Unknown</i>	222,533	212,635	233,478	222,999	233,232	229,581	227,476
<i>65-74</i>							
<i>White</i>	323,365	290,647	320,713	303,701	322,730	314,666	314,725
<i>Non-white</i>	63,623	59,446	65,334	60,221	64,729	63,315	63,084
<i>Unknown</i>	59,064	54,627	59,813	57,790	60,605	59,207	59,518
<i>75-84</i>							
<i>White</i>	200,023	179,782	199,504	188,165	200,951	195,965	195,823
<i>Non-white</i>	31,360	28,861	31,678	29,529	31,587	30,777	30,692
<i>Unknown</i>	23,894	22,011	24,052	22,919	24,395	23,678	23,879
<i>85+</i>							
<i>White</i>	81,879	74,373	80,790	77,030	81,450	79,152	79,299
<i>Non-white</i>	11,246	10,594	11,320	10,700	11,236	11,247	11,097
<i>Unknown</i>	9,673	8,835	9,680	9,285	9,689	9,515	9,519
HCTZ combination products							
<i>0-40</i>							
<i>White</i>	7,176	6,780	7,181	6,747	7,032	6,861	6,705
<i>Non-white</i>	4,667	4,444	4,721	4,372	4,594	4,513	4,358
<i>Unknown</i>	43,625	41,613	45,737	42,465	44,437	43,451	42,047
<i>41-64</i>							
<i>White</i>	123,835	115,609	125,569	116,522	123,097	119,857	117,812
<i>Non-white</i>	61,527	57,937	63,040	57,936	61,219	59,999	58,447
<i>Unknown</i>	457,940	436,839	474,675	450,310	468,498	459,125	451,622
<i>65-74</i>							
<i>White</i>	508,044	455,958	503,538	473,088	501,870	486,880	485,019
<i>Non-white</i>	101,313	93,447	103,684	95,776	101,804	99,195	98,636
<i>Unknown</i>	99,880	93,150	101,587	96,585	102,055	99,835	98,727

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>75-84</b>							
<i>White</i>	282,786	253,405	279,705	264,084	279,865	272,461	270,929
<i>Non-white</i>	48,361	44,864	49,222	45,654	48,908	47,214	46,873
<i>Unknown</i>	37,752	34,372	37,713	36,092	37,706	36,856	36,494
<b>85+</b>							
<i>White</i>	94,690	85,419	93,163	87,708	92,355	89,405	89,204
<i>Non-white</i>	14,655	13,500	14,799	13,895	14,584	14,237	14,185
<i>Unknown</i>	12,271	11,287	12,328	11,627	12,145	11,926	11,845
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<b>0-40</b>							
<i>White</i>	14,412	13,626	14,580	13,721	14,245	14,064	13,728
<i>Non-white</i>	9,532	9,071	9,725	9,139	9,476	9,335	9,074
<i>Unknown</i>	73,171	69,968	77,527	72,342	75,741	74,392	72,334
<b>41-64</b>							
<i>White</i>	231,848	216,384	235,589	219,680	231,922	227,085	223,102
<i>Non-white</i>	117,816	110,708	120,436	111,261	117,525	115,015	112,827
<i>Unknown</i>	705,944	673,550	734,793	699,128	728,664	715,607	705,724
<b>65-74</b>							
<i>White</i>	879,350	789,665	872,893	823,314	873,217	849,659	847,910
<i>Non-white</i>	175,912	163,046	180,281	166,837	178,055	174,063	172,917
<i>Unknown</i>	167,322	155,627	170,083	162,669	171,450	167,889	167,088
<b>75-84</b>							
<i>White</i>	519,543	466,539	516,662	487,740	518,246	505,652	503,277
<i>Non-white</i>	86,185	79,631	87,461	81,480	87,179	84,650	84,115
<i>Unknown</i>	65,733	60,173	66,130	63,189	66,407	64,909	64,710

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<i>85+</i>							
<i>White</i>	195,302	177,168	193,039	182,900	192,915	187,328	186,994
<i>Non-white</i>	28,323	26,295	28,552	26,953	28,285	27,908	27,711
<i>Unknown</i>	24,000	21,998	24,011	22,945	23,928	23,448	23,426
<b>Denominators</b>							
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<i>0-40</i>							
<i>White</i>	55,111	52,342	56,038	53,075	55,491	54,485	53,457
<i>Non-white</i>	29,821	28,441	30,706	28,689	29,831	29,479	28,883
<i>Unknown</i>	220,000	210,728	232,599	218,763	229,049	225,049	220,504
<i>41-64</i>							
<i>White</i>	790,229	745,802	802,781	756,420	793,968	779,182	768,969
<i>Non-white</i>	323,987	306,261	330,017	308,228	323,258	318,026	312,388
<i>Unknown</i>	1,586,159	1,520,363	1,649,833	1,573,637	1,637,544	1,607,756	1,587,947
<i>65-74</i>							
<i>White</i>	2,448,924	2,235,600	2,444,224	2,321,192	2,448,524	2,390,998	2,389,046
<i>Non-white</i>	454,843	425,947	463,962	435,806	459,922	451,951	449,249
<i>Unknown</i>	431,176	404,604	439,465	421,745	443,198	434,456	433,823
<i>75-84</i>							
<i>White</i>	1,737,117	1,591,060	1,733,357	1,651,133	1,740,563	1,704,908	1,701,677
<i>Non-white</i>	266,795	250,030	271,180	255,688	269,441	264,700	262,734
<i>Unknown</i>	206,570	192,417	208,910	200,100	209,671	205,683	205,603
<i>85+</i>							
<i>White</i>	929,055	861,405	920,491	882,912	920,577	901,994	901,517
<i>Non-white</i>	117,936	110,950	118,545	112,988	118,054	116,250	115,810
<i>Unknown</i>	105,402	98,847	105,896	101,929	105,891	103,914	104,216

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators						
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.942	0.943	0.940	0.938	0.941	0.941	0.941
<i>0-40: Non-white</i>	0.934	0.936	0.932	0.930	0.933	0.930	0.928
<i>0-40: Unknown</i>	0.954	0.955	0.953	0.952	0.953	0.952	0.951
<i>41-64</i>							
<i>41-64: White</i>	0.934	0.935	0.933	0.932	0.933	0.931	0.932
<i>41-64: Non-white</i>	0.930	0.931	0.928	0.927	0.928	0.926	0.927
<i>41-64: Unknown</i>	0.959	0.959	0.959	0.958	0.958	0.957	0.957
<i>65-74</i>							
<i>65-74: White</i>	0.941	0.941	0.940	0.939	0.940	0.939	0.939
<i>65-74: Non-white</i>	0.933	0.933	0.933	0.931	0.931	0.929	0.931
<i>65-74: Unknown</i>	0.945	0.945	0.944	0.944	0.944	0.943	0.943
<i>75-84</i>							
<i>75-84: White</i>	0.925	0.925	0.923	0.923	0.924	0.922	0.924
<i>75-84: Non-white</i>	0.921	0.922	0.920	0.919	0.919	0.917	0.918
<i>75-84: Unknown</i>	0.933	0.932	0.930	0.930	0.930	0.928	0.929
<i>85+</i>							
<i>85+: White</i>	0.900	0.898	0.897	0.897	0.897	0.896	0.897
<i>85+: Non-white</i>	0.911	0.912	0.910	0.909	0.909	0.909	0.908
<i>85+: Unknown</i>	0.910	0.911	0.912	0.908	0.908	0.910	0.908

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>								
HCTZ-containing numerator, full denominator								
<i>0-40</i>								
<i>0-40: White</i>	0.246	0.245	0.244	0.243	0.242	0.243	0.242	
<i>0-40: Non-white</i>	0.298	0.299	0.295	0.296	0.296	0.295	0.291	
<i>0-40: Unknown</i>	0.317	0.317	0.318	0.315	0.315	0.315	0.312	
<i>41-64</i>								
<i>41-64: White</i>	0.274	0.271	0.274	0.271	0.272	0.271	0.270	
<i>41-64: Non-white</i>	0.338	0.336	0.339	0.335	0.337	0.335	0.335	
<i>41-64: Unknown</i>	0.427	0.425	0.427	0.426	0.426	0.426	0.425	
<i>65-74</i>								
<i>65-74: White</i>	0.338	0.333	0.336	0.333	0.335	0.334	0.333	
<i>65-74: Non-white</i>	0.361	0.357	0.363	0.356	0.360	0.358	0.358	
<i>65-74: Unknown</i>	0.367	0.364	0.365	0.364	0.365	0.364	0.363	
<i>75-84</i>								
<i>75-84: White</i>	0.277	0.271	0.275	0.273	0.275	0.274	0.273	
<i>75-84: Non-white</i>	0.297	0.294	0.297	0.293	0.297	0.293	0.294	
<i>75-84: Unknown</i>	0.297	0.292	0.294	0.294	0.295	0.293	0.292	
<i>85+</i>								
<i>85+: White</i>	0.189	0.185	0.188	0.186	0.188	0.186	0.186	
<i>85+: Non-white</i>	0.219	0.216	0.219	0.217	0.218	0.218	0.217	
<i>85+: Unknown</i>	0.207	0.203	0.207	0.204	0.205	0.205	0.204	

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	Aug-17	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18
<b>HCTZ-containing</b>							
HCTZ-containing products							
<i>0-40</i>							
White	13,018	12,498	12,672	12,433	12,136	12,299	11,531
Non-white	8,701	8,248	8,343	8,176	8,019	8,074	7,694
Unknown	70,178	65,341	66,936	65,222	65,116	63,896	61,515
<i>41-64</i>							
White	212,029	200,407	206,816	200,743	198,517	200,445	185,931
Non-white	107,294	101,352	104,567	101,371	99,535	100,549	93,381
Unknown	685,080	644,349	665,512	646,932	653,652	618,179	585,694
<i>65-74</i>							
White	804,653	764,159	805,600	769,034	773,735	807,189	716,685
Non-white	163,836	155,180	162,187	155,062	154,961	158,716	144,939
Unknown	160,169	152,848	159,265	154,003	155,365	154,918	142,833
<i>75-84</i>							
White	467,973	448,065	472,141	452,877	457,505	475,619	421,607
Non-white	78,629	74,405	77,368	74,245	73,991	75,471	69,035
Unknown	60,642	57,983	60,441	58,175	58,356	59,712	54,351
<i>85+</i>							
White	168,794	160,844	167,742	161,195	159,247	164,574	148,229
Non-white	25,211	24,300	25,157	23,877	23,678	24,226	22,022
Unknown	21,303	20,384	21,058	20,115	20,110	20,479	18,599
HCTZ single ingredient/monotherapy							
<i>0-40</i>							
White	6,378	6,157	6,205	6,088	5,931	6,023	5,643
Non-white	4,244	4,033	4,084	3,997	3,901	3,979	3,822
Unknown	27,562	25,566	26,460	25,622	25,442	25,186	24,413

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>41-64</b>							
White	93,467	88,206	91,152	87,974	86,937	88,029	81,348
Non-white	47,850	45,258	46,752	45,332	44,392	45,132	41,952
Unknown	230,705	217,551	225,331	219,103	220,812	208,627	198,061
<b>65-74</b>							
White	318,245	302,308	319,205	304,426	306,398	320,693	284,487
Non-white	64,315	60,890	63,672	60,845	60,854	62,324	56,962
Unknown	60,475	57,467	60,059	57,780	58,273	58,428	54,018
<b>75-84</b>							
White	197,464	188,671	199,071	191,005	192,190	201,429	178,798
Non-white	31,347	29,606	30,841	29,558	29,424	30,294	27,594
Unknown	23,968	23,127	23,916	23,112	23,041	23,670	21,682
<b>85+</b>							
White	79,618	76,332	79,159	76,200	75,608	78,027	70,506
Non-white	11,135	10,631	11,052	10,488	10,329	10,598	9,710
Unknown	9,570	9,071	9,348	9,044	9,032	9,124	8,361
<b>HCTZ combination products</b>							
<b>0-40</b>							
White	6,706	6,399	6,536	6,415	6,263	6,336	5,945
Non-white	4,513	4,272	4,306	4,232	4,157	4,138	3,926
Unknown	43,022	40,131	40,832	39,952	40,015	39,062	37,445
<b>41-64</b>							
White	119,753	113,272	116,814	113,860	112,609	113,503	105,512
Non-white	60,083	56,678	58,432	56,619	55,673	56,016	51,952
Unknown	458,015	430,085	443,812	431,358	436,290	412,843	390,592
<b>65-74</b>							
White	490,008	465,161	489,960	467,957	470,576	490,156	435,280
Non-white	100,311	94,984	99,282	94,937	94,774	97,079	88,589
Unknown	100,466	96,029	99,947	96,909	97,772	97,197	89,428

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>75-84</b>							
White	272,557	261,228	274,994	263,752	267,216	276,252	244,583
Non-white	47,637	45,102	46,870	44,982	44,871	45,505	41,725
Unknown	36,968	35,115	36,794	35,329	35,569	36,295	32,935
<b>85+</b>							
White	89,883	85,197	89,260	85,631	84,293	87,213	78,294
Non-white	14,197	13,782	14,210	13,486	13,448	13,734	12,414
Unknown	11,843	11,400	11,801	11,154	11,156	11,439	10,320
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<b>0-40</b>							
White	13,831	13,305	13,456	13,221	12,894	13,113	12,280
Non-white	9,327	8,851	8,929	8,790	8,635	8,708	8,308
Unknown	73,780	68,773	70,434	68,643	68,660	67,365	64,950
<b>41-64</b>							
White	227,704	215,378	222,223	215,842	213,833	215,861	200,573
Non-white	115,823	109,488	113,027	109,730	107,769	108,963	101,367
Unknown	716,053	673,582	695,793	676,905	684,329	647,170	613,874
<b>65-74</b>							
White	856,708	814,082	858,478	820,355	825,859	861,833	766,353
Non-white	176,163	167,000	174,527	167,101	167,130	171,285	156,635
Unknown	169,835	162,378	169,165	163,678	165,240	164,864	152,246
<b>75-84</b>							
White	507,107	485,741	511,390	491,581	496,737	516,433	458,462
Non-white	85,614	81,145	84,302	81,103	80,661	82,377	75,499
Unknown	65,262	62,525	65,186	62,722	62,945	64,403	58,850



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<b>85+</b>							
White	188,223	179,575	187,093	179,812	178,049	184,155	166,044
Non-white	27,782	26,703	27,724	26,352	26,189	26,746	24,418
Unknown	23,440	22,381	23,223	22,183	22,126	22,595	20,613
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<b>0-40</b>							
White	54,498	52,255	53,447	52,313	51,487	52,651	49,351
Non-white	29,594	28,428	28,842	28,379	27,991	28,669	27,221
Unknown	226,648	211,962	219,502	215,764	216,213	213,708	205,596
<b>41-64</b>							
White	783,554	747,405	769,457	750,294	742,324	748,676	702,096
Non-white	319,878	305,801	314,750	306,698	302,716	306,393	287,123
Unknown	1,613,556	1,523,422	1,574,146	1,538,782	1,554,249	1,473,548	1,405,631
<b>65-74</b>							
White	2,417,158	2,314,643	2,424,301	2,331,780	2,342,775	2,427,934	2,196,311
Non-white	457,549	438,290	455,759	439,741	438,868	448,652	415,435
Unknown	441,512	423,229	440,841	429,075	431,863	433,306	403,689
<b>75-84</b>							
White	1,718,855	1,658,412	1,733,127	1,676,597	1,689,583	1,741,514	1,582,951
Non-white	266,688	256,737	264,903	256,329	255,468	259,576	241,011
Unknown	208,145	200,028	208,510	201,531	201,819	206,622	191,846
<b>85+</b>							
White	909,075	878,021	908,141	880,170	876,083	893,541	823,911
Non-white	116,821	112,839	116,408	112,034	111,989	113,581	105,443
Unknown	104,772	100,806	104,425	100,907	99,959	102,164	95,008

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators						
	Aug-17	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.941	0.939	0.942	0.940	0.941	0.938	0.939
<i>0-40: Non-white</i>	0.933	0.932	0.934	0.930	0.929	0.927	0.926
<i>0-40: Unknown</i>	0.951	0.950	0.950	0.950	0.948	0.949	0.947
<i>41-64</i>							
<i>41-64: White</i>	0.931	0.930	0.931	0.930	0.928	0.929	0.927
<i>41-64: Non-white</i>	0.926	0.926	0.925	0.924	0.924	0.923	0.921
<i>41-64: Unknown</i>	0.957	0.957	0.956	0.956	0.955	0.955	0.954
<i>65-74</i>							
<i>65-74: White</i>	0.939	0.939	0.938	0.937	0.937	0.937	0.935
<i>65-74: Non-white</i>	0.930	0.929	0.929	0.928	0.927	0.927	0.925
<i>65-74: Unknown</i>	0.943	0.941	0.941	0.941	0.940	0.940	0.938
<i>75-84</i>							
<i>75-84: White</i>	0.923	0.922	0.923	0.921	0.921	0.921	0.920
<i>75-84: Non-white</i>	0.918	0.917	0.918	0.915	0.917	0.916	0.914
<i>75-84: Unknown</i>	0.929	0.927	0.927	0.928	0.927	0.927	0.924
<i>85+</i>							
<i>85+: White</i>	0.897	0.896	0.897	0.896	0.894	0.894	0.893
<i>85+: Non-white</i>	0.907	0.910	0.907	0.906	0.904	0.906	0.902
<i>85+: Unknown</i>	0.909	0.911	0.907	0.907	0.909	0.906	0.902

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.239	0.239	0.237	0.238	0.236	0.234	0.234
<i>0-40: Non-white</i>	0.294	0.290	0.289	0.288	0.286	0.282	0.283
<i>0-40: Unknown</i>	0.310	0.308	0.305	0.302	0.301	0.299	0.299
<i>41-64</i>							
<i>41-64: White</i>	0.271	0.268	0.269	0.268	0.267	0.268	0.265
<i>41-64: Non-white</i>	0.335	0.331	0.332	0.331	0.329	0.328	0.325
<i>41-64: Unknown</i>	0.425	0.423	0.423	0.420	0.421	0.420	0.417
<i>65-74</i>							
<i>65-74: White</i>	0.333	0.330	0.332	0.330	0.330	0.332	0.326
<i>65-74: Non-white</i>	0.358	0.354	0.356	0.353	0.353	0.354	0.349
<i>65-74: Unknown</i>	0.363	0.361	0.361	0.359	0.360	0.358	0.354
<i>75-84</i>							
<i>75-84: White</i>	0.272	0.270	0.272	0.270	0.271	0.273	0.266
<i>75-84: Non-white</i>	0.295	0.290	0.292	0.290	0.290	0.291	0.286
<i>75-84: Unknown</i>	0.291	0.290	0.290	0.289	0.289	0.289	0.283
<i>85+</i>							
<i>85+: White</i>	0.186	0.183	0.185	0.183	0.182	0.184	0.180
<i>85+: Non-white</i>	0.216	0.215	0.216	0.213	0.211	0.213	0.209
<i>85+: Unknown</i>	0.203	0.202	0.202	0.199	0.201	0.200	0.196

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	Mar-18	Apr-18	May-18	Jun-18	Jul-18	Aug-18	Sep-18
<b>HCTZ-containing</b>							
HCTZ-containing products							
0-40							
White	12,268	11,957	12,141	11,654	11,775	11,957	10,893
Non-white	8,173	7,948	8,041	7,707	7,617	7,973	7,193
Unknown	66,145	64,077	64,931	62,186	61,596	62,683	58,644
41-64							
White	198,176	193,485	195,803	188,155	191,775	193,675	176,087
Non-white	99,659	96,269	97,430	93,161	95,000	96,506	86,763
Unknown	625,452	607,769	617,903	596,028	598,147	605,827	569,565
65-74							
White	776,365	773,894	776,339	747,758	785,851	779,288	713,217
Non-white	155,709	153,402	153,922	148,694	154,377	155,985	141,549
Unknown	154,331	153,423	155,262	148,983	155,405	155,576	144,598
75-84							
White	458,942	459,500	461,807	445,894	470,020	465,427	427,524
Non-white	73,993	72,775	73,918	71,384	74,085	74,329	67,599
Unknown	59,206	58,632	59,676	57,317	60,169	60,079	55,060
85+							
White	157,506	157,624	158,608	152,394	159,109	157,122	144,512
Non-white	23,575	23,256	23,542	22,744	23,709	23,220	21,491
Unknown	20,071	19,724	20,053	19,360	20,222	20,227	18,370
HCTZ single ingredient/monotherapy							
0-40							
White	5,930	5,817	5,995	5,721	5,787	5,897	5,429
Non-white	4,002	3,992	4,035	3,869	3,864	4,060	3,670
Unknown	26,366	25,440	26,003	24,842	24,857	25,074	23,557

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>41-64</b>							
<i>White</i>	86,929	85,036	86,713	83,386	84,781	85,916	78,866
<i>Non-white</i>	44,843	43,331	44,179	42,255	43,162	43,712	39,724
<i>Unknown</i>	212,331	206,249	211,242	204,624	205,102	208,670	196,910
<b>65-74</b>							
<i>White</i>	308,819	308,710	311,540	301,255	312,495	312,188	289,479
<i>Non-white</i>	61,100	60,483	61,118	59,077	60,887	61,992	56,494
<i>Unknown</i>	57,953	58,111	59,278	56,746	58,507	59,266	55,263
<b>75-84</b>							
<i>White</i>	194,351	195,101	197,275	190,849	198,688	198,285	185,050
<i>Non-white</i>	29,369	29,173	29,688	28,666	29,565	29,833	27,514
<i>Unknown</i>	23,425	23,370	24,037	22,979	23,906	24,237	22,281
<b>85+</b>							
<i>White</i>	74,870	75,138	75,982	73,130	75,759	75,146	69,988
<i>Non-white</i>	10,318	10,315	10,578	10,093	10,585	10,338	9,639
<i>Unknown</i>	9,017	8,723	9,157	8,666	9,021	9,140	8,436
<b>HCTZ combination products</b>							
<b>0-40</b>							
<i>White</i>	6,402	6,214	6,215	5,998	6,053	6,133	5,513
<i>Non-white</i>	4,219	3,987	4,062	3,887	3,792	3,957	3,560
<i>Unknown</i>	40,137	38,984	39,315	37,676	37,102	37,967	35,409
<b>41-64</b>							
<i>White</i>	112,314	109,458	110,137	105,758	108,082	108,869	98,147
<i>Non-white</i>	55,404	53,473	53,832	51,422	52,458	53,389	47,547
<i>Unknown</i>	416,453	404,736	409,979	394,526	396,656	400,744	375,631
<b>65-74</b>							
<i>White</i>	471,081	468,509	468,334	449,797	477,442	470,997	426,980
<i>Non-white</i>	95,313	93,618	93,552	90,295	94,256	94,817	85,695
<i>Unknown</i>	97,098	95,996	96,741	92,895	97,735	97,166	89,982

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<i>75-84</i>							
<i>White</i>	266,632	266,291	266,569	257,026	273,845	269,514	244,271
<i>Non-white</i>	44,936	43,901	44,546	43,029	44,897	44,848	40,405
<i>Unknown</i>	36,055	35,534	35,927	34,635	36,608	36,179	33,049
<i>85+</i>							
<i>White</i>	83,282	83,106	83,313	79,864	84,112	82,689	75,113
<i>Non-white</i>	13,359	13,046	13,077	12,716	13,253	13,006	11,944
<i>Unknown</i>	11,132	11,067	10,978	10,771	11,294	11,175	10,017
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>0-40</i>							
<i>White</i>	13,144	12,768	13,020	12,497	12,664	12,821	11,699
<i>Non-white</i>	8,859	8,617	8,721	8,373	8,316	8,689	7,824
<i>Unknown</i>	69,923	67,746	68,732	65,871	65,249	66,432	62,170
<i>41-64</i>							
<i>White</i>	214,056	209,258	211,882	203,819	207,704	209,699	191,175
<i>Non-white</i>	108,295	104,911	106,135	101,766	103,686	105,386	94,924
<i>Unknown</i>	656,016	638,083	649,201	626,740	628,465	637,154	599,496
<i>65-74</i>							
<i>White</i>	830,902	828,891	832,336	802,270	841,561	835,233	765,664
<i>Non-white</i>	168,568	166,129	167,013	161,524	167,243	169,023	153,942
<i>Unknown</i>	164,633	163,730	165,831	159,258	165,980	166,272	154,894
<i>75-84</i>							
<i>White</i>	499,938	500,414	503,911	486,876	511,651	507,404	466,842
<i>Non-white</i>	81,044	79,754	81,141	78,412	81,156	81,442	74,396
<i>Unknown</i>	64,122	63,496	64,738	62,225	65,137	65,076	59,844

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<b>85+</b>							
<i>White</i>	176,852	176,894	178,618	171,466	178,439	176,823	162,992
<i>Non-white</i>	26,233	25,876	26,244	25,370	26,332	25,840	24,049
<i>Unknown</i>	22,178	21,856	22,220	21,426	22,406	22,390	20,371
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<b>0-40</b>							
<i>White</i>	52,577	51,656	52,201	50,232	51,034	51,859	47,898
<i>Non-white</i>	29,029	27,981	28,274	27,387	27,674	28,177	25,927
<i>Unknown</i>	220,098	213,975	218,037	209,352	209,577	213,960	201,132
<b>41-64</b>							
<i>White</i>	742,349	727,384	736,841	710,265	722,448	730,066	674,503
<i>Non-white</i>	304,581	295,890	299,027	289,002	293,579	297,258	272,786
<i>Unknown</i>	1,494,071	1,456,502	1,479,717	1,432,012	1,435,736	1,456,934	1,379,742
<b>65-74</b>							
<i>White</i>	2,360,277	2,352,429	2,362,074	2,287,691	2,366,459	2,362,765	2,210,079
<i>Non-white</i>	444,205	437,627	440,675	428,052	439,801	444,108	413,764
<i>Unknown</i>	433,746	431,287	437,642	422,067	434,848	438,459	413,675
<b>75-84</b>							
<i>White</i>	1,700,641	1,700,710	1,715,496	1,667,737	1,720,174	1,720,328	1,622,219
<i>Non-white</i>	256,528	253,559	256,397	249,544	255,765	256,865	241,465
<i>Unknown</i>	205,539	205,249	208,538	201,111	207,777	208,967	196,299
<b>85+</b>							
<i>White</i>	868,401	863,519	870,646	846,256	865,412	865,083	819,610
<i>Non-white</i>	111,939	110,326	111,751	108,954	111,273	111,390	105,890
<i>Unknown</i>	100,349	100,016	101,317	97,800	100,639	100,924	95,397

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators						
	Mar-18	Apr-18	May-18	Jun-18	Jul-18	Aug-18	Sep-18
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.933	0.936	0.932	0.933	0.930	0.933	0.931
<i>0-40: Non-white</i>	0.923	0.922	0.922	0.920	0.916	0.918	0.919
<i>0-40: Unknown</i>	0.946	0.946	0.945	0.944	0.944	0.944	0.943
<i>41-64</i>							
<i>41-64: White</i>	0.926	0.925	0.924	0.923	0.923	0.924	0.921
<i>41-64: Non-white</i>	0.920	0.918	0.918	0.915	0.916	0.916	0.914
<i>41-64: Unknown</i>	0.953	0.952	0.952	0.951	0.952	0.951	0.950
<i>65-74</i>							
<i>65-74: White</i>	0.934	0.934	0.933	0.932	0.934	0.933	0.932
<i>65-74: Non-white</i>	0.924	0.923	0.922	0.921	0.923	0.923	0.919
<i>65-74: Unknown</i>	0.937	0.937	0.936	0.935	0.936	0.936	0.934
<i>75-84</i>							
<i>75-84: White</i>	0.918	0.918	0.916	0.916	0.919	0.917	0.916
<i>75-84: Non-white</i>	0.913	0.912	0.911	0.910	0.913	0.913	0.909
<i>75-84: Unknown</i>	0.923	0.923	0.922	0.921	0.924	0.923	0.920
<i>85+</i>							
<i>85+: White</i>	0.891	0.891	0.888	0.889	0.892	0.889	0.887
<i>85+: Non-white</i>	0.899	0.899	0.897	0.896	0.900	0.899	0.894
<i>85+: Unknown</i>	0.905	0.902	0.902	0.904	0.903	0.903	0.902



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.233	0.231	0.233	0.232	0.231	0.231	0.227
<i>0-40: Non-white</i>	0.282	0.284	0.284	0.281	0.275	0.283	0.277
<i>0-40: Unknown</i>	0.301	0.299	0.298	0.297	0.294	0.293	0.292
<i>41-64</i>							
<i>41-64: White</i>	0.267	0.266	0.266	0.265	0.265	0.265	0.261
<i>41-64: Non-white</i>	0.327	0.325	0.326	0.322	0.324	0.325	0.318
<i>41-64: Unknown</i>	0.419	0.417	0.418	0.416	0.417	0.416	0.413
<i>65-74</i>							
<i>65-74: White</i>	0.329	0.329	0.329	0.327	0.332	0.330	0.323
<i>65-74: Non-white</i>	0.351	0.351	0.349	0.347	0.351	0.351	0.342
<i>65-74: Unknown</i>	0.356	0.356	0.355	0.353	0.357	0.355	0.350
<i>75-84</i>							
<i>75-84: White</i>	0.270	0.270	0.269	0.267	0.273	0.271	0.264
<i>75-84: Non-white</i>	0.288	0.287	0.288	0.286	0.290	0.289	0.280
<i>75-84: Unknown</i>	0.288	0.286	0.286	0.285	0.290	0.288	0.280
<i>85+</i>							
<i>85+: White</i>	0.181	0.183	0.182	0.180	0.184	0.182	0.176
<i>85+: Non-white</i>	0.211	0.211	0.211	0.209	0.213	0.208	0.203
<i>85+: Unknown</i>	0.200	0.197	0.198	0.198	0.201	0.200	0.193

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	Oct-18	Nov-18	Dec-18	Jan-19	Feb-19	Mar-19	Apr-19
<b>HCTZ-containing</b>							
HCTZ-containing products							
<i>0-40</i>							
<i>White</i>	11,405	10,900	10,702	10,764	9,947	10,355	10,319
<i>Non-white</i>	7,606	7,279	7,006	6,999	6,507	6,943	6,953
<i>Unknown</i>	61,841	58,668	57,566	58,397	54,698	58,481	58,197
<i>41-64</i>							
<i>White</i>	189,166	178,927	176,869	178,592	163,323	171,036	171,696
<i>Non-white</i>	93,938	88,090	86,435	87,895	80,829	83,825	84,498
<i>Unknown</i>	602,251	576,173	573,846	564,599	528,662	561,022	559,399
<i>65-74</i>							
<i>White</i>	791,112	735,022	733,800	784,717	691,827	737,872	764,279
<i>Non-white</i>	155,130	144,153	142,748	151,122	135,492	144,455	146,835
<i>Unknown</i>	157,704	148,823	148,956	150,269	136,109	146,357	148,531
<i>75-84</i>							
<i>White</i>	476,148	440,806	442,746	470,960	414,885	442,526	458,851
<i>Non-white</i>	74,042	69,047	67,994	71,613	64,515	68,442	69,843
<i>Unknown</i>	60,840	56,692	55,996	57,900	51,958	54,776	56,595
<i>85+</i>							
<i>White</i>	157,723	147,323	146,589	154,290	138,158	144,975	149,291
<i>Non-white</i>	23,226	21,564	21,329	22,307	20,243	21,154	21,616
<i>Unknown</i>	19,977	18,837	18,517	18,727	17,162	17,993	18,419
HCTZ single ingredient/monotherapy							
<i>0-40</i>							
<i>White</i>	5,650	5,456	5,345	5,407	5,009	5,211	5,240
<i>Non-white</i>	3,815	3,663	3,550	3,584	3,362	3,663	3,639
<i>Unknown</i>	24,960	23,722	23,175	23,914	22,446	24,441	24,660

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<i>41-64</i>							
<i>White</i>	83,821	79,584	79,076	79,962	73,657	77,630	78,295
<i>Non-white</i>	42,592	40,164	39,507	40,552	37,929	39,182	40,086
<i>Unknown</i>	207,234	199,252	198,596	197,586	187,702	201,977	202,706
<i>65-74</i>							
<i>White</i>	315,292	297,713	298,130	321,030	286,568	306,491	319,653
<i>Non-white</i>	61,480	57,603	57,013	61,480	55,887	59,902	61,127
<i>Unknown</i>	59,765	57,082	57,114	58,119	53,163	57,699	58,808
<i>75-84</i>							
<i>White</i>	201,663	189,570	191,519	204,280	182,359	195,283	202,968
<i>Non-white</i>	29,551	27,692	27,616	29,094	26,787	28,586	29,244
<i>Unknown</i>	24,354	22,827	22,637	23,601	21,222	22,658	23,491
<i>85+</i>							
<i>White</i>	75,135	70,792	71,156	74,578	67,476	71,264	73,284
<i>Non-white</i>	10,328	9,560	9,602	9,999	9,153	9,825	9,885
<i>Unknown</i>	9,069	8,518	8,490	8,472	7,921	8,381	8,588
HCTZ combination products							
<i>0-40</i>							
<i>White</i>	5,804	5,495	5,404	5,413	4,984	5,197	5,129
<i>Non-white</i>	3,836	3,663	3,499	3,461	3,188	3,331	3,366
<i>Unknown</i>	37,241	35,299	34,724	34,880	32,619	34,451	33,905
<i>41-64</i>							
<i>White</i>	106,379	100,304	98,740	99,594	90,510	94,299	94,364
<i>Non-white</i>	51,866	48,413	47,398	47,874	43,405	45,134	44,934
<i>Unknown</i>	398,218	380,028	378,351	370,781	344,515	362,876	360,399
<i>65-74</i>							
<i>White</i>	479,453	440,568	438,874	467,706	408,556	434,953	448,470
<i>Non-white</i>	94,337	87,212	86,330	90,438	80,317	85,316	86,510
<i>Unknown</i>	98,710	92,487	92,545	93,060	83,734	89,527	90,566

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<i>75-84</i>							
<i>White</i>	276,585	253,116	253,046	268,947	234,416	249,399	258,071
<i>Non-white</i>	44,822	41,639	40,683	42,876	38,052	40,231	40,948
<i>Unknown</i>	36,774	34,149	33,643	34,603	31,045	32,412	33,424
<i>85+</i>							
<i>White</i>	83,235	77,097	76,003	80,401	71,265	74,373	76,690
<i>Non-white</i>	12,998	12,086	11,805	12,409	11,181	11,445	11,820
<i>Unknown</i>	10,997	10,407	10,113	10,350	9,331	9,698	9,913
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>0-40</i>							
<i>White</i>	12,268	11,740	11,522	11,592	10,686	11,157	11,096
<i>Non-white</i>	8,317	7,949	7,669	7,700	7,130	7,636	7,611
<i>Unknown</i>	65,626	62,398	61,224	62,136	58,151	62,397	62,112
<i>41-64</i>							
<i>White</i>	205,131	194,311	192,358	193,988	177,518	186,115	186,942
<i>Non-white</i>	102,708	96,601	94,723	96,482	88,802	92,172	92,985
<i>Unknown</i>	634,121	607,080	605,016	595,217	557,781	592,429	590,930
<i>65-74</i>							
<i>White</i>	847,951	789,269	789,171	842,285	743,941	793,999	821,665
<i>Non-white</i>	168,421	156,756	155,470	164,542	147,760	157,598	160,281
<i>Unknown</i>	168,722	159,463	159,763	160,931	146,089	157,274	159,461
<i>75-84</i>							
<i>White</i>	519,142	481,975	484,311	514,475	454,160	484,837	502,336
<i>Non-white</i>	81,351	75,868	74,971	78,942	71,108	75,525	77,030
<i>Unknown</i>	65,976	61,547	60,960	62,952	56,435	59,743	61,655

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<b>85+</b>							
White	177,424	166,469	165,768	173,818	156,193	164,087	168,532
Non-white	25,913	24,016	23,850	24,879	22,607	23,677	24,228
Unknown	22,216	20,893	20,676	20,832	19,183	20,076	20,541
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<b>0-40</b>							
White	50,457	48,638	47,802	48,027	45,133	47,482	47,111
Non-white	27,186	26,048	25,638	25,948	24,271	25,627	25,596
Unknown	213,736	205,840	203,404	206,570	195,080	209,717	209,296
<b>41-64</b>							
White	716,730	687,644	681,168	687,971	637,672	666,009	669,556
Non-white	290,856	276,850	273,070	278,769	258,775	269,913	271,043
Unknown	1,455,314	1,402,296	1,399,838	1,377,191	1,300,862	1,383,415	1,380,653
<b>65-74</b>							
White	2,393,287	2,268,336	2,272,224	2,395,536	2,161,880	2,301,824	2,365,202
Non-white	444,952	421,174	418,966	440,618	404,464	428,957	435,251
Unknown	444,725	426,100	426,688	431,147	397,818	425,781	432,721
<b>75-84</b>							
White	1,753,443	1,665,962	1,675,155	1,752,299	1,591,225	1,689,711	1,734,541
Non-white	258,086	245,031	243,206	254,263	233,322	246,776	249,972
Unknown	211,938	201,498	199,987	204,643	187,446	198,660	202,680
<b>85+</b>							
White	868,819	832,012	829,972	857,923	792,009	828,356	842,165
Non-white	111,619	106,361	106,092	109,317	100,852	106,348	107,349
Unknown	101,019	97,053	96,141	97,022	90,485	94,765	95,873

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators							
	Oct-18	Nov-18	Dec-18	Jan-19	Feb-19	Mar-19	Apr-19	
<b>Proportions, limited denominator</b>								
HCTZ-containing numerator, limited denominator								
<i>0-40</i>								
<i>0-40: White</i>	0.930	0.928	0.929	0.929	0.931	0.928	0.930	
<i>0-40: Non-white</i>	0.915	0.916	0.914	0.909	0.913	0.909	0.914	
<i>0-40: Unknown</i>	0.942	0.940	0.940	0.940	0.941	0.937	0.937	
<i>41-64</i>								
<i>41-64: White</i>	0.922	0.921	0.919	0.921	0.920	0.919	0.918	
<i>41-64: Non-white</i>	0.915	0.912	0.913	0.911	0.910	0.909	0.909	
<i>41-64: Unknown</i>	0.950	0.949	0.948	0.949	0.948	0.947	0.947	
<i>65-74</i>								
<i>65-74: White</i>	0.933	0.931	0.930	0.932	0.930	0.929	0.930	
<i>65-74: Non-white</i>	0.921	0.920	0.918	0.918	0.917	0.917	0.916	
<i>65-74: Unknown</i>	0.935	0.933	0.932	0.934	0.932	0.931	0.931	
<i>75-84</i>								
<i>75-84: White</i>	0.917	0.915	0.914	0.915	0.914	0.913	0.913	
<i>75-84: Non-white</i>	0.910	0.910	0.907	0.907	0.907	0.906	0.907	
<i>75-84: Unknown</i>	0.922	0.921	0.919	0.920	0.921	0.917	0.918	
<i>85+</i>								
<i>85+: White</i>	0.889	0.885	0.884	0.888	0.885	0.884	0.886	
<i>85+: Non-white</i>	0.896	0.898	0.894	0.897	0.895	0.893	0.892	
<i>85+: Unknown</i>	0.899	0.902	0.896	0.899	0.895	0.896	0.897	

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.226	0.224	0.224	0.224	0.220	0.218	0.219
<i>0-40: Non-white</i>	0.280	0.279	0.273	0.270	0.268	0.271	0.272
<i>0-40: Unknown</i>	0.289	0.285	0.283	0.283	0.280	0.279	0.278
<i>41-64</i>							
<i>41-64: White</i>	0.264	0.260	0.260	0.260	0.256	0.257	0.256
<i>41-64: Non-white</i>	0.323	0.318	0.317	0.315	0.312	0.311	0.312
<i>41-64: Unknown</i>	0.414	0.411	0.410	0.410	0.406	0.406	0.405
<i>65-74</i>							
<i>65-74: White</i>	0.331	0.324	0.323	0.328	0.320	0.321	0.323
<i>65-74: Non-white</i>	0.349	0.342	0.341	0.343	0.335	0.337	0.337
<i>65-74: Unknown</i>	0.355	0.349	0.349	0.349	0.342	0.344	0.343
<i>75-84</i>							
<i>75-84: White</i>	0.272	0.265	0.264	0.269	0.261	0.262	0.265
<i>75-84: Non-white</i>	0.287	0.282	0.280	0.282	0.277	0.277	0.279
<i>75-84: Unknown</i>	0.287	0.281	0.280	0.283	0.277	0.276	0.279
<i>85+</i>							
<i>85+: White</i>	0.182	0.177	0.177	0.180	0.174	0.175	0.177
<i>85+: Non-white</i>	0.208	0.203	0.201	0.204	0.201	0.199	0.201
<i>85+: Unknown</i>	0.198	0.194	0.193	0.193	0.190	0.190	0.192

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	May-19	Jun-19	Jul-19	Aug-19	Sep-19	Oct-19	Nov-19
<b>HCTZ-containing</b>							
HCTZ-containing products							
<i>0-40</i>							
White	10,369	9,745	10,183	9,718	9,378	9,740	9,145
Non-white	6,907	6,524	6,641	6,657	6,196	6,358	5,982
Unknown	57,979	54,732	56,465	55,670	53,336	55,461	51,933
<i>41-64</i>							
White	170,688	160,347	168,875	163,593	155,798	162,211	150,108
Non-white	83,807	78,337	82,524	79,790	75,847	79,115	72,820
Unknown	558,316	532,121	543,874	537,980	520,170	541,281	506,494
<i>65-74</i>							
White	752,020	708,532	761,221	729,846	703,961	749,049	685,100
Non-white	145,394	137,378	146,956	141,793	135,570	144,067	131,731
Unknown	148,833	141,783	149,031	146,362	142,197	150,314	140,686
<i>75-84</i>							
White	451,036	426,163	458,919	438,181	424,798	452,630	412,969
Non-white	69,648	65,432	69,805	67,662	64,304	68,228	62,711
Unknown	55,917	53,140	56,505	54,696	52,702	55,876	51,522
<i>85+</i>							
White	147,755	139,266	148,688	142,521	137,937	145,602	134,057
Non-white	21,471	20,216	21,515	20,792	20,054	20,939	19,203
Unknown	18,358	17,074	18,500	17,667	17,064	18,149	16,496
HCTZ single ingredient/monotherapy							
<i>0-40</i>							
White	5,215	4,940	5,178	5,014	4,896	5,201	4,962
Non-white	3,671	3,393	3,495	3,584	3,362	3,552	3,411
Unknown	24,572	23,374	24,294	24,491	23,868	25,705	24,721



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>41-64</b>							
White	78,253	74,169	77,863	76,806	74,697	80,045	75,780
Non-white	39,646	37,338	39,631	38,649	37,569	40,400	38,547
Unknown	203,854	196,347	201,440	203,987	203,553	223,362	216,882
<b>65-74</b>							
White	316,729	300,909	322,428	316,302	314,492	347,267	328,630
Non-white	61,183	58,263	62,052	61,229	60,276	67,054	63,635
Unknown	59,239	56,903	59,984	60,574	60,623	67,542	65,395
<b>75-84</b>							
White	201,510	191,872	205,156	201,120	200,122	219,738	207,495
Non-white	29,462	27,831	29,634	29,286	28,686	31,781	30,598
Unknown	23,442	22,471	23,818	23,520	23,486	26,140	24,768
<b>85+</b>							
White	73,156	69,253	73,818	72,008	71,026	76,792	73,128
Non-white	9,945	9,568	10,030	9,737	9,791	10,623	10,036
Unknown	8,612	8,141	8,789	8,500	8,395	9,298	8,778
<b>HCTZ combination products</b>							
<b>0-40</b>							
White	5,209	4,858	5,064	4,768	4,525	4,602	4,241
Non-white	3,285	3,176	3,188	3,114	2,868	2,843	2,605
Unknown	33,796	31,720	32,527	31,654	29,981	30,466	27,869
<b>41-64</b>							
White	93,428	87,037	91,956	87,728	81,994	83,238	75,256
Non-white	44,679	41,426	43,414	41,608	38,718	39,291	34,805
Unknown	358,233	339,500	346,222	338,511	321,934	325,576	296,928
<b>65-74</b>							
White	438,935	410,821	442,368	416,959	392,930	406,493	360,357
Non-white	84,990	79,775	85,659	81,274	76,005	77,959	68,868
Unknown	90,391	85,664	89,836	86,600	82,603	84,164	76,617

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>75-84</b>							
White	251,656	236,311	255,911	239,169	226,800	235,670	207,822
Non-white	40,547	37,882	40,491	38,695	35,950	36,868	32,495
Unknown	32,794	30,947	33,002	31,508	29,547	30,157	27,145
<b>85+</b>							
White	75,245	70,649	75,511	71,160	67,596	69,708	61,685
Non-white	11,624	10,734	11,589	11,159	10,365	10,460	9,288
Unknown	9,841	9,020	9,795	9,241	8,760	8,999	7,818
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<b>0-40</b>							
White	11,176	10,500	10,939	10,459	10,117	10,479	9,890
Non-white	7,573	7,201	7,340	7,325	6,866	7,062	6,616
Unknown	61,870	58,566	60,365	59,558	57,075	59,466	55,754
<b>41-64</b>							
White	186,164	174,857	184,145	178,607	170,219	177,155	164,075
Non-white	92,303	86,451	90,950	88,193	83,792	87,754	80,701
Unknown	590,329	562,826	575,271	569,620	550,982	573,657	537,096
<b>65-74</b>							
White	809,671	763,079	819,410	786,300	758,702	807,714	739,572
Non-white	158,818	150,112	160,471	155,272	148,385	157,630	144,560
Unknown	160,149	152,370	160,346	157,603	153,038	161,884	151,624
<b>75-84</b>							
White	494,531	467,068	502,241	480,656	465,798	495,805	453,475
Non-white	76,863	72,501	77,278	74,917	71,383	75,731	69,579
Unknown	60,947	58,089	61,629	59,746	57,659	61,048	56,412

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<b>85+</b>							
White	167,002	157,585	167,733	161,474	156,091	164,506	152,059
Non-white	24,060	22,665	24,183	23,349	22,515	23,524	21,690
Unknown	20,547	19,117	20,643	19,756	19,020	20,287	18,464
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<b>0-40</b>							
White	47,530	45,112	46,733	45,805	44,151	45,783	43,473
Non-white	25,438	24,265	25,131	24,774	23,606	24,971	23,169
Unknown	208,979	199,779	204,890	204,129	198,269	207,590	196,103
<b>41-64</b>							
White	667,437	632,686	662,426	647,091	622,636	645,800	605,040
Non-white	269,739	255,616	266,817	260,677	250,672	261,662	243,611
Unknown	1,381,806	1,321,731	1,349,792	1,342,664	1,306,504	1,360,603	1,281,904
<b>65-74</b>							
White	2,344,816	2,230,700	2,369,075	2,300,160	2,234,873	2,359,411	2,189,856
Non-white	432,932	412,671	437,629	427,288	413,119	436,098	405,154
Unknown	434,517	416,148	436,998	432,341	422,486	446,537	420,545
<b>75-84</b>							
White	1,721,178	1,643,239	1,744,095	1,693,302	1,652,279	1,737,509	1,616,903
Non-white	250,004	238,458	251,640	245,601	237,745	250,155	232,665
Unknown	202,178	193,761	203,828	199,841	194,418	204,832	191,507
<b>85+</b>							
White	839,356	804,371	843,675	823,246	805,018	836,987	790,022
Non-white	106,940	102,532	107,679	105,336	102,304	106,918	100,080
Unknown	96,397	91,757	96,275	94,344	91,695	95,809	90,366

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators						
	May-19	Jun-19	Jul-19	Aug-19	Sep-19	Oct-19	Nov-19
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.928	0.928	0.931	0.929	0.927	0.929	0.925
<i>0-40: Non-white</i>	0.912	0.906	0.905	0.909	0.902	0.900	0.904
<i>0-40: Unknown</i>	0.937	0.935	0.935	0.935	0.934	0.933	0.931
<i>41-64</i>							
<i>41-64: White</i>	0.917	0.917	0.917	0.916	0.915	0.916	0.915
<i>41-64: Non-white</i>	0.908	0.906	0.907	0.905	0.905	0.902	0.902
<i>41-64: Unknown</i>	0.946	0.945	0.945	0.944	0.944	0.944	0.943
<i>65-74</i>							
<i>65-74: White</i>	0.929	0.929	0.929	0.928	0.928	0.927	0.926
<i>65-74: Non-white</i>	0.915	0.915	0.916	0.913	0.914	0.914	0.911
<i>65-74: Unknown</i>	0.929	0.931	0.929	0.929	0.929	0.929	0.928
<i>75-84</i>							
<i>75-84: White</i>	0.912	0.912	0.914	0.912	0.912	0.913	0.911
<i>75-84: Non-white</i>	0.906	0.902	0.903	0.903	0.901	0.901	0.901
<i>75-84: Unknown</i>	0.917	0.915	0.917	0.915	0.914	0.915	0.913
<i>85+</i>							
<i>85+: White</i>	0.885	0.884	0.886	0.883	0.884	0.885	0.882
<i>85+: Non-white</i>	0.892	0.892	0.890	0.890	0.891	0.890	0.885
<i>85+: Unknown</i>	0.893	0.893	0.896	0.894	0.897	0.895	0.893

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.218	0.216	0.218	0.212	0.212	0.213	0.210
<i>0-40: Non-white</i>	0.272	0.269	0.264	0.269	0.262	0.255	0.258
<i>0-40: Unknown</i>	0.277	0.274	0.276	0.273	0.269	0.267	0.265
<i>41-64</i>							
<i>41-64: White</i>	0.256	0.253	0.255	0.253	0.250	0.251	0.248
<i>41-64: Non-white</i>	0.311	0.306	0.309	0.306	0.303	0.302	0.299
<i>41-64: Unknown</i>	0.404	0.403	0.403	0.401	0.398	0.398	0.395
<i>65-74</i>							
<i>65-74: White</i>	0.321	0.318	0.321	0.317	0.315	0.317	0.313
<i>65-74: Non-white</i>	0.336	0.333	0.336	0.332	0.328	0.330	0.325
<i>65-74: Unknown</i>	0.343	0.341	0.341	0.339	0.337	0.337	0.335
<i>75-84</i>							
<i>75-84: White</i>	0.262	0.259	0.263	0.259	0.257	0.261	0.255
<i>75-84: Non-white</i>	0.279	0.274	0.277	0.275	0.270	0.273	0.270
<i>75-84: Unknown</i>	0.277	0.274	0.277	0.274	0.271	0.273	0.269
<i>85+</i>							
<i>85+: White</i>	0.176	0.173	0.176	0.173	0.171	0.174	0.170
<i>85+: Non-white</i>	0.201	0.197	0.200	0.197	0.196	0.196	0.192
<i>85+: Unknown</i>	0.190	0.186	0.192	0.187	0.186	0.189	0.183

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20	May-20	Jun-20
<b>HCTZ-containing</b>							
HCTZ-containing products							
<i>0-40</i>							
White	9,365	9,401	8,854	9,583	8,904	8,608	8,929
Non-white	6,037	6,118	5,736	6,304	5,833	5,688	5,853
Unknown	50,360	55,116	52,242	58,269	52,108	50,425	51,719
<i>41-64</i>							
White	157,638	156,448	144,613	160,220	146,784	142,489	149,497
Non-white	76,543	75,831	70,450	78,773	72,519	69,458	73,163
Unknown	500,754	525,596	497,638	556,407	501,602	490,586	505,417
<i>65-74</i>							
White	742,420	758,998	682,960	801,762	701,254	691,390	749,982
Non-white	139,845	143,392	130,985	152,362	134,510	130,448	142,896
Unknown	146,821	151,672	141,631	161,285	144,623	143,550	151,722
<i>75-84</i>							
White	449,777	455,235	410,590	481,958	421,159	416,756	453,004
Non-white	66,492	67,810	61,942	71,202	63,133	61,938	66,942
Unknown	54,125	55,528	52,312	59,036	52,989	53,016	55,821
<i>85+</i>							
White	143,010	145,469	132,824	150,442	135,693	133,315	142,649
Non-white	20,458	20,751	19,051	21,186	19,385	18,783	20,051
Unknown	17,244	17,948	16,273	18,278	16,951	16,519	17,377
HCTZ single ingredient/monotherapy							
<i>0-40</i>							
White	5,172	5,270	4,931	5,340	4,998	4,854	5,087
Non-white	3,496	3,580	3,307	3,687	3,404	3,320	3,463
Unknown	24,584	27,395	26,090	29,153	26,198	25,118	26,206

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>41-64</b>							
White	81,626	81,660	75,814	83,958	77,042	75,092	78,836
Non-white	41,332	41,555	38,325	42,808	39,457	37,582	39,763
Unknown	220,746	234,854	223,884	250,724	225,729	220,282	228,682
<b>65-74</b>							
White	366,020	375,900	340,157	398,976	347,535	342,817	373,299
Non-white	69,015	71,610	65,256	75,497	67,082	64,463	70,720
Unknown	70,097	73,193	68,753	77,835	69,866	68,823	73,093
<b>75-84</b>							
White	230,668	235,691	214,269	250,059	218,123	216,683	234,887
Non-white	33,402	34,350	31,473	36,026	31,616	31,154	33,572
Unknown	26,879	28,051	26,226	29,747	26,787	26,556	27,901
<b>85+</b>							
White	79,350	81,431	74,970	84,460	76,317	75,042	79,917
Non-white	11,138	11,443	10,396	11,585	10,617	10,135	10,870
Unknown	9,329	9,794	9,011	10,046	9,314	9,010	9,355
<b>HCTZ combination products</b>							
<b>0-40</b>							
White	4,248	4,183	3,973	4,304	3,945	3,790	3,896
Non-white	2,580	2,576	2,461	2,650	2,459	2,387	2,427
Unknown	26,336	28,310	26,624	29,646	26,309	25,650	25,934
<b>41-64</b>							
White	77,017	75,785	69,602	77,279	70,596	68,181	71,539
Non-white	35,765	34,787	32,570	36,499	33,523	32,310	33,846
Unknown	286,469	296,893	278,520	311,400	280,116	274,069	281,037
<b>65-74</b>							
White	380,911	387,719	346,436	407,378	357,396	351,898	380,525
Non-white	71,729	72,700	66,465	77,820	68,219	66,683	72,974
Unknown	78,012	79,692	73,842	84,649	75,638	75,552	79,608

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<i>75-84</i>							
<i>White</i>	221,829	222,154	198,352	234,519	205,192	201,964	220,364
<i>Non-white</i>	33,490	33,897	30,844	35,641	31,878	31,089	33,731
<i>Unknown</i>	27,640	27,854	26,392	29,664	26,510	26,741	28,221
<i>85+</i>							
<i>White</i>	64,547	64,827	58,499	66,728	59,983	58,815	63,384
<i>Non-white</i>	9,459	9,423	8,747	9,728	8,853	8,737	9,267
<i>Unknown</i>	8,040	8,270	7,355	8,333	7,706	7,587	8,117
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>0-40</i>							
<i>White</i>	10,124	10,176	9,584	10,395	9,655	9,378	9,708
<i>Non-white</i>	6,676	6,800	6,326	7,010	6,497	6,311	6,546
<i>Unknown</i>	54,044	59,220	56,185	62,554	56,064	54,310	55,674
<i>41-64</i>							
<i>White</i>	172,677	171,308	158,570	175,557	160,816	156,431	164,042
<i>Non-white</i>	84,939	84,153	78,272	87,527	80,568	77,215	81,376
<i>Unknown</i>	531,341	557,981	528,901	591,290	533,262	521,895	537,372
<i>65-74</i>							
<i>White</i>	801,132	819,278	738,193	865,043	757,279	746,837	809,986
<i>Non-white</i>	153,286	157,082	143,951	166,928	147,481	143,291	156,560
<i>Unknown</i>	158,268	163,808	153,081	174,164	156,177	155,188	163,871
<i>75-84</i>							
<i>White</i>	493,146	499,746	451,875	528,640	462,115	458,025	497,126
<i>Non-white</i>	73,874	75,367	68,962	79,074	70,082	68,798	74,270
<i>Unknown</i>	59,247	60,922	57,412	64,762	58,022	58,072	61,062



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<i>85+</i>							
<i>White</i>	161,869	164,660	150,803	170,040	153,657	150,889	161,045
<i>Non-white</i>	22,968	23,402	21,458	23,790	21,791	21,137	22,479
<i>Unknown</i>	19,275	20,054	18,391	20,452	19,000	18,546	19,414
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<i>0-40</i>							
<i>White</i>	45,107	45,073	42,761	46,165	42,649	41,890	43,353
<i>Non-white</i>	23,968	24,021	22,702	24,893	23,246	22,631	23,437
<i>Unknown</i>	192,458	211,034	201,595	223,420	199,225	195,347	201,615
<i>41-64</i>							
<i>White</i>	632,806	626,703	588,160	641,694	596,321	580,519	606,649
<i>Non-white</i>	254,685	252,988	238,124	261,434	242,744	233,826	245,043
<i>Unknown</i>	1,272,229	1,338,329	1,279,723	1,418,994	1,285,685	1,262,154	1,300,798
<i>65-74</i>							
<i>White</i>	2,346,950	2,386,693	2,191,192	2,509,205	2,227,363	2,208,339	2,371,989
<i>Non-white</i>	428,002	433,699	404,058	456,643	411,021	400,664	430,591
<i>Unknown</i>	438,558	456,203	430,218	483,264	436,873	435,417	457,364
<i>75-84</i>							
<i>White</i>	1,729,961	1,747,579	1,614,557	1,833,676	1,632,431	1,622,141	1,738,395
<i>Non-white</i>	245,296	248,507	232,398	258,007	233,263	227,863	243,142
<i>Unknown</i>	200,679	208,162	196,949	218,754	198,722	198,255	207,344
<i>85+</i>							
<i>White</i>	826,942	837,828	785,376	859,462	785,702	773,827	812,206
<i>Non-white</i>	104,979	105,683	99,976	108,036	98,645	95,725	100,354
<i>Unknown</i>	93,578	96,737	91,303	98,955	91,387	89,830	92,897

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators						
	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20	May-20	Jun-20
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.925	0.924	0.924	0.922	0.922	0.918	0.920
<i>0-40: Non-white</i>	0.904	0.900	0.907	0.899	0.898	0.901	0.894
<i>0-40: Unknown</i>	0.932	0.931	0.930	0.931	0.929	0.928	0.929
<i>41-64</i>							
<i>41-64: White</i>	0.913	0.913	0.912	0.913	0.913	0.911	0.911
<i>41-64: Non-white</i>	0.901	0.901	0.900	0.900	0.900	0.900	0.899
<i>41-64: Unknown</i>	0.942	0.942	0.941	0.941	0.941	0.940	0.941
<i>65-74</i>							
<i>65-74: White</i>	0.927	0.926	0.925	0.927	0.926	0.926	0.926
<i>65-74: Non-white</i>	0.912	0.913	0.910	0.913	0.912	0.910	0.913
<i>65-74: Unknown</i>	0.928	0.926	0.925	0.926	0.926	0.925	0.926
<i>75-84</i>							
<i>75-84: White</i>	0.912	0.911	0.909	0.912	0.911	0.910	0.911
<i>75-84: Non-white</i>	0.900	0.900	0.898	0.900	0.901	0.900	0.901
<i>75-84: Unknown</i>	0.914	0.911	0.911	0.912	0.913	0.913	0.914
<i>85+</i>							
<i>85+: White</i>	0.883	0.883	0.881	0.885	0.883	0.884	0.886
<i>85+: Non-white</i>	0.891	0.887	0.888	0.891	0.890	0.889	0.892
<i>85+: Unknown</i>	0.895	0.895	0.885	0.894	0.892	0.891	0.895

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.208	0.209	0.207	0.208	0.209	0.205	0.206
<i>0-40: Non-white</i>	0.252	0.255	0.253	0.253	0.251	0.251	0.250
<i>0-40: Unknown</i>	0.262	0.261	0.259	0.261	0.262	0.258	0.257
<i>41-64</i>							
<i>41-64: White</i>	0.249	0.250	0.246	0.250	0.246	0.245	0.246
<i>41-64: Non-white</i>	0.301	0.300	0.296	0.301	0.299	0.297	0.299
<i>41-64: Unknown</i>	0.394	0.393	0.389	0.392	0.390	0.389	0.389
<i>65-74</i>							
<i>65-74: White</i>	0.316	0.318	0.312	0.320	0.315	0.313	0.316
<i>65-74: Non-white</i>	0.327	0.331	0.324	0.334	0.327	0.326	0.332
<i>65-74: Unknown</i>	0.335	0.332	0.329	0.334	0.331	0.330	0.332
<i>75-84</i>							
<i>75-84: White</i>	0.260	0.260	0.254	0.263	0.258	0.257	0.261
<i>75-84: Non-white</i>	0.271	0.273	0.267	0.276	0.271	0.272	0.275
<i>75-84: Unknown</i>	0.270	0.267	0.266	0.270	0.267	0.267	0.269
<i>85+</i>							
<i>85+: White</i>	0.173	0.174	0.169	0.175	0.173	0.172	0.176
<i>85+: Non-white</i>	0.195	0.196	0.191	0.196	0.197	0.196	0.200
<i>85+: Unknown</i>	0.184	0.186	0.178	0.185	0.185	0.184	0.187

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21
<b>HCTZ-containing</b>							
HCTZ-containing products							
0-40							
White	8,755	8,648	8,443	8,394	8,038	8,342	8,033
Non-white	5,672	5,642	5,527	5,412	5,236	5,444	5,235
Unknown	51,277	49,380	47,943	48,122	45,486	47,057	46,607
41-64							
White	146,185	142,647	141,257	140,873	135,345	141,904	132,662
Non-white	71,882	69,503	69,355	69,641	65,508	70,243	65,013
Unknown	493,786	484,890	477,174	476,265	453,575	474,441	460,227
65-74							
White	719,689	714,989	712,392	715,536	689,712	741,372	701,078
Non-white	137,312	136,165	136,717	137,093	131,241	141,926	132,194
Unknown	148,787	146,306	145,430	147,325	141,338	151,502	145,781
75-84							
White	432,705	430,122	429,017	429,505	415,134	445,077	418,549
Non-white	64,209	64,262	63,816	63,880	61,189	65,869	61,107
Unknown	54,537	53,918	53,756	53,686	51,766	55,526	53,686
85+							
White	137,704	136,141	135,297	135,154	130,322	136,979	129,669
Non-white	19,634	18,924	19,077	19,062	18,003	19,366	18,218
Unknown	17,148	16,513	16,517	16,598	15,724	16,739	16,379
HCTZ single ingredient/monotherapy							
0-40							
White	5,066	4,922	4,773	4,778	4,554	4,673	4,527
Non-white	3,307	3,323	3,238	3,088	3,058	3,106	3,054
Unknown	26,325	25,169	24,291	24,224	22,676	23,393	23,181

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>41-64</b>							
White	77,401	75,229	73,817	73,732	70,591	73,512	68,907
Non-white	39,014	37,506	37,347	37,207	34,930	37,362	34,799
Unknown	224,114	219,659	214,549	212,244	201,331	209,995	202,697
<b>65-74</b>							
White	356,744	353,579	349,946	349,054	335,954	360,326	340,928
Non-white	67,878	67,000	66,749	66,221	63,473	68,266	63,987
Unknown	71,625	69,907	69,129	69,664	66,544	70,958	68,494
<b>75-84</b>							
White	224,474	222,211	220,283	219,703	211,729	226,160	213,681
Non-white	31,953	31,878	31,259	31,237	29,941	31,899	29,845
Unknown	27,446	26,653	26,510	26,479	25,322	27,052	26,343
<b>85+</b>							
White	77,443	76,348	75,320	74,962	72,193	75,720	71,567
Non-white	10,579	10,106	10,151	10,041	9,516	10,141	9,559
Unknown	9,413	9,015	8,882	8,866	8,499	8,825	8,647
<b>HCTZ combination products</b>							
<b>0-40</b>							
White	3,737	3,777	3,722	3,657	3,524	3,709	3,546
Non-white	2,396	2,337	2,318	2,346	2,202	2,367	2,209
Unknown	25,445	24,607	23,982	24,223	23,044	23,938	23,697
<b>41-64</b>							
White	69,635	68,198	68,157	67,852	65,388	69,092	64,374
Non-white	33,330	32,436	32,388	32,808	30,927	33,243	30,521
Unknown	274,027	268,990	265,682	266,913	254,729	267,034	259,948
<b>65-74</b>							
White	366,658	364,717	365,642	369,643	356,614	384,147	363,038
Non-white	70,176	69,852	70,624	71,546	68,337	74,327	68,763
Unknown	78,073	77,201	77,029	78,381	75,400	81,249	77,937

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>75-84</b>							
White	210,296	209,808	210,525	211,557	205,005	220,661	206,422
Non-white	32,570	32,705	32,854	32,914	31,491	34,228	31,494
Unknown	27,383	27,533	27,500	27,451	26,643	28,699	27,566
<b>85+</b>							
White	60,889	60,377	60,559	60,741	58,619	61,792	58,544
Non-white	9,165	8,890	9,014	9,114	8,558	9,317	8,733
Unknown	7,828	7,576	7,712	7,797	7,278	7,977	7,792
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<b>0-40</b>							
White	9,527	9,409	9,183	9,128	8,807	9,090	8,750
Non-white	6,336	6,266	6,168	6,061	5,817	6,084	5,838
Unknown	55,100	53,131	51,617	51,849	49,031	50,689	50,291
<b>41-64</b>							
White	160,390	156,559	155,107	154,529	148,656	155,822	145,796
Non-white	79,980	77,242	77,254	77,483	73,107	78,358	72,522
Unknown	525,290	515,944	507,827	507,227	483,036	505,710	490,503
<b>65-74</b>							
White	777,622	772,121	769,792	772,998	745,549	801,745	758,042
Non-white	150,692	149,560	149,965	150,444	144,245	155,841	145,447
Unknown	160,723	158,108	157,209	159,245	153,033	163,765	157,717
<b>75-84</b>							
White	474,917	472,187	470,746	471,434	456,411	488,847	459,683
Non-white	71,399	71,184	70,684	71,006	67,930	73,049	67,954
Unknown	59,788	59,053	58,844	58,725	56,734	60,811	58,846

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<b>85+</b>							
<i>White</i>	155,715	153,573	152,654	152,600	146,999	154,513	146,338
<i>Non-white</i>	22,077	21,276	21,420	21,463	20,254	21,645	20,544
<i>Unknown</i>	19,156	18,433	18,355	18,510	17,596	18,657	18,276
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<b>0-40</b>							
<i>White</i>	42,874	42,198	41,598	42,054	40,414	42,111	40,777
<i>Non-white</i>	23,172	22,667	22,437	22,678	21,501	22,655	21,589
<i>Unknown</i>	199,464	195,060	192,461	194,193	186,492	195,019	195,296
<b>41-64</b>							
<i>White</i>	594,878	583,281	579,348	578,142	557,847	584,357	546,119
<i>Non-white</i>	241,564	234,901	234,140	234,488	224,484	237,268	219,828
<i>Unknown</i>	1,273,850	1,253,588	1,239,083	1,242,423	1,187,768	1,243,257	1,213,527
<b>65-74</b>							
<i>White</i>	2,293,560	2,284,659	2,287,418	2,298,778	2,234,040	2,380,003	2,257,390
<i>Non-white</i>	418,538	415,103	418,076	421,142	405,201	432,517	406,806
<i>Unknown</i>	449,205	445,522	445,134	451,196	434,768	463,639	449,818
<b>75-84</b>							
<i>White</i>	1,676,638	1,673,445	1,672,195	1,677,183	1,631,428	1,728,489	1,635,627
<i>Non-white</i>	236,478	234,406	234,885	235,868	226,810	240,945	226,974
<i>Unknown</i>	203,819	202,028	202,049	202,834	195,543	208,620	203,489
<b>85+</b>							
<i>White</i>	793,089	785,401	782,640	784,877	759,282	785,551	749,833
<i>Non-white</i>	98,784	96,714	96,781	97,210	93,145	97,322	92,249
<i>Unknown</i>	91,822	89,489	89,392	89,709	86,425	90,283	87,957

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators						
	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.919	0.919	0.919	0.920	0.913	0.918	0.918
<i>0-40: Non-white</i>	0.895	0.900	0.896	0.893	0.900	0.895	0.897
<i>0-40: Unknown</i>	0.931	0.929	0.929	0.928	0.928	0.928	0.927
<i>41-64</i>							
<i>41-64: White</i>	0.911	0.911	0.911	0.912	0.910	0.911	0.910
<i>41-64: Non-white</i>	0.899	0.900	0.898	0.899	0.896	0.896	0.896
<i>41-64: Unknown</i>	0.940	0.940	0.940	0.939	0.939	0.938	0.938
<i>65-74</i>							
<i>65-74: White</i>	0.925	0.926	0.925	0.926	0.925	0.925	0.925
<i>65-74: Non-white</i>	0.911	0.910	0.912	0.911	0.910	0.911	0.909
<i>65-74: Unknown</i>	0.926	0.925	0.925	0.925	0.924	0.925	0.924
<i>75-84</i>							
<i>75-84: White</i>	0.911	0.911	0.911	0.911	0.910	0.910	0.911
<i>75-84: Non-white</i>	0.899	0.903	0.903	0.900	0.901	0.902	0.899
<i>75-84: Unknown</i>	0.912	0.913	0.914	0.914	0.912	0.913	0.912
<i>85+</i>							
<i>85+: White</i>	0.884	0.886	0.886	0.886	0.887	0.887	0.886
<i>85+: Non-white</i>	0.889	0.889	0.891	0.888	0.889	0.895	0.887
<i>85+: Unknown</i>	0.895	0.896	0.900	0.897	0.894	0.897	0.896



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.204	0.205	0.203	0.200	0.199	0.198	0.197
<i>0-40: Non-white</i>	0.245	0.249	0.246	0.239	0.244	0.240	0.242
<i>0-40: Unknown</i>	0.257	0.253	0.249	0.248	0.244	0.241	0.239
<i>41-64</i>							
<i>41-64: White</i>	0.246	0.245	0.244	0.244	0.243	0.243	0.243
<i>41-64: Non-white</i>	0.298	0.296	0.296	0.297	0.292	0.296	0.296
<i>41-64: Unknown</i>	0.388	0.387	0.385	0.383	0.382	0.382	0.379
<i>65-74</i>							
<i>65-74: White</i>	0.314	0.313	0.311	0.311	0.309	0.312	0.311
<i>65-74: Non-white</i>	0.328	0.328	0.327	0.326	0.324	0.328	0.325
<i>65-74: Unknown</i>	0.331	0.328	0.327	0.327	0.325	0.327	0.324
<i>75-84</i>							
<i>75-84: White</i>	0.258	0.257	0.257	0.256	0.254	0.257	0.256
<i>75-84: Non-white</i>	0.272	0.274	0.272	0.271	0.270	0.273	0.269
<i>75-84: Unknown</i>	0.268	0.267	0.266	0.265	0.265	0.266	0.264
<i>85+</i>							
<i>85+: White</i>	0.174	0.173	0.173	0.172	0.172	0.174	0.173
<i>85+: Non-white</i>	0.199	0.196	0.197	0.196	0.193	0.199	0.197
<i>85+: Unknown</i>	0.187	0.185	0.185	0.185	0.182	0.185	0.186

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month						
	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>							
HCTZ-containing products							
<i>0-40</i>							
White	7,541	8,218	7,965	7,725	7,902	7,694	7,620
Non-white	4,810	5,375	5,196	4,894	5,018	4,926	4,724
Unknown	43,560	48,837	46,901	45,365	46,279	45,625	44,440
<i>41-64</i>							
White	121,918	135,783	130,074	124,428	129,095	125,047	123,788
Non-white	59,361	65,990	62,715	59,566	62,259	60,200	59,046
Unknown	431,835	481,832	462,352	451,901	463,496	455,175	450,022
<i>65-74</i>							
White	633,971	726,296	697,406	668,255	704,262	688,891	684,007
Non-white	119,161	136,481	130,147	124,218	130,507	128,005	126,362
Unknown	141,219	160,410	155,500	153,498	161,623	159,588	161,769
<i>75-84</i>							
White	379,906	436,579	417,188	403,833	426,008	416,144	417,346
Non-white	56,372	63,960	61,192	59,106	62,559	60,643	60,871
Unknown	51,105	58,440	55,372	54,889	57,678	56,527	57,080
<i>85+</i>							
White	119,286	134,963	129,573	125,759	131,398	129,304	128,721
Non-white	16,670	18,933	18,211	17,577	18,507	18,161	17,896
Unknown	15,202	17,255	16,801	16,258	17,216	16,863	16,684
HCTZ single ingredient/monotherapy							
<i>0-40</i>							
White	4,229	4,607	4,436	4,323	4,410	4,290	4,239
Non-white	2,783	3,095	3,019	2,812	2,919	2,886	2,757
Unknown	21,381	24,015	23,088	22,322	22,776	22,431	21,705

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<b>41-64</b>							
White	63,476	70,260	67,367	64,415	66,573	64,747	63,604
Non-white	31,495	34,917	33,195	31,734	33,121	31,880	31,210
Unknown	189,986	212,258	203,559	198,328	203,789	199,634	196,981
<b>65-74</b>							
White	307,801	352,172	337,581	324,696	341,268	333,870	331,111
Non-white	57,602	65,426	62,375	59,748	62,406	61,335	60,415
Unknown	65,924	74,550	72,625	71,542	75,195	74,466	75,234
<b>75-84</b>							
White	193,802	221,459	212,297	205,889	216,502	211,437	211,787
Non-white	27,360	30,939	29,569	28,827	30,148	29,363	29,249
Unknown	24,819	28,508	26,976	26,641	28,216	27,507	27,621
<b>85+</b>							
White	66,177	74,546	71,401	69,795	72,740	71,122	71,068
Non-white	8,781	9,931	9,454	9,117	9,604	9,419	9,339
Unknown	8,022	9,113	8,905	8,593	9,060	8,960	8,800
<b>HCTZ combination products</b>							
<b>0-40</b>							
White	3,358	3,660	3,569	3,439	3,531	3,441	3,419
Non-white	2,050	2,311	2,207	2,109	2,126	2,067	1,991
Unknown	22,446	25,115	24,110	23,275	23,740	23,435	22,988
<b>41-64</b>							
White	58,981	66,157	63,317	60,584	63,112	60,875	60,710
Non-white	28,157	31,421	29,833	28,116	29,448	28,603	28,127
Unknown	243,960	272,159	261,260	255,841	262,065	257,791	255,187
<b>65-74</b>							
White	328,646	377,150	362,531	346,038	365,650	357,627	355,344
Non-white	62,038	71,592	68,316	64,956	68,639	67,164	66,431
Unknown	75,911	86,601	83,520	82,592	87,091	85,759	87,200

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>							
<i>75-84</i>							
<i>White</i>	187,456	216,854	206,380	199,373	211,055	206,127	207,040
<i>Non-white</i>	29,218	33,291	31,865	30,497	32,628	31,512	31,837
<i>Unknown</i>	26,494	30,177	28,618	28,461	29,685	29,237	29,679
<i>85+</i>							
<i>White</i>	53,533	60,902	58,633	56,422	59,145	58,636	58,074
<i>Non-white</i>	7,939	9,068	8,837	8,524	8,971	8,814	8,620
<i>Unknown</i>	7,229	8,218	7,952	7,724	8,234	7,958	7,942
<b>Denominators</b>							
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic							
<i>0-40</i>							
<i>White</i>	8,247	9,004	8,725	8,447	8,662	8,423	8,355
<i>Non-white</i>	5,378	6,035	5,843	5,501	5,601	5,543	5,293
<i>Unknown</i>	47,000	52,801	50,623	48,925	49,993	49,222	47,898
<i>41-64</i>							
<i>White</i>	134,110	149,551	143,216	137,026	142,095	137,758	136,456
<i>Non-white</i>	66,322	73,838	70,181	66,659	69,632	67,377	66,141
<i>Unknown</i>	460,825	514,258	493,707	482,828	495,256	486,446	480,893
<i>65-74</i>							
<i>White</i>	686,662	786,310	755,054	724,231	762,705	745,693	740,546
<i>Non-white</i>	131,193	150,133	143,547	136,936	143,619	141,060	139,262
<i>Unknown</i>	152,956	173,722	168,440	166,435	174,886	172,979	175,111
<i>75-84</i>							
<i>White</i>	418,091	480,443	458,925	444,848	468,453	457,392	459,140
<i>Non-white</i>	62,676	71,228	68,081	65,789	69,514	67,595	67,774
<i>Unknown</i>	56,053	63,995	60,828	60,180	63,347	62,058	62,661

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>							
<b>85+</b>							
<i>White</i>	134,907	152,567	146,627	142,315	148,415	146,225	145,310
<i>Non-white</i>	18,685	21,315	20,504	19,781	20,840	20,527	20,117
<i>Unknown</i>	16,935	19,269	18,767	18,161	19,171	18,873	18,611
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive							
<b>0-40</b>							
<i>White</i>	38,610	42,066	40,665	39,705	40,559	39,641	39,273
<i>Non-white</i>	20,348	22,348	21,499	20,762	21,109	20,759	20,355
<i>Unknown</i>	182,946	205,870	198,003	192,147	197,724	194,932	191,240
<b>41-64</b>							
<i>White</i>	508,284	560,951	539,149	518,589	536,685	523,107	517,138
<i>Non-white</i>	203,300	223,478	214,210	205,153	212,176	206,732	202,976
<i>Unknown</i>	1,146,738	1,272,277	1,227,240	1,201,243	1,230,971	1,215,311	1,203,302
<b>65-74</b>							
<i>White</i>	2,076,957	2,345,220	2,264,320	2,190,353	2,288,377	2,248,848	2,239,714
<i>Non-white</i>	373,349	419,491	403,876	387,947	404,370	397,829	393,809
<i>Unknown</i>	436,837	493,391	481,927	476,272	499,164	497,204	501,752
<b>75-84</b>							
<i>White</i>	1,511,383	1,704,719	1,642,777	1,603,123	1,676,606	1,646,953	1,652,194
<i>Non-white</i>	210,238	235,670	227,361	220,498	231,172	226,677	226,176
<i>Unknown</i>	194,380	218,869	212,116	208,484	219,743	216,584	218,557
<b>85+</b>							
<i>White</i>	701,863	778,249	753,914	739,807	767,591	756,227	756,608
<i>Non-white</i>	86,043	95,721	92,472	90,243	94,181	92,468	91,930
<i>Unknown</i>	83,445	93,273	90,374	89,240	92,946	91,817	91,876

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators						
	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>Proportions, limited denominator</b>							
HCTZ-containing numerator, limited denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.914	0.913	0.913	0.915	0.912	0.913	0.912
<i>0-40: Non-white</i>	0.894	0.891	0.889	0.890	0.896	0.889	0.892
<i>0-40: Unknown</i>	0.927	0.925	0.926	0.927	0.926	0.927	0.928
<i>41-64</i>							
<i>41-64: White</i>	0.909	0.908	0.908	0.908	0.909	0.908	0.907
<i>41-64: Non-white</i>	0.895	0.894	0.894	0.894	0.894	0.893	0.893
<i>41-64: Unknown</i>	0.937	0.937	0.936	0.936	0.936	0.936	0.936
<i>65-74</i>							
<i>65-74: White</i>	0.923	0.924	0.924	0.923	0.923	0.924	0.924
<i>65-74: Non-white</i>	0.908	0.909	0.907	0.907	0.909	0.907	0.907
<i>65-74: Unknown</i>	0.923	0.923	0.923	0.922	0.924	0.923	0.924
<i>75-84</i>							
<i>75-84: White</i>	0.909	0.909	0.909	0.908	0.909	0.910	0.909
<i>75-84: Non-white</i>	0.899	0.898	0.899	0.898	0.900	0.897	0.898
<i>75-84: Unknown</i>	0.912	0.913	0.910	0.912	0.911	0.911	0.911
<i>85+</i>							
<i>85+: White</i>	0.884	0.885	0.884	0.884	0.885	0.884	0.886
<i>85+: Non-white</i>	0.892	0.888	0.888	0.889	0.888	0.885	0.890
<i>85+: Unknown</i>	0.898	0.895	0.895	0.895	0.898	0.893	0.896

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>							
HCTZ-containing numerator, full denominator							
<i>0-40</i>							
<i>0-40: White</i>	0.195	0.195	0.196	0.195	0.195	0.194	0.194
<i>0-40: Non-white</i>	0.236	0.241	0.242	0.236	0.238	0.237	0.232
<i>0-40: Unknown</i>	0.238	0.237	0.237	0.236	0.234	0.234	0.232
<i>41-64</i>							
<i>41-64: White</i>	0.240	0.242	0.241	0.240	0.241	0.239	0.239
<i>41-64: Non-white</i>	0.292	0.295	0.293	0.290	0.293	0.291	0.291
<i>41-64: Unknown</i>	0.377	0.379	0.377	0.376	0.377	0.375	0.374
<i>65-74</i>							
<i>65-74: White</i>	0.305	0.310	0.308	0.305	0.308	0.306	0.305
<i>65-74: Non-white</i>	0.319	0.325	0.322	0.320	0.323	0.322	0.321
<i>65-74: Unknown</i>	0.323	0.325	0.323	0.322	0.324	0.321	0.322
<i>75-84</i>							
<i>75-84: White</i>	0.251	0.256	0.254	0.252	0.254	0.253	0.253
<i>75-84: Non-white</i>	0.268	0.271	0.269	0.268	0.271	0.268	0.269
<i>75-84: Unknown</i>	0.263	0.267	0.261	0.263	0.262	0.261	0.261
<i>85+</i>							
<i>85+: White</i>	0.170	0.173	0.172	0.170	0.171	0.171	0.170
<i>85+: Non-white</i>	0.194	0.198	0.197	0.195	0.197	0.196	0.195
<i>85+: Unknown</i>	0.182	0.185	0.186	0.182	0.185	0.184	0.182

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
<i>0-40</i>					
White	7,231	7,237	7,159	7,182	6,764
Non-white	4,620	4,523	4,460	4,464	4,182
Unknown	43,289	42,726	41,618	40,764	25,429
<i>41-64</i>					
White	119,700	117,934	115,825	116,894	107,848
Non-white	57,816	56,747	55,522	56,246	51,347
Unknown	442,318	439,770	426,539	423,178	272,519
<i>65-74</i>					
White	667,630	667,118	655,460	671,372	631,558
Non-white	124,110	123,123	120,510	122,337	111,029
Unknown	159,984	161,092	160,573	163,198	149,940
<i>75-84</i>					
White	408,629	411,713	409,717	422,891	402,323
Non-white	59,819	59,392	58,943	60,450	55,398
Unknown	56,609	56,547	56,688	58,053	54,462
<i>85+</i>					
White	125,444	125,550	124,615	126,018	121,957
Non-white	17,662	17,507	17,155	17,535	16,217
Unknown	16,524	16,481	16,268	16,581	15,294
HCTZ single ingredient/monotherapy					
<i>0-40</i>					
White	4,044	4,003	3,960	3,998	3,811
Non-white	2,678	2,613	2,597	2,601	2,453
Unknown	21,072	20,706	20,090	19,628	12,625



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>					
<i>41-64</i>					
<i>White</i>	61,714	60,508	59,743	60,564	56,582
<i>Non-white</i>	30,689	29,778	29,160	30,098	27,674
<i>Unknown</i>	193,488	191,979	185,486	186,449	122,588
<i>65-74</i>					
<i>White</i>	322,479	321,463	316,261	326,892	311,114
<i>Non-white</i>	59,121	58,604	57,366	59,169	54,443
<i>Unknown</i>	74,302	74,495	74,274	76,309	71,499
<i>75-84</i>					
<i>White</i>	207,229	207,621	207,338	215,707	207,513
<i>Non-white</i>	28,596	28,537	28,247	29,148	27,347
<i>Unknown</i>	27,472	27,299	27,288	28,375	26,952
<i>85+</i>					
<i>White</i>	69,277	68,826	68,738	69,629	68,166
<i>Non-white</i>	9,134	9,018	8,866	9,036	8,588
<i>Unknown</i>	8,692	8,664	8,471	8,761	8,135
HCTZ combination products					
<i>0-40</i>					
<i>White</i>	3,219	3,263	3,220	3,221	2,985
<i>Non-white</i>	1,968	1,935	1,881	1,879	1,751
<i>Unknown</i>	22,446	22,238	21,761	21,378	12,932
<i>41-64</i>					
<i>White</i>	58,493	57,933	56,594	56,881	51,749
<i>Non-white</i>	27,400	27,233	26,597	26,407	23,933
<i>Unknown</i>	250,913	249,852	243,030	239,133	151,219
<i>65-74</i>					
<i>White</i>	347,546	348,032	341,474	347,005	322,901
<i>Non-white</i>	65,445	64,953	63,584	63,622	57,074
<i>Unknown</i>	86,279	87,206	86,919	87,558	79,107

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>					
<b>75-84</b>					
White	202,828	205,499	203,756	208,728	196,320
Non-white	31,434	31,064	30,916	31,526	28,257
Unknown	29,337	29,471	29,587	29,921	27,772
<b>85+</b>					
White	56,566	57,144	56,292	56,855	54,254
Non-white	8,594	8,553	8,331	8,563	7,683
Unknown	7,887	7,866	7,854	7,871	7,209
<b>Denominators</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
<b>0-40</b>					
White	7,915	7,924	7,856	7,862	7,424
Non-white	5,167	5,090	5,033	5,042	4,727
Unknown	46,836	46,174	45,093	44,182	27,601
<b>41-64</b>					
White	131,847	130,057	127,708	129,110	118,975
Non-white	64,738	63,673	62,171	63,123	57,601
Unknown	472,902	470,455	456,550	453,269	292,929
<b>65-74</b>					
White	722,921	722,010	710,127	727,865	684,697
Non-white	136,694	135,714	132,925	135,024	122,575
Unknown	173,272	174,630	174,134	177,035	162,819
<b>75-84</b>					
White	449,306	452,181	451,015	465,542	442,861
Non-white	66,533	65,988	65,808	67,334	61,881
Unknown	62,071	62,085	62,301	63,771	59,820

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>					
<b>85+</b>					
White	141,718	141,796	140,648	142,301	137,855
Non-white	19,912	19,742	19,344	19,812	18,344
Unknown	18,414	18,417	18,147	18,554	17,084
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
<b>0-40</b>					
White	38,106	37,643	37,626	38,035	36,003
Non-white	19,803	19,633	19,280	19,459	18,529
Unknown	188,130	185,850	184,219	181,319	114,721
<b>41-64</b>					
White	501,799	495,736	490,214	495,954	456,464
Non-white	198,434	196,016	192,481	195,671	179,803
Unknown	1,186,449	1,182,864	1,157,127	1,150,903	762,437
<b>65-74</b>					
White	2,186,923	2,192,921	2,166,748	2,215,306	2,080,182
Non-white	386,894	385,348	379,495	386,872	351,462
Unknown	498,795	503,516	503,761	513,797	476,838
<b>75-84</b>					
White	1,622,656	1,633,758	1,635,641	1,679,486	1,598,439
Non-white	222,760	222,919	221,620	226,524	210,250
Unknown	217,133	217,940	219,209	224,730	211,372
<b>85+</b>					
White	741,384	742,428	739,790	748,643	722,373
Non-white	90,630	90,412	89,323	91,219	85,393
Unknown	90,420	90,986	90,400	91,750	84,413

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>Proportions, limited denominator</b>					
HCTZ-containing numerator, limited denominator					
<i>0-40</i>					
<i>0-40: White</i>	0.914	0.913	0.911	0.914	0.911
<i>0-40: Non-white</i>	0.894	0.889	0.886	0.885	0.885
<i>0-40: Unknown</i>	0.924	0.925	0.923	0.923	0.921
<i>41-64</i>					
<i>41-64: White</i>	0.908	0.907	0.907	0.905	0.906
<i>41-64: Non-white</i>	0.893	0.891	0.893	0.891	0.891
<i>41-64: Unknown</i>	0.935	0.935	0.934	0.934	0.930
<i>65-74</i>					
<i>65-74: White</i>	0.924	0.924	0.923	0.922	0.922
<i>65-74: Non-white</i>	0.908	0.907	0.907	0.906	0.906
<i>65-74: Unknown</i>	0.923	0.922	0.922	0.922	0.921
<i>75-84</i>					
<i>75-84: White</i>	0.909	0.911	0.908	0.908	0.908
<i>75-84: Non-white</i>	0.899	0.900	0.896	0.898	0.895
<i>75-84: Unknown</i>	0.912	0.911	0.910	0.910	0.910
<i>85+</i>					
<i>85+: White</i>	0.885	0.885	0.886	0.886	0.885
<i>85+: Non-white</i>	0.887	0.887	0.887	0.885	0.884
<i>85+: Unknown</i>	0.897	0.895	0.896	0.894	0.895

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>					
HCTZ-containing numerator, full denominator					
<i>0-40</i>					
<i>0-40: White</i>	0.190	0.192	0.190	0.189	0.188
<i>0-40: Non-white</i>	0.233	0.230	0.231	0.229	0.226
<i>0-40: Unknown</i>	0.230	0.230	0.226	0.225	0.222
<i>41-64</i>					
<i>41-64: White</i>	0.239	0.238	0.236	0.236	0.236
<i>41-64: Non-white</i>	0.291	0.290	0.288	0.287	0.286
<i>41-64: Unknown</i>	0.373	0.372	0.369	0.368	0.357
<i>65-74</i>					
<i>65-74: White</i>	0.305	0.304	0.303	0.303	0.304
<i>65-74: Non-white</i>	0.321	0.320	0.318	0.316	0.316
<i>65-74: Unknown</i>	0.321	0.320	0.319	0.318	0.314
<i>75-84</i>					
<i>75-84: White</i>	0.252	0.252	0.250	0.252	0.252
<i>75-84: Non-white</i>	0.269	0.266	0.266	0.267	0.263
<i>75-84: Unknown</i>	0.261	0.259	0.259	0.258	0.258
<i>85+</i>					
<i>85+: White</i>	0.169	0.169	0.168	0.168	0.169
<i>85+: Non-white</i>	0.195	0.194	0.192	0.192	0.190
<i>85+: Unknown</i>	0.183	0.181	0.180	0.181	0.181

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Patients with dispensing per month				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
<i>0-40</i>					
White	6,133	6,514	2,196	2,276	2,228
Non-white	3,649	3,971	1,310	1,282	1,315
Unknown	22,993	4,473	3,469	3,445	3,432
<i>41-64</i>					
White	82,654	89,522	28,233	28,560	28,029
Non-white	37,357	40,520	12,493	12,627	12,460
Unknown	237,958	45,167	37,685	38,021	37,122
<i>65-74</i>					
White	496,266	553,914	31,034	31,415	30,451
Non-white	69,554	76,820	9,047	9,342	9,168
Unknown	104,141	54,354	11,761	12,009	11,771
<i>75-84</i>					
White	313,995	353,479	16,740	17,005	16,623
Non-white	36,299	40,121	3,167	3,271	3,172
Unknown	42,258	20,323	3,705	3,853	3,629
<i>85+</i>					
White	98,876	108,312	4,212	4,252	4,070
Non-white	11,736	13,037	663	649	613
Unknown	12,153	5,678	980	994	1,013
HCTZ single ingredient/monotherapy					
<i>0-40</i>					
White	3,445	3,631	1,026	1,115	1,063
Non-white	2,141	2,346	677	673	683
Unknown	11,498	2,268	1,685	1,673	1,682

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>					
<b>41-64</b>					
White	43,622	46,998	12,954	13,123	12,828
Non-white	20,431	22,032	5,792	5,821	5,753
Unknown	107,676	20,577	16,468	16,605	16,189
<b>65-74</b>					
White	246,033	272,431	15,009	15,306	14,735
Non-white	34,859	38,046	4,382	4,446	4,377
Unknown	49,892	26,636	5,335	5,407	5,441
<b>75-84</b>					
White	162,803	182,729	8,689	8,739	8,616
Non-white	18,065	19,730	1,472	1,578	1,545
Unknown	20,928	10,083	1,794	1,857	1,747
<b>85+</b>					
White	55,528	60,536	2,359	2,386	2,255
Non-white	6,325	6,884	352	319	315
Unknown	6,423	2,955	525	514	519
<b>HCTZ combination products</b>					
<b>0-40</b>					
White	2,718	2,912	1,175	1,172	1,178
Non-white	1,520	1,642	639	612	640
Unknown	11,610	2,228	1,801	1,783	1,761
<b>41-64</b>					
White	39,403	42,889	15,385	15,549	15,309
Non-white	17,120	18,713	6,754	6,857	6,760
Unknown	131,334	24,831	21,376	21,597	21,102
<b>65-74</b>					
White	252,132	283,640	16,133	16,213	15,796
Non-white	34,975	39,096	4,701	4,923	4,827
Unknown	54,678	27,938	6,472	6,652	6,365

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>HCTZ-containing</b>					
<i>75-84</i>					
<i>White</i>	152,332	172,181	8,097	8,306	8,061
<i>Non-white</i>	18,365	20,563	1,708	1,705	1,636
<i>Unknown</i>	21,501	10,339	1,932	2,015	1,897
<i>85+</i>					
<i>White</i>	43,740	48,211	1,863	1,877	1,829
<i>Non-white</i>	5,449	6,204	316	331	299
<i>Unknown</i>	5,769	2,749	460	480	497
<b>Denominators</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
<i>0-40</i>					
<i>White</i>	6,733	7,178	2,381	2,466	2,414
<i>Non-white</i>	4,133	4,526	1,447	1,414	1,461
<i>Unknown</i>	24,936	4,921	3,785	3,766	3,758
<i>41-64</i>					
<i>White</i>	91,121	99,057	30,324	30,708	30,185
<i>Non-white</i>	41,895	45,543	13,644	13,802	13,602
<i>Unknown</i>	255,648	48,936	40,488	40,868	39,919
<i>65-74</i>					
<i>White</i>	538,469	601,272	33,543	33,921	32,975
<i>Non-white</i>	77,216	85,066	9,930	10,256	10,024
<i>Unknown</i>	113,422	59,438	12,753	13,016	12,748
<i>75-84</i>					
<i>White</i>	347,038	390,042	18,265	18,581	18,179
<i>Non-white</i>	40,561	45,008	3,530	3,632	3,531
<i>Unknown</i>	46,548	22,464	4,100	4,232	4,047



Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Denominators</b>					
<b>85+</b>					
White	112,054	122,841	4,702	4,760	4,580
Non-white	13,333	14,746	744	750	686
Unknown	13,633	6,304	1,106	1,108	1,109
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
<b>0-40</b>					
White	32,723	35,410	12,438	12,876	12,565
Non-white	16,225	17,720	5,476	5,421	2,987
Unknown	103,615	24,638	17,536	17,760	17,359
<b>41-64</b>					
White	351,611	378,994	84,635	86,147	84,762
Non-white	133,002	142,886	33,727	34,304	33,887
Unknown	661,480	136,588	102,336	103,376	101,747
<b>65-74</b>					
White	1,652,854	1,820,358	101,894	104,256	101,437
Non-white	231,694	251,733	26,649	27,476	27,141
Unknown	339,712	182,988	35,750	36,149	35,569
<b>75-84</b>					
White	1,269,616	1,403,749	66,917	68,199	66,200
Non-white	142,688	155,426	11,160	11,420	11,154
Unknown	168,059	79,842	13,623	14,028	13,517
<b>85+</b>					
White	599,062	651,138	24,373	24,865	24,282
Non-white	64,733	70,554	3,156	3,245	3,120
Unknown	69,119	31,601	5,238	5,276	5,263

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

	Proportion of numerators / denominators				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>Proportions, limited denominator</b>					
HCTZ-containing numerator, limited denominator					
<i>0-40</i>					
<i>0-40: White</i>	0.911	0.907	0.922	0.923	0.923
<i>0-40: Non-white</i>	0.883	0.877	0.905	0.907	0.900
<i>0-40: Unknown</i>	0.922	0.909	0.917	0.915	0.913
<i>41-64</i>					
<i>41-64: White</i>	0.907	0.904	0.931	0.930	0.929
<i>41-64: Non-white</i>	0.892	0.890	0.916	0.915	0.916
<i>41-64: Unknown</i>	0.931	0.923	0.931	0.930	0.930
<i>65-74</i>					
<i>65-74: White</i>	0.922	0.921	0.925	0.926	0.923
<i>65-74: Non-white</i>	0.901	0.903	0.911	0.911	0.915
<i>65-74: Unknown</i>	0.918	0.914	0.922	0.923	0.923
<i>75-84</i>					
<i>75-84: White</i>	0.905	0.906	0.917	0.915	0.914
<i>75-84: Non-white</i>	0.895	0.891	0.897	0.901	0.898
<i>75-84: Unknown</i>	0.908	0.905	0.904	0.910	0.897
<i>85+</i>					
<i>85+: White</i>	0.882	0.882	0.896	0.893	0.889
<i>85+: Non-white</i>	0.880	0.884	0.891	0.865	0.894
<i>85+: Unknown</i>	0.891	0.901	0.886	0.897	0.913

Table 5. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month

<b>Proportions, full denominator</b>					
HCTZ-containing numerator, full denominator					
<i>0-40</i>					
<i>0-40: White</i>	0.187	0.184	0.177	0.177	0.177
<i>0-40: Non-white</i>	0.225	0.224	0.239	0.236	0.440
<i>0-40: Unknown</i>	0.222	0.182	0.198	0.194	0.198
<i>41-64</i>					
<i>41-64: White</i>	0.235	0.236	0.334	0.332	0.331
<i>41-64: Non-white</i>	0.281	0.284	0.370	0.368	0.368
<i>41-64: Unknown</i>	0.360	0.331	0.368	0.368	0.365
<i>65-74</i>					
<i>65-74: White</i>	0.300	0.304	0.305	0.301	0.300
<i>65-74: Non-white</i>	0.300	0.305	0.339	0.340	0.338
<i>65-74: Unknown</i>	0.307	0.297	0.329	0.332	0.331
<i>75-84</i>					
<i>75-84: White</i>	0.247	0.252	0.250	0.249	0.251
<i>75-84: Non-white</i>	0.254	0.258	0.284	0.286	0.284
<i>75-84: Unknown</i>	0.251	0.255	0.272	0.275	0.268
<i>85+</i>					
<i>85+: White</i>	0.165	0.166	0.173	0.171	0.168
<i>85+: Non-white</i>	0.181	0.185	0.210	0.200	0.196
<i>85+: Unknown</i>	0.176	0.180	0.187	0.188	0.192

Figure 5 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month




Figure 5 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by age group (years), race, and calendar year/month




Table 6a. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b>HCTZ-containing products</b>					
<i>6.25 mg</i>	266,716	3,317,186	3,331,663	130,785,425	2.0
<i>12.5 mg</i>	7,629,138	73,995,109	74,413,724	130,785,425	58.3
<i>15 mg</i>	1,793	14,817	14,892	130,785,425	0.0
<i>25 mg</i>	8,729,186	89,789,768	90,204,099	130,785,425	66.7
<i>50 mg</i>	463,423	4,435,797	4,449,645	130,785,425	3.5
<b>HCTZ single ingredient/monotherapy</b>					
<i>12.5 mg</i>	3,676,554	26,753,466	26,822,881	130,785,425	28.1
<i>25 mg</i>	5,184,316	46,503,648	46,627,893	130,785,425	39.6
<i>50 mg</i>	263,320	2,243,971	2,249,452	130,785,425	2.0
<b>HCTZ combination products</b>					
<i>6.25 mg</i>	266,716	3,317,186	3,331,663	130,785,425	2.0
<i>12.5 mg</i>	4,703,868	47,360,850	47,590,846	130,785,425	36.0
<i>15 mg</i>	1,793	14,817	14,892	130,785,425	0.0
<i>25 mg</i>	4,271,230	43,379,084	43,576,209	130,785,425	32.7
<i>50 mg</i>	204,601	2,192,367	2,200,193	130,785,425	1.6

<sup>1</sup>Eligible members includes those who have at least one day of enrollment during the query period.

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg	65,528	59,736	65,419	61,356	64,733	62,809	62,165	62,816
12.5 mg	1,304,007	1,204,024	1,322,174	1,244,792	1,315,681	1,283,871	1,272,831	1,291,525
15 mg	620	535	604	552	566	553	512	512
25 mg	1,649,235	1,517,194	1,663,507	1,570,425	1,656,455	1,617,154	1,605,739	1,624,363
50 mg	87,841	79,891	87,889	82,206	86,820	84,779	83,619	84,689
HCTZ single ingredient/monotherapy								
12.5 mg	388,068	359,322	395,681	373,422	397,395	390,237	387,755	394,579
25 mg	781,403	718,013	788,188	746,253	788,321	769,475	766,872	775,707
50 mg	40,833	36,893	40,789	38,388	40,535	39,496	39,279	39,779
HCTZ combination products								
6.25 mg	65,528	59,736	65,419	61,356	64,733	62,809	62,165	62,816
12.5 mg	920,575	848,661	931,200	875,533	922,928	898,226	889,377	901,465
15 mg	620	535	604	552	566	553	512	512
25 mg	872,209	803,053	879,747	828,108	872,488	851,829	842,912	852,861
50 mg	47,045	43,019	47,134	43,842	46,321	45,305	44,363	44,940
	Eligible members per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
Enrollees with at least one day of coverage	62,229,431	62,191,560	62,228,731	62,164,229	62,111,028	62,123,634	62,130,040	62,204,794

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>HCTZ-containing 6.25 mg</i>	1.1	1.0	1.1	1.0	1.0	1.0	1.0	1.0
<i>HCTZ-containing 12.5 mg</i>	21.0	19.4	21.2	20.0	21.2	20.7	20.5	20.8
<i>HCTZ-containing 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ-containing 25 mg</i>	26.5	24.4	26.7	25.3	26.7	26.0	25.8	26.1
<i>HCTZ-containing 50 mg</i>	1.4	1.3	1.4	1.3	1.4	1.4	1.3	1.4
HCTZ single ingredient								
<i>HCTZ single ingredient 12.5 mg</i>	6.2	5.8	6.4	6.0	6.4	6.3	6.2	6.3
<i>HCTZ single ingredient 25 mg</i>	12.6	11.5	12.7	12.0	12.7	12.4	12.3	12.5
<i>HCTZ single ingredient 50 mg</i>	0.7	0.6	0.7	0.6	0.7	0.6	0.6	0.6
HCTZ combination products								
<i>HCTZ combination 6.25 mg</i>	1.1	1.0	1.1	1.0	1.0	1.0	1.0	1.0
<i>HCTZ combination 12.5 mg</i>	14.8	13.6	15.0	14.1	14.9	14.5	14.3	14.5
<i>HCTZ combination 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ combination 25 mg</i>	14.0	12.9	14.1	13.3	14.0	13.7	13.6	13.7
<i>HCTZ combination 50 mg</i>	0.8	0.7	0.8	0.7	0.7	0.7	0.7	0.7



Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg	60,190	62,239	60,064	60,147	60,326	54,429	58,256	57,508
12.5 mg	1,224,775	1,279,774	1,235,612	1,238,380	1,255,712	1,148,999	1,237,297	1,222,447
15 mg	497	531	452	483	459	372	412	361
25 mg	1,539,363	1,606,980	1,543,902	1,549,854	1,564,442	1,422,570	1,532,447	1,512,619
50 mg	80,539	82,599	78,997	80,010	79,637	71,821	77,265	76,180
HCTZ single ingredient/monotherapy								
12.5 mg	374,544	392,286	378,651	379,100	387,574	355,534	383,980	381,508
25 mg	735,606	768,622	738,221	738,855	749,735	680,775	732,519	724,582
50 mg	38,007	39,125	37,384	37,982	38,005	34,398	36,853	36,711
HCTZ combination products								
6.25 mg	60,190	62,239	60,064	60,147	60,326	54,429	58,256	57,508
12.5 mg	854,287	891,840	861,119	863,341	872,452	797,243	857,517	845,060
15 mg	497	531	452	483	459	372	412	361
25 mg	807,494	842,434	809,633	814,750	818,644	745,284	803,866	791,760
50 mg	42,566	43,496	41,630	42,054	41,669	37,448	40,442	39,496
	Eligible members per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
Enrollees with at least one day of coverage	61,836,252	61,845,502	61,869,177	61,873,272	61,213,863	61,123,877	61,109,989	61,024,866

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>HCTZ-containing 6.25 mg</i>	1.0	1.0	1.0	1.0	1.0	0.9	0.9	0.9
<i>HCTZ-containing 12.5 mg</i>	19.8	20.7	20.0	20.0	20.5	18.8	20.2	20.0
<i>HCTZ-containing 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ-containing 25 mg</i>	24.9	26.0	25.0	25.0	25.6	23.3	25.1	24.8
<i>HCTZ-containing 50 mg</i>	1.3	1.3	1.3	1.3	1.3	1.2	1.3	1.2
HCTZ single ingredient								
<i>HCTZ single ingredient 12.5 mg</i>	6.1	6.3	6.1	6.1	6.3	5.8	6.3	6.3
<i>HCTZ single ingredient 25 mg</i>	11.9	12.4	11.9	11.9	12.2	11.1	12.0	11.9
<i>HCTZ single ingredient 50 mg</i>	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
HCTZ combination products								
<i>HCTZ combination 6.25 mg</i>	1.0	1.0	1.0	1.0	1.0	0.9	1.0	0.9
<i>HCTZ combination 12.5 mg</i>	13.8	14.4	13.9	14.0	14.3	13.0	14.0	13.8
<i>HCTZ combination 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ combination 25 mg</i>	13.1	13.6	13.1	13.2	13.4	12.2	13.2	13.0
<i>HCTZ combination 50 mg</i>	0.7	0.7	0.7	0.7	0.7	0.6	0.7	0.6

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg	57,330	55,415	56,282	56,559	52,526	57,254	53,778	53,274
12.5 mg	1,232,456	1,186,877	1,241,500	1,246,711	1,140,801	1,251,490	1,171,322	1,166,769
15 mg	375	347	356	359	335	354	331	345
25 mg	1,528,209	1,471,334	1,513,982	1,508,332	1,393,221	1,513,660	1,420,508	1,413,806
50 mg	77,066	74,273	75,625	75,702	70,286	75,499	71,078	70,544
HCTZ single ingredient/monotherapy								
12.5 mg	389,946	376,155	387,237	391,516	362,297	390,381	370,585	370,485
25 mg	733,617	707,803	726,628	729,502	679,149	731,352	691,346	690,704
50 mg	37,136	35,888	36,778	36,709	34,231	36,796	34,921	34,723
HCTZ combination products								
6.25 mg	57,330	55,415	56,282	56,559	52,526	57,254	53,778	53,274
12.5 mg	846,828	814,853	859,488	860,248	782,586	865,630	804,886	800,446
15 mg	375	347	356	359	335	354	331	345
25 mg	798,504	767,241	792,163	783,354	717,637	786,179	732,868	726,685
50 mg	39,955	38,409	38,872	39,017	36,080	38,728	36,189	35,857
	Eligible members per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
Enrollees with at least one day of coverage	60,985,306	61,006,669	60,989,906	61,092,592	61,161,878	61,189,962	61,179,325	61,155,027

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>HCTZ-containing 6.25 mg</i>	0.9	0.9	0.9	0.9	0.8	0.9	0.9	0.9
<i>HCTZ-containing 12.5 mg</i>	20.2	19.5	20.4	20.4	18.7	20.5	19.1	19.1
<i>HCTZ-containing 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ-containing 25 mg</i>	25.1	24.1	24.8	24.7	22.8	24.7	23.2	23.1
<i>HCTZ-containing 50 mg</i>	1.3	1.2	1.2	1.2	1.1	1.2	1.2	1.2
HCTZ single ingredient								
<i>HCTZ single ingredient 12.5 mg</i>	6.4	6.2	6.3	6.4	5.9	6.4	6.1	6.1
<i>HCTZ single ingredient 25 mg</i>	12.0	11.6	11.9	11.9	11.1	12.0	11.3	11.3
<i>HCTZ single ingredient 50 mg</i>	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
HCTZ combination products								
<i>HCTZ combination 6.25 mg</i>	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
<i>HCTZ combination 12.5 mg</i>	13.9	13.4	14.1	14.1	12.8	14.1	13.2	13.1
<i>HCTZ combination 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ combination 25 mg</i>	13.1	12.6	13.0	12.8	11.7	12.8	12.0	11.9
<i>HCTZ combination 50 mg</i>	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg	55,415	50,309	52,248	53,231	52,681	49,326	52,250	50,967
12.5 mg	1,216,721	1,097,046	1,163,721	1,190,115	1,177,585	1,110,713	1,176,363	1,137,604
15 mg	343	267	324	288	291	268	293	243
25 mg	1,460,575	1,315,726	1,400,264	1,426,911	1,413,466	1,338,180	1,415,815	1,370,063
50 mg	72,388	65,100	68,767	70,009	69,504	65,642	69,333	67,864
HCTZ single ingredient/monotherapy								
12.5 mg	386,941	356,742	382,989	395,873	398,371	380,058	403,261	402,030
25 mg	723,114	655,127	698,629	714,887	709,253	674,759	712,621	702,065
50 mg	35,564	32,332	34,332	35,002	34,941	33,426	35,564	34,462
HCTZ combination products								
6.25 mg	55,415	50,309	52,248	53,231	52,681	49,326	52,250	50,967
12.5 mg	834,832	744,849	786,001	799,604	784,605	735,558	778,314	741,093
15 mg	343	267	324	288	291	268	293	243
25 mg	742,245	664,728	705,933	716,324	708,383	667,367	707,357	672,723
50 mg	36,858	32,799	34,464	35,034	34,604	32,267	33,849	33,447
	<b>Eligible members per month</b>							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
Enrollees with at least one day of coverage	60,886,631	60,813,142	60,826,591	60,746,637	60,686,962	60,624,928	60,662,237	60,651,542

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>HCTZ-containing 6.25 mg</i>	0.9	0.8	0.8	0.9	0.8	0.8	0.8	0.8
<i>HCTZ-containing 12.5 mg</i>	20.0	18.0	19.1	19.6	19.4	18.3	19.4	18.8
<i>HCTZ-containing 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ-containing 25 mg</i>	24.0	21.6	23.0	23.5	23.3	22.1	23.3	22.6
<i>HCTZ-containing 50 mg</i>	1.2	1.1	1.1	1.2	1.1	1.1	1.1	1.1
HCTZ single ingredient								
<i>HCTZ single ingredient 12.5 mg</i>	6.4	5.9	6.3	6.5	6.6	6.3	6.6	6.6
<i>HCTZ single ingredient 25 mg</i>	11.9	10.8	11.5	11.8	11.7	11.1	11.7	11.6
<i>HCTZ single ingredient 50 mg</i>	0.6	0.5	0.6	0.6	0.6	0.6	0.6	0.6
HCTZ combination products								
<i>HCTZ combination 6.25 mg</i>	0.9	0.8	0.9	0.9	0.9	0.8	0.9	0.8
<i>HCTZ combination 12.5 mg</i>	13.7	12.2	12.9	13.2	12.9	12.1	12.8	12.2
<i>HCTZ combination 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ combination 25 mg</i>	12.2	10.9	11.6	11.8	11.7	11.0	11.7	11.1
<i>HCTZ combination 50 mg</i>	0.6	0.5	0.6	0.6	0.6	0.5	0.6	0.6

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg	48,516	51,226	47,200	49,035	50,905	46,431	53,014	46,956
12.5 mg	1,097,799	1,167,354	1,078,046	1,127,877	1,159,480	1,064,294	1,211,531	1,078,716
15 mg	240	209	161	159	113	72	53	21
25 mg	1,320,095	1,387,422	1,275,315	1,349,959	1,381,564	1,267,524	1,464,376	1,299,399
50 mg	65,804	68,053	62,936	66,709	67,147	61,750	70,946	63,000
HCTZ single ingredient/monotherapy								
12.5 mg	402,042	446,441	428,178	462,955	491,340	455,449	523,037	463,211
25 mg	692,606	757,378	719,991	779,439	794,128	729,112	834,051	741,173
50 mg	33,938	35,190	32,451	34,489	34,946	32,411	36,841	33,157
HCTZ combination products								
6.25 mg	48,516	51,226	47,200	49,035	50,905	46,431	53,014	46,956
12.5 mg	702,014	729,540	657,598	672,900	676,371	615,254	696,896	621,704
15 mg	240	209	161	159	113	72	53	21
25 mg	632,830	638,131	562,692	577,909	593,879	543,336	636,373	563,040
50 mg	31,899	32,900	30,515	32,245	32,229	29,369	34,127	29,869
	Eligible members per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
Enrollees with at least one day of coverage	60,683,951	60,706,276	60,703,605	60,686,255	61,089,472	60,949,008	60,913,111	60,771,289

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>HCTZ-containing 6.25 mg</i>	0.8	0.8	0.8	0.8	0.8	0.7	0.9	0.8
<i>HCTZ-containing 12.5 mg</i>	18.1	19.2	17.8	18.6	19.0	17.5	19.9	17.8
<i>HCTZ-containing 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ-containing 25 mg</i>	21.8	22.9	21.0	22.2	22.6	20.8	24.0	21.4
<i>HCTZ-containing 50 mg</i>	1.1	1.1	1.0	1.1	1.1	1.0	1.2	1.0
HCTZ single ingredient								
<i>HCTZ single ingredient 12.5 mg</i>	6.6	7.4	7.1	7.6	8.0	7.5	8.6	7.6
<i>HCTZ single ingredient 25 mg</i>	11.4	12.5	11.9	12.8	13.0	12.0	13.7	12.2
<i>HCTZ single ingredient 50 mg</i>	0.6	0.6	0.5	0.6	0.6	0.5	0.6	0.5
HCTZ combination products								
<i>HCTZ combination 6.25 mg</i>	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.8
<i>HCTZ combination 12.5 mg</i>	11.6	12.0	10.8	11.1	11.1	10.1	11.4	10.2
<i>HCTZ combination 15 mg</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>HCTZ combination 25 mg</i>	10.4	10.5	9.3	9.5	9.7	8.9	10.4	9.3
<i>HCTZ combination 50 mg</i>	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.5



Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg	46,362	49,197	47,183	46,857	46,427	46,505	44,429	47,683
12.5 mg	1,058,939	1,125,331	1,088,938	1,076,153	1,068,431	1,072,917	1,029,475	1,095,152
15 mg	19	13	*****	*****	*****	*****	*****	*****
25 mg	1,276,181	1,366,650	1,321,273	1,303,120	1,295,436	1,295,749	1,244,255	1,326,256
50 mg	61,992	66,311	64,061	63,369	62,635	62,576	59,753	63,962
HCTZ single ingredient/monotherapy								
12.5 mg	455,202	490,111	477,321	468,028	458,443	456,091	434,909	459,416
25 mg	726,495	774,653	745,570	734,699	728,184	725,910	696,960	741,434
50 mg	32,619	35,067	33,867	33,586	33,314	33,277	31,934	34,286
HCTZ combination products								
6.25 mg	46,362	49,197	47,183	46,857	46,427	46,505	44,429	47,683
12.5 mg	609,186	641,808	618,383	614,012	614,833	621,638	598,683	640,075
15 mg	19	13	*****	*****	*****	*****	*****	*****
25 mg	553,930	596,588	579,872	572,084	570,755	573,176	550,148	588,094
50 mg	29,402	31,266	30,212	29,805	29,343	29,326	27,836	29,700
	<b>Eligible members per month</b>							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
Enrollees with at least one day of coverage	60,620,412	60,527,157	60,414,419	60,300,149	60,017,165	59,954,097	59,949,698	59,918,233

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>HCTZ-containing 6.25 mg</i>	0.7	0.8	0.8	0.8	0.7	0.7	0.7	0.8
<i>HCTZ-containing 12.5 mg</i>	17.5	18.6	18.0	17.8	17.8	17.9	17.2	18.3
<i>HCTZ-containing 15 mg</i>	0.0	0.0	*****	*****	*****	*****	*****	*****
<i>HCTZ-containing 25 mg</i>	21.1	22.6	21.9	21.6	21.6	21.6	20.8	22.1
<i>HCTZ-containing 50 mg</i>	1.0	1.1	1.1	1.1	1.0	1.0	1.0	1.1
HCTZ single ingredient								
<i>HCTZ single ingredient 12.5 mg</i>	7.5	8.1	7.9	7.8	7.6	7.6	7.3	7.7
<i>HCTZ single ingredient 25 mg</i>	12.0	12.8	12.3	12.2	12.1	12.1	11.6	12.4
<i>HCTZ single ingredient 50 mg</i>	0.5	0.6	0.6	0.6	0.6	0.6	0.5	0.6
HCTZ combination products								
<i>HCTZ combination 6.25 mg</i>	0.8	0.8	0.8	0.8	0.8	0.8	0.7	0.8
<i>HCTZ combination 12.5 mg</i>	10.0	10.6	10.2	10.2	10.2	10.4	10.0	10.7
<i>HCTZ combination 15 mg</i>	0.0	0.0	*****	*****	*****	*****	*****	*****
<i>HCTZ combination 25 mg</i>	9.1	9.9	9.6	9.5	9.5	9.6	9.2	9.8
<i>HCTZ combination 50 mg</i>	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg	44,916	41,149	46,494	44,015	42,253	44,508	43,150	42,717
12.5 mg	1,042,854	960,558	1,090,452	1,046,268	1,010,996	1,058,546	1,036,116	1,029,837
15 mg	*****	*****	0	*****	*****	0	*****	0
25 mg	1,257,516	1,155,034	1,312,236	1,257,766	1,216,776	1,271,798	1,245,403	1,239,005
50 mg	60,191	54,591	62,306	59,813	57,429	60,112	58,756	58,940
HCTZ single ingredient/monotherapy								
12.5 mg	437,048	401,015	454,558	434,782	421,676	441,071	430,445	426,408
25 mg	704,702	646,126	731,720	702,679	679,274	708,698	694,571	689,983
50 mg	32,321	29,706	33,860	32,494	31,403	32,942	32,121	32,228
HCTZ combination products								
6.25 mg	44,916	41,149	46,494	44,015	42,253	44,508	43,150	42,717
12.5 mg	609,695	563,045	640,019	615,220	592,746	621,125	609,176	606,811
15 mg	*****	*****	0	*****	*****	0	*****	0
25 mg	555,765	511,457	583,722	558,055	540,169	565,934	553,466	551,581
50 mg	27,888	24,902	28,465	27,337	26,047	27,185	26,655	26,728
	Eligible members per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
Enrollees with at least one day of coverage	59,781,113	59,645,359	59,627,640	59,563,961	59,525,867	59,558,070	59,609,299	59,732,038

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>HCTZ-containing 6.25 mg</i>	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
<i>HCTZ-containing 12.5 mg</i>	17.4	16.1	18.3	17.6	17.0	17.8	17.4	17.2
<i>HCTZ-containing 15 mg</i>	*****	*****	0	*****	*****	0	*****	0
<i>HCTZ-containing 25 mg</i>	21.0	19.4	22.0	21.1	20.4	21.4	20.9	20.7
<i>HCTZ-containing 50 mg</i>	1.0	0.9	1.0	1.0	1.0	1.0	1.0	1.0
HCTZ single ingredient								
<i>HCTZ single ingredient 12.5 mg</i>	7.3	6.7	7.6	7.3	7.1	7.4	7.2	7.1
<i>HCTZ single ingredient 25 mg</i>	11.8	10.8	12.3	11.8	11.4	11.9	11.7	11.6
<i>HCTZ single ingredient 50 mg</i>	0.5	0.5	0.6	0.5	0.5	0.6	0.5	0.5
HCTZ combination products								
<i>HCTZ combination 6.25 mg</i>	0.8	0.7	0.8	0.7	0.7	0.7	0.7	0.7
<i>HCTZ combination 12.5 mg</i>	10.2	9.4	10.7	10.3	10.0	10.4	10.2	10.2
<i>HCTZ combination 15 mg</i>	*****	*****	0	*****	*****	0	*****	0
<i>HCTZ combination 25 mg</i>	9.3	8.6	9.8	9.4	9.1	9.5	9.3	9.2
<i>HCTZ combination 50 mg</i>	0.5	0.4	0.5	0.5	0.4	0.5	0.4	0.4

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
6.25 mg	42,120	41,758	40,856	41,853	36,917
12.5 mg	1,010,124	1,009,773	996,061	1,011,804	885,567
15 mg	*****	0	*****	*****	0
25 mg	1,212,080	1,208,977	1,187,666	1,206,782	1,062,320
50 mg	57,029	57,020	56,123	56,550	49,915
HCTZ single ingredient/monotherapy					
12.5 mg	418,030	414,956	410,794	419,307	376,030
25 mg	674,015	671,244	659,760	679,119	608,823
50 mg	31,467	31,433	30,786	31,416	27,680
HCTZ combination products					
6.25 mg	42,120	41,758	40,856	41,853	36,917
12.5 mg	595,334	598,085	588,439	595,963	512,578
15 mg	*****	0	*****	*****	0
25 mg	540,529	540,122	530,243	530,833	456,082
50 mg	25,576	25,604	25,351	25,150	22,251
	<b>Eligible members per month</b>				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
Enrollees with at least one day of coverage	59,762,995	59,765,302	59,810,685	59,853,545	49,088,999

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
<i>HCTZ-containing 6.25 mg</i>	0.7	0.7	0.7	0.7	0.6
<i>HCTZ-containing 12.5 mg</i>	16.9	16.9	16.7	16.9	18.0
<i>HCTZ-containing 15 mg</i>	*****	0	*****	*****	0
<i>HCTZ-containing 25 mg</i>	20.3	20.2	19.9	20.2	21.6
<i>HCTZ-containing 50 mg</i>	1.0	1.0	0.9	0.9	1.0
HCTZ single ingredient					
<i>HCTZ single ingredient 12.5 mg</i>	7.0	6.9	6.9	7.0	7.7
<i>HCTZ single ingredient 25 mg</i>	11.3	11.2	11.0	11.3	12.4
<i>HCTZ single ingredient 50 mg</i>	0.5	0.5	0.5	0.5	0.6
HCTZ combination products					
<i>HCTZ combination 6.25 mg</i>	0.7	0.7	0.7	0.7	0.8
<i>HCTZ combination 12.5 mg</i>	10.0	10.0	9.8	10.0	10.4
<i>HCTZ combination 15 mg</i>	*****	0	*****	*****	0
<i>HCTZ combination 25 mg</i>	9.0	9.0	8.9	8.9	9.3
<i>HCTZ combination 50 mg</i>	0.4	0.4	0.4	0.4	0.5

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Patients with dispensing per month				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
6.25 mg	27,881	24,476	2,729	2,675	2,583
12.5 mg	690,494	620,178	74,875	75,676	73,634
15 mg	0	0	0	0	0
25 mg	825,078	742,715	86,225	87,601	85,847
50 mg	39,049	35,197	3,567	3,713	3,673
HCTZ single ingredient/monotherapy					
12.5 mg	296,903	274,467	28,202	28,709	27,912
25 mg	473,313	426,183	48,466	48,884	47,881
50 mg	21,814	19,679	2,077	2,220	2,190
HCTZ combination products					
6.25 mg	27,881	24,476	2,729	2,675	2,583
12.5 mg	395,960	347,879	46,907	47,230	45,946
15 mg	0	0	0	0	0
25 mg	353,619	318,192	37,942	38,891	38,149
50 mg	17,242	15,531	1,493	1,495	1,485
	<b>Eligible members per month</b>				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
Enrollees with at least one day of coverage	43,774,291	29,085,316	8,254,494	8,291,948	8,319,950

Table 6b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month

	Number of patients with dispensing per 1,000 eligible members				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
<i>HCTZ-containing 6.25 mg</i>	0.4	0.4	0.0	0.0	0.0
<i>HCTZ-containing 12.5 mg</i>	15.8	21.3	9.1	9.1	8.9
<i>HCTZ-containing 15 mg</i>	0	0	0	0	0
<i>HCTZ-containing 25 mg</i>	18.8	25.5	10.4	10.6	10.3
<i>HCTZ-containing 50 mg</i>	0.9	1.2	0.4	0.4	0.4
HCTZ single ingredient					
<i>HCTZ single ingredient 12.5 mg</i>	6.8	9.4	3.4	3.5	3.4
<i>HCTZ single ingredient 25 mg</i>	10.8	14.7	5.9	5.9	5.8
<i>HCTZ single ingredient 50 mg</i>	0.5	0.7	0.3	0.3	0.3
HCTZ combination products					
<i>HCTZ combination 6.25 mg</i>	0.6	0.8	0.3	0.3	0.3
<i>HCTZ combination 12.5 mg</i>	9.0	12.0	5.7	5.7	5.5
<i>HCTZ combination 15 mg</i>	0	0	0	0	0
<i>HCTZ combination 25 mg</i>	8.1	10.9	4.6	4.7	4.6
<i>HCTZ combination 50 mg</i>	0.4	0.5	0.2	0.2	0.2



Figure 6. Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month




Figure 6 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month




Figure 6 (Continued). Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month




Table 7a. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and race

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members <sup>1</sup>	Number of Exposed Patients per 1,000 Eligible Members
<b>HCTZ-containing products</b>					
<i>6.25 mg</i>					
White	152,236	1,992,293	1,994,632	38,778,668	3.9
Non-white <sup>2</sup>	22,357	250,826	251,166	8,104,621	2.8
Unknown	92,123	1,074,067	1,085,865	83,902,136	1.1
<i>12.5 mg</i>					
White	4,077,059	41,675,146	41,775,618	38,778,668	105.1
Non-white <sup>2</sup>	907,141	8,294,334	8,314,925	8,104,621	111.9
Unknown	2,644,938	24,025,629	24,323,181	83,902,136	31.5
<i>15 mg</i>					
White	1,083	9,413	9,416	38,778,668	0.0
Non-white <sup>2</sup>	285	2,339	2,350	8,104,621	0.0
Unknown	425	3,065	3,126	83,902,136	0.0
<i>25 mg</i>					
White	4,677,511	50,659,450	50,742,477	38,778,668	120.6
Non-white <sup>2</sup>	1,178,107	11,736,281	11,759,604	8,104,621	145.4
Unknown	2,873,568	27,394,037	27,702,018	83,902,136	34.2
<i>50 mg</i>					
White	262,601	2,644,302	2,645,778	38,778,668	6.8
Non-white <sup>2</sup>	62,449	567,628	568,021	8,104,621	7.7
Unknown	138,373	1,223,867	1,235,846	83,902,136	1.6
<b>HCTZ single ingredient/monotherapy</b>					
<i>12.5 mg</i>					
White	2,115,607	16,326,958	16,343,572	38,778,668	54.6
Non-white <sup>2</sup>	444,710	3,115,023	3,118,639	8,104,621	54.9
Unknown	1,116,237	7,311,485	7,360,670	83,902,136	13.3

Table 7a. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and race

HCTZ single ingredient/monotherapy					
<i>25 mg</i>					
<i>White</i>	2,837,292	26,930,488	26,945,165	38,778,668	73.2
<i>Non-white</i> <sup>2</sup>	705,085	6,114,314	6,117,781	8,104,621	87.0
<i>Unknown</i>	1,641,939	13,458,846	13,564,947	83,902,136	19.6
<i>50 mg</i>					
<i>White</i>	146,583	1,321,853	1,322,473	38,778,668	3.8
<i>Non-white</i> <sup>2</sup>	35,798	282,732	282,902	8,104,621	4.4
<i>Unknown</i>	80,939	639,386	644,077	83,902,136	1.0
HCTZ combination products					
<i>6.25 mg</i>					
<i>White</i>	152,236	1,992,293	1,994,632	38,778,668	3.9
<i>Non-white</i> <sup>2</sup>	22,357	250,826	251,166	8,104,621	2.8
<i>Unknown</i>	92,123	1,074,067	1,085,865	83,902,136	1.1
<i>12.5 mg</i>					
<i>White</i>	2,395,049	25,407,239	25,432,047	38,778,668	61.8
<i>Non-white</i> <sup>2</sup>	553,761	5,190,134	5,196,287	8,104,621	68.3
<i>Unknown</i>	1,755,058	16,763,477	16,962,512	83,902,136	20.9
<i>15 mg</i>					
<i>White</i>	1,083	9,413	9,416	38,778,668	0.0
<i>Non-white</i> <sup>2</sup>	285	2,339	2,350	8,104,621	0.0
<i>Unknown</i>	425	3,065	3,126	83,902,136	0.0
<i>25 mg</i>					
<i>White</i>	2,239,316	23,770,876	23,797,314	38,778,668	57.7
<i>Non-white</i> <sup>2</sup>	581,311	5,634,297	5,641,823	8,104,621	71.7
<i>Unknown</i>	1,450,603	13,973,911	14,137,072	83,902,136	17.3
<i>50 mg</i>					
<i>White</i>	118,842	1,322,688	1,323,305	38,778,668	3.1
<i>Non-white</i> <sup>2</sup>	27,215	284,955	285,119	8,104,621	3.4
<i>Unknown</i>	58,544	584,724	591,769	83,902,136	0.7

<sup>1</sup>Eligible members includes those who have at least one day of enrollment during the query period.

<sup>2</sup>Non-white racial category includes American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and Multi-racial.

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
White	38,095	34,059	37,504	34,988	37,302	36,056	35,827	36,170
Non-white	5,045	4,603	4,902	4,600	4,911	4,710	4,720	4,775
Unknown	22,388	21,074	23,013	21,768	22,520	22,043	21,618	21,871
12.5 mg								
White	484,761	437,918	482,223	453,011	479,997	465,268	463,052	467,897
Non-white	103,077	95,713	105,522	97,484	103,822	101,130	100,014	101,704
Unknown	332,737	315,030	343,455	325,038	339,109	331,828	326,311	331,864
15 mg								
White	397	347	383	353	353	357	333	321
Non-white	98	84	97	90	101	84	78	92
Unknown	125	104	124	109	112	112	101	99
25 mg								
White	469,053	422,743	464,971	437,362	462,549	450,571	447,373	451,273
Non-white	117,094	109,014	119,722	110,612	117,137	114,279	112,750	115,204
Unknown	286,062	271,296	295,054	280,134	292,802	286,979	282,789	286,384
50 mg								
White	27,942	25,160	27,645	25,538	27,333	26,514	26,148	26,367
Non-white	6,125	5,605	6,220	5,653	6,037	5,884	5,742	5,885
Unknown	12,978	12,254	13,269	12,651	12,951	12,907	12,473	12,688

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy									
<i>12.5 mg</i>									
<i>White</i>	235,188	214,508	235,961	222,619	237,690	233,386	231,745	235,699	
<i>Non-white</i>	46,448	43,485	47,722	44,510	47,378	46,376	46,506	47,276	
<i>Unknown</i>	106,432	101,329	111,998	106,293	112,327	110,475	109,504	111,604	
<i>25 mg</i>									
<i>White</i>	448,231	404,492	445,212	421,413	446,703	434,662	434,522	438,166	
<i>Non-white</i>	107,946	100,806	109,713	101,363	108,290	105,780	104,571	107,088	
<i>Unknown</i>	225,226	212,715	233,263	223,477	233,328	229,033	227,779	230,453	
<i>50 mg</i>									
<i>White</i>	24,258	21,425	23,933	22,228	23,665	22,944	22,860	23,313	
<i>Non-white</i>	5,286	4,838	5,242	5,043	5,205	5,134	5,062	5,053	
<i>Unknown</i>	11,289	10,630	11,614	11,117	11,665	11,418	11,357	11,413	
HCTZ combination products									
<i>6.25 mg</i>									
<i>White</i>	38,095	34,059	37,504	34,988	37,302	36,056	35,827	36,170	
<i>Non-white</i>	5,045	4,603	4,902	4,600	4,911	4,710	4,720	4,775	
<i>Unknown</i>	22,388	21,074	23,013	21,768	22,520	22,043	21,618	21,871	
<i>12.5 mg</i>									
<i>White</i>	484,761	437,918	482,223	453,011	479,997	465,268	463,052	467,897	
<i>Non-white</i>	103,077	95,713	105,522	97,484	103,822	101,130	100,014	101,704	
<i>Unknown</i>	332,737	315,030	343,455	325,038	339,109	331,828	326,311	331,864	
<i>15 mg</i>									
<i>White</i>	397	347	383	353	353	357	333	321	
<i>Non-white</i>	98	84	97	90	101	84	78	92	
<i>Unknown</i>	125	104	124	109	112	112	101	99	
<i>25 mg</i>									
<i>White</i>	469,053	422,743	464,971	437,362	462,549	450,571	447,373	451,273	
<i>Non-white</i>	117,094	109,014	119,722	110,612	117,137	114,279	112,750	115,204	
<i>Unknown</i>	286,062	271,296	295,054	280,134	292,802	286,979	282,789	286,384	

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ combination products								
<i>50 mg</i>								
<i>White</i>	27,942	25,160	27,645	25,538	27,333	26,514	26,148	26,367
<i>Non-white</i>	6,125	5,605	6,220	5,653	6,037	5,884	5,742	5,885
<i>Unknown</i>	12,978	12,254	13,269	12,651	12,951	12,907	12,473	12,688
<b>Eligible members per month</b>								
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
Enrollees with at least one day of coverage								
<i>White</i>	22,824,758	22,837,050	22,857,466	22,850,534	22,834,257	22,863,667	22,973,864	23,025,283
<i>Non-white</i>	3,995,414	3,996,883	4,000,539	3,995,068	3,984,309	3,988,519	4,008,767	4,020,966
<i>Unknown</i>	35,409,259	35,357,627	35,370,726	35,318,627	35,292,462	35,271,448	35,147,409	35,158,545
<b>Number of patients with dispensing per 1,000 eligible members</b>								
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>6.25 mg</i>								
<i>6.25 mg: White</i>	1.7	1.5	1.6	1.5	1.6	1.6	1.6	1.6
<i>6.25 mg: Non-white</i>	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2
<i>6.25 mg: Unknown</i>	0.6	0.6	0.7	0.6	0.6	0.6	0.6	0.6
<i>12.5 mg</i>								
<i>12.5 mg: White</i>	21.2	19.2	21.1	19.8	21.0	20.3	20.2	20.3
<i>12.5 mg: Non-white</i>	25.8	23.9	26.4	24.4	26.1	25.4	24.9	25.3
<i>12.5 mg: Unknown</i>	9.4	8.9	9.7	9.2	9.6	9.4	9.3	9.4
<i>15 mg</i>								
<i>15 mg: White</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Non-white</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Unknown</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0



Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>									
<i>25 mg</i>									
<i>25 mg: White</i>	20.6	18.5	20.3	19.1	20.3	19.7	19.5	19.6	
<i>25 mg: Non-white</i>	29.3	27.3	29.9	27.7	29.4	28.7	28.1	28.7	
<i>25 mg: Unknown</i>	8.1	7.7	8.3	7.9	8.3	8.1	8.0	8.1	
<i>50 mg</i>									
<i>50 mg: White</i>	1.2	1.1	1.2	1.1	1.2	1.2	1.1	1.1	
<i>50 mg: Non-white</i>	1.5	1.4	1.6	1.4	1.5	1.5	1.4	1.5	
<i>50 mg: Unknown</i>	0.4	0.3	0.4	0.4	0.4	0.4	0.4	0.4	

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
White	34,988	36,152	34,894	34,800	35,963	31,760	34,185	33,985
Non-white	4,536	4,719	4,521	4,527	4,580	4,138	4,373	4,324
Unknown	20,666	21,368	20,649	20,820	19,783	18,531	19,698	19,199
12.5 mg								
White	445,264	468,060	450,181	450,674	468,524	419,753	452,667	449,844
Non-white	96,702	100,408	96,545	95,512	97,945	89,860	96,200	94,391
Unknown	312,321	323,372	314,393	317,155	305,983	287,630	308,650	300,825
15 mg								
White	322	347	285	303	306	244	251	250
Non-white	77	76	84	77	66	61	70	40
Unknown	98	108	83	103	87	67	91	71
25 mg								
White	428,700	450,454	430,858	433,470	446,988	398,625	431,752	428,941
Non-white	108,639	113,082	108,511	108,135	109,308	100,284	108,098	104,943
Unknown	270,155	278,898	270,264	273,145	262,348	246,375	264,016	257,876
50 mg								
White	24,979	25,797	24,513	24,660	25,110	22,125	24,050	23,614
Non-white	5,626	5,647	5,393	5,427	5,433	4,985	5,312	5,122
Unknown	11,961	12,052	11,724	11,967	11,126	10,338	11,080	10,760

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy								
<i>12.5 mg</i>								
<i>White</i>	224,552	235,890	226,821	227,708	237,552	214,437	232,306	232,218
<i>Non-white</i>	44,952	47,222	45,488	44,766	46,128	42,972	45,947	45,418
<i>Unknown</i>	105,040	109,174	106,342	106,626	103,894	98,125	105,727	103,872
<i>25 mg</i>								
<i>White</i>	416,694	437,881	418,934	418,969	436,048	387,958	418,847	417,956
<i>Non-white</i>	101,023	104,715	100,469	99,725	101,817	93,147	99,496	97,672
<i>Unknown</i>	217,889	226,026	218,818	220,161	211,870	199,670	214,176	208,954
<i>50 mg</i>								
<i>White</i>	22,157	22,987	21,913	22,145	22,645	20,134	21,680	21,771
<i>Non-white</i>	4,920	4,987	4,775	4,888	4,893	4,390	4,723	4,674
<i>Unknown</i>	10,930	11,151	10,696	10,949	10,467	9,874	10,450	10,266
HCTZ combination products								
<i>6.25 mg</i>								
<i>White</i>	34,988	36,152	34,894	34,800	35,963	31,760	34,185	33,985
<i>Non-white</i>	4,536	4,719	4,521	4,527	4,580	4,138	4,373	4,324
<i>Unknown</i>	20,666	21,368	20,649	20,820	19,783	18,531	19,698	19,199
<i>12.5 mg</i>								
<i>White</i>	445,264	468,060	450,181	450,674	468,524	419,753	452,667	449,844
<i>Non-white</i>	96,702	100,408	96,545	95,512	97,945	89,860	96,200	94,391
<i>Unknown</i>	312,321	323,372	314,393	317,155	305,983	287,630	308,650	300,825
<i>15 mg</i>								
<i>White</i>	322	347	285	303	306	244	251	250
<i>Non-white</i>	77	76	84	77	66	61	70	40
<i>Unknown</i>	98	108	83	103	87	67	91	71
<i>25 mg</i>								
<i>White</i>	428,700	450,454	430,858	433,470	446,988	398,625	431,752	428,941
<i>Non-white</i>	108,639	113,082	108,511	108,135	109,308	100,284	108,098	104,943
<i>Unknown</i>	270,155	278,898	270,264	273,145	262,348	246,375	264,016	257,876

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ combination products								
<i>50 mg</i>								
<i>White</i>	24,979	25,797	24,513	24,660	25,110	22,125	24,050	23,614
<i>Non-white</i>	5,626	5,647	5,393	5,427	5,433	4,985	5,312	5,122
<i>Unknown</i>	11,961	12,052	11,724	11,967	11,126	10,338	11,080	10,760
<b>Eligible members per month</b>								
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
Enrollees with at least one day of coverage								
<i>White</i>	23,074,999	23,112,009	23,138,361	23,163,012	23,161,604	23,169,891	23,189,890	23,181,331
<i>Non-white</i>	4,031,434	4,040,463	4,044,741	4,054,825	4,044,706	4,042,942	4,045,149	4,033,490
<i>Unknown</i>	34,729,819	34,693,030	34,686,075	34,655,435	34,007,553	33,911,044	33,874,950	33,810,045
<b>Number of patients with dispensing per 1,000 eligible members</b>								
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>6.25 mg</i>								
<i>6.25 mg: White</i>	1.5	1.6	1.5	1.5	1.6	1.4	1.5	1.5
<i>6.25 mg: Non-white</i>	1.1	1.2	1.1	1.1	1.1	1.0	1.1	1.1
<i>6.25 mg: Unknown</i>	0.6	0.6	0.6	0.6	0.6	0.5	0.6	0.6
<i>12.5 mg</i>								
<i>12.5 mg: White</i>	19.3	20.3	19.5	19.5	20.2	18.1	19.5	19.4
<i>12.5 mg: Non-white</i>	24.0	24.9	23.9	23.6	24.2	22.2	23.8	23.4
<i>12.5 mg: Unknown</i>	9.0	9.3	9.1	9.2	9.0	8.5	9.1	8.9
<i>15 mg</i>								
<i>15 mg: White</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Non-white</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Unknown</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>								
<i>25 mg</i>								
<i>25 mg: White</i>	18.6	19.5	18.6	18.7	19.3	17.2	18.6	18.5
<i>25 mg: Non-white</i>	26.9	28.0	26.8	26.7	27.0	24.8	26.7	26.0
<i>25 mg: Unknown</i>	7.8	8.0	7.8	7.9	7.7	7.3	7.8	7.6
<i>50 mg</i>								
<i>50 mg: White</i>	1.1	1.1	1.1	1.1	1.1	1.0	1.0	1.0
<i>50 mg: Non-white</i>	1.4	1.4	1.3	1.3	1.3	1.2	1.3	1.3
<i>50 mg: Unknown</i>	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
White	33,788	32,662	33,628	33,479	31,026	34,249	31,838	31,518
Non-white	4,296	4,216	4,160	4,327	3,958	4,252	3,970	3,939
Unknown	19,246	18,537	18,494	18,753	17,542	18,753	17,970	17,817
12.5 mg								
White	449,029	432,010	464,321	460,332	413,643	467,063	428,661	426,782
Non-white	94,284	90,670	95,888	97,257	87,070	96,020	89,065	87,794
Unknown	303,515	292,173	299,279	302,659	281,873	302,547	287,160	285,870
15 mg								
White	244	225	235	219	219	234	207	214
Non-white	55	56	47	64	47	48	58	61
Unknown	76	66	74	76	69	72	66	70
25 mg								
White	430,819	413,581	432,906	424,668	386,426	430,064	397,168	394,750
Non-white	106,072	102,077	104,682	104,289	94,143	103,326	95,913	93,945
Unknown	261,613	251,583	254,575	254,397	237,068	252,789	239,787	237,990
50 mg								
White	23,813	22,905	23,342	23,402	21,462	23,224	21,644	21,405
Non-white	5,205	5,042	5,128	5,135	4,677	5,070	4,784	4,645
Unknown	10,937	10,462	10,402	10,480	9,941	10,434	9,761	9,807

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy								
<i>12.5 mg</i>								
<i>White</i>	236,363	228,643	236,888	237,857	220,584	238,812	225,929	227,186
<i>Non-white</i>	46,417	44,600	45,874	47,123	42,538	45,809	43,413	42,790
<i>Unknown</i>	107,166	102,912	104,475	106,536	99,175	105,760	101,243	100,509
<i>25 mg</i>								
<i>White</i>	421,267	406,607	420,744	419,931	389,895	423,041	398,501	399,282
<i>Non-white</i>	98,993	95,232	97,986	98,728	90,594	97,775	91,409	90,605
<i>Unknown</i>	213,357	205,964	207,898	210,843	198,660	210,536	201,436	200,817
<i>50 mg</i>								
<i>White</i>	21,974	21,081	21,890	21,806	20,143	21,809	20,691	20,509
<i>Non-white</i>	4,702	4,609	4,674	4,602	4,337	4,676	4,302	4,356
<i>Unknown</i>	10,460	10,198	10,214	10,301	9,751	10,311	9,928	9,858
HCTZ combination products								
<i>6.25 mg</i>								
<i>White</i>	33,788	32,662	33,628	33,479	31,026	34,249	31,838	31,518
<i>Non-white</i>	4,296	4,216	4,160	4,327	3,958	4,252	3,970	3,939
<i>Unknown</i>	19,246	18,537	18,494	18,753	17,542	18,753	17,970	17,817
<i>12.5 mg</i>								
<i>White</i>	449,029	432,010	464,321	460,332	413,643	467,063	428,661	426,782
<i>Non-white</i>	94,284	90,670	95,888	97,257	87,070	96,020	89,065	87,794
<i>Unknown</i>	303,515	292,173	299,279	302,659	281,873	302,547	287,160	285,870
<i>15 mg</i>								
<i>White</i>	244	225	235	219	219	234	207	214
<i>Non-white</i>	55	56	47	64	47	48	58	61
<i>Unknown</i>	76	66	74	76	69	72	66	70
<i>25 mg</i>								
<i>White</i>	430,819	413,581	432,906	424,668	386,426	430,064	397,168	394,750
<i>Non-white</i>	106,072	102,077	104,682	104,289	94,143	103,326	95,913	93,945
<i>Unknown</i>	261,613	251,583	254,575	254,397	237,068	252,789	239,787	237,990

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ combination products</b>								
<i>50 mg</i>								
<i>White</i>	23,813	22,905	23,342	23,402	21,462	23,224	21,644	21,405
<i>Non-white</i>	5,205	5,042	5,128	5,135	4,677	5,070	4,784	4,645
<i>Unknown</i>	10,937	10,462	10,402	10,480	9,941	10,434	9,761	9,807
	<b>Eligible members per month</b>							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>Enrollees with at least one day of coverage</b>								
<i>White</i>	23,174,114	23,207,276	23,250,999	23,307,434	23,357,403	23,390,771	23,406,300	23,414,813
<i>Non-white</i>	4,019,865	4,022,834	4,037,138	4,050,287	4,056,144	4,059,831	4,061,294	4,063,774
<i>Unknown</i>	33,791,327	33,776,559	33,701,769	33,734,871	33,748,331	33,739,360	33,711,731	33,676,440
	<b>Number of patients with dispensing per 1,000 eligible members</b>							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
<b>HCTZ-containing products</b>								
<i>6.25 mg</i>								
<i>6.25 mg: White</i>	1.5	1.4	1.4	1.4	1.3	1.5	1.4	1.3
<i>6.25 mg: Non-white</i>	1.1	1.0	1.0	1.1	1.0	1.0	1.0	1.0
<i>6.25 mg: Unknown</i>	0.6	0.5	0.5	0.6	0.5	0.6	0.5	0.5
<i>12.5 mg</i>								
<i>12.5 mg: White</i>	19.4	18.6	20.0	19.8	17.7	20.0	18.3	18.2
<i>12.5 mg: Non-white</i>	23.5	22.5	23.8	24.0	21.5	23.7	21.9	21.6
<i>12.5 mg: Unknown</i>	9.0	8.7	8.9	9.0	8.4	9.0	8.5	8.5
<i>15 mg</i>								
<i>15 mg: White</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Non-white</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Unknown</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0



Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>								
<i>25 mg</i>								
<i>25 mg: White</i>	18.6	17.8	18.6	18.2	16.5	18.4	17.0	16.9
<i>25 mg: Non-white</i>	26.4	25.4	25.9	25.7	23.2	25.5	23.6	23.1
<i>25 mg: Unknown</i>	7.7	7.4	7.6	7.5	7.0	7.5	7.1	7.1
<i>50 mg</i>								
<i>50 mg: White</i>	1.0	1.0	1.0	1.0	0.9	1.0	0.9	0.9
<i>50 mg: Non-white</i>	1.3	1.3	1.3	1.3	1.2	1.2	1.2	1.1
<i>50 mg: Unknown</i>	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
White	33,511	29,968	31,180	31,920	31,747	29,567	31,853	30,941
Non-white	4,132	3,737	3,841	4,023	3,963	3,663	3,909	3,834
Unknown	17,772	16,604	17,227	17,288	16,971	16,096	16,488	16,192
12.5 mg								
White	456,509	398,704	421,470	434,601	423,640	395,430	425,549	399,249
Non-white	91,929	82,001	86,376	87,223	85,686	80,184	85,268	81,012
Unknown	286,394	264,144	278,155	277,780	275,279	259,944	267,497	260,832
15 mg								
White	231	166	207	197	185	172	193	151
Non-white	49	41	50	40	52	37	41	40
Unknown	63	60	67	51	54	59	59	52
25 mg								
White	412,645	363,871	387,575	397,400	390,669	367,536	394,983	371,686
Non-white	96,972	86,777	91,456	92,528	91,628	85,478	91,399	87,207
Unknown	232,628	214,080	226,902	226,396	226,086	214,353	220,975	213,830
50 mg								
White	22,537	19,836	20,789	21,476	21,047	19,440	20,870	20,339
Non-white	4,865	4,327	4,510	4,484	4,507	4,221	4,344	4,359
Unknown	9,456	8,636	9,165	9,074	9,050	8,606	8,635	8,749

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy								
<i>12.5 mg</i>								
<i>White</i>	240,248	218,410	233,579	243,474	243,744	231,941	248,173	245,434
<i>Non-white</i>	44,925	42,020	44,900	45,980	46,518	44,103	47,016	46,780
<i>Unknown</i>	101,768	96,312	104,510	106,419	108,109	104,014	108,072	109,816
<i>25 mg</i>								
<i>White</i>	425,775	379,277	404,067	417,272	412,540	391,219	417,080	407,508
<i>Non-white</i>	95,788	87,462	92,411	94,158	93,533	88,553	93,826	91,822
<i>Unknown</i>	201,551	188,388	202,151	203,457	203,180	194,987	201,715	202,735
<i>50 mg</i>								
<i>White</i>	21,417	19,281	20,249	20,931	20,791	19,866	21,275	20,315
<i>Non-white</i>	4,512	4,114	4,336	4,395	4,403	4,147	4,497	4,382
<i>Unknown</i>	9,635	8,937	9,747	9,676	9,747	9,413	9,792	9,765
HCTZ combination products								
<i>6.25 mg</i>								
<i>White</i>	33,511	29,968	31,180	31,920	31,747	29,567	31,853	30,941
<i>Non-white</i>	4,132	3,737	3,841	4,023	3,963	3,663	3,909	3,834
<i>Unknown</i>	17,772	16,604	17,227	17,288	16,971	16,096	16,488	16,192
<i>12.5 mg</i>								
<i>White</i>	456,509	398,704	421,470	434,601	423,640	395,430	425,549	399,249
<i>Non-white</i>	91,929	82,001	86,376	87,223	85,686	80,184	85,268	81,012
<i>Unknown</i>	286,394	264,144	278,155	277,780	275,279	259,944	267,497	260,832
<i>15 mg</i>								
<i>White</i>	231	166	207	197	185	172	193	151
<i>Non-white</i>	49	41	50	40	52	37	41	40
<i>Unknown</i>	63	60	67	51	54	59	59	52
<i>25 mg</i>								
<i>White</i>	412,645	363,871	387,575	397,400	390,669	367,536	394,983	371,686
<i>Non-white</i>	96,972	86,777	91,456	92,528	91,628	85,478	91,399	87,207
<i>Unknown</i>	232,628	214,080	226,902	226,396	226,086	214,353	220,975	213,830

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ combination products								
<i>50 mg</i>								
<i>White</i>	22,537	19,836	20,789	21,476	21,047	19,440	20,870	20,339
<i>Non-white</i>	4,865	4,327	4,510	4,484	4,507	4,221	4,344	4,359
<i>Unknown</i>	9,456	8,636	9,165	9,074	9,050	8,606	8,635	8,749
<b>Eligible members per month</b>								
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
Enrollees with at least one day of coverage								
<i>White</i>	23,644,803	23,661,488	23,686,385	23,683,169	23,673,706	23,696,794	23,756,609	23,803,936
<i>Non-white</i>	4,060,858	4,060,926	4,065,766	4,060,155	4,048,132	4,047,633	4,058,435	4,068,816
<i>Unknown</i>	33,180,970	33,090,728	33,074,440	33,003,313	32,965,124	32,880,501	32,847,193	32,778,790
<b>Number of patients with dispensing per 1,000 eligible members</b>								
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
HCTZ-containing products								
<i>6.25 mg</i>								
<i>6.25 mg: White</i>	1.4	1.3	1.3	1.3	1.3	1.2	1.3	1.3
<i>6.25 mg: Non-white</i>	1.0	0.9	0.9	1.0	1.0	0.9	1.0	0.9
<i>6.25 mg: Unknown</i>	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
<i>12.5 mg</i>								
<i>12.5 mg: White</i>	19.3	16.9	17.8	18.4	17.9	16.7	17.9	16.8
<i>12.5 mg: Non-white</i>	22.6	20.2	21.2	21.5	21.2	19.8	21.0	19.9
<i>12.5 mg: Unknown</i>	8.6	8.0	8.4	8.4	8.4	7.9	8.1	8.0
<i>15 mg</i>								
<i>15 mg: White</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Non-white</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>15 mg: Unknown</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>								
<i>25 mg</i>								
<i>25 mg: White</i>	17.5	15.4	16.4	16.8	16.5	15.5	16.6	15.6
<i>25 mg: Non-white</i>	23.9	21.4	22.5	22.8	22.6	21.1	22.5	21.4
<i>25 mg: Unknown</i>	7.0	6.5	6.9	6.9	6.9	6.5	6.7	6.5
<i>50 mg</i>								
<i>50 mg: White</i>	1.0	0.8	0.9	0.9	0.9	0.8	0.9	0.9
<i>50 mg: Non-white</i>	1.2	1.1	1.1	1.1	1.1	1.0	1.1	1.1
<i>50 mg: Unknown</i>	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
White	29,102	31,207	28,655	30,268	31,445	28,405	32,696	28,734
Non-white	3,726	3,842	3,494	3,744	3,877	3,521	4,018	3,632
Unknown	15,688	16,177	15,051	15,023	15,583	14,505	16,300	14,590
12.5 mg								
White	378,206	396,338	353,422	371,952	370,720	330,652	380,433	337,705
Non-white	75,714	78,792	70,288	72,594	71,197	65,501	73,711	66,169
Unknown	248,094	254,410	233,888	228,354	234,454	219,101	242,752	217,830
15 mg								
White	157	131	97	97	62	39	29	*****
Non-white	37	30	29	22	23	15	*****	*****
Unknown	46	48	35	40	28	18	15	11
25 mg								
White	349,237	354,513	310,665	328,247	334,656	301,740	358,188	314,047
Non-white	80,792	81,077	70,807	72,920	74,674	68,680	80,601	71,643
Unknown	202,801	202,541	181,220	176,742	184,549	172,916	197,584	177,350
50 mg								
White	19,379	20,000	18,519	20,006	19,939	17,876	20,890	18,228
Non-white	4,162	4,284	3,900	4,217	4,083	3,826	4,461	3,852
Unknown	8,358	8,616	8,096	8,022	8,207	7,667	8,776	7,789

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy								
<i>12.5 mg</i>								
<i>White</i>	244,792	271,190	258,004	284,935	299,519	274,121	317,374	279,843
<i>Non-white</i>	46,325	51,635	49,275	53,656	56,723	52,122	59,632	53,250
<i>Unknown</i>	110,925	123,616	120,899	124,364	135,098	129,206	146,031	130,118
<i>25 mg</i>								
<i>White</i>	402,394	439,420	414,919	459,357	462,197	419,217	485,560	426,673
<i>Non-white</i>	89,565	97,945	93,443	100,930	102,047	93,184	106,040	95,160
<i>Unknown</i>	200,647	220,013	211,629	219,152	229,884	216,711	242,451	219,340
<i>50 mg</i>								
<i>White</i>	20,015	20,810	19,096	20,733	20,752	19,011	21,926	19,372
<i>Non-white</i>	4,277	4,410	3,994	4,297	4,358	3,928	4,416	4,170
<i>Unknown</i>	9,646	9,970	9,361	9,459	9,836	9,472	10,499	9,615
HCTZ combination products								
<i>6.25 mg</i>								
<i>White</i>	29,102	31,207	28,655	30,268	31,445	28,405	32,696	28,734
<i>Non-white</i>	3,726	3,842	3,494	3,744	3,877	3,521	4,018	3,632
<i>Unknown</i>	15,688	16,177	15,051	15,023	15,583	14,505	16,300	14,590
<i>12.5 mg</i>								
<i>White</i>	378,206	396,338	353,422	371,952	370,720	330,652	380,433	337,705
<i>Non-white</i>	75,714	78,792	70,288	72,594	71,197	65,501	73,711	66,169
<i>Unknown</i>	248,094	254,410	233,888	228,354	234,454	219,101	242,752	217,830
<i>15 mg</i>								
<i>White</i>	157	131	97	97	62	39	29	*****
<i>Non-white</i>	37	30	29	22	23	15	*****	*****
<i>Unknown</i>	46	48	35	40	28	18	15	11
<i>25 mg</i>								
<i>White</i>	349,237	354,513	310,665	328,247	334,656	301,740	358,188	314,047
<i>Non-white</i>	80,792	81,077	70,807	72,920	74,674	68,680	80,601	71,643
<i>Unknown</i>	202,801	202,541	181,220	176,742	184,549	172,916	197,584	177,350

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ combination products								
50 mg								
White	19,379	20,000	18,519	20,006	19,939	17,876	20,890	18,228
Non-white	4,162	4,284	3,900	4,217	4,083	3,826	4,461	3,852
Unknown	8,358	8,616	8,096	8,022	8,207	7,667	8,776	7,789
	Eligible members per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
Enrollees with at least one day of coverage								
White	23,842,815	23,876,952	23,903,253	23,915,695	24,164,029	24,163,256	24,171,767	24,195,739
Non-white	4,073,163	4,084,216	4,093,209	4,102,147	4,098,487	4,094,647	4,093,419	4,093,223
Unknown	32,767,973	32,745,108	32,707,143	32,668,413	32,826,956	32,691,105	32,647,925	32,482,327
	Number of patients with dispensing per 1,000 eligible members							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
HCTZ-containing								
HCTZ-containing products								
6.25 mg								
6.25 mg: White	1.2	1.3	1.2	1.3	1.3	1.2	1.4	1.2
6.25 mg: Non-white	0.9	0.9	0.9	0.9	0.9	0.9	1.0	0.9
6.25 mg: Unknown	0.5	0.5	0.5	0.5	0.5	0.4	0.5	0.4
12.5 mg								
12.5 mg: White	15.9	16.6	14.8	15.6	15.3	13.7	15.7	14.0
12.5 mg: Non-white	18.6	19.3	17.2	17.7	17.4	16.0	18.0	16.2
12.5 mg: Unknown	7.6	7.8	7.2	7.0	7.1	6.7	7.4	6.7
15 mg								
15 mg: White	0.0	0.0	0.0	0.0	0.0	0.0	0.0	*****
15 mg: Non-white	0.0	0.0	0.0	0.0	0.0	0.0	*****	*****
15 mg: Unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0



Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>								
<i>25 mg</i>								
<i>25 mg: White</i>	14.6	14.8	13.0	13.7	13.8	12.5	14.8	13.0
<i>25 mg: Non-white</i>	19.8	19.9	17.3	17.8	18.2	16.8	19.7	17.5
<i>25 mg: Unknown</i>	6.2	6.2	5.5	5.4	5.6	5.3	6.1	5.5
<b>HCTZ-containing</b>								
<i>50 mg</i>								
<i>50 mg: White</i>	0.8	0.8	0.8	0.8	0.8	0.7	0.9	0.8
<i>50 mg: Non-white</i>	1.0	1.0	1.0	1.0	1.0	0.9	1.1	0.9
<i>50 mg: Unknown</i>	0.3	0.3	0.2	0.2	0.3	0.2	0.3	0.2

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
White	28,584	30,521	29,170	29,111	28,875	28,938	27,729	29,960
Non-white	3,450	3,776	3,631	3,559	3,585	3,598	3,457	3,711
Unknown	14,328	14,900	14,382	14,187	13,967	13,969	13,243	14,012
12.5 mg								
White	330,415	353,871	339,311	338,277	340,509	344,576	332,749	357,749
Non-white	64,725	68,850	66,861	66,556	66,929	68,041	64,840	70,437
Unknown	214,046	219,087	212,211	209,179	207,395	209,021	201,094	211,889
15 mg								
White	12	*****	*****	0	0	0	0	0
Non-white	*****	*****	0	*****	*****	0	0	0
Unknown	*****	*****	*****	*****	*****	*****	*****	*****
25 mg								
White	309,382	337,887	326,167	323,093	322,910	323,683	313,111	335,094
Non-white	69,678	76,008	73,559	72,674	73,184	73,672	70,049	75,850
Unknown	174,870	182,693	180,146	176,317	174,661	175,821	166,988	177,150
50 mg								
White	17,939	19,382	18,474	18,250	18,136	18,123	17,219	18,519
Non-white	3,695	4,037	3,995	3,844	3,908	3,863	3,569	3,889
Unknown	7,768	7,847	7,743	7,711	7,299	7,340	7,048	7,292

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy									
<i>12.5 mg</i>									
<i>White</i>	276,281	300,110	289,644	285,074	280,210	279,187	267,771	283,632	
<i>Non-white</i>	51,589	55,742	53,700	53,088	52,123	51,626	49,232	52,324	
<i>Unknown</i>	127,332	134,259	133,977	129,866	126,110	125,278	117,906	123,460	
<i>25 mg</i>									
<i>White</i>	420,838	453,398	433,611	429,319	426,020	425,449	410,267	438,254	
<i>Non-white</i>	91,582	98,830	95,383	93,119	93,124	92,528	88,165	94,815	
<i>Unknown</i>	214,075	222,425	216,576	212,261	209,040	207,933	198,528	208,365	
<i>50 mg</i>									
<i>White</i>	19,211	20,834	20,004	19,958	19,814	19,656	18,903	20,554	
<i>Non-white</i>	3,916	4,293	4,139	4,067	3,966	4,113	3,920	4,065	
<i>Unknown</i>	9,492	9,940	9,724	9,561	9,534	9,508	9,111	9,667	
HCTZ combination products									
<i>6.25 mg</i>									
<i>White</i>	28,584	30,521	29,170	29,111	28,875	28,938	27,729	29,960	
<i>Non-white</i>	3,450	3,776	3,631	3,559	3,585	3,598	3,457	3,711	
<i>Unknown</i>	14,328	14,900	14,382	14,187	13,967	13,969	13,243	14,012	
<i>12.5 mg</i>									
<i>White</i>	330,415	353,871	339,311	338,277	340,509	344,576	332,749	357,749	
<i>Non-white</i>	64,725	68,850	66,861	66,556	66,929	68,041	64,840	70,437	
<i>Unknown</i>	214,046	219,087	212,211	209,179	207,395	209,021	201,094	211,889	
<i>15 mg</i>									
<i>White</i>	12	*****	*****	0	0	0	0	0	
<i>Non-white</i>	*****	*****	0	*****	*****	0	0	0	
<i>Unknown</i>	*****	*****	*****	*****	*****	*****	*****	*****	
<i>25 mg</i>									
<i>White</i>	309,382	337,887	326,167	323,093	322,910	323,683	313,111	335,094	
<i>Non-white</i>	69,678	76,008	73,559	72,674	73,184	73,672	70,049	75,850	
<i>Unknown</i>	174,870	182,693	180,146	176,317	174,661	175,821	166,988	177,150	

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ combination products</b>									
<i>50 mg</i>									
<i>White</i>	17,939	19,382	18,474	18,250	18,136	18,123	17,219	18,519	
<i>Non-white</i>	3,695	4,037	3,995	3,844	3,908	3,863	3,569	3,889	
<i>Unknown</i>	7,768	7,847	7,743	7,711	7,299	7,340	7,048	7,292	
	<b>Eligible members per month</b>								
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	
<b>Enrollees with at least one day of coverage</b>									
<i>White</i>	24,199,398	24,220,699	24,280,794	24,297,872	24,331,161	24,343,613	24,356,375	24,349,632	
<i>Non-white</i>	4,086,354	4,087,344	4,096,302	4,091,338	4,094,046	4,094,364	4,099,164	4,106,604	
<i>Unknown</i>	32,334,660	32,219,114	32,037,323	31,910,939	31,591,958	31,516,120	31,494,159	31,461,997	
	<b>Number of patients with dispensing per 1,000 eligible members</b>								
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	
<b>HCTZ-containing</b>									
<b>HCTZ-containing products</b>									
<i>6.25 mg</i>									
<i>6.25 mg: White</i>	1.2	1.3	1.2	1.2	1.2	1.2	1.1	1.2	
<i>6.25 mg: Non-white</i>	0.8	0.9	0.9	0.9	0.9	0.9	0.8	0.9	
<i>6.25 mg: Unknown</i>	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.4	
<i>12.5 mg</i>									
<i>12.5 mg: White</i>	13.7	14.6	14.0	13.9	14.0	14.2	13.7	14.7	
<i>12.5 mg: Non-white</i>	15.8	16.8	16.3	16.3	16.3	16.6	15.8	17.2	
<i>12.5 mg: Unknown</i>	6.6	6.8	6.6	6.6	6.6	6.6	6.4	6.7	
<i>15 mg</i>									
<i>15 mg: White</i>	0	*****	*****	0	0	0	0	0	
<i>15 mg: Non-white</i>	*****	*****	0	*****	*****	0	0	0	
<i>15 mg: Unknown</i>	*****	*****	*****	*****	*****	*****	*****	*****	

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>								
<i>25 mg</i>								
<i>25 mg: White</i>	12.8	14.0	13.4	13.3	13.3	13.3	12.9	13.8
<i>25 mg: Non-white</i>	17.1	18.6	18.0	17.8	17.9	18.0	17.1	18.5
<i>25 mg: Unknown</i>	5.4	5.7	5.6	5.5	5.5	5.6	5.3	5.6
<i>50 mg</i>								
<i>50 mg: White</i>	0.7	0.8	0.8	0.8	0.7	0.7	0.7	0.8
<i>50 mg: Non-white</i>	0.9	1.0	1.0	0.9	1.0	0.9	0.9	0.9
<i>50 mg: Unknown</i>	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2

\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
White	27,941	25,368	28,929	27,351	26,090	27,610	26,691	26,613
Non-white	3,450	3,136	3,530	3,322	3,176	3,337	3,244	3,195
Unknown	13,525	12,645	14,035	13,342	12,987	13,561	13,215	12,909
12.5 mg								
White	337,750	306,865	351,859	338,445	323,774	341,482	334,606	333,177
Non-white	65,153	59,600	67,846	64,800	61,701	65,440	63,684	63,065
Unknown	206,792	196,580	220,314	211,975	207,271	214,203	210,886	210,569
15 mg								
White	0	0	0	0	*****	0	0	0
Non-white	0	0	0	0	0	0	0	0
Unknown	*****	*****	0	*****	0	0	*****	0
25 mg								
White	314,761	286,034	328,359	313,536	301,710	318,513	310,586	309,947
Non-white	69,889	63,846	73,110	69,860	66,361	69,970	68,301	67,694
Unknown	171,115	161,577	182,253	174,659	172,098	177,451	174,579	173,940
50 mg								
White	17,371	15,293	17,583	16,925	15,904	16,734	16,533	16,493
Non-white	3,619	3,190	3,652	3,471	3,331	3,502	3,325	3,442
Unknown	6,898	6,419	7,230	6,941	6,812	6,949	6,797	6,793

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy								
<i>12.5 mg</i>								
<i>White</i>	268,644	244,535	277,995	266,216	257,526	270,289	263,750	261,501
<i>Non-white</i>	49,050	44,496	50,369	47,704	46,281	48,264	46,979	46,226
<i>Unknown</i>	119,354	111,984	126,194	120,862	117,869	122,518	119,716	118,681
<i>25 mg</i>								
<i>White</i>	414,138	375,269	427,603	410,251	395,172	414,152	405,093	403,276
<i>Non-white</i>	88,659	80,352	90,470	86,470	82,661	86,502	84,591	83,422
<i>Unknown</i>	201,905	190,505	213,647	205,958	201,441	208,044	204,887	203,285
<i>50 mg</i>								
<i>White</i>	18,969	17,424	19,807	18,858	18,317	19,193	18,646	18,892
<i>Non-white</i>	3,987	3,538	3,986	3,921	3,723	3,902	3,754	3,789
<i>Unknown</i>	9,365	8,744	10,067	9,715	9,363	9,847	9,721	9,547
HCTZ combination products								
<i>6.25 mg</i>								
<i>White</i>	27,941	25,368	28,929	27,351	26,090	27,610	26,691	26,613
<i>Non-white</i>	3,450	3,136	3,530	3,322	3,176	3,337	3,244	3,195
<i>Unknown</i>	13,525	12,645	14,035	13,342	12,987	13,561	13,215	12,909
<i>12.5 mg</i>								
<i>White</i>	337,750	306,865	351,859	338,445	323,774	341,482	334,606	333,177
<i>Non-white</i>	65,153	59,600	67,846	64,800	61,701	65,440	63,684	63,065
<i>Unknown</i>	206,792	196,580	220,314	211,975	207,271	214,203	210,886	210,569
<i>15 mg</i>								
<i>White</i>	0	0	0	0	*****	0	0	0
<i>Non-white</i>	0	0	0	0	0	0	0	0
<i>Unknown</i>	*****	*****	0	*****	0	0	*****	0
<i>25 mg</i>								
<i>White</i>	314,761	286,034	328,359	313,536	301,710	318,513	310,586	309,947
<i>Non-white</i>	69,889	63,846	73,110	69,860	66,361	69,970	68,301	67,694
<i>Unknown</i>	171,115	161,577	182,253	174,659	172,098	177,451	174,579	173,940

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ combination products								
50 mg								
White	17,371	15,293	17,583	16,925	15,904	16,734	16,533	16,493
Non-white	3,619	3,190	3,652	3,471	3,331	3,502	3,325	3,442
Unknown	6,898	6,419	7,230	6,941	6,812	6,949	6,797	6,793
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
Enrollees with at least one day of coverage								
White	23,964,473	23,898,411	23,865,241	23,825,399	23,804,948	23,805,278	23,844,559	23,861,039
Non-white	4,021,627	3,995,598	3,977,665	3,958,063	3,942,666	3,936,866	3,940,526	3,946,434
Unknown	31,795,013	31,751,350	31,784,734	31,780,499	31,778,253	31,815,926	31,824,214	31,924,565
	Number of patients with dispensing per 1,000 eligible members							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
HCTZ-containing products								
6.25 mg								
6.25 mg: White	1.2	1.1	1.2	1.1	1.1	1.2	1.1	1.1
6.25 mg: Non-white	0.9	0.8	0.9	0.8	0.8	0.8	0.8	0.8
6.25 mg: Unknown	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
12.5 mg								
12.5 mg: White	14.1	12.8	14.7	14.2	13.6	14.3	14.0	14.0
12.5 mg: Non-white	16.2	14.9	17.1	16.4	15.6	16.6	16.2	16.0
12.5 mg: Unknown	6.5	6.2	6.9	6.7	6.5	6.7	6.6	6.6
15 mg								
15 mg: White	0	0	0	0	*****	0	0	0
15 mg: Non-white	0	0	0	0	0	0	0	0
15 mg: Unknown	*****	*****	0	*****	0	0	*****	0



Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>								
<i>25 mg</i>								
<i>25 mg: White</i>	13.1	12.0	13.8	13.2	12.7	13.4	13.0	13.0
<i>25 mg: Non-white</i>	17.4	16.0	18.4	17.7	16.8	17.8	17.3	17.2
<i>25 mg: Unknown</i>	5.4	5.1	5.7	5.5	5.4	5.6	5.5	5.4
<i>50 mg</i>								
<i>50 mg: White</i>	0.7	0.6	0.7	0.7	0.7	0.7	0.7	0.7
<i>50 mg: Non-white</i>	0.9	0.8	0.9	0.9	0.8	0.9	0.8	0.9
<i>50 mg: Unknown</i>	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2

\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

	Patients with dispensing per month				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
6.25 mg					
White	26,056	25,951	25,592	26,433	24,844
Non-white	3,188	3,124	3,063	3,107	2,934
Unknown	12,876	12,683	12,201	12,313	9,139
12.5 mg					
White	325,889	328,661	323,932	330,861	310,217
Non-white	62,165	61,774	60,404	61,742	55,507
Unknown	207,280	207,650	204,103	203,360	146,854
15 mg					
White	0	0	0	0	0
Non-white	0	0	0	0	0
Unknown	*****	0	*****	*****	0
25 mg					
White	302,633	303,070	297,657	301,338	279,949
Non-white	66,515	66,063	64,869	64,284	57,758
Unknown	171,381	170,989	167,717	165,211	118,375
50 mg					
White	15,658	15,885	15,715	15,663	14,789
Non-white	3,302	3,136	3,313	3,190	2,830
Unknown	6,616	6,583	6,323	6,297	4,632

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy					
<i>12.5 mg</i>					
<i>White</i>	255,327	254,354	253,042	259,643	247,710
<i>Non-white</i>	45,596	44,863	44,076	45,192	41,644
<i>Unknown</i>	117,107	115,739	113,676	114,472	86,676
<i>25 mg</i>					
<i>White</i>	393,002	391,538	386,825	400,551	383,770
<i>Non-white</i>	81,351	80,496	78,939	81,660	75,888
<i>Unknown</i>	199,662	199,210	193,996	196,908	149,165
<i>50 mg</i>					
<i>White</i>	18,301	18,420	18,030	18,531	17,561
<i>Non-white</i>	3,690	3,614	3,623	3,593	3,343
<i>Unknown</i>	9,476	9,399	9,133	9,292	6,776
HCTZ combination products					
<i>6.25 mg</i>					
<i>White</i>	26,056	25,951	25,592	26,433	24,844
<i>Non-white</i>	3,188	3,124	3,063	3,107	2,934
<i>Unknown</i>	12,876	12,683	12,201	12,313	9,139
<i>12.5 mg</i>					
<i>White</i>	325,889	328,661	323,932	330,861	310,217
<i>Non-white</i>	62,165	61,774	60,404	61,742	55,507
<i>Unknown</i>	207,280	207,650	204,103	203,360	146,854
<i>15 mg</i>					
<i>White</i>	0	0	0	0	0
<i>Non-white</i>	0	0	0	0	0
<i>Unknown</i>	*****	0	*****	*****	0
<i>25 mg</i>					
<i>White</i>	302,633	303,070	297,657	301,338	279,949
<i>Non-white</i>	66,515	66,063	64,869	64,284	57,758
<i>Unknown</i>	171,381	170,989	167,717	165,211	118,375

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ combination products</b>					
<i>50 mg</i>					
<i>White</i>	15,658	15,885	15,715	15,663	14,789
<i>Non-white</i>	3,302	3,136	3,313	3,190	2,830
<i>Unknown</i>	6,616	6,583	6,323	6,297	4,632
	<b>Eligible members per month</b>				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
Enrollees with at least one day of coverage					
<i>White</i>	23,856,274	23,843,589	23,837,115	23,830,034	23,421,808
<i>Non-white</i>	3,940,901	3,931,041	3,933,780	3,938,655	3,829,051
<i>Unknown</i>	31,965,820	31,990,672	32,039,790	32,084,856	21,838,140
	<b>Number of patients with dispensing per 1,000 eligible members</b>				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
HCTZ-containing products					
<i>6.25 mg</i>					
<i>6.25 mg: White</i>	1.1	1.1	1.1	1.1	1.1
<i>6.25 mg: Non-white</i>	0.8	0.8	0.8	0.8	0.8
<i>6.25 mg: Unknown</i>	0.4	0.4	0.4	0.4	0.4
<i>12.5 mg</i>					
<i>12.5 mg: White</i>	13.7	13.8	13.6	13.9	13.2
<i>12.5 mg: Non-white</i>	15.8	15.7	15.4	15.7	14.5
<i>12.5 mg: Unknown</i>	6.5	6.5	6.4	6.3	6.7
<i>15 mg</i>					
<i>15 mg: White</i>	0	0	0	0	0
<i>15 mg: Non-white</i>	0	0	0	0	0
<i>15 mg: Unknown</i>	*****	0	*****	*****	0

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>						
<i>25 mg</i>						
<i>25 mg: White</i>	12.7	12.7	12.5	12.6	12.0	
<i>25 mg: Non-white</i>	16.9	16.8	16.5	16.3	15.1	
<i>25 mg: Unknown</i>	5.4	5.3	5.2	5.1	5.4	
<i>50 mg</i>						
<i>50 mg: White</i>	0.7	0.7	0.7	0.7	0.6	
<i>50 mg: Non-white</i>	0.8	0.8	0.8	0.8	0.7	
<i>50 mg: Unknown</i>	0.2	0.2	0.2	0.2	0.2	

\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<i>HCTZ-containing</i>	Patients with dispensing per month				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
HCTZ-containing products					
6.25 mg					
White	18,910	20,725	1,573	1,488	1,483
Non-white	1,741	1,898	303	307	309
Unknown	7,230	1,853	853	880	791
12.5 mg					
White	240,970	269,768	22,347	22,552	21,926
Non-white	36,515	41,003	7,086	7,142	6,959
Unknown	118,475	37,108	17,474	17,536	17,061
15 mg					
White	0	0	0	0	0
Non-white	0	0	0	0	0
Unknown	0	0	0	0	0
25 mg					
White	220,019	248,204	18,035	18,380	18,073
Non-white	37,452	41,553	6,505	6,726	6,660
Unknown	96,148	28,435	13,402	13,785	13,416
50 mg					
White	11,656	12,606	807	796	794
Non-white	1,901				
Unknown	3,685	899	417	409	425

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

HCTZ single ingredient/monotherapy					
<i>12.5 mg</i>					
<i>White</i>	197,538	219,082	14,527	14,770	14,312
<i>Non-white</i>	28,851	31,472	4,301	4,436	4,283
<i>Unknown</i>	70,514	23,913	9,374	9,503	9,317
<i>25 mg</i>					
<i>White</i>	301,504	333,710	24,545	24,864	24,147
<i>Non-white</i>	50,888	55,328	8,083	8,095	8,093
<i>Unknown</i>	120,921	37,145	15,838	15,925	15,641
<i>50 mg</i>					
<i>White</i>	13,844	15,431	1,066	1,144	1,137
<i>Non-white</i>	2,331	2,567	329	343	342
<i>Unknown</i>	5,639	1,681	682	733	711
HCTZ combination products					
<i>6.25 mg</i>					
<i>White</i>	18,910	20,725	1,573	1,488	1,483
<i>Non-white</i>	1,741	1,898	303	307	309
<i>Unknown</i>	7,230	1,853	853	880	791
<i>12.5 mg</i>					
<i>White</i>	240,970	269,768	22,347	22,552	21,926
<i>Non-white</i>	36,515	41,003	7,086	7,142	6,959
<i>Unknown</i>	118,475	37,108	17,474	17,536	17,061
<i>15 mg</i>					
<i>White</i>	0	0	0	0	0
<i>Non-white</i>	0	0	0	0	0
<i>Unknown</i>	0	0	0	0	0
<i>25 mg</i>					
<i>White</i>	220,019	248,204	18,035	18,380	18,073
<i>Non-white</i>	37,452	41,553	6,505	6,726	6,660
<i>Unknown</i>	96,148	28,435	13,402	13,785	13,416

Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ combination products</b>						
<i>50 mg</i>						
<i>White</i>	11,656	12,606	807	796	794	
<i>Non-white</i>	1,901	2,026	269	290	266	
<i>Unknown</i>	3,685	899	417	409	425	
	<b>Eligible members per month</b>					
	Feb-22	Mar-22	Apr-22	May-22	Jun-22	
<b>Enrollees with at least one day of coverage</b>						
<i>White</i>	20,524,330	20,520,459	3,106,042	3,117,618	3,123,734	
<i>Non-white</i>	3,039,061	3,032,922	1,008,885	1,012,666	1,015,707	
<i>Unknown</i>	20,210,900	5,531,935	4,139,567	4,161,664	4,180,509	
	<b>Number of patients with dispensing per 1,000 eligible members</b>					
	Feb-22	Mar-22	Apr-22	May-22	Jun-22	
<b>HCTZ-containing</b>						
<b>HCTZ-containing products</b>						
<i>6.25 mg</i>						
<i>6.25 mg: White</i>	0.9	1.0	0.5	0.5	0.5	
<i>6.25 mg: Non-white</i>	0.6	0.6	0.3	0.3	0.3	
<i>6.25 mg: Unknown</i>	0.4	0.3	0.2	0.2	0.2	
<i>12.5 mg</i>						
<i>12.5 mg: White</i>	11.7	13.1	7.2	7.2	7.0	
<i>12.5 mg: Non-white</i>	12.0	13.5	7.0	7.1	6.9	
<i>12.5 mg: Unknown</i>	5.9	6.7	4.2	4.2	4.1	
<i>15 mg</i>						
<i>15 mg: White</i>	0	0	0	0	0	
<i>15 mg: Non-white</i>	0	0	0	0	0	
<i>15 mg: Unknown</i>	0	0	0	0	0	



Table 7b. Total number of patients dispensed HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength, race, and calendar year/month

<b>HCTZ-containing</b>					
<i>25 mg</i>					
<i>25 mg: White</i>	10.7	12.1	5.8	5.9	5.8
<i>25 mg: Non-white</i>	12.3	13.7	6.4	6.6	6.6
<i>25 mg: Unknown</i>	4.8	5.1	3.2	3.3	3.2
<i>50 mg</i>					
<i>50 mg: White</i>	0.6	0.6	0.3	0.3	0.3
<i>50 mg: Non-white</i>	0.6	0.0	0.0	0.0	0.0
<i>50 mg: Unknown</i>	0.2	0.2	0.1	0.1	0.1

Figure 7. Proportional use of HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by strength and calendar year/month




Table 8a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members	Number of Exposed Patients per 1,000 Eligible Members
<b>HCTZ-containing</b>					
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>					
Any HCTZ-containing products	1,653,637	18,358,682	18,438,526	7,565,567	218.6
HCTZ single ingredient/monotherapy	933,714	8,445,388	8,460,658	7,565,567	123.4
HCTZ combination products	911,571	9,944,853	9,977,872	7,565,567	120.5
ACEI + HCTZ	272,126	2,852,021	2,856,648	7,565,567	36.0
ARB + HCTZ	407,166	4,307,316	4,320,378	7,565,567	53.8
Potassium-sparing diuretic + HCTZ	227,274	2,329,431	2,333,223	7,565,567	30.0
Beta blocker + HCTZ	32,170	377,286	378,113	7,565,567	4.3
ARB + CCB + HCTZ	8,241	81,048	81,219	7,565,567	1.1
Direct renin inhibitor + HCTZ	649	7,841	7,848	7,565,567	0.1
Central alpha 2 agonist + HCTZ	56	444	444	7,565,567	0.0
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>					
Any HCTZ-containing products	13,988,768	152,912,221	153,975,484	127,155,376	110.0
HCTZ single ingredient/monotherapy	7,564,535	67,012,693	67,239,565	127,155,376	59.5
HCTZ combination products	8,018,946	86,209,215	86,735,927	127,155,376	63.1
ACEI + HCTZ	3,008,898	30,478,626	30,584,342	127,155,376	23.7
ARB + HCTZ	3,531,323	36,830,420	37,076,701	127,155,376	27.8
Potassium-sparing diuretic + HCTZ	1,463,829	14,829,985	14,887,366	127,155,376	11.5
Beta blocker + HCTZ	271,919	3,179,228	3,195,343	127,155,376	2.1
ARB + CCB + HCTZ	97,124	936,499	941,682	127,155,376	0.8
Direct renin inhibitor + HCTZ	4,262	47,453	48,038	127,155,376	0.0
Central alpha 2 agonist + HCTZ	341	2,427	2,457	127,155,376	0.0

Table 8a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer

<b>Non-HCTZ-containing</b>					
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	259,689	1,795,393	1,801,038	7,565,567	34.3
Chlorothiazide	769	5,196	5,216	7,565,567	0.1
Bendroflumethiazide	65	444	450	7,565,567	0.0
Thiazide-like diuretics	259,083	1,789,764	1,795,372	7,565,567	34.2
ACEIs	1,890,274	21,993,067	22,084,946	7,565,567	249.9
CCBs	2,272,446	27,329,570	27,503,367	7,565,567	300.4
Potassium-sparing diuretics	415,910	3,633,610	3,644,878	7,565,567	55.0
Loop diuretics	1,569,029	15,808,853	15,988,112	7,565,567	207.4
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	1,709,735	12,519,414	12,577,799	127,155,376	13.4
Chlorothiazide	6,052	36,323	36,756	127,155,376	0.0
Bendroflumethiazide	531	4,631	4,671	127,155,376	0.0
Thiazide-like diuretics	1,704,355	12,478,579	12,536,372	127,155,376	13.4
ACEIs	15,678,179	174,191,094	175,144,442	127,155,376	123.3
CCBs	16,172,960	185,766,055	187,120,830	127,155,376	127.2
Potassium-sparing diuretics	3,235,266	26,931,078	27,140,364	127,155,376	25.4
Loop diuretics	8,834,589	89,419,234	90,429,627	127,155,376	69.5

Table 8a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer

<b>Denominators</b>					
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	1,851,753	20,145,837	20,239,563	7,565,567	244.8
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	4,562,009	79,059,280	89,460,157	7,565,567	603.0
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	15,271,101	165,350,171	166,553,283	127,155,376	120.1
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	36,082,764	563,447,497	646,387,733	127,155,376	283.8

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	277,252	251,170	280,694	267,784	286,292	281,909	282,793	287,743
HCTZ single ingredient/monotherapy	113,705	102,920	115,377	110,291	117,923	116,611	117,073	119,495
HCTZ combination products	164,693	149,324	166,585	158,583	169,606	166,582	166,935	169,544
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	2,812,284	2,594,932	2,840,770	2,675,598	2,820,593	2,750,205	2,726,013	2,759,174
HCTZ single ingredient/monotherapy	1,092,772	1,008,007	1,105,216	1,044,205	1,104,302	1,078,700	1,073,288	1,086,627
HCTZ combination products	1,733,551	1,599,165	1,749,775	1,644,087	1,730,242	1,684,983	1,665,731	1,686,059
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	22,873	20,908	23,657	22,541	24,169	23,921	23,645	24,179
ACEIs	334,773	305,155	337,811	321,528	343,928	336,160	337,569	344,216
CCBs	373,499	342,411	378,464	363,117	385,542	378,959	381,756	388,792
Potassium-sparing diuretics	46,434	42,533	47,342	46,070	48,659	48,499	48,967	49,837
Loop diuretics	209,809	193,814	213,370	206,314	219,494	219,238	219,259	223,917
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	185,755	170,119	190,563	180,940	189,977	188,792	186,097	189,153
ACEIs	3,190,567	2,942,151	3,205,409	3,012,687	3,166,944	3,078,669	3,053,556	3,096,095
CCBs	3,056,586	2,827,036	3,087,963	2,912,298	3,058,867	2,986,917	2,963,393	3,010,233
Potassium-sparing diuretics	401,051	372,786	410,510	388,666	412,660	406,657	403,200	413,477
Loop diuretics	1,423,095	1,320,821	1,436,367	1,368,831	1,446,819	1,430,590	1,419,606	1,436,288

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	299,730	271,733	303,950	289,985	310,038	305,425	306,060	311,540
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	996,383	921,245	1,011,736	975,338	1,034,002	1,021,443	1,027,437	1,046,125
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,994,143	2,761,459	3,027,242	2,852,968	3,006,610	2,935,113	2,908,421	2,944,455
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,703,252	8,111,049	8,792,534	8,344,331	8,747,227	8,564,094	8,504,888	8,618,013
<b>Eligible members per month</b>								
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b><i>Evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	3,614,084	3,649,708	3,694,216	3,729,606	3,777,664	3,823,648	3,857,896	3,911,351
<b><i>No evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	58,686,583	58,600,523	58,599,175	58,496,300	58,402,273	58,366,038	58,334,488	58,365,919

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing	76.7	68.8	76.0	71.8	75.8	73.7	73.3	73.6
Skin cancer: HCTZ single ingredient	31.5	28.2	31.2	29.6	31.2	30.5	30.3	30.6
Skin cancer: HCTZ combination	45.6	40.9	45.1	42.5	44.9	43.6	43.3	43.3
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing	47.9	44.3	48.5	45.7	48.3	47.1	46.7	47.3
No skin cancer: HCTZ single ingredient	18.6	17.2	18.9	17.9	18.9	18.5	18.4	18.6
No skin cancer: HCTZ combination	29.5	27.3	29.9	28.1	29.6	28.9	28.6	28.9
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	6.3	5.7	6.4	6.0	6.4	6.3	6.1	6.2
Skin cancer: ACEIs	92.6	83.6	91.4	86.2	91.0	87.9	87.5	88.0
Skin cancer: CCBs	103.3	93.8	102.4	97.4	102.1	99.1	99.0	99.4
Skin cancer: Potassium-sparing diuretics	12.8	11.7	12.8	12.4	12.9	12.7	12.7	12.7
Skin cancer: Loop diuretics	58.1	53.1	57.8	55.3	58.1	57.3	56.8	57.2
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.2	2.9	3.3	3.1	3.3	3.2	3.2	3.2
No skin cancer: ACEIs	54.4	50.2	54.7	51.5	54.2	52.7	52.3	53.0
No skin cancer: CCBs	52.1	48.2	52.7	49.8	52.4	51.2	50.8	51.6
No skin cancer: Potassium-sparing diuretics	6.8	6.4	7.0	6.6	7.1	7.0	6.9	7.1
No skin cancer: Loop diuretics	24.2	22.5	24.5	23.4	24.8	24.5	24.3	24.6



Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Skin cancer: Limited denominator	82.9	74.5	82.3	77.8	82.1	79.9	79.3	79.7
Skin cancer: Full denominator	275.7	252.4	273.9	261.5	273.7	267.1	266.3	267.5
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
No skin cancer: Limited denominator	51.0	47.1	51.7	48.8	51.5	50.3	49.9	50.4
No skin cancer: Full denominator	148.3	138.4	150.0	142.6	149.8	146.7	145.8	147.7

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	277,037	294,228	284,137	289,948	292,836	261,948	285,935	287,708
HCTZ single ingredient/monotherapy	114,860	121,900	117,787	120,374	121,706	109,258	118,963	119,858
HCTZ combination products	163,379	173,538	167,560	170,804	172,397	153,807	168,247	169,023
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	2,613,002	2,721,129	2,618,969	2,623,595	2,651,005	2,421,858	2,603,166	2,565,689
HCTZ single ingredient/monotherapy	1,029,866	1,074,244	1,032,637	1,032,052	1,049,647	958,015	1,030,479	1,019,006
HCTZ combination products	1,595,293	1,660,040	1,598,817	1,603,644	1,614,083	1,474,988	1,585,287	1,558,696
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	23,460	24,704	24,293	24,958	25,445	23,620	26,162	26,184
ACEIs	331,799	351,882	340,030	345,835	348,848	314,050	340,947	340,345
CCBs	376,971	400,500	390,188	396,502	405,841	367,151	400,222	400,800
Potassium-sparing diuretics	48,469	51,364	50,232	50,754	51,638	47,155	51,363	51,367
Loop diuretics	216,427	226,552	219,203	221,863	223,719	205,908	221,501	223,180
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	180,864	188,497	184,202	186,036	190,167	176,476	193,169	192,526
ACEIs	2,940,969	3,062,135	2,950,732	2,948,825	2,994,499	2,735,042	2,925,466	2,867,430
CCBs	2,874,811	2,997,697	2,909,543	2,917,978	2,984,014	2,742,719	2,945,529	2,903,796
Potassium-sparing diuretics	394,189	411,275	400,356	400,789	406,196	375,507	404,873	400,938
Loop diuretics	1,368,172	1,404,132	1,352,577	1,346,107	1,355,907	1,255,166	1,338,964	1,328,329

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	300,142	318,557	308,056	314,528	317,832	285,197	311,650	313,482
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	1,015,993	1,072,188	1,043,168	1,059,857	1,068,971	977,790	1,056,424	1,061,182
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,790,406	2,905,899	2,799,571	2,806,101	2,837,483	2,595,015	2,792,600	2,754,581
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,233,188	8,540,593	8,274,006	8,280,240	8,377,532	7,752,255	8,264,324	8,164,009
	<b>Eligible members per month</b>							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage	3,950,184	3,998,669	4,038,803	4,063,737	3,965,629	3,993,726	4,029,765	4,065,020
<b>No evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage	57,949,286	57,920,551	57,892,341	57,859,538	57,315,755	57,185,325	57,138,227	57,023,923

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing	70.1	73.6	70.4	71.4	73.8	65.6	71.0	70.8
Skin cancer: HCTZ single ingredient	29.1	30.5	29.2	29.6	30.7	27.4	29.5	29.5
Skin cancer: HCTZ combination	41.4	43.4	41.5	42.0	43.5	38.5	41.8	41.6
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing	45.1	47.0	45.2	45.3	46.3	42.4	45.6	45.0
No skin cancer: HCTZ single ingredient	17.8	18.5	17.8	17.8	18.3	16.8	18.0	17.9
No skin cancer: HCTZ combination	27.5	28.7	27.6	27.7	28.2	25.8	27.7	27.3
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	5.9	6.2	6.0	6.1	6.4	5.9	6.5	6.4
Skin cancer: ACEIs	84.0	88.0	84.2	85.1	88.0	78.6	84.6	83.7
Skin cancer: CCBs	95.4	100.2	96.6	97.6	102.3	91.9	99.3	98.6
Skin cancer: Potassium-sparing diuretics	12.3	12.8	12.4	12.5	13.0	11.8	12.7	12.6
Skin cancer: Loop diuretics	54.8	56.7	54.3	54.6	56.4	51.6	55.0	54.9
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.1	3.3	3.2	3.2	3.3	3.1	3.4	3.4
No skin cancer: ACEIs	50.8	52.9	51.0	51.0	52.2	47.8	51.2	50.3
No skin cancer: CCBs	49.6	51.8	50.3	50.4	52.1	48.0	51.6	50.9
No skin cancer: Potassium-sparing diuretics	6.8	7.1	6.9	6.9	7.1	6.6	7.1	7.0
No skin cancer: Loop diuretics	23.6	24.2	23.4	23.3	23.7	21.9	23.4	23.3

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Skin cancer: Limited denominator	76.0	79.7	76.3	77.4	80.1	71.4	77.3	77.1
Skin cancer: Full denominator	257.2	268.1	258.3	260.8	269.6	244.8	262.2	261.1
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
No skin cancer: Limited denominator	48.2	50.2	48.4	48.5	49.5	45.4	48.9	48.3
No skin cancer: Full denominator	142.1	147.5	142.9	143.1	146.2	135.6	144.6	143.2

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	291,209	282,981	299,382	297,852	276,200	308,322	288,699	291,252
HCTZ single ingredient/monotherapy	122,463	118,914	124,294	124,753	117,324	128,085	122,075	123,807
HCTZ combination products	170,050	165,329	176,616	174,639	160,091	181,590	167,889	168,676
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	2,587,715	2,490,096	2,568,945	2,571,439	2,366,555	2,573,253	2,413,270	2,399,486
HCTZ single ingredient/monotherapy	1,034,166	997,102	1,022,489	1,028,807	954,872	1,026,409	970,995	968,602
HCTZ combination products	1,566,279	1,504,774	1,560,654	1,556,441	1,422,980	1,559,355	1,453,886	1,442,254
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	27,079	26,371	26,947	27,397	26,006	28,351	27,382	28,107
ACEIs	343,926	333,359	344,266	347,213	328,393	357,682	340,899	344,559
CCBs	405,665	395,085	407,266	412,056	392,537	426,906	410,550	415,857
Potassium-sparing diuretics	53,030	51,798	53,936	54,426	51,377	55,927	54,446	54,759
Loop diuretics	230,181	225,000	231,466	232,647	219,847	234,648	225,602	228,847
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	197,539	191,964	194,211	196,736	184,910	199,072	190,595	191,923
ACEIs	2,873,885	2,764,800	2,816,987	2,833,066	2,639,672	2,831,658	2,692,586	2,678,096
CCBs	2,924,165	2,823,812	2,878,073	2,897,495	2,719,727	2,926,249	2,794,545	2,790,611
Potassium-sparing diuretics	411,212	397,026	409,278	413,790	389,198	418,851	400,939	401,486
Loop diuretics	1,367,698	1,325,583	1,350,614	1,353,790	1,261,338	1,329,301	1,264,042	1,262,934

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	317,879	308,963	325,943	324,791	301,852	336,211	315,696	318,958
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	1,077,615	1,052,524	1,090,626	1,097,669	1,042,944	1,130,994	1,084,427	1,096,614
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,781,381	2,678,563	2,759,460	2,764,261	2,548,091	2,768,484	2,600,257	2,588,064
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,237,426	7,972,022	8,147,786	8,185,404	7,674,759	8,207,528	7,823,441	7,799,548
	<b>Eligible members per month</b>							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b><i>Evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	4,107,977	4,145,564	4,177,169	4,224,657	4,260,842	4,308,097	4,341,387	4,363,043
<b><i>No evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	56,943,083	56,922,954	56,877,421	56,937,285	56,963,823	56,952,477	56,895,160	56,841,145

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing	70.9	68.3	71.7	70.5	64.8	71.6	66.5	66.8
Skin cancer: HCTZ single ingredient	29.8	28.7	29.8	29.5	27.5	29.7	28.1	28.4
Skin cancer: HCTZ combination	41.4	39.9	42.3	41.3	37.6	42.2	38.7	38.7
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing	45.4	43.7	45.2	45.2	41.5	45.2	42.4	42.2
No skin cancer: HCTZ single ingredient	18.2	17.5	18.0	18.1	16.8	18.0	17.1	17.0
No skin cancer: HCTZ combination	27.5	26.4	27.4	27.3	25.0	27.4	25.6	25.4
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	6.6	6.4	6.5	6.5	6.1	6.6	6.3	6.4
Skin cancer: ACEIs	83.7	80.4	82.4	82.2	77.1	83.0	78.5	79.0
Skin cancer: CCBs	98.8	95.3	97.5	97.5	92.1	99.1	94.6	95.3
Skin cancer: Potassium-sparing diuretics	12.9	12.5	12.9	12.9	12.1	13.0	12.5	12.6
Skin cancer: Loop diuretics	56.0	54.3	55.4	55.1	51.6	54.5	52.0	52.5
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.5	3.4	3.4	3.5	3.2	3.5	3.3	3.4
No skin cancer: ACEIs	50.5	48.6	49.5	49.8	46.3	49.7	47.3	47.1
No skin cancer: CCBs	51.4	49.6	50.6	50.9	47.7	51.4	49.1	49.1
No skin cancer: Potassium-sparing diuretics	7.2	7.0	7.2	7.3	6.8	7.4	7.0	7.1
No skin cancer: Loop diuretics	24.0	23.3	23.7	23.8	22.1	23.3	22.2	22.2



Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Skin cancer: Limited denominator	77.4	74.5	78.0	76.9	70.8	78.0	72.7	73.1
Skin cancer: Full denominator	262.3	253.9	261.1	259.8	244.8	262.5	249.8	251.3
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
No skin cancer: Limited denominator	48.8	47.1	48.5	48.5	44.7	48.6	45.7	45.5
No skin cancer: Full denominator	144.7	140.0	143.3	143.8	134.7	144.1	137.5	137.2

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	296,407	263,593	282,573	294,090	292,130	277,864	298,408	288,778
HCTZ single ingredient/monotherapy	126,339	113,839	122,656	127,786	128,031	122,722	131,290	130,318
HCTZ combination products	171,485	150,992	161,267	167,745	165,497	156,474	168,533	159,814
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	2,492,299	2,250,522	2,387,276	2,430,881	2,405,960	2,272,667	2,400,779	2,323,744
HCTZ single ingredient/monotherapy	1,015,142	926,733	989,406	1,013,750	1,010,271	961,946	1,016,110	1,004,308
HCTZ combination products	1,491,060	1,336,007	1,411,162	1,430,562	1,408,947	1,322,911	1,397,718	1,333,125
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	28,057	25,585	27,874	28,590	28,529	27,523	28,767	28,483
ACEIs	346,663	312,228	337,868	347,745	346,069	330,071	352,234	343,542
CCBs	420,973	383,293	411,437	423,619	421,766	403,061	430,451	421,564
Potassium-sparing diuretics	55,183	50,193	54,467	55,830	56,198	54,449	58,105	57,021
Loop diuretics	229,629	210,650	224,210	230,994	234,605	225,764	238,787	233,764
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	197,673	181,266	194,563	197,494	198,980	188,194	198,248	195,114
ACEIs	2,780,371	2,530,156	2,699,132	2,731,499	2,708,293	2,560,225	2,690,380	2,628,574
CCBs	2,907,129	2,659,782	2,827,855	2,863,358	2,843,403	2,698,163	2,841,018	2,779,881
Potassium-sparing diuretics	412,946	379,618	405,392	413,218	415,396	396,749	418,337	412,747
Loop diuretics	1,296,867	1,191,660	1,258,967	1,283,124	1,293,638	1,238,825	1,305,406	1,270,451

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	324,028	288,775	310,061	322,253	320,243	305,005	326,779	316,890
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	1,102,195	1,008,230	1,076,519	1,109,712	1,109,851	1,066,714	1,131,839	1,108,913
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,686,260	2,428,528	2,578,249	2,624,756	2,601,300	2,457,688	2,595,581	2,515,498
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	8,061,787	7,410,858	7,843,913	7,956,471	7,916,191	7,543,600	7,911,016	7,734,370
	<b>Eligible members per month</b>							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage	4,239,488	4,268,581	4,302,163	4,338,390	4,377,991	4,411,217	4,447,764	4,488,924
<b>No evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage	56,718,317	56,601,759	56,582,303	56,471,757	56,373,918	56,275,372	56,278,874	56,227,927

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing	69.9	61.8	65.7	67.8	66.7	63.0	67.1	64.3
Skin cancer: HCTZ single ingredient	29.8	26.7	28.5	29.5	29.2	27.8	29.5	29.0
Skin cancer: HCTZ combination	40.4	35.4	37.5	38.7	37.8	35.5	37.9	35.6
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing	43.9	39.8	42.2	43.0	42.7	40.4	42.7	41.3
No skin cancer: HCTZ single ingredient	17.9	16.4	17.5	18.0	17.9	17.1	18.1	17.9
No skin cancer: HCTZ combination	26.3	23.6	24.9	25.3	25.0	23.5	24.8	23.7
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	6.6	6.0	6.5	6.6	6.5	6.2	6.5	6.3
Skin cancer: ACEIs	81.8	73.1	78.5	80.2	79.0	74.8	79.2	76.5
Skin cancer: CCBs	99.3	89.8	95.6	97.6	96.3	91.4	96.8	93.9
Skin cancer: Potassium-sparing diuretics	13.0	11.8	12.7	12.9	12.8	12.3	13.1	12.7
Skin cancer: Loop diuretics	54.2	49.3	52.1	53.2	53.6	51.2	53.7	52.1
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.5	3.2	3.4	3.5	3.5	3.3	3.5	3.5
No skin cancer: ACEIs	49.0	44.7	47.7	48.4	48.0	45.5	47.8	46.7
No skin cancer: CCBs	51.3	47.0	50.0	50.7	50.4	47.9	50.5	49.4
No skin cancer: Potassium-sparing diuretics	7.3	6.7	7.2	7.3	7.4	7.1	7.4	7.3
No skin cancer: Loop diuretics	22.9	21.1	22.3	22.7	22.9	22.0	23.2	22.6

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Skin cancer: Limited denominator	76.4	67.7	72.1	74.3	73.1	69.1	73.5	70.6
Skin cancer: Full denominator	260.0	236.2	250.2	255.8	253.5	241.8	254.5	247.0
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
No skin cancer: Limited denominator	47.4	42.9	45.6	46.5	46.1	43.7	46.1	44.7
No skin cancer: Full denominator	142.1	130.9	138.6	140.9	140.4	134.0	140.6	137.6

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	280,468	300,437	276,944	301,737	293,847	268,674	315,306	276,107
HCTZ single ingredient/monotherapy	129,738	143,472	137,083	152,165	149,214	137,486	160,842	140,680
HCTZ combination products	152,203	158,941	141,653	151,567	146,479	132,598	156,336	136,853
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	2,238,533	2,358,137	2,173,755	2,278,743	2,351,102	2,159,205	2,471,225	2,200,974
HCTZ single ingredient/monotherapy	994,976	1,090,838	1,039,562	1,120,501	1,166,392	1,075,263	1,228,796	1,093,211
HCTZ combination products	1,258,209	1,287,320	1,152,027	1,176,315	1,202,427	1,097,993	1,259,653	1,121,316
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	27,668	29,463	27,787	30,072	29,427	27,448	31,376	27,725
ACEIs	336,794	358,166	332,257	357,646	349,090	320,987	370,758	327,105
CCBs	412,820	439,973	412,418	444,521	437,756	407,119	468,244	412,463
Potassium-sparing diuretics	55,752	59,335	55,589	59,668	58,883	54,673	62,250	55,333
Loop diuretics	226,925	238,341	222,945	239,594	233,995	218,525	245,368	221,407
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	188,082	199,177	186,135	195,592	203,072	189,714	212,344	190,458
ACEIs	2,547,877	2,680,744	2,483,399	2,596,856	2,677,301	2,469,580	2,791,665	2,491,664
CCBs	2,696,545	2,845,391	2,661,078	2,799,489	2,896,731	2,696,742	3,040,614	2,727,869
Potassium-sparing diuretics	399,882	420,865	393,841	411,739	425,986	398,557	445,294	402,093
Loop diuretics	1,224,986	1,268,438	1,179,308	1,241,301	1,259,987	1,173,277	1,300,799	1,194,806

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	307,792	329,480	304,388	331,405	322,853	295,784	346,262	303,451
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	1,086,467	1,150,362	1,078,669	1,156,694	1,129,248	1,054,193	1,198,269	1,069,435
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,423,506	2,553,735	2,356,886	2,471,011	2,550,696	2,345,932	2,680,363	2,388,618
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	7,510,521	7,866,864	7,349,287	7,676,202	7,886,978	7,362,558	8,240,496	7,432,835
	<b>Eligible members per month</b>							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage	4,527,100	4,572,735	4,603,849	4,627,097	4,508,674	4,536,745	4,552,849	4,542,780
<b>No evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage	56,223,243	56,204,581	56,156,408	56,110,599	56,654,492	56,474,126	56,406,016	56,248,709

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing	62.0	65.7	60.2	65.2	65.2	59.2	69.3	60.8
Skin cancer: HCTZ single ingredient	28.7	31.4	29.8	32.9	33.1	30.3	35.3	31.0
Skin cancer: HCTZ combination	33.6	34.8	30.8	32.8	32.5	29.2	34.3	30.1
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing	39.8	42.0	38.7	40.6	41.5	38.2	43.8	39.1
No skin cancer: HCTZ single ingredient	17.7	19.4	18.5	20.0	20.6	19.0	21.8	19.4
No skin cancer: HCTZ combination	22.4	22.9	20.5	21.0	21.2	19.4	22.3	19.9
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	6.1	6.4	6.0	6.5	6.5	6.1	6.9	6.1
Skin cancer: ACEIs	74.4	78.3	72.2	77.3	77.4	70.8	81.4	72.0
Skin cancer: CCBs	91.2	96.2	89.6	96.1	97.1	89.7	102.8	90.8
Skin cancer: Potassium-sparing diuretics	12.3	13.0	12.1	12.9	13.1	12.1	13.7	12.2
Skin cancer: Loop diuretics	50.1	52.1	48.4	51.8	51.9	48.2	53.9	48.7
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.3	3.5	3.3	3.5	3.6	3.4	3.8	3.4
No skin cancer: ACEIs	45.3	47.7	44.2	46.3	47.3	43.7	49.5	44.3
No skin cancer: CCBs	48.0	50.6	47.4	49.9	51.1	47.8	53.9	48.5
No skin cancer: Potassium-sparing diuretics	7.1	7.5	7.0	7.3	7.5	7.1	7.9	7.1
No skin cancer: Loop diuretics	21.8	22.6	21.0	22.1	22.2	20.8	23.1	21.2



Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Skin cancer: Limited denominator	68.0	72.1	66.1	71.6	71.6	65.2	76.1	66.8
Skin cancer: Full denominator	240.0	251.6	234.3	250.0	250.5	232.4	263.2	235.4
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
No skin cancer: Limited denominator	43.1	45.4	42.0	44.0	45.0	41.5	47.5	42.5
No skin cancer: Full denominator	133.6	140.0	130.9	136.8	139.2	130.4	146.1	132.1

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	273,434	295,899	284,344	284,772	284,251	286,254	279,436	300,613
HCTZ single ingredient/monotherapy	139,602	151,129	144,914	144,888	143,754	143,781	140,131	150,538
HCTZ combination products	135,138	146,280	140,863	141,201	141,776	143,730	140,387	151,313
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	2,159,237	2,298,787	2,224,586	2,192,974	2,177,191	2,179,976	2,087,959	2,220,828
HCTZ single ingredient/monotherapy	1,071,180	1,144,369	1,107,697	1,087,476	1,072,370	1,067,554	1,020,078	1,080,664
HCTZ combination products	1,100,180	1,168,414	1,130,589	1,117,655	1,115,791	1,123,077	1,077,267	1,150,319
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	27,350	29,676	28,627	28,333	28,344	28,444	28,134	30,363
ACEIs	323,051	347,398	336,722	337,901	338,486	342,253	332,209	356,600
CCBs	409,474	437,461	423,266	424,582	428,693	433,495	425,198	455,799
Potassium-sparing diuretics	54,666	58,905	57,496	56,623	57,791	58,379	56,569	60,853
Loop diuretics	220,830	235,811	229,266	226,922	225,940	226,042	219,218	230,937
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	189,050	199,266	194,058	190,795	189,938	190,827	184,335	195,644
ACEIs	2,440,887	2,596,845	2,519,016	2,492,914	2,484,073	2,489,409	2,388,880	2,533,816
CCBs	2,675,429	2,827,960	2,747,880	2,721,278	2,722,723	2,743,518	2,648,859	2,816,131
Potassium-sparing diuretics	396,932	421,245	412,209	408,036	407,510	410,906	397,397	421,425
Loop diuretics	1,184,069	1,259,584	1,232,793	1,203,472	1,191,629	1,181,840	1,131,917	1,183,354

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	300,460	325,195	312,617	312,782	312,257	314,363	307,247	330,586
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	1,062,362	1,134,707	1,102,488	1,103,534	1,108,107	1,118,976	1,094,789	1,164,603
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,345,513	2,494,963	2,415,702	2,380,926	2,364,264	2,367,989	2,269,701	2,413,658
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	7,323,393	7,737,610	7,531,997	7,452,016	7,426,712	7,451,088	7,187,927	7,584,462
	<b>Eligible members per month</b>							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b><i>Evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	4,553,069	4,588,044	4,620,226	4,652,149	4,685,826	4,720,284	4,745,410	4,763,692
<b><i>No evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	56,108,330	56,000,579	55,856,446	55,711,496	55,394,304	55,296,736	55,259,471	55,202,432

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing	60.1	64.5	61.5	61.2	60.7	60.6	58.9	63.1
Skin cancer: HCTZ single ingredient	30.7	32.9	31.4	31.1	30.7	30.5	29.5	31.6
Skin cancer: HCTZ combination	29.7	31.9	30.5	30.4	30.3	30.4	29.6	31.8
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing	38.5	41.0	39.8	39.4	39.3	39.4	37.8	40.2
No skin cancer: HCTZ single ingredient	19.1	20.4	19.8	19.5	19.4	19.3	18.5	19.6
No skin cancer: HCTZ combination	19.6	20.9	20.2	20.1	20.1	20.3	19.5	20.8
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	6.0	6.5	6.2	6.1	6.0	6.0	5.9	6.4
Skin cancer: ACEIs	71.0	75.7	72.9	72.6	72.2	72.5	70.0	74.9
Skin cancer: CCBs	89.9	95.3	91.6	91.3	91.5	91.8	89.6	95.7
Skin cancer: Potassium-sparing diuretics	12.0	12.8	12.4	12.2	12.3	12.4	11.9	12.8
Skin cancer: Loop diuretics	48.5	51.4	49.6	48.8	48.2	47.9	46.2	48.5
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.4	3.6	3.5	3.4	3.4	3.5	3.3	3.5
No skin cancer: ACEIs	43.5	46.4	45.1	44.7	44.8	45.0	43.2	45.9
No skin cancer: CCBs	47.7	50.5	49.2	48.8	49.2	49.6	47.9	51.0
No skin cancer: Potassium-sparing diuretics	7.1	7.5	7.4	7.3	7.4	7.4	7.2	7.6
No skin cancer: Loop diuretics	21.1	22.5	22.1	21.6	21.5	21.4	20.5	21.4

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Skin cancer: Limited denominator	66.0	70.9	67.7	67.2	66.6	66.6	64.7	69.4
Skin cancer: Full denominator	233.3	247.3	238.6	237.2	236.5	237.1	230.7	244.5
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
No skin cancer: Limited denominator	41.8	44.6	43.2	42.7	42.7	42.8	41.1	43.7
No skin cancer: Full denominator	130.5	138.2	134.8	133.8	134.1	134.7	130.1	137.4

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	275,670	253,948	291,670	280,755	273,609	289,035	283,333	284,793
HCTZ single ingredient/monotherapy	138,346	127,611	146,429	140,464	137,607	144,937	141,488	142,260
HCTZ combination products	138,402	127,291	146,440	141,373	137,071	145,179	142,830	143,573
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products	2,118,556	1,947,817	2,207,292	2,115,590	2,043,463	2,134,486	2,089,201	2,075,235
HCTZ single ingredient/monotherapy	1,031,782	945,956	1,069,187	1,025,275	991,078	1,033,646	1,011,730	1,002,689
HCTZ combination products	1,096,065	1,010,050	1,148,040	1,099,445	1,060,786	1,109,816	1,086,096	1,080,853
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	27,809	26,024	29,732	28,846	28,101	29,485	28,838	28,912
ACEIs	326,153	301,817	344,799	331,636	323,239	341,142	334,158	336,780
CCBs	424,095	393,425	448,177	431,488	423,915	445,013	436,839	440,726
Potassium-sparing diuretics	56,504	52,452	60,381	58,802	58,110	60,868	60,589	60,871
Loop diuretics	213,814	199,363	227,347	221,283	218,665	230,805	227,223	226,526
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	187,273	174,598	198,516	190,655	185,565	191,887	188,287	187,032
ACEIs	2,408,103	2,226,426	2,508,517	2,402,556	2,316,995	2,413,844	2,364,478	2,349,382
CCBs	2,707,637	2,508,545	2,827,370	2,719,708	2,633,038	2,737,961	2,691,749	2,681,398
Potassium-sparing diuretics	405,590	378,803	429,785	417,413	407,568	425,898	419,776	419,225
Loop diuretics	1,121,870	1,044,772	1,180,801	1,146,779	1,124,796	1,178,071	1,158,325	1,143,370

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	303,140	279,699	321,075	309,270	301,377	318,202	311,878	313,385
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	1,079,285	1,007,790	1,138,219	1,103,098	1,084,507	1,137,511	1,120,222	1,127,990
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,303,162	2,120,178	2,402,959	2,303,524	2,226,459	2,323,669	2,274,989	2,259,789
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	7,265,568	6,765,105	7,570,216	7,304,669	7,096,956	7,373,271	7,252,090	7,215,857
	<b>Eligible members per month</b>							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b><i>Evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	4,601,187	4,613,701	4,648,798	4,679,218	4,710,279	4,747,655	4,777,668	4,815,877
<b><i>No evidence of skin cancer in enrollment history</i></b>								
Enrollees with at least one day of coverage	55,239,828	55,081,756	55,042,255	54,945,340	54,876,072	54,874,268	54,890,373	54,984,343

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Number of patients with dispensing per 1,000 eligible members							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing	59.9	55.0	62.7	60.0	58.1	60.9	59.3	59.1
Skin cancer: HCTZ single ingredient	30.1	27.7	31.5	30.0	29.2	30.5	29.6	29.5
Skin cancer: HCTZ combination	30.1	27.6	31.5	30.2	29.1	30.6	29.9	29.8
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing	38.4	35.4	40.1	38.5	37.2	38.9	38.1	37.7
No skin cancer: HCTZ single ingredient	18.7	17.2	19.4	18.7	18.1	18.8	18.4	18.2
No skin cancer: HCTZ combination	19.8	18.3	20.9	20.0	19.3	20.2	19.8	19.7
<b>Non-HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	6.0	5.6	6.4	6.2	6.0	6.2	6.0	6.0
Skin cancer: ACEIs	70.9	65.4	74.2	70.9	68.6	71.9	69.9	69.9
Skin cancer: CCBs	92.2	85.3	96.4	92.2	90.0	93.7	91.4	91.5
Skin cancer: Potassium-sparing diuretics	12.3	11.4	13.0	12.6	12.3	12.8	12.7	12.6
Skin cancer: Loop diuretics	46.5	43.2	48.9	47.3	46.4	48.6	47.6	47.0
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.4	3.2	3.6	3.5	3.4	3.5	3.4	3.4
No skin cancer: ACEIs	43.6	40.4	45.6	43.7	42.2	44.0	43.1	42.7
No skin cancer: CCBs	49.0	45.5	51.4	49.5	48.0	49.9	49.0	48.8
No skin cancer: Potassium-sparing diuretics	7.3	6.9	7.8	7.6	7.4	7.8	7.6	7.6
No skin cancer: Loop diuretics	20.3	19.0	21.5	20.9	20.5	21.5	21.1	20.8



Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
Skin cancer: Limited denominator	65.9	60.6	69.1	66.1	64.0	67.0	65.3	65.1
Skin cancer: Full denominator	234.6	218.4	244.8	235.7	230.2	239.6	234.5	234.2
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
No skin cancer: Limited denominator	41.7	38.5	43.7	41.9	40.6	42.3	41.4	41.1
No skin cancer: Full denominator	131.5	122.8	137.5	132.9	129.3	134.4	132.1	131.2

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products	280,312	282,026	280,125	290,143	265,194
HCTZ single ingredient/monotherapy	140,115	139,887	139,701	145,845	135,043
HCTZ combination products	141,186	143,141	141,389	145,406	131,138
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products	2,030,803	2,025,174	1,990,664	2,016,720	1,760,874
HCTZ single ingredient/monotherapy	979,727	974,102	958,067	980,370	874,361
HCTZ combination products	1,059,055	1,058,977	1,040,269	1,045,008	893,912
<b>Non-HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	28,343	28,530	28,830	29,758	27,647
ACEIs	331,797	334,936	333,382	344,047	314,502
CCBs	436,237	439,704	443,687	457,060	428,775
Potassium-sparing diuretics	59,770	60,531	61,336	63,118	58,699
Loop diuretics	221,868	221,354	221,737	229,288	212,694
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	183,022	182,624	181,537	185,572	165,649
ACEIs	2,302,079	2,301,086	2,266,604	2,302,800	2,019,348
CCBs	2,631,887	2,642,594	2,629,748	2,676,704	2,435,195
Potassium-sparing diuretics	410,354	411,430	410,119	417,812	361,142
Loop diuretics	1,110,212	1,096,609	1,084,052	1,104,858	1,017,937

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	308,382	310,228	308,652	319,586	292,552
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	1,113,344	1,121,920	1,123,730	1,156,776	1,069,640
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	2,211,554	2,205,417	2,169,903	2,199,911	1,924,408
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	7,074,092	7,073,353	7,000,407	7,099,985	6,316,529
<b>Eligible members per month</b>					
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>Evidence of skin cancer in enrollment history</b>					
Enrollees with at least one day of coverage	4,847,249	4,877,682	4,907,207	4,930,152	4,629,640
<b>No evidence of skin cancer in enrollment history</b>					
Enrollees with at least one day of coverage	54,978,349	54,950,540	54,961,449	54,974,036	44,517,405
<b>Number of patients with dispensing per 1,000 eligible members</b>					
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: HCTZ-containing	57.8	57.8	57.1	58.9	57.3
Skin cancer: HCTZ single ingredient	28.9	28.7	28.5	29.6	29.2
Skin cancer: HCTZ combination	29.1	29.3	28.8	29.5	28.3

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: HCTZ-containing	36.9	36.9	36.2	36.7	39.6
No skin cancer: HCTZ single ingredient	17.8	17.7	17.4	17.8	19.6
No skin cancer: HCTZ combination	19.3	19.3	18.9	19.0	20.1
<b>Non-HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	5.8	5.8	5.9	6.0	6.0
Skin cancer: ACEIs	68.5	68.7	67.9	69.8	67.9
Skin cancer: CCBs	90.0	90.1	90.4	92.7	92.6
Skin cancer: Potassium-sparing diuretics	12.3	12.4	12.5	12.8	12.7
Skin cancer: Loop diuretics	45.8	45.4	45.2	46.5	45.9
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.3	3.3	3.3	3.4	3.7
No skin cancer: ACEIs	41.9	41.9	41.2	41.9	45.4
No skin cancer: CCBs	47.9	48.1	47.8	48.7	54.7
No skin cancer: Potassium-sparing diuretics	7.5	7.5	7.5	7.6	8.1
No skin cancer: Loop diuretics	20.2	20.0	19.7	20.1	22.9
<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: Limited denominator	63.6	63.6	62.9	64.8	63.2
Skin cancer: Full denominator	229.7	230.0	229.0	234.6	231.0
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: Limited denominator	40.2	40.1	39.5	40.0	43.2
No skin cancer: Full denominator	128.7	128.7	127.4	129.2	141.9

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

	Patients with dispensing per month				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products	217,715	223,229	8,092	8,375	8,376
HCTZ single ingredient/monotherapy	111,640	114,783	3,884	4,037	4,021
HCTZ combination products	106,865	109,316	4,238	4,367	4,386
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products	1,358,174	1,192,731	158,588	160,604	156,703
HCTZ single ingredient/monotherapy	677,962	602,988	74,625	75,512	73,720
HCTZ combination products	685,723	594,697	84,571	85,696	83,560
<b>Non-HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	23,223	24,261	670	765	745
ACEIs	258,055	264,029	9,235	9,811	9,536
CCBs	355,632	367,671	11,046	11,400	11,089
Potassium-sparing diuretics	49,627	51,496	1,498	1,534	1,526
Loop diuretics	179,390	189,383	4,368	4,442	4,489
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	129,329	118,866	13,564	13,688	13,534
ACEIs	1,571,982	1,411,442	171,065	173,045	168,548
CCBs	1,880,576	1,752,083	184,753	188,333	183,799
Potassium-sparing diuretics	288,908	249,943	37,040	38,165	37,461
Loop diuretics	791,655	787,011	56,930	58,739	57,970

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	240,688	247,225	8,751	9,132	9,114
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	894,156	914,209	29,017	30,142	29,781
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic	1,485,903	1,309,838	171,975	174,123	170,086
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive	4,940,486	4,467,176	515,765	524,497	513,401
<b>Eligible members per month</b>					
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>Evidence of skin cancer in enrollment history</b>					
Enrollees with at least one day of coverage	4,220,299	3,802,314	270,123	275,168	279,879
<b>No evidence of skin cancer in enrollment history</b>					
Enrollees with at least one day of coverage	39,596,314	25,326,949	7,990,953	8,023,788	8,046,608
<b>Number of patients with dispensing per 1,000 eligible members</b>					
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: HCTZ-containing	51.6	58.7	30.0	30.4	29.9
Skin cancer: HCTZ single ingredient	26.5	30.2	14.4	14.7	14.4
Skin cancer: HCTZ combination	25.3	28.7	15.7	15.9	15.7

Table 8b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: HCTZ-containing	34.3	47.1	19.8	20.0	19.5
No skin cancer: HCTZ single ingredient	17.1	23.8	9.3	9.4	9.2
No skin cancer: HCTZ combination	17.3	23.5	10.6	10.7	10.4
<b>Non-HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	5.5	6.4	2.5	2.8	2.7
Skin cancer: ACEIs	61.1	69.4	34.2	35.7	34.1
Skin cancer: CCBs	84.3	96.7	40.9	41.4	39.6
Skin cancer: Potassium-sparing diuretics	11.8	13.5	5.5	5.6	5.5
Skin cancer: Loop diuretics	42.5	49.8	16.2	16.1	16.0
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics	3.3	4.7	1.7	1.7	1.7
No skin cancer: ACEIs	39.7	55.7	21.4	21.6	20.9
No skin cancer: CCBs	47.5	69.2	23.1	23.5	22.8
No skin cancer: Potassium-sparing diuretics	7.3	9.9	4.6	4.8	4.7
No skin cancer: Loop diuretics	20.0	31.1	7.1	7.3	7.2
<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: Limited denominator	57.0	65.0	32.4	33.2	32.6
Skin cancer: Full denominator	211.9	240.4	107.4	109.5	106.4
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: Limited denominator	37.5	51.7	21.5	21.7	21.1
No skin cancer: Full denominator	124.8	176.4	64.5	65.4	63.8

Figure 8. Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month






Figure 8 (Continued). Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Figure 8 (Continued). Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by calendar year/month




Table 9a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and age group (years)

	Patients	Episodes	Dispensings (adjusted code count)	Eligible Members	Number of Exposed Patients per 1,000 Eligible Members
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Any HCTZ-containing products					
0-40	1,921	13,996	14,185	76,866	25.0
41-64	155,499	1,611,496	1,630,632	1,185,389	131.2
65-74	681,807	6,195,562	6,219,046	3,131,320	217.7
75-84	778,800	7,359,120	7,383,939	3,285,061	237.1
85+	334,142	3,178,508	3,190,724	1,711,313	195.3
HCTZ single ingredient/monotherapy					
0-40	1,025	6,395	6,445	76,866	13.3
41-64	76,081	647,258	651,380	1,185,389	64.2
65-74	359,025	2,724,803	2,728,336	3,131,320	114.7
75-84	436,908	3,436,816	3,441,358	3,285,061	133.0
85+	197,854	1,630,116	1,633,139	1,711,313	115.6
HCTZ combination products					
0-40	1,038	7,649	7,740	76,866	13.5
41-64	93,497	968,337	979,252	1,185,389	78.9
65-74	389,773	3,481,330	3,490,713	3,131,320	124.5
75-84	421,634	3,933,994	3,942,582	3,285,061	128.3
85+	166,353	1,553,543	1,557,585	1,711,313	97.2
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Any HCTZ-containing products					
0-40	650,415	4,722,732	4,785,142	55,380,471	11.7
41-64	4,944,864	49,973,967	50,587,407	41,806,126	118.3
65-74	6,208,162	60,074,773	60,321,377	28,657,688	216.6
75-84	3,051,425	29,114,798	29,220,248	13,191,267	231.3
85+	919,484	9,025,951	9,061,310	5,050,884	182.0

Table 9a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and age group (years)

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ single ingredient/monotherapy					
0-40	362,172	2,154,214	2,172,946	55,380,471	6.5
41-64	2,491,816	20,590,504	20,731,969	41,806,126	59.6
65-74	3,282,398	26,302,769	26,341,476	28,657,688	114.5
75-84	1,682,631	13,390,962	13,409,216	13,191,267	127.6
85+	536,280	4,574,244	4,583,958	5,050,884	106.2
HCTZ combination products					
0-40	346,073	2,579,294	2,612,194	55,380,471	6.2
41-64	2,934,422	29,508,935	29,855,439	41,806,126	70.2
65-74	3,579,209	33,881,290	33,979,908	28,657,688	124.9
75-84	1,681,232	15,773,125	15,811,031	13,191,267	127.5
85+	466,266	4,466,571	4,477,355	5,050,884	92.3
<b>Non-HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics					
0-40	203	1,220	1,244	76,866	2.6
41-64	15,046	111,146	112,117	1,185,389	12.7
65-74	78,392	505,852	506,868	3,131,320	25.0
75-84	118,248	736,050	737,670	3,285,061	36.0
85+	74,084	441,125	443,139	1,711,313	43.3
ACEIs					
0-40	2,507	19,465	19,629	76,866	32.6
41-64	178,882	1,834,321	1,849,507	1,185,389	150.9
65-74	734,728	6,750,775	6,773,456	3,131,320	234.6
75-84	877,192	8,674,922	8,705,297	3,285,061	267.0
85+	436,492	4,713,584	4,737,057	1,711,313	255.1

Table 9a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and age group (years)

<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
CCBs					
0-40	2,167	15,602	15,799	76,866	28.2
41-64	149,981	1,488,832	1,504,258	1,185,389	126.5
65-74	774,617	7,124,820	7,161,117	3,131,320	247.4
75-84	1,098,312	11,120,033	11,182,819	3,285,061	334.3
85+	652,126	7,580,283	7,639,374	1,711,313	381.1
Potassium-sparing diuretics					
0-40	2,060	14,166	14,551	76,866	26.8
41-64	30,939	267,097	270,076	1,185,389	26.1
65-74	121,493	909,845	912,018	3,131,320	38.8
75-84	189,310	1,439,749	1,442,819	3,285,061	57.6
85+	121,547	1,002,753	1,005,414	1,711,313	71.0
Loop diuretics					
0-40	789	4,165	4,233	76,866	10.3
41-64	67,692	561,562	567,239	1,185,389	57.1
65-74	361,583	2,670,091	2,688,530	3,131,320	115.5
75-84	706,971	5,826,576	5,877,654	3,285,061	215.2
85+	631,216	6,746,459	6,850,456	1,711,313	368.8
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics					
0-40	58,855	337,082	341,101	55,380,471	1.1
41-64	480,832	3,439,629	3,470,093	41,806,126	11.5
65-74	697,663	4,751,211	4,762,093	28,657,688	24.3
75-84	436,429	2,829,310	2,836,924	13,191,267	33.1
85+	178,653	1,162,182	1,167,588	5,050,884	35.4

Table 9a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and age group (years)

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
ACEIs					
0-40	806,846	6,031,540	6,097,338	55,380,471	14.6
41-64	5,472,029	54,668,047	55,131,569	41,806,126	130.9
65-74	6,696,017	65,014,400	65,234,821	28,657,688	233.7
75-84	3,457,028	34,652,156	34,781,926	13,191,267	262.1
85+	1,235,196	13,824,951	13,898,788	5,050,884	244.6
CCBs					
0-40	680,794	4,594,694	4,657,283	55,380,471	12.3
41-64	4,614,438	45,230,358	45,705,554	41,806,126	110.4
65-74	6,877,020	67,707,896	68,076,062	28,657,688	240.0
75-84	4,345,587	45,505,745	45,779,039	13,191,267	329.4
85+	1,869,306	22,727,362	22,902,892	5,050,884	370.1
Potassium-sparing diuretics					
0-40	609,478	3,750,747	3,838,934	55,380,471	11.0
41-64	891,524	7,323,336	7,403,535	41,806,126	21.3
65-74	1,047,939	8,205,104	8,227,103	28,657,688	36.6
75-84	670,266	5,205,557	5,217,543	13,191,267	50.8
85+	285,231	2,446,334	2,453,249	5,050,884	56.5
Loop diuretics					
0-40	195,714	1,093,529	1,105,766	55,380,471	3.5
41-64	2,022,337	17,224,981	17,414,255	41,806,126	48.4
65-74	3,260,881	27,094,915	27,327,187	28,657,688	113.8
75-84	2,708,836	24,728,245	24,990,463	13,191,267	205.4
85+	1,655,254	19,277,564	19,591,956	5,050,884	327.7

Table 9a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and age group (years)

<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
0-40	2,085	15,216	15,429	76,866	27.1
41-64	167,435	1,722,034	1,742,748	1,185,389	141.2
65-74	742,648	6,699,210	6,725,914	3,131,320	237.2
75-84	870,943	8,091,949	8,121,609	3,285,061	265.1
85+	395,733	3,617,428	3,633,863	1,711,313	231.2
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
0-40	7,664	64,209	69,641	76,866	99.7
41-64	402,921	5,241,545	5,933,770	1,185,389	339.9
65-74	1,699,421	21,590,180	24,260,904	3,131,320	542.7
75-84	2,152,044	31,374,256	35,329,946	3,285,061	655.1
85+	1,241,545	20,789,090	23,865,896	1,711,313	725.5
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
0-40	696,767	5,058,216	5,126,243	55,380,471	12.6
41-64	5,314,559	53,387,240	54,057,501	41,806,126	127.1
65-74	6,740,684	64,797,973	65,083,470	28,657,688	235.2
75-84	3,391,749	31,926,693	32,057,172	13,191,267	257.1
85+	1,067,799	10,180,049	10,228,897	5,050,884	211.4

Table 9a. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer and age group (years)

<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>					
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
0-40	2,357,027	18,853,438	20,825,602	55,380,471	42.6
41-64	12,118,140	155,757,419	179,712,789	41,806,126	289.9
65-74	15,106,226	204,598,558	233,948,291	28,657,688	527.1
75-84	8,421,100	124,791,795	142,825,692	13,191,267	638.4
85+	3,469,601	59,446,287	69,075,359	5,050,884	686.9



Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	245	243	268	245	260	269	256	281
41-64	25,777	24,638	27,270	26,188	27,931	27,923	27,716	28,541
65-74	97,345	87,646	98,121	93,271	99,852	97,964	98,254	99,676
75-84	104,962	94,395	105,855	101,220	108,342	106,934	107,354	109,068
85+	48,955	44,266	49,217	46,882	49,949	48,855	49,244	50,229
HCTZ single ingredient/monotherapy								
0-40	109	96	113	96	97	113	104	117
41-64	9,072	8,737	9,658	9,358	9,930	9,978	9,962	10,286
65-74	38,049	34,199	38,311	36,544	39,062	38,447	38,665	39,503
75-84	43,791	39,345	44,361	42,482	45,530	45,108	45,286	46,027
85+	22,701	20,552	22,946	21,819	23,324	22,977	23,067	23,585
HCTZ combination products								
0-40	137	147	156	150	164	157	152	164
41-64	16,855	16,023	17,776	16,962	18,168	18,107	17,919	18,418
65-74	59,678	53,835	60,264	57,088	61,212	59,959	59,999	60,617
75-84	61,610	55,432	61,943	59,160	63,268	62,264	62,522	63,513
85+	26,428	23,895	26,470	25,237	26,815	26,117	26,361	26,859
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	92,054	87,902	96,381	90,012	94,169	92,461	89,904	91,617
41-64	977,306	926,909	1,008,760	951,546	995,437	975,219	960,225	975,903
65-74	1,052,570	955,015	1,051,205	989,145	1,048,717	1,020,006	1,016,575	1,029,038
75-84	516,403	466,509	513,164	482,728	512,317	497,351	494,811	498,221
85+	174,526	158,862	171,914	162,538	170,617	165,662	164,986	165,100

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ single ingredient/monotherapy								
0-40	37,223	35,649	39,407	37,052	38,794	38,298	37,397	38,067
41-64	356,145	337,352	368,773	348,777	366,259	359,567	355,422	361,753
65-74	408,023	370,530	407,573	385,178	409,022	398,760	398,676	403,560
75-84	211,495	191,311	210,878	198,136	211,423	205,324	205,123	206,769
85+	80,109	73,253	78,852	75,200	79,065	76,950	76,856	76,749
HCTZ combination products								
0-40	137	147	156	150	164	157	152	164
41-64	16,855	16,023	17,776	16,962	18,168	18,107	17,919	18,418
65-74	59,678	53,835	60,264	57,088	61,212	59,959	59,999	60,617
75-84	61,610	55,432	61,943	59,160	63,268	62,264	62,522	63,513
85+	26,428	23,895	26,470	25,237	26,815	26,117	26,361	26,859
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	259	260	288	264	276	293	282	311
41-64	27,125	25,914	28,731	27,601	29,388	29,425	29,231	30,096
65-74	103,819	93,513	104,843	99,631	106,695	104,694	104,870	106,471
75-84	113,854	102,483	115,019	109,989	117,692	116,311	116,585	118,486
85+	54,710	49,585	55,117	52,523	56,035	54,741	55,128	56,235
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	955	899	1,030	970	1,014	1,060	1,006	1,087
41-64	74,295	71,344	77,781	75,208	79,798	79,219	79,131	81,197
65-74	291,622	267,488	295,735	283,765	301,304	296,862	298,197	302,829
75-84	377,396	347,029	382,581	368,811	392,222	387,904	390,352	397,521
85+	252,577	234,796	255,150	246,924	260,184	256,858	259,220	264,053

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	96,857	92,406	101,544	94,938	99,186	97,499	94,854	96,628
41-64	1,028,508	974,740	1,062,141	1,002,487	1,048,763	1,028,306	1,012,451	1,029,528
65-74	1,118,818	1,014,852	1,118,481	1,053,221	1,116,080	1,086,960	1,083,090	1,096,295
75-84	557,641	503,876	555,279	522,437	554,196	538,929	535,552	539,549
85+	192,943	175,883	190,508	180,292	189,115	183,967	183,024	183,237
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	303,980	290,614	318,316	299,560	313,359	307,957	301,838	309,655
41-64	2,626,222	2,501,161	2,705,017	2,563,185	2,675,154	2,625,898	2,590,329	2,635,990
65-74	3,043,774	2,798,916	3,052,358	2,895,269	3,050,764	2,980,916	2,974,313	3,013,866
75-84	1,833,462	1,686,717	1,831,264	1,738,401	1,827,898	1,787,758	1,779,989	1,796,600
85+	900,147	836,637	890,130	851,129	884,672	865,583	862,596	866,936
<b>Eligible members per month</b>								
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage								
0-40	24,381	24,669	25,193	25,410	25,824	26,168	26,145	26,497
41-64	450,030	455,630	462,913	467,779	475,079	481,574	483,171	490,904
65-74	1,205,898	1,216,845	1,231,518	1,241,576	1,257,343	1,271,936	1,282,826	1,299,101
75-84	1,259,130	1,272,235	1,289,360	1,302,724	1,320,763	1,337,640	1,354,287	1,375,145
85+	697,159	701,828	709,040	714,006	721,647	729,238	736,560	746,229

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Enrollees with at least one day of coverage								
0-40	21,435,383	21,391,126	21,389,225	21,342,682	21,319,791	21,304,553	21,231,875	21,249,461
41-64	17,032,573	16,992,598	16,992,625	16,940,935	16,896,103	16,876,621	16,828,680	16,816,026
65-74	12,192,876	12,199,413	12,217,989	12,217,022	12,210,663	12,222,439	12,308,389	12,335,036
75-84	5,863,899	5,855,775	5,860,555	5,854,419	5,850,944	5,848,781	5,871,788	5,882,080
85+	2,414,391	2,399,616	2,392,126	2,378,010	2,367,912	2,360,477	2,361,203	2,357,707

	<b>Number of patients with dispensing per 1,000 eligible members</b>							
	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing								
0-40: Skin cancer, HCTZ-containing	10.0	9.9	10.6	9.6	10.1	10.3	9.8	10.6
41-64: Skin cancer, HCTZ-containing	57.3	54.1	58.9	56.0	58.8	58.0	57.4	58.1
65-74: Skin cancer, HCTZ-containing	80.7	72.0	79.7	75.1	79.4	77.0	76.6	76.7
75-84: Skin cancer, HCTZ-containing	83.4	74.2	82.1	77.7	82.0	79.9	79.3	79.3
85+: Skin cancer, HCTZ-containing	70.2	63.1	69.4	65.7	69.2	67.0	66.9	67.3
Skin cancer: HCTZ single ingredient								
0-40: Skin cancer, HCTZ single ingredient	4.5	3.9	4.5	3.8	3.8	4.3	4.0	4.4
41-64: Skin cancer, HCTZ single ingredient	20.2	19.2	20.9	20.0	20.9	20.7	20.6	21.0
65-74: Skin cancer, HCTZ single ingredient	31.6	28.1	31.1	29.4	31.1	30.2	30.1	30.4
75-84: Skin cancer, HCTZ single ingredient	34.8	30.9	34.4	32.6	34.5	33.7	33.4	33.5
85+: Skin cancer, HCTZ single ingredient	32.6	29.3	32.4	30.6	32.3	31.5	31.3	31.6
Skin cancer: HCTZ combination								
0-40: Skin cancer, HCTZ combination	5.6	6.0	6.2	5.9	6.4	6.0	5.8	6.2
41-64: Skin cancer, HCTZ combination	37.5	35.2	38.4	36.3	38.2	37.6	37.1	37.5
65-74: Skin cancer, HCTZ combination	49.5	44.2	48.9	46.0	48.7	47.1	46.8	46.7
75-84: Skin cancer, HCTZ combination	48.9	43.6	48.0	45.4	47.9	46.5	46.2	46.2
85+: Skin cancer, HCTZ combination	37.9	34.0	37.3	35.3	37.2	35.8	35.8	36.0

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing								
<i>0-40: No skin cancer, HCTZ-containing</i>	4.3	4.1	4.5	4.2	4.4	4.3	4.2	4.3
<i>41-64: No skin cancer, HCTZ-containing</i>	57.4	54.5	59.4	56.2	58.9	57.8	57.1	58.0
<i>65-74: No skin cancer, HCTZ-containing</i>	86.3	78.3	86.0	81.0	85.9	83.5	82.6	83.4
<i>75-84: No skin cancer, HCTZ-containing</i>	88.1	79.7	87.6	82.5	87.6	85.0	84.3	84.7
<i>85+: No skin cancer, HCTZ-containing</i>	72.3	66.2	71.9	68.4	72.1	70.2	69.9	70.0
No skin cancer: HCTZ single ingredient								
<i>0-40: No skin cancer, HCTZ single ingredient</i>	1.7	1.7	1.8	1.7	1.8	1.8	1.8	1.8
<i>41-64: No skin cancer, HCTZ single ingredient</i>	20.9	19.9	21.7	20.6	21.7	21.3	21.1	21.5
<i>65-74: No skin cancer, HCTZ single ingredient</i>	33.5	30.4	33.4	31.5	33.5	32.6	32.4	32.7
<i>75-84: No skin cancer, HCTZ single ingredient</i>	36.1	32.7	36.0	33.8	36.1	35.1	34.9	35.2
<i>85+: No skin cancer, HCTZ single ingredient</i>	33.2	30.5	33.0	31.6	33.4	32.6	32.5	32.6
No skin cancer: HCTZ combination								
<i>0-40: No skin cancer, HCTZ combination</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>41-64: No skin cancer, HCTZ combination</i>	1.0	0.9	1.0	1.0	1.1	1.1	1.1	1.1
<i>65-74: No skin cancer, HCTZ combination</i>	4.9	4.4	4.9	4.7	5.0	4.9	4.9	4.9
<i>75-84: No skin cancer, HCTZ combination</i>	10.5	9.5	10.6	10.1	10.8	10.6	10.6	10.8
<i>85+: No skin cancer, HCTZ combination</i>	10.9	10.0	11.1	10.6	11.3	11.1	11.2	11.4
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Limited denominator								
<i>0-40: Skin cancer, limited denominator</i>	10.6	10.5	11.4	10.4	10.7	11.2	10.8	11.7
<i>41-64: Skin cancer, limited denominator</i>	60.3	56.9	62.1	59.0	61.9	61.1	60.5	61.3
<i>65-74: Skin cancer, limited denominator</i>	86.1	76.8	85.1	80.2	84.9	82.3	81.7	82.0
<i>75-84: Skin cancer, limited denominator</i>	90.4	80.6	89.2	84.4	89.1	87.0	86.1	86.2
<i>85+: Skin cancer, limited denominator</i>	78.5	70.7	77.7	73.6	77.6	75.1	74.8	75.4

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Full denominator								
<i>0-40: Skin cancer, full denominator</i>	39.2	36.4	40.9	38.2	39.3	40.5	38.5	41.0
<i>41-64: Skin cancer, full denominator</i>	165.1	156.6	168.0	160.8	168.0	164.5	163.8	165.4
<i>65-74: Skin cancer, full denominator</i>	241.8	219.8	240.1	228.6	239.6	233.4	232.5	233.1
<i>75-84: Skin cancer, full denominator</i>	299.7	272.8	296.7	283.1	297.0	290.0	288.2	289.1
<i>85+: Skin cancer, full denominator</i>	362.3	334.5	359.9	345.8	360.5	352.2	351.9	353.8
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Limited denominator								
<i>0-40: No skin cancer, limited denominator</i>	4.5	4.3	4.7	4.4	4.7	4.6	4.5	4.5
<i>41-64: No skin cancer, limited denominator</i>	60.4	57.4	62.5	59.2	62.1	60.9	60.2	61.2
<i>65-74: No skin cancer, limited denominator</i>	91.8	83.2	91.5	86.2	91.4	88.9	88.0	88.9
<i>75-84: No skin cancer, limited denominator</i>	95.1	86.0	94.7	89.2	94.7	92.1	91.2	91.7
<i>85+: No skin cancer, limited denominator</i>	79.9	73.3	79.6	75.8	79.9	77.9	77.5	77.7
No skin cancer: Full denominator								
<i>0-40: No skin cancer, full denominator</i>	14.2	13.6	14.9	14.0	14.7	14.5	14.2	14.6
<i>41-64: No skin cancer, full denominator</i>	154.2	147.2	159.2	151.3	158.3	155.6	153.9	156.8
<i>65-74: No skin cancer, full denominator</i>	249.6	229.4	249.8	237.0	249.8	243.9	241.6	244.3
<i>75-84: No skin cancer, full denominator</i>	312.7	288.0	312.5	296.9	312.4	305.7	303.1	305.4
<i>85+: No skin cancer, full denominator</i>	372.8	348.7	372.1	357.9	373.6	366.7	365.3	367.7

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	259	283	274	257	244	224	243	237
41-64	27,548	28,765	28,557	29,003	26,682	25,026	26,993	26,446
65-74	95,927	101,799	97,713	100,316	101,032	89,570	97,799	98,824
75-84	105,209	112,622	108,604	111,106	114,420	101,569	111,932	112,726
85+	48,129	50,819	49,022	49,308	50,505	45,580	49,006	49,492
HCTZ single ingredient/monotherapy								
0-40	106	111	110	104	108	90	101	101
41-64	9,954	10,337	10,300	10,511	9,599	9,053	9,758	9,612
65-74	37,716	40,348	38,434	39,594	39,901	35,397	38,608	39,192
75-84	44,355	47,354	45,959	46,791	48,402	43,188	47,152	47,694
85+	22,741	23,774	22,999	23,390	23,715	21,538	23,358	23,266
HCTZ combination products								
0-40	153	172	166	153	138	137	143	139
41-64	17,759	18,581	18,411	18,635	17,226	16,101	17,380	16,973
65-74	58,645	61,868	59,706	61,138	61,558	54,524	59,636	60,020
75-84	61,273	65,700	63,079	64,782	66,495	58,837	65,264	65,476
85+	25,570	27,249	26,215	26,120	27,006	24,218	25,847	26,424
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	85,830	87,668	85,557	85,015	84,025	80,516	86,343	83,747
41-64	918,581	948,158	920,516	922,725	892,510	839,990	896,317	871,096
65-74	976,286	1,025,311	980,415	983,780	1,019,850	914,907	988,651	981,941
75-84	475,264	497,375	476,708	478,765	496,415	443,433	480,237	478,194
85+	157,416	163,156	156,173	153,738	158,794	143,278	152,165	151,124

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ single ingredient/monotherapy								
0-40	35,651	36,638	35,597	35,170	35,080	33,788	36,197	35,149
41-64	341,068	352,907	342,118	341,633	332,198	312,310	334,352	325,010
65-74	382,959	402,613	384,626	385,948	401,561	360,075	389,277	388,127
75-84	197,052	206,491	197,723	197,869	207,003	184,889	200,005	199,953
85+	73,299	75,793	72,737	71,587	74,042	67,043	70,856	70,916
HCTZ combination products								
0-40	153	172	166	153	138	137	143	139
41-64	17,759	18,581	18,411	18,635	17,226	16,101	17,380	16,973
65-74	58,645	61,868	59,706	61,138	61,558	54,524	59,636	60,020
75-84	61,273	65,700	63,079	64,782	66,495	58,837	65,264	65,476
85+	25,570	27,249	26,215	26,120	27,006	24,218	25,847	26,424
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	284	306	299	284	265	240	263	253
41-64	29,050	30,374	30,124	30,672	28,137	26,544	28,675	28,087
65-74	102,535	108,701	104,522	107,435	108,148	96,175	105,148	106,109
75-84	114,378	122,261	118,146	120,880	124,605	110,831	122,280	123,219
85+	53,935	56,983	55,002	55,302	56,730	51,429	55,328	55,835
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	1,016	1,093	1,046	1,063	973	954	1,012	996
41-64	78,820	82,266	81,472	82,982	76,787	72,622	78,418	77,074
65-74	292,908	309,607	299,738	305,993	307,194	278,122	301,588	303,062
75-84	386,787	409,891	398,715	405,783	415,462	377,897	410,970	414,538
85+	256,930	269,906	262,670	264,504	269,104	248,580	264,973	265,920



Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	90,647	92,513	90,355	89,906	88,921	85,298	91,663	88,880
41-64	969,420	1,000,699	972,381	975,283	943,877	889,281	949,720	924,185
65-74	1,040,955	1,093,537	1,046,643	1,050,831	1,089,897	979,084	1,059,001	1,052,693
75-84	515,057	538,670	517,278	519,485	538,646	481,992	522,856	520,464
85+	174,745	181,078	173,353	171,075	176,789	159,655	169,959	168,807
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	291,631	300,700	295,412	294,629	294,055	281,214	300,694	292,620
41-64	2,497,929	2,576,245	2,514,431	2,516,411	2,451,958	2,322,313	2,462,716	2,402,834
65-74	2,883,607	3,011,726	2,901,184	2,907,827	3,003,108	2,737,560	2,936,997	2,918,646
75-84	1,728,712	1,797,053	1,736,052	1,741,356	1,792,616	1,638,138	1,752,066	1,745,312
85+	834,992	859,391	830,658	823,729	840,470	775,932	815,957	808,191
<b>Eligible members per month</b>								
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage								
0-40	26,635	26,815	27,044	27,049	25,098	25,417	25,765	25,908
41-64	494,009	499,134	504,292	506,044	470,026	474,157	479,171	482,962
65-74	1,309,494	1,323,399	1,332,812	1,337,665	1,310,688	1,317,243	1,327,691	1,336,877
75-84	1,393,013	1,414,430	1,431,828	1,446,373	1,425,820	1,439,066	1,456,342	1,471,772
85+	754,099	762,833	769,053	773,657	760,457	762,098	767,623	772,184

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Enrollees with at least one day of coverage								
0-40	21,018,548	20,993,927	20,989,428	20,975,877	20,707,599	20,634,918	20,605,132	20,550,666
41-64	16,616,327	16,584,489	16,559,702	16,537,305	16,167,387	16,109,975	16,088,798	16,029,741
65-74	12,345,400	12,358,141	12,345,347	12,343,130	12,452,896	12,449,997	12,463,942	12,453,026
75-84	5,890,643	5,908,036	5,911,870	5,926,141	5,934,125	5,931,306	5,945,575	5,947,842
85+	2,351,722	2,348,163	2,337,945	2,331,034	2,319,122	2,298,982	2,291,892	2,281,039
	<b>Number of patients with dispensing per 1,000 eligible members</b>							
	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Apr-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing								
0-40: Skin cancer, HCTZ-containing	9.7	10.6	10.1	9.5	9.7	8.8	9.4	9.1
41-64: Skin cancer, HCTZ-containing	55.8	57.6	56.6	57.3	56.8	52.8	56.3	54.8
65-74: Skin cancer, HCTZ-containing	73.3	76.9	73.3	75.0	77.1	68.0	73.7	73.9
75-84: Skin cancer, HCTZ-containing	75.5	79.6	75.8	76.8	80.2	70.6	76.9	76.6
85+: Skin cancer, HCTZ-containing	63.8	66.6	63.7	63.7	66.4	59.8	63.8	64.1
Skin cancer: HCTZ single ingredient								
0-40: Skin cancer, HCTZ single ingredient	4.0	4.1	4.1	3.8	4.3	3.5	3.9	3.9
41-64: Skin cancer, HCTZ single ingredient	20.1	20.7	20.4	20.8	20.4	19.1	20.4	19.9
65-74: Skin cancer, HCTZ single ingredient	28.8	30.5	28.8	29.6	30.4	26.9	29.1	29.3
75-84: Skin cancer, HCTZ single ingredient	31.8	33.5	32.1	32.4	33.9	30.0	32.4	32.4
85+: Skin cancer, HCTZ single ingredient	30.2	31.2	29.9	30.2	31.2	28.3	30.4	30.1
Skin cancer: HCTZ combination								
0-40: Skin cancer, HCTZ combination	5.7	6.4	6.1	5.7	5.5	5.4	5.6	5.4
41-64: Skin cancer, HCTZ combination	35.9	37.2	36.5	36.8	36.6	34.0	36.3	35.1
65-74: Skin cancer, HCTZ combination	44.8	46.7	44.8	45.7	47.0	41.4	44.9	44.9
75-84: Skin cancer, HCTZ combination	44.0	46.4	44.1	44.8	46.6	40.9	44.8	44.5
85+: Skin cancer, HCTZ combination	33.9	35.7	34.1	33.8	35.5	31.8	33.7	34.2

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing								
0-40: No skin cancer, HCTZ-containing	4.1	4.2	4.1	4.1	4.1	3.9	4.2	4.1
41-64: No skin cancer, HCTZ-containing	55.3	57.2	55.6	55.8	55.2	52.1	55.7	54.3
65-74: No skin cancer, HCTZ-containing	79.1	83.0	79.4	79.7	81.9	73.5	79.3	78.9
75-84: No skin cancer, HCTZ-containing	80.7	84.2	80.6	80.8	83.7	74.8	80.8	80.4
85+: No skin cancer, HCTZ-containing	66.9	69.5	66.8	66.0	68.5	62.3	66.4	66.3
No skin cancer: HCTZ single ingredient								
0-40: No skin cancer, HCTZ single ingredient	1.7	1.7	1.7	1.7	1.7	1.6	1.8	1.7
41-64: No skin cancer, HCTZ single ingredient	20.5	21.3	20.7	20.7	20.5	19.4	20.8	20.3
65-74: No skin cancer, HCTZ single ingredient	31.0	32.6	31.2	31.3	32.2	28.9	31.2	31.2
75-84: No skin cancer, HCTZ single ingredient	33.5	35.0	33.4	33.4	34.9	31.2	33.6	33.6
85+: No skin cancer, HCTZ single ingredient	31.2	32.3	31.1	30.7	31.9	29.2	30.9	31.1
No skin cancer: HCTZ combination								
0-40: No skin cancer, HCTZ combination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
41-64: No skin cancer, HCTZ combination	1.1	1.1	1.1	1.1	1.1	1.0	1.1	1.1
65-74: No skin cancer, HCTZ combination	4.8	5.0	4.8	5.0	4.9	4.4	4.8	4.8
75-84: No skin cancer, HCTZ combination	10.4	11.1	10.7	10.9	11.2	9.9	11.0	11.0
85+: No skin cancer, HCTZ combination	10.9	11.6	11.2	11.2	11.6	10.5	11.3	11.6
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Limited denominator								
0-40: Skin cancer, limited denominator	10.7	11.4	11.1	10.5	10.6	9.4	10.2	9.8
41-64: Skin cancer, limited denominator	58.8	60.9	59.7	60.6	59.9	56.0	59.8	58.2
65-74: Skin cancer, limited denominator	78.3	82.1	78.4	80.3	82.5	73.0	79.2	79.4
75-84: Skin cancer, limited denominator	82.1	86.4	82.5	83.6	87.4	77.0	84.0	83.7
85+: Skin cancer, limited denominator	71.5	74.7	71.5	71.5	74.6	67.5	72.1	72.3

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Full denominator								
<i>0-40: Skin cancer, full denominator</i>	38.1	40.8	38.7	39.3	38.8	37.5	39.3	38.4
<i>41-64: Skin cancer, full denominator</i>	159.6	164.8	161.6	164.0	163.4	153.2	163.7	159.6
<i>65-74: Skin cancer, full denominator</i>	223.7	233.9	224.9	228.8	234.4	211.1	227.2	226.7
<i>75-84: Skin cancer, full denominator</i>	277.7	289.8	278.5	280.6	291.4	262.6	282.2	281.7
<i>85+: Skin cancer, full denominator</i>	340.7	353.8	341.5	341.9	353.9	326.2	345.2	344.4
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Limited denominator								
<i>0-40: No skin cancer, limited denominator</i>	4.3	4.4	4.3	4.3	4.3	4.1	4.4	4.3
<i>41-64: No skin cancer, limited denominator</i>	58.3	60.3	58.7	59.0	58.4	55.2	59.0	57.7
<i>65-74: No skin cancer, limited denominator</i>	84.3	88.5	84.8	85.1	87.5	78.6	85.0	84.5
<i>75-84: No skin cancer, limited denominator</i>	87.4	91.2	87.5	87.7	90.8	81.3	87.9	87.5
<i>85+: No skin cancer, limited denominator</i>	74.3	77.1	74.1	73.4	76.2	69.4	74.2	74.0
No skin cancer: Full denominator								
<i>0-40: No skin cancer, full denominator</i>	13.9	14.3	14.1	14.0	14.2	13.6	14.6	14.2
<i>41-64: No skin cancer, full denominator</i>	150.3	155.3	151.8	152.2	151.7	144.2	153.1	149.9
<i>65-74: No skin cancer, full denominator</i>	233.6	243.7	235.0	235.6	241.2	219.9	235.6	234.4
<i>75-84: No skin cancer, full denominator</i>	293.5	304.2	293.7	293.8	302.1	276.2	294.7	293.4
<i>85+: No skin cancer, full denominator</i>	355.1	366.0	355.3	353.4	362.4	337.5	356.0	354.3

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	248	236	241	236	227	221	232	233
41-64	27,370	26,773	27,083	27,789	26,385	28,172	27,198	27,550
65-74	99,510	96,368	102,279	100,978	93,543	104,918	97,852	98,595
75-84	114,146	111,291	118,466	118,053	109,128	122,996	114,619	115,951
85+	49,978	48,342	51,356	50,855	46,944	52,071	48,821	48,953
HCTZ single ingredient/monotherapy								
0-40	118	103	103	111	97	87	105	96
41-64	9,947	9,852	9,899	10,221	9,709	10,253	10,055	10,149
65-74	39,898	38,544	40,274	40,245	37,827	41,284	39,580	39,820
75-84	48,722	47,349	49,891	50,043	47,061	51,892	49,149	50,093
85+	23,791	23,078	24,141	24,154	22,638	24,590	23,194	23,658
HCTZ combination products								
0-40	133	134	141	128	133	138	128	141
41-64	17,570	17,074	17,339	17,760	16,806	18,069	17,296	17,539
65-74	60,047	58,261	62,520	61,258	56,164	64,079	58,711	59,206
75-84	65,929	64,416	69,201	68,607	62,515	71,627	65,958	66,316
85+	26,398	25,459	27,441	26,922	24,487	27,708	25,809	25,492
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	84,865	81,311	80,747	82,378	76,503	80,631	76,615	75,041
41-64	883,799	850,592	857,865	868,249	806,045	857,210	816,017	809,625
65-74	986,061	949,092	993,393	989,925	905,839	999,085	930,174	926,941
75-84	481,288	463,327	485,850	481,811	441,066	488,061	451,940	450,804
85+	152,243	146,161	151,702	149,731	137,437	148,865	138,909	137,492

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ single ingredient/monotherapy								
0-40	35,915	34,329	34,405	34,920	32,559	34,338	32,736	31,974
41-64	332,201	320,414	323,157	328,088	305,799	323,406	308,948	307,039
65-74	392,059	378,545	391,626	393,226	363,414	395,273	372,825	372,450
75-84	202,290	195,153	202,281	202,323	187,787	203,694	190,949	191,688
85+	71,934	68,813	71,232	70,480	65,429	69,946	65,678	65,595
HCTZ combination products								
0-40	133	134	141	128	133	138	128	141
41-64	17,570	17,074	17,339	17,760	16,806	18,069	17,296	17,539
65-74	60,047	58,261	62,520	61,258	56,164	64,079	58,711	59,206
75-84	65,929	64,416	69,201	68,607	62,515	71,627	65,958	66,316
85+	26,398	25,459	27,441	26,922	24,487	27,708	25,809	25,492
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	259	255	254	249	249	234	249	247
41-64	29,129	28,450	28,805	29,520	28,086	30,009	28,976	29,400
65-74	107,089	103,766	109,918	108,675	100,947	112,858	105,567	106,501
75-84	124,863	121,827	129,222	128,945	119,473	134,471	125,628	127,302
85+	56,587	54,696	57,797	57,465	53,129	58,703	55,303	55,547
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	991	1,004	966	982	964	1,015	973	972
41-64	79,347	77,322	78,426	80,158	76,494	81,586	79,510	80,190
65-74	306,615	298,501	309,994	310,366	293,313	319,936	305,350	308,628
75-84	420,740	412,025	428,866	431,711	411,067	448,539	428,739	435,893
85+	270,422	264,075	272,883	275,056	261,520	280,490	270,253	271,434

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	90,214	86,486	85,975	87,694	81,444	85,977	81,838	80,168
41-64	938,123	903,898	911,077	922,751	857,525	911,981	869,042	862,724
65-74	1,058,145	1,019,313	1,064,907	1,061,916	973,576	1,072,295	999,952	997,939
75-84	524,963	505,711	528,770	525,012	481,622	532,028	493,781	492,960
85+	170,517	163,574	169,401	167,611	154,295	166,863	156,084	154,761
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	297,524	285,970	287,320	293,016	273,996	290,367	279,554	275,875
41-64	2,436,368	2,354,064	2,373,479	2,404,256	2,250,653	2,381,471	2,287,381	2,274,004
65-74	2,934,150	2,839,613	2,931,438	2,935,388	2,744,499	2,963,443	2,810,533	2,809,533
75-84	1,760,069	1,706,667	1,755,212	1,754,814	1,649,191	1,775,343	1,684,025	1,682,658
85+	813,539	789,172	804,677	802,625	759,562	801,254	765,341	760,944
<b>Eligible members per month</b>								
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage								
0-40	26,256	26,441	26,469	26,829	26,831	26,959	27,099	27,094
41-64	488,823	493,141	495,595	501,502	504,678	509,324	513,005	514,098
65-74	1,349,914	1,360,684	1,369,292	1,382,946	1,392,365	1,407,225	1,416,145	1,421,641
75-84	1,490,022	1,506,864	1,523,349	1,543,364	1,560,221	1,580,586	1,595,474	1,607,800
85+	778,361	784,060	790,075	797,983	803,703	810,872	815,326	819,005

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Enrollees with at least one day of coverage								
<i>0-40</i>	20,529,238	20,513,893	20,466,826	20,504,462	20,510,987	20,495,841	20,466,194	20,433,412
<i>41-64</i>	15,996,414	15,982,731	15,951,438	15,938,126	15,919,176	15,892,901	15,860,933	15,831,936
<i>65-74</i>	12,446,061	12,459,717	12,504,550	12,533,433	12,561,084	12,578,783	12,579,568	12,588,887
<i>75-84</i>	5,949,007	5,953,814	5,966,399	5,978,997	5,987,627	5,998,241	5,996,883	6,003,940
<i>85+</i>	2,271,245	2,263,533	2,258,922	2,254,825	2,248,455	2,243,360	2,234,090	2,228,138
	<b>Number of patients with dispensing per 1,000 eligible members</b>							
	May-18	Jun-18	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing								
<i>0-40: Skin cancer, HCTZ-containing</i>	9.4	8.9	9.1	8.8	8.5	8.2	8.6	8.6
<i>41-64: Skin cancer, HCTZ-containing</i>	56.0	54.3	54.6	55.4	52.3	55.3	53.0	53.6
<i>65-74: Skin cancer, HCTZ-containing</i>	73.7	70.8	74.7	73.0	67.2	74.6	69.1	69.4
<i>75-84: Skin cancer, HCTZ-containing</i>	76.6	73.9	77.8	76.5	69.9	77.8	71.8	72.1
<i>85+: Skin cancer, HCTZ-containing</i>	64.2	61.7	65.0	63.7	58.4	64.2	59.9	59.8
Skin cancer: HCTZ single ingredient								
<i>0-40: Skin cancer, HCTZ single ingredient</i>	4.5	3.9	3.9	4.1	3.6	3.2	3.9	3.5
<i>41-64: Skin cancer, HCTZ single ingredient</i>	20.3	20.0	20.0	20.4	19.2	20.1	19.6	19.7
<i>65-74: Skin cancer, HCTZ single ingredient</i>	29.6	28.3	29.4	29.1	27.2	29.3	27.9	28.0
<i>75-84: Skin cancer, HCTZ single ingredient</i>	32.7	31.4	32.8	32.4	30.2	32.8	30.8	31.2
<i>85+: Skin cancer, HCTZ single ingredient</i>	30.6	29.4	30.6	30.3	28.2	30.3	28.4	28.9
Skin cancer: HCTZ combination								
<i>0-40: Skin cancer, HCTZ combination</i>	5.1	5.1	5.3	4.8	5.0	5.1	4.7	5.2
<i>41-64: Skin cancer, HCTZ combination</i>	35.9	34.6	35.0	35.4	33.3	35.5	33.7	34.1
<i>65-74: Skin cancer, HCTZ combination</i>	44.5	42.8	45.7	44.3	40.3	45.5	41.5	41.6
<i>75-84: Skin cancer, HCTZ combination</i>	44.2	42.7	45.4	44.5	40.1	45.3	41.3	41.2
<i>85+: Skin cancer, HCTZ combination</i>	33.9	32.5	34.7	33.7	30.5	34.2	31.7	31.1



Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing								
<i>0-40: No skin cancer, HCTZ-containing</i>	4.1	4.0	3.9	4.0	3.7	3.9	3.7	3.7
<i>41-64: No skin cancer, HCTZ-containing</i>	55.2	53.2	53.8	54.5	50.6	53.9	51.4	51.1
<i>65-74: No skin cancer, HCTZ-containing</i>	79.2	76.2	79.4	79.0	72.1	79.4	73.9	73.6
<i>75-84: No skin cancer, HCTZ-containing</i>	80.9	77.8	81.4	80.6	73.7	81.4	75.4	75.1
<i>85+: No skin cancer, HCTZ-containing</i>	67.0	64.6	67.2	66.4	61.1	66.4	62.2	61.7
No skin cancer: HCTZ single ingredient								
<i>0-40: No skin cancer, HCTZ single ingredient</i>	1.7	1.7	1.7	1.7	1.6	1.7	1.6	1.6
<i>41-64: No skin cancer, HCTZ single ingredient</i>	20.8	20.0	20.3	20.6	19.2	20.3	19.5	19.4
<i>65-74: No skin cancer, HCTZ single ingredient</i>	31.5	30.4	31.3	31.4	28.9	31.4	29.6	29.6
<i>75-84: No skin cancer, HCTZ single ingredient</i>	34.0	32.8	33.9	33.8	31.4	34.0	31.8	31.9
<i>85+: No skin cancer, HCTZ single ingredient</i>	31.7	30.4	31.5	31.3	29.1	31.2	29.4	29.4
No skin cancer: HCTZ combination								
<i>0-40: No skin cancer, HCTZ combination</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>41-64: No skin cancer, HCTZ combination</i>	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
<i>65-74: No skin cancer, HCTZ combination</i>	4.8	4.7	5.0	4.9	4.5	5.1	4.7	4.7
<i>75-84: No skin cancer, HCTZ combination</i>	11.1	10.8	11.6	11.5	10.4	11.9	11.0	11.0
<i>85+: No skin cancer, HCTZ combination</i>	11.6	11.2	12.1	11.9	10.9	12.4	11.6	11.4
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Limited denominator								
<i>0-40: Skin cancer, limited denominator</i>	9.9	9.6	9.6	9.3	9.3	8.7	9.2	9.1
<i>41-64: Skin cancer, limited denominator</i>	59.6	57.7	58.1	58.9	55.7	58.9	56.5	57.2
<i>65-74: Skin cancer, limited denominator</i>	79.3	76.3	80.3	78.6	72.5	80.2	74.5	74.9
<i>75-84: Skin cancer, limited denominator</i>	83.8	80.8	84.8	83.5	76.6	85.1	78.7	79.2
<i>85+: Skin cancer, limited denominator</i>	72.7	69.8	73.2	72.0	66.1	72.4	67.8	67.8

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Full denominator								
<i>0-40: Skin cancer, full denominator</i>	37.7	38.0	36.5	36.6	35.9	37.6	35.9	35.9
<i>41-64: Skin cancer, full denominator</i>	162.3	156.8	158.2	159.8	151.6	160.2	155.0	156.0
<i>65-74: Skin cancer, full denominator</i>	227.1	219.4	226.4	224.4	210.7	227.4	215.6	217.1
<i>75-84: Skin cancer, full denominator</i>	282.4	273.4	281.5	279.7	263.5	283.8	268.7	271.1
<i>85+: Skin cancer, full denominator</i>	347.4	336.8	345.4	344.7	325.4	345.9	331.5	331.4
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Limited denominator								
<i>0-40: No skin cancer, limited denominator</i>	4.4	4.2	4.2	4.3	4.0	4.2	4.0	3.9
<i>41-64: No skin cancer, limited denominator</i>	58.6	56.6	57.1	57.9	53.9	57.4	54.8	54.5
<i>65-74: No skin cancer, limited denominator</i>	85.0	81.8	85.2	84.7	77.5	85.2	79.5	79.3
<i>75-84: No skin cancer, limited denominator</i>	88.2	84.9	88.6	87.8	80.4	88.7	82.3	82.1
<i>85+: No skin cancer, limited denominator</i>	75.1	72.3	75.0	74.3	68.6	74.4	69.9	69.5
No skin cancer: Full denominator								
<i>0-40: No skin cancer, full denominator</i>	14.5	13.9	14.0	14.3	13.4	14.2	13.7	13.5
<i>41-64: No skin cancer, full denominator</i>	152.3	147.3	148.8	150.8	141.4	149.8	144.2	143.6
<i>65-74: No skin cancer, full denominator</i>	235.7	227.9	234.4	234.2	218.5	235.6	223.4	223.2
<i>75-84: No skin cancer, full denominator</i>	295.9	286.7	294.2	293.5	275.4	296.0	280.8	280.3
<i>85+: No skin cancer, full denominator</i>	358.2	348.6	356.2	356.0	337.8	357.2	342.6	341.5

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month							
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b><i>HCTZ-containing</i></b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
HCTZ-containing products								
0-40	198	200	210	211	220	229	231	218
41-64	25,653	24,075	25,569	25,731	26,164	25,002	25,786	25,834
65-74	100,392	88,102	95,529	99,669	98,677	94,063	100,675	97,378
75-84	119,849	105,880	113,590	118,873	117,341	111,828	121,026	116,589
85+	50,359	45,353	47,708	49,635	49,760	46,767	50,727	48,787
HCTZ single ingredient/monotherapy								
0-40	92	105	92	96	105	113	104	105
41-64	9,467	9,023	9,707	9,810	10,017	9,619	9,958	10,271
65-74	40,803	36,299	39,480	41,297	41,311	39,897	42,177	42,056
75-84	51,766	46,463	50,004	52,408	52,091	49,919	53,990	53,359
85+	24,226	21,958	23,388	24,190	24,522	23,181	25,075	24,539
HCTZ combination products								
0-40	110	98	119	116	117	118	129	114
41-64	16,326	15,196	16,016	16,078	16,323	15,531	15,969	15,764
65-74	60,094	52,184	56,493	58,880	57,826	54,616	58,964	55,748
75-84	68,630	59,923	64,120	67,034	65,790	62,418	67,624	63,742
85+	26,349	23,597	24,534	25,651	25,457	23,805	25,870	24,459
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
HCTZ-containing products								
0-40	75,962	70,952	75,569	75,258	75,036	70,772	73,059	71,827
41-64	805,462	748,756	790,341	789,881	786,669	745,820	769,512	755,557
65-74	985,764	875,345	933,182	960,008	947,616	893,651	956,576	920,652
75-84	480,662	425,490	452,171	466,431	459,285	432,922	464,229	443,967
85+	144,978	130,212	136,431	139,709	137,836	129,793	137,989	132,208

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ single ingredient/monotherapy								
0-40	32,813	30,712	33,223	33,443	33,354	31,594	32,864	32,984
41-64	308,642	290,272	309,092	311,287	311,744	298,239	308,983	309,181
65-74	399,849	359,329	384,621	398,305	395,855	376,188	402,304	396,059
75-84	205,230	183,911	196,532	203,301	202,335	192,262	204,632	200,571
85+	68,832	62,592	66,088	67,573	67,196	63,783	67,568	65,716
HCTZ combination products								
0-40	110	98	119	116	117	118	129	114
41-64	16,326	15,196	16,016	16,078	16,323	15,531	15,969	15,764
65-74	60,094	52,184	56,493	58,880	57,826	54,616	58,964	55,748
75-84	68,630	59,923	64,120	67,034	65,790	62,418	67,624	63,742
85+	26,349	23,597	24,534	25,651	25,457	23,805	25,870	24,459
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	215	219	226	226	237	247	253	236
41-64	27,306	25,671	27,300	27,450	27,996	26,727	27,598	27,642
65-74	108,199	95,247	103,379	107,669	106,665	101,775	108,771	105,272
75-84	131,339	116,073	124,896	130,566	129,013	122,955	132,772	128,264
85+	57,018	51,589	54,300	56,378	56,368	53,330	57,429	55,510
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	943	858	934	920	947	925	949	958
41-64	75,358	70,954	75,408	76,286	77,435	74,097	76,894	76,776
65-74	309,261	280,373	300,895	311,579	310,507	297,820	316,381	309,218
75-84	441,940	401,236	430,774	445,440	444,476	427,913	456,058	445,758
85+	275,206	255,130	268,913	275,925	276,947	266,289	282,102	276,680

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	81,213	75,748	80,964	80,593	80,383	76,021	78,392	77,106
41-64	858,412	798,448	843,443	843,426	840,822	797,427	822,794	808,808
65-74	1,059,618	942,564	1,005,524	1,033,773	1,022,026	963,810	1,031,502	993,935
75-84	525,077	465,645	495,229	510,474	503,356	474,720	508,406	487,078
85+	162,530	146,400	153,558	156,944	155,255	146,047	155,146	149,088
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	279,602	263,626	281,893	281,084	281,001	268,232	275,811	273,750
41-64	2,268,723	2,126,442	2,244,057	2,245,091	2,241,669	2,136,048	2,202,289	2,173,775
65-74	2,958,449	2,684,033	2,855,973	2,921,945	2,902,141	2,761,981	2,927,667	2,850,902
75-84	1,769,654	1,610,970	1,704,660	1,742,058	1,729,225	1,647,791	1,743,833	1,693,291
85+	789,334	728,382	760,776	769,688	765,965	732,535	765,741	746,477
<b>Eligible members per month</b>								
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage								
0-40	25,222	25,308	25,583	25,804	26,092	26,271	26,308	26,446
41-64	483,329	486,794	490,888	495,035	499,719	502,519	504,374	508,596
65-74	1,380,634	1,389,427	1,400,061	1,412,264	1,426,634	1,437,290	1,449,968	1,462,502
75-84	1,574,102	1,586,051	1,600,877	1,614,901	1,630,875	1,645,167	1,662,735	1,679,757
85+	802,024	805,384	810,568	814,876	820,772	826,217	833,316	841,064

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Enrollees with at least one day of coverage								
0-40	20,096,265	20,025,461	20,006,491	19,948,769	19,915,294	19,845,393	19,810,826	19,753,527
41-64	15,644,916	15,584,294	15,566,537	15,506,525	15,460,715	15,416,537	15,393,230	15,357,224
65-74	12,867,513	12,877,957	12,906,091	12,913,537	12,918,643	12,940,575	13,008,174	13,045,562
75-84	6,112,628	6,107,771	6,116,424	6,112,389	6,108,446	6,110,450	6,126,798	6,137,516
85+	2,253,080	2,240,305	2,235,145	2,224,184	2,216,488	2,209,935	2,208,333	2,207,573
<b>Number of patients with dispensing per 1,000 eligible members</b>								
	Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing								
0-40: Skin cancer, HCTZ-containing	7.9	7.9	8.2	8.2	8.4	8.7	8.8	8.2
41-64: Skin cancer, HCTZ-containing	53.1	49.5	52.1	52.0	52.4	49.8	51.1	50.8
65-74: Skin cancer, HCTZ-containing	72.7	63.4	68.2	70.6	69.2	65.4	69.4	66.6
75-84: Skin cancer, HCTZ-containing	76.1	66.8	71.0	73.6	71.9	68.0	72.8	69.4
85+: Skin cancer, HCTZ-containing	62.8	56.3	58.9	60.9	60.6	56.6	60.9	58.0
Skin cancer: HCTZ single ingredient								
0-40: Skin cancer, HCTZ single ingredient	3.6	4.1	3.6	3.7	4.0	4.3	4.0	4.0
41-64: Skin cancer, HCTZ single ingredient	19.6	18.5	19.8	19.8	20.0	19.1	19.7	20.2
65-74: Skin cancer, HCTZ single ingredient	29.6	26.1	28.2	29.2	29.0	27.8	29.1	28.8
75-84: Skin cancer, HCTZ single ingredient	32.9	29.3	31.2	32.5	31.9	30.3	32.5	31.8
85+: Skin cancer, HCTZ single ingredient	30.2	27.3	28.9	29.7	29.9	28.1	30.1	29.2
Skin cancer: HCTZ combination								
0-40: Skin cancer, HCTZ combination	4.4	3.9	4.7	4.5	4.5	4.5	4.9	4.3
41-64: Skin cancer, HCTZ combination	33.8	31.2	32.6	32.5	32.7	30.9	31.7	31.0
65-74: Skin cancer, HCTZ combination	43.5	37.6	40.4	41.7	40.5	38.0	40.7	38.1
75-84: Skin cancer, HCTZ combination	43.6	37.8	40.1	41.5	40.3	37.9	40.7	37.9
85+: Skin cancer, HCTZ combination	32.9	29.3	30.3	31.5	31.0	28.8	31.0	29.1

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing								
<i>0-40: No skin cancer, HCTZ-containing</i>	3.8	3.5	3.8	3.8	3.8	3.6	3.7	3.6
<i>41-64: No skin cancer, HCTZ-containing</i>	51.5	48.0	50.8	50.9	50.9	48.4	50.0	49.2
<i>65-74: No skin cancer, HCTZ-containing</i>	76.6	68.0	72.3	74.3	73.4	69.1	73.5	70.6
<i>75-84: No skin cancer, HCTZ-containing</i>	78.6	69.7	73.9	76.3	75.2	70.8	75.8	72.3
<i>85+: No skin cancer, HCTZ-containing</i>	64.3	58.1	61.0	62.8	62.2	58.7	62.5	59.9
No skin cancer: HCTZ single ingredient								
<i>0-40: No skin cancer, HCTZ single ingredient</i>	1.6	1.5	1.7	1.7	1.7	1.6	1.7	1.7
<i>41-64: No skin cancer, HCTZ single ingredient</i>	19.7	18.6	19.9	20.1	20.2	19.3	20.1	20.1
<i>65-74: No skin cancer, HCTZ single ingredient</i>	31.1	27.9	29.8	30.8	30.6	29.1	30.9	30.4
<i>75-84: No skin cancer, HCTZ single ingredient</i>	33.6	30.1	32.1	33.3	33.1	31.5	33.4	32.7
<i>85+: No skin cancer, HCTZ single ingredient</i>	30.6	27.9	29.6	30.4	30.3	28.9	30.6	29.8
No skin cancer: HCTZ combination								
<i>0-40: No skin cancer, HCTZ combination</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>41-64: No skin cancer, HCTZ combination</i>	1.0	1.0	1.0	1.0	1.1	1.0	1.0	1.0
<i>65-74: No skin cancer, HCTZ combination</i>	4.7	4.1	4.4	4.6	4.5	4.2	4.5	4.3
<i>75-84: No skin cancer, HCTZ combination</i>	11.2	9.8	10.5	11.0	10.8	10.2	11.0	10.4
<i>85+: No skin cancer, HCTZ combination</i>	11.7	10.5	11.0	11.5	11.5	10.8	11.7	11.1
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Limited denominator								
<i>0-40: Skin cancer, limited denominator</i>	8.5	8.7	8.8	8.8	9.1	9.4	9.6	8.9
<i>41-64: Skin cancer, limited denominator</i>	56.5	52.7	55.6	55.5	56.0	53.2	54.7	54.3
<i>65-74: Skin cancer, limited denominator</i>	78.4	68.6	73.8	76.2	74.8	70.8	75.0	72.0
<i>75-84: Skin cancer, limited denominator</i>	83.4	73.2	78.0	80.9	79.1	74.7	79.9	76.4
<i>85+: Skin cancer, limited denominator</i>	71.1	64.1	67.0	69.2	68.7	64.5	68.9	66.0

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Full denominator								
<i>0-40: Skin cancer, full denominator</i>	37.4	33.9	36.5	35.7	36.3	35.2	36.1	36.2
<i>41-64: Skin cancer, full denominator</i>	155.9	145.8	153.6	154.1	155.0	147.5	152.5	151.0
<i>65-74: Skin cancer, full denominator</i>	224.0	201.8	214.9	220.6	217.7	207.2	218.2	211.4
<i>75-84: Skin cancer, full denominator</i>	280.8	253.0	269.1	275.8	272.5	260.1	274.3	265.4
<i>85+: Skin cancer, full denominator</i>	343.1	316.8	331.8	338.6	337.4	322.3	338.5	329.0
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Limited denominator								
<i>0-40: No skin cancer, limited denominator</i>	4.0	3.8	4.0	4.0	4.0	3.8	4.0	3.9
<i>41-64: No skin cancer, limited denominator</i>	54.9	51.2	54.2	54.4	54.4	51.7	53.5	52.7
<i>65-74: No skin cancer, limited denominator</i>	82.3	73.2	77.9	80.1	79.1	74.5	79.3	76.2
<i>75-84: No skin cancer, limited denominator</i>	85.9	76.2	81.0	83.5	82.4	77.7	83.0	79.4
<i>85+: No skin cancer, limited denominator</i>	72.1	65.3	68.7	70.6	70.0	66.1	70.3	67.5
No skin cancer: Full denominator								
<i>0-40: No skin cancer, full denominator</i>	13.9	13.2	14.1	14.1	14.1	13.5	13.9	13.9
<i>41-64: No skin cancer, full denominator</i>	145.0	136.4	144.2	144.8	145.0	138.6	143.1	141.5
<i>65-74: No skin cancer, full denominator</i>	229.9	208.4	221.3	226.3	224.6	213.4	225.1	218.5
<i>75-84: No skin cancer, full denominator</i>	289.5	263.8	278.7	285.0	283.1	269.7	284.6	275.9
<i>85+: No skin cancer, full denominator</i>	350.3	325.1	340.4	346.1	345.6	331.5	346.8	338.1



Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month							
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	215	235	237	205	234	169	215	189
41-64	24,957	26,135	24,645	25,193	24,196	22,868	25,844	23,082
65-74	94,446	101,522	93,039	102,792	99,355	90,115	107,201	92,892
75-84	113,400	121,976	112,040	123,168	120,044	109,326	129,611	112,692
85+	47,478	50,613	47,008	50,425	50,059	46,221	52,488	47,288
HCTZ single ingredient/monotherapy								
0-40	103	120	118	101	122	88	106	102
41-64	10,169	11,056	10,788	11,328	10,907	10,544	11,815	10,579
65-74	41,852	46,814	44,540	50,223	48,949	44,441	52,923	45,787
75-84	53,059	58,991	56,101	62,683	61,592	56,682	66,659	57,914
85+	24,566	26,511	25,549	27,851	27,664	25,741	29,372	26,318
HCTZ combination products								
0-40	117	119	120	107	114	83	112	89
41-64	15,003	15,382	14,156	14,155	13,534	12,520	14,279	12,685
65-74	53,070	55,364	49,097	53,215	50,998	46,128	54,929	47,592
75-84	60,881	63,710	56,595	61,218	59,186	53,174	63,651	55,352
85+	23,146	24,386	21,696	22,891	22,662	20,703	23,381	21,147
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	68,695	71,324	66,823	65,557	70,402	66,663	73,941	66,656
41-64	726,876	756,494	704,788	709,763	733,710	689,845	769,579	697,829
65-74	887,313	941,945	864,499	926,322	954,738	865,481	1,008,238	887,503
75-84	428,418	454,782	415,171	447,246	458,550	415,531	482,598	424,594
85+	127,586	134,088	122,755	130,298	134,118	121,930	137,423	124,743

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ single ingredient/monotherapy								
0-40	32,023	34,338	32,976	33,151	36,124	34,240	38,074	34,498
41-64	305,654	332,758	320,426	332,388	347,177	327,481	365,685	331,653
65-74	393,553	435,069	413,128	454,924	471,764	429,731	499,398	438,697
75-84	199,241	218,681	206,764	228,274	236,508	215,291	249,181	218,616
85+	64,653	70,209	66,398	71,976	75,010	68,637	76,722	69,932
HCTZ combination products								
0-40	117	119	120	107	114	83	112	89
41-64	15,003	15,382	14,156	14,155	13,534	12,520	14,279	12,685
65-74	53,070	55,364	49,097	53,215	50,998	46,128	54,929	47,592
75-84	60,881	63,710	56,595	61,218	59,186	53,174	63,651	55,352
85+	23,146	24,386	21,696	22,891	22,662	20,703	23,381	21,147
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	235	254	257	226	257	190	235	212
41-64	26,723	28,013	26,386	27,016	25,995	24,525	27,799	24,784
65-74	102,188	109,915	100,934	111,366	107,577	97,874	116,051	100,740
75-84	124,741	133,951	123,388	135,475	132,163	120,619	142,648	123,976
85+	53,936	57,397	53,453	57,374	56,908	52,603	59,591	53,778
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	969	969	967	942	966	873	1,019	870
41-64	74,765	78,213	74,067	76,346	73,264	70,279	77,639	70,702
65-74	302,191	321,822	300,127	325,434	314,953	292,177	337,342	297,168
75-84	437,630	464,361	433,268	469,005	457,500	424,563	488,221	432,586
85+	271,319	285,518	270,615	285,480	283,053	266,648	294,550	268,516

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	73,823	76,753	72,003	70,618	75,940	71,905	79,724	72,004
41-64	778,290	810,576	755,497	761,966	787,482	741,231	826,601	749,870
65-74	957,969	1,017,355	934,845	1,001,350	1,032,625	937,374	1,090,115	960,205
75-84	470,116	498,662	456,093	490,818	503,898	457,647	529,842	466,249
85+	143,699	150,935	138,767	146,751	151,221	138,054	154,698	140,672
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	265,059	277,378	261,782	260,592	279,167	266,186	293,459	264,251
41-64	2,105,153	2,189,974	2,056,571	2,083,492	2,144,878	2,035,815	2,244,607	2,054,083
65-74	2,768,593	2,920,593	2,715,675	2,888,351	2,962,014	2,733,537	3,112,019	2,778,188
75-84	1,647,084	1,728,454	1,608,004	1,707,171	1,747,095	1,619,556	1,822,425	1,631,900
85+	727,890	754,435	709,996	740,179	757,407	710,174	772,031	707,248
<b>Eligible members per month</b>								
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage								
0-40	26,538	26,721	26,752	26,734	24,961	25,188	25,265	24,829
41-64	511,548	515,171	518,273	519,377	488,055	490,702	491,954	487,672
65-74	1,474,085	1,490,392	1,499,935	1,506,972	1,470,862	1,480,338	1,485,165	1,477,535
75-84	1,695,249	1,712,522	1,724,897	1,736,629	1,700,749	1,711,465	1,720,813	1,721,684
85+	848,629	856,876	861,606	865,874	851,479	854,693	857,799	857,104

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Enrollees with at least one day of coverage								
0-40	19,727,632	19,700,287	19,662,003	19,629,573	19,696,042	19,607,065	19,574,640	19,452,195
41-64	15,333,802	15,300,009	15,266,234	15,234,928	15,202,544	15,125,266	15,095,630	15,022,941
65-74	13,079,580	13,113,210	13,128,208	13,142,100	13,479,298	13,466,231	13,482,644	13,507,349
75-84	6,140,943	6,148,291	6,147,638	6,155,636	6,298,322	6,283,197	6,285,979	6,288,763
85+	2,205,786	2,204,880	2,198,577	2,194,784	2,237,620	2,226,112	2,221,322	2,215,499
<b>Number of patients with dispensing per 1,000 eligible members</b>								
	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing								
0-40: Skin cancer, HCTZ-containing	8.1	8.8	8.9	7.7	9.4	6.7	8.5	7.6
41-64: Skin cancer, HCTZ-containing	48.8	50.7	47.6	48.5	49.6	46.6	52.5	47.3
65-74: Skin cancer, HCTZ-containing	64.1	68.1	62.0	68.2	67.5	60.9	72.2	62.9
75-84: Skin cancer, HCTZ-containing	66.9	71.2	65.0	70.9	70.6	63.9	75.3	65.5
85+: Skin cancer, HCTZ-containing	55.9	59.1	54.6	58.2	58.8	54.1	61.2	55.2
Skin cancer: HCTZ single ingredient								
0-40: Skin cancer, HCTZ single ingredient	3.9	4.5	4.4	3.8	4.9	3.5	4.2	4.1
41-64: Skin cancer, HCTZ single ingredient	19.9	21.5	20.8	21.8	22.3	21.5	24.0	21.7
65-74: Skin cancer, HCTZ single ingredient	28.4	31.4	29.7	33.3	33.3	30.0	35.6	31.0
75-84: Skin cancer, HCTZ single ingredient	31.3	34.4	32.5	36.1	36.2	33.1	38.7	33.6
85+: Skin cancer, HCTZ single ingredient	28.9	30.9	29.7	32.2	32.5	30.1	34.2	30.7
Skin cancer: HCTZ combination								
0-40: Skin cancer, HCTZ combination	4.4	4.5	4.5	4.0	4.6	3.3	4.4	3.6
41-64: Skin cancer, HCTZ combination	29.3	29.9	27.3	27.3	27.7	25.5	29.0	26.0
65-74: Skin cancer, HCTZ combination	36.0	37.1	32.7	35.3	34.7	31.2	37.0	32.2
75-84: Skin cancer, HCTZ combination	35.9	37.2	32.8	35.3	34.8	31.1	37.0	32.1
85+: Skin cancer, HCTZ combination	27.3	28.5	25.2	26.4	26.6	24.2	27.3	24.7

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing								
0-40: No skin cancer, HCTZ-containing	3.5	3.6	3.4	3.3	3.6	3.4	3.8	3.4
41-64: No skin cancer, HCTZ-containing	47.4	49.4	46.2	46.6	48.3	45.6	51.0	46.5
65-74: No skin cancer, HCTZ-containing	67.8	71.8	65.9	70.5	70.8	64.3	74.8	65.7
75-84: No skin cancer, HCTZ-containing	69.8	74.0	67.5	72.7	72.8	66.1	76.8	67.5
85+: No skin cancer, HCTZ-containing	57.8	60.8	55.8	59.4	59.9	54.8	61.9	56.3
No skin cancer: HCTZ single ingredient								
0-40: No skin cancer, HCTZ single ingredient	1.6	1.7	1.7	1.7	1.8	1.7	1.9	1.8
41-64: No skin cancer, HCTZ single ingredient	19.9	21.7	21.0	21.8	22.8	21.7	24.2	22.1
65-74: No skin cancer, HCTZ single ingredient	30.1	33.2	31.5	34.6	35.0	31.9	37.0	32.5
75-84: No skin cancer, HCTZ single ingredient	32.4	35.6	33.6	37.1	37.6	34.3	39.6	34.8
85+: No skin cancer, HCTZ single ingredient	29.3	31.8	30.2	32.8	33.5	30.8	34.5	31.6
No skin cancer: HCTZ combination								
0-40: No skin cancer, HCTZ combination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
41-64: No skin cancer, HCTZ combination	1.0	1.0	0.9	0.9	0.9	0.8	0.9	0.8
65-74: No skin cancer, HCTZ combination	4.1	4.2	3.7	4.0	3.8	3.4	4.1	3.5
75-84: No skin cancer, HCTZ combination	9.9	10.4	9.2	9.9	9.4	8.5	10.1	8.8
85+: No skin cancer, HCTZ combination	10.5	11.1	9.9	10.4	10.1	9.3	10.5	9.5
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Limited denominator								
0-40: Skin cancer, limited denominator	8.9	9.5	9.6	8.5	10.3	7.5	9.3	8.5
41-64: Skin cancer, limited denominator	52.2	54.4	50.9	52.0	53.3	50.0	56.5	50.8
65-74: Skin cancer, limited denominator	69.3	73.7	67.3	73.9	73.1	66.1	78.1	68.2
75-84: Skin cancer, limited denominator	73.6	78.2	71.5	78.0	77.7	70.5	82.9	72.0
85+: Skin cancer, limited denominator	63.6	67.0	62.0	66.3	66.8	61.5	69.5	62.7

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Full denominator								
<i>0-40: Skin cancer, full denominator</i>	36.5	36.3	36.1	35.2	38.7	34.7	40.3	35.0
<i>41-64: Skin cancer, full denominator</i>	146.2	151.8	142.9	147.0	150.1	143.2	157.8	145.0
<i>65-74: Skin cancer, full denominator</i>	205.0	215.9	200.1	216.0	214.1	197.4	227.1	201.1
<i>75-84: Skin cancer, full denominator</i>	258.2	271.2	251.2	270.1	269.0	248.1	283.7	251.3
<i>85+: Skin cancer, full denominator</i>	319.7	333.2	314.1	329.7	332.4	312.0	343.4	313.3
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Limited denominator								
<i>0-40: No skin cancer, limited denominator</i>	3.7	3.9	3.7	3.6	3.9	3.7	4.1	3.7
<i>41-64: No skin cancer, limited denominator</i>	50.8	53.0	49.5	50.0	51.8	49.0	54.8	49.9
<i>65-74: No skin cancer, limited denominator</i>	73.2	77.6	71.2	76.2	76.6	69.6	80.9	71.1
<i>75-84: No skin cancer, limited denominator</i>	76.6	81.1	74.2	79.7	80.0	72.8	84.3	74.1
<i>85+: No skin cancer, limited denominator</i>	65.1	68.5	63.1	66.9	67.6	62.0	69.6	63.5
No skin cancer: Full denominator								
<i>0-40: No skin cancer, full denominator</i>	13.4	14.1	13.3	13.3	14.2	13.6	15.0	13.6
<i>41-64: No skin cancer, full denominator</i>	137.3	143.1	134.7	136.8	141.1	134.6	148.7	136.7
<i>65-74: No skin cancer, full denominator</i>	211.7	222.7	206.9	219.8	219.7	203.0	230.8	205.7
<i>75-84: No skin cancer, full denominator</i>	268.2	281.1	261.6	277.3	277.4	257.8	289.9	259.5
<i>85+: No skin cancer, full denominator</i>	330.0	342.2	322.9	337.2	338.5	319.0	347.6	319.2

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	173	190	175	186	177	182	179	187
41-64	22,873	24,020	23,125	23,131	22,865	22,930	22,416	23,817
65-74	91,452	99,410	95,717	95,989	95,419	96,851	94,101	102,185
75-84	112,140	122,182	116,598	117,057	117,627	117,837	115,458	124,569
85+	46,819	50,135	48,761	48,436	48,181	48,486	47,309	49,902
HCTZ single ingredient/monotherapy								
0-40	79	95	86	91	81	91	89	92
41-64	10,534	11,037	10,656	10,724	10,428	10,487	10,165	10,625
65-74	44,928	49,112	47,169	46,966	46,409	47,089	45,343	49,396
75-84	57,922	62,957	59,868	60,276	60,085	59,572	58,606	62,951
85+	26,149	27,945	27,154	26,840	26,757	26,552	25,940	27,495
HCTZ combination products								
0-40	94	97	90	98	97	93	93	96
41-64	12,502	13,153	12,672	12,580	12,567	12,578	12,373	13,314
65-74	46,974	50,778	49,026	49,456	49,412	50,187	49,124	53,234
75-84	54,705	59,847	57,282	57,281	58,076	58,747	57,274	62,095
85+	20,873	22,423	21,804	21,803	21,633	22,144	21,536	22,599
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ-containing products								
0-40	64,548	66,311	65,530	63,484	61,736	61,747	58,581	60,656
41-64	679,675	704,073	688,744	673,930	664,937	663,871	632,022	662,788
65-74	873,960	945,215	910,097	901,502	899,143	903,128	868,212	932,641
75-84	419,577	453,604	434,865	431,258	428,977	429,252	412,639	441,931
85+	121,803	129,952	125,735	123,148	122,720	122,335	116,744	123,188

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ single ingredient/monotherapy								
0-40	33,213	34,661	34,612	33,323	32,221	31,999	30,199	31,080
41-64	322,428	336,255	329,878	321,682	315,293	312,704	296,693	310,250
65-74	431,185	468,009	449,090	443,534	439,424	437,861	420,637	450,162
75-84	216,474	233,411	224,011	220,475	217,974	217,855	208,391	222,172
85+	68,042	72,205	70,285	68,633	67,601	67,319	64,270	67,193
HCTZ combination products								
0-40	94	97	90	98	97	93	93	96
41-64	12,502	13,153	12,672	12,580	12,567	12,578	12,373	13,314
65-74	46,974	50,778	49,026	49,456	49,412	50,187	49,124	53,234
75-84	54,705	59,847	57,282	57,281	58,076	58,747	57,274	62,095
85+	20,873	22,423	21,804	21,803	21,633	22,144	21,536	22,599
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	194	214	194	205	206	205	202	209
41-64	24,546	25,832	24,878	24,822	24,569	24,618	24,075	25,666
65-74	99,194	107,790	103,821	104,045	103,586	105,019	102,160	110,951
75-84	123,446	134,573	128,364	128,993	129,309	129,582	127,340	137,177
85+	53,111	56,833	55,395	54,747	54,609	54,973	53,498	56,636
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	864	897	848	898	902	914	910	929
41-64	69,712	72,838	71,175	70,795	70,792	71,274	69,345	73,682
65-74	294,652	317,258	307,083	307,918	308,896	313,655	306,992	329,569
75-84	431,406	463,995	448,962	450,733	454,011	456,970	447,674	479,705
85+	266,099	280,197	274,875	273,636	273,918	276,573	270,220	281,189



Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	69,805	71,714	70,770	68,601	66,762	66,834	63,453	65,654
41-64	731,012	756,977	740,799	724,945	715,637	714,644	680,734	714,242
65-74	946,153	1,022,654	985,250	975,779	973,406	977,698	940,693	1,010,429
75-84	461,456	497,911	477,752	473,447	470,983	471,605	453,745	485,560
85+	137,467	146,117	141,567	138,544	137,830	137,612	131,356	138,188
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	259,004	267,510	264,666	259,028	255,598	258,013	247,499	258,858
41-64	2,006,867	2,079,758	2,039,220	2,001,090	1,981,868	1,983,877	1,900,822	1,991,284
65-74	2,749,971	2,942,999	2,854,523	2,837,648	2,841,987	2,857,753	2,767,228	2,946,820
75-84	1,617,012	1,725,155	1,668,193	1,659,395	1,655,369	1,659,163	1,606,321	1,698,572
85+	693,377	725,408	708,975	698,109	695,050	695,370	668,727	692,079
<b>Eligible members per month</b>								
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage								
0-40	24,767	24,960	25,067	25,145	25,101	25,175	25,224	25,207
41-64	487,993	491,214	492,636	495,303	496,487	498,979	501,173	502,322
65-74	1,481,021	1,494,506	1,506,628	1,516,886	1,529,335	1,541,580	1,550,257	1,557,952
75-84	1,729,220	1,743,415	1,757,972	1,771,511	1,785,735	1,799,722	1,809,561	1,818,390
85+	857,125	861,637	867,716	873,293	878,670	883,994	886,740	888,024

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Enrollees with at least one day of coverage								
	2017	2018	2019	2020	2021	2022	2022	2022
0-40	19,346,714	19,258,644	19,118,956	19,018,580	18,786,325	18,725,902	18,699,336	18,675,006
41-64	14,972,619	14,925,591	14,867,893	14,815,322	14,707,925	14,654,175	14,625,741	14,599,874
65-74	13,542,240	13,569,115	13,631,472	13,651,038	13,676,297	13,695,649	13,709,852	13,716,397
75-84	6,292,924	6,297,377	6,309,220	6,308,210	6,305,716	6,303,960	6,300,050	6,298,200
85+	2,202,604	2,195,172	2,194,345	2,189,044	2,182,552	2,176,438	2,166,953	2,155,547

	<b>Number of patients with dispensing per 1,000 eligible members</b>							
	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing								
0-40: Skin cancer, HCTZ-containing	7.0	7.6	7.0	7.4	7.1	7.2	7.1	7.4
41-64: Skin cancer, HCTZ-containing	46.9	48.9	46.9	46.7	46.1	46.0	44.7	47.4
65-74: Skin cancer, HCTZ-containing	61.7	66.5	63.5	63.3	62.4	62.8	60.7	65.6
75-84: Skin cancer, HCTZ-containing	64.9	70.1	66.3	66.1	65.9	65.5	63.8	68.5
85+: Skin cancer, HCTZ-containing	54.6	58.2	56.2	55.5	54.8	54.8	53.4	56.2
Skin cancer: HCTZ single ingredient								
0-40: Skin cancer, HCTZ single ingredient	3.2	3.8	3.4	3.6	3.2	3.6	3.5	3.6
41-64: Skin cancer, HCTZ single ingredient	21.6	22.5	21.6	21.7	21.0	21.0	20.3	21.2
65-74: Skin cancer, HCTZ single ingredient	30.3	32.9	31.3	31.0	30.3	30.5	29.2	31.7
75-84: Skin cancer, HCTZ single ingredient	33.5	36.1	34.1	34.0	33.6	33.1	32.4	34.6
85+: Skin cancer, HCTZ single ingredient	30.5	32.4	31.3	30.7	30.5	30.0	29.3	31.0
Skin cancer: HCTZ combination								
0-40: Skin cancer, HCTZ combination	3.8	3.9	3.6	3.9	3.9	3.7	3.7	3.8
41-64: Skin cancer, HCTZ combination	25.6	26.8	25.7	25.4	25.3	25.2	24.7	26.5
65-74: Skin cancer, HCTZ combination	31.7	34.0	32.5	32.6	32.3	32.6	31.7	34.2
75-84: Skin cancer, HCTZ combination	31.6	34.3	32.6	32.3	32.5	32.6	31.7	34.1
85+: Skin cancer, HCTZ combination	24.4	26.0	25.1	25.0	24.6	25.0	24.3	25.4

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing								
<i>0-40: No skin cancer, HCTZ-containing</i>	3.3	3.4	3.4	3.3	3.3	3.3	3.1	3.2
<i>41-64: No skin cancer, HCTZ-containing</i>	45.4	47.2	46.3	45.5	45.2	45.3	43.2	45.4
<i>65-74: No skin cancer, HCTZ-containing</i>	64.5	69.7	66.8	66.0	65.7	65.9	63.3	68.0
<i>75-84: No skin cancer, HCTZ-containing</i>	66.7	72.0	68.9	68.4	68.0	68.1	65.5	70.2
<i>85+: No skin cancer, HCTZ-containing</i>	55.3	59.2	57.3	56.3	56.2	56.2	53.9	57.1
No skin cancer: HCTZ single ingredient								
<i>0-40: No skin cancer, HCTZ single ingredient</i>	1.7	1.8	1.8	1.8	1.7	1.7	1.6	1.7
<i>41-64: No skin cancer, HCTZ single ingredient</i>	21.5	22.5	22.2	21.7	21.4	21.3	20.3	21.3
<i>65-74: No skin cancer, HCTZ single ingredient</i>	31.8	34.5	32.9	32.5	32.1	32.0	30.7	32.8
<i>75-84: No skin cancer, HCTZ single ingredient</i>	34.4	37.1	35.5	35.0	34.6	34.6	33.1	35.3
<i>85+: No skin cancer, HCTZ single ingredient</i>	30.9	32.9	32.0	31.4	31.0	30.9	29.7	31.2
No skin cancer: HCTZ combination								
<i>0-40: No skin cancer, HCTZ combination</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>41-64: No skin cancer, HCTZ combination</i>	0.8	0.9	0.9	0.8	0.9	0.9	0.8	0.9
<i>65-74: No skin cancer, HCTZ combination</i>	3.5	3.7	3.6	3.6	3.6	3.7	3.6	3.9
<i>75-84: No skin cancer, HCTZ combination</i>	8.7	9.5	9.1	9.1	9.2	9.3	9.1	9.9
<i>85+: No skin cancer, HCTZ combination</i>	9.5	10.2	9.9	10.0	9.9	10.2	9.9	10.5

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Limited denominator								
0-40: Skin cancer, limited denominator	7.8	8.6	7.7	8.2	8.2	8.1	8.0	8.3
41-64: Skin cancer, limited denominator	50.3	52.6	50.5	50.1	49.5	49.3	48.0	51.1
65-74: Skin cancer, limited denominator	67.0	72.1	68.9	68.6	67.7	68.1	65.9	71.2
75-84: Skin cancer, limited denominator	71.4	77.2	73.0	72.8	72.4	72.0	70.4	75.4
85+: Skin cancer, limited denominator	62.0	66.0	63.8	62.7	62.1	62.2	60.3	63.8
Skin cancer: Full denominator								
0-40: Skin cancer, full denominator	34.9	35.9	33.8	35.7	35.9	36.3	36.1	36.9
41-64: Skin cancer, full denominator	142.9	148.3	144.5	142.9	142.6	142.8	138.4	146.7
65-74: Skin cancer, full denominator	199.0	212.3	203.8	203.0	202.0	203.5	198.0	211.5
75-84: Skin cancer, full denominator	249.5	266.1	255.4	254.4	254.2	253.9	247.4	263.8
85+: Skin cancer, full denominator	310.5	325.2	316.8	313.3	311.7	312.9	304.7	316.6
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Limited denominator								
0-40: No skin cancer, limited denominator	3.6	3.7	3.7	3.6	3.6	3.6	3.4	3.5
41-64: No skin cancer, limited denominator	48.8	50.7	49.8	48.9	48.7	48.8	46.5	48.9
65-74: No skin cancer, limited denominator	69.9	75.4	72.3	71.5	71.2	71.4	68.6	73.7
75-84: No skin cancer, limited denominator	73.3	79.1	75.7	75.1	74.7	74.8	72.0	77.1
85+: No skin cancer, limited denominator	62.4	66.6	64.5	63.3	63.2	63.2	60.6	64.1
No skin cancer: Full denominator								
0-40: No skin cancer, full denominator	13.4	13.9	13.8	13.6	13.6	13.8	13.2	13.9
41-64: No skin cancer, full denominator	134.0	139.3	137.2	135.1	134.7	135.4	130.0	136.4
65-74: No skin cancer, full denominator	203.1	216.9	209.4	207.9	207.8	208.7	201.8	214.8
75-84: No skin cancer, full denominator	257.0	273.9	264.4	263.1	262.5	263.2	255.0	269.7
85+: No skin cancer, full denominator	314.8	330.5	323.1	318.9	318.5	319.5	308.6	321.1

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month							
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b><i>HCTZ-containing</i></b>								
<b><i>Evidence of skin cancer in enrollment history prior to exposure</i></b>								
HCTZ-containing products								
0-40	177	172	180	185	184	202	182	166
41-64	21,448	20,472	22,785	21,878	21,426	22,521	21,994	21,835
65-74	92,943	85,403	98,704	95,006	92,504	97,461	95,703	96,063
75-84	114,615	105,046	121,229	116,457	113,457	120,273	117,660	118,863
85+	46,503	42,864	48,810	47,261	46,062	48,621	47,820	47,892
HCTZ single ingredient/monotherapy								
0-40	93	92	93	94	89	102	87	78
41-64	9,774	9,249	10,360	9,850	9,677	10,122	9,880	9,717
65-74	45,094	41,259	47,766	45,896	44,781	46,860	46,111	46,093
75-84	58,000	53,307	61,286	58,882	57,673	61,079	59,384	60,124
85+	25,392	23,707	26,941	25,755	25,397	26,801	26,038	26,264
HCTZ combination products								
0-40	85	82	89	93	96	103	95	89
41-64	11,782	11,333	12,549	12,141	11,855	12,514	12,217	12,217
65-74	48,240	44,482	51,357	49,489	48,097	50,915	49,936	50,335
75-84	57,036	52,095	60,413	58,004	56,192	59,654	58,645	59,150
85+	21,267	19,304	22,050	21,663	20,843	22,006	21,950	21,792
<b><i>No evidence of skin cancer in enrollment history prior to exposure</i></b>								
HCTZ-containing products								
0-40	59,698	55,739	62,250	59,877	57,800	58,997	58,063	56,619
41-64	636,465	592,646	660,843	633,272	614,477	632,343	618,437	611,032
65-74	886,138	808,962	924,526	888,063	853,501	898,964	880,809	876,104
75-84	418,743	382,346	437,772	417,305	404,384	425,998	415,673	416,455
85+	117,768	108,297	122,354	117,332	113,547	118,513	116,515	115,413

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
HCTZ single ingredient/monotherapy								
0-40	30,669	28,301	31,624	30,449	29,368	30,003	29,520	28,624
41-64	296,634	275,710	307,087	294,275	284,805	293,369	286,383	282,084
65-74	428,329	390,074	444,406	426,693	411,217	432,020	423,571	420,680
75-84	211,880	192,680	219,633	209,966	203,693	213,800	208,933	208,546
85+	64,382	59,274	66,656	64,013	62,119	64,609	63,466	62,946
HCTZ combination products								
0-40	85	82	89	93	96	103	95	89
41-64	11,782	11,333	12,549	12,141	11,855	12,514	12,217	12,217
65-74	48,240	44,482	51,357	49,489	48,097	50,915	49,936	50,335
75-84	57,036	52,095	60,413	58,004	56,192	59,654	58,645	59,150
85+	21,267	19,304	22,050	21,663	20,843	22,006	21,950	21,792
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	194	186	199	202	201	217	192	181
41-64	23,080	22,019	24,554	23,609	23,086	24,258	23,785	23,547
65-74	100,993	92,908	107,231	103,321	100,614	105,937	103,944	104,396
75-84	126,167	115,847	133,725	128,482	125,167	132,702	129,677	130,994
85+	52,725	48,749	55,407	53,697	52,334	55,132	54,309	54,297
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	856	797	910	865	863	895	864	837
41-64	66,920	63,784	70,437	68,212	67,212	70,035	68,283	68,590
65-74	302,897	282,162	320,517	309,900	304,668	319,612	314,975	315,571
75-84	444,283	412,555	469,151	454,061	444,985	468,816	461,275	466,124
85+	264,679	248,752	277,728	270,456	267,132	278,576	275,271	277,342

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic								
0-40	64,685	60,439	67,642	64,989	62,672	64,039	62,996	61,366
41-64	685,754	639,244	713,119	683,505	663,435	682,741	667,807	659,955
65-74	960,244	877,917	1,002,982	963,740	927,026	975,309	955,819	950,558
75-84	460,335	420,984	481,967	459,364	445,667	468,641	457,387	458,603
85+	132,441	121,781	137,757	132,212	127,941	133,310	131,326	129,746
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive								
0-40	256,809	241,110	269,378	259,303	251,754	258,497	254,468	250,032
41-64	1,912,631	1,794,589	1,986,391	1,912,471	1,857,846	1,909,885	1,876,938	1,854,922
65-74	2,811,389	2,605,136	2,937,907	2,840,524	2,750,167	2,872,595	2,829,159	2,820,049
75-84	1,622,046	1,503,605	1,690,415	1,628,411	1,587,362	1,659,001	1,629,200	1,631,063
85+	665,488	622,684	689,711	666,502	652,322	676,307	665,390	663,246
<b>Eligible members per month</b>								
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>Evidence of skin cancer in enrollment history</b>								
Enrollees with at least one day of coverage								
0-40	23,947	24,078	24,370	24,498	24,620	24,776	24,685	24,785
41-64	477,705	479,573	484,023	486,854	489,746	493,240	493,951	496,717
65-74	1,505,113	1,511,387	1,526,280	1,536,742	1,547,322	1,560,664	1,570,457	1,581,164
75-84	1,760,874	1,765,174	1,778,365	1,789,288	1,802,532	1,818,051	1,834,981	1,854,530
85+	860,983	859,167	864,605	868,926	874,284	880,482	887,141	893,916

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
Enrollees with at least one day of coverage								
0-40	18,760,815	18,703,660	18,691,984	18,648,015	18,610,437	18,609,092	18,582,532	18,648,188
41-64	14,614,332	14,554,952	14,532,349	14,489,042	14,463,153	14,452,337	14,439,799	14,434,511
65-74	13,714,396	13,703,118	13,717,078	13,707,113	13,708,389	13,719,976	13,776,195	13,796,238
75-84	6,260,940	6,235,376	6,236,086	6,228,517	6,232,230	6,240,637	6,265,399	6,291,106
85+	2,139,607	2,118,931	2,114,808	2,108,022	2,103,572	2,100,779	2,102,476	2,102,398
<b>Number of patients with dispensing per 1,000 eligible members</b>								
	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21
<b>HCTZ-containing</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: HCTZ-containing								
0-40: Skin cancer, HCTZ-containing	7.4	7.1	7.4	7.6	7.5	8.2	7.4	6.7
41-64: Skin cancer, HCTZ-containing	44.9	42.7	47.1	44.9	43.7	45.7	44.5	44.0
65-74: Skin cancer, HCTZ-containing	61.8	56.5	64.7	61.8	59.8	62.4	60.9	60.8
75-84: Skin cancer, HCTZ-containing	65.1	59.5	68.2	65.1	62.9	66.2	64.1	64.1
85+: Skin cancer, HCTZ-containing	54.0	49.9	56.5	54.4	52.7	55.2	53.9	53.6
Skin cancer: HCTZ single ingredient								
0-40: Skin cancer, HCTZ single ingredient	3.9	3.8	3.8	3.8	3.6	4.1	3.5	3.1
41-64: Skin cancer, HCTZ single ingredient	20.5	19.3	21.4	20.2	19.8	20.5	20.0	19.6
65-74: Skin cancer, HCTZ single ingredient	30.0	27.3	31.3	29.9	28.9	30.0	29.4	29.2
75-84: Skin cancer, HCTZ single ingredient	32.9	30.2	34.5	32.9	32.0	33.6	32.4	32.4
85+: Skin cancer, HCTZ single ingredient	29.5	27.6	31.2	29.6	29.0	30.4	29.4	29.4
Skin cancer: HCTZ combination								
0-40: Skin cancer, HCTZ combination	3.5	3.4	3.7	3.8	3.9	4.2	3.8	3.6
41-64: Skin cancer, HCTZ combination	24.7	23.6	25.9	24.9	24.2	25.4	24.7	24.6
65-74: Skin cancer, HCTZ combination	32.1	29.4	33.6	32.2	31.1	32.6	31.8	31.8
75-84: Skin cancer, HCTZ combination	32.4	29.5	34.0	32.4	31.2	32.8	32.0	31.9
85+: Skin cancer, HCTZ combination	24.7	22.5	25.5	24.9	23.8	25.0	24.7	24.4



Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: HCTZ-containing								
<i>0-40: No skin cancer, HCTZ-containing</i>	3.2	3.0	3.3	3.2	3.1	3.2	3.1	3.0
<i>41-64: No skin cancer, HCTZ-containing</i>	43.6	40.7	45.5	43.7	42.5	43.8	42.8	42.3
<i>65-74: No skin cancer, HCTZ-containing</i>	64.6	59.0	67.4	64.8	62.3	65.5	63.9	63.5
<i>75-84: No skin cancer, HCTZ-containing</i>	66.9	61.3	70.2	67.0	64.9	68.3	66.3	66.2
<i>85+: No skin cancer, HCTZ-containing</i>	55.0	51.1	57.9	55.7	54.0	56.4	55.4	54.9
No skin cancer: HCTZ single ingredient								
<i>0-40: No skin cancer, HCTZ single ingredient</i>	1.6	1.5	1.7	1.6	1.6	1.6	1.6	1.5
<i>41-64: No skin cancer, HCTZ single ingredient</i>	20.3	18.9	21.1	20.3	19.7	20.3	19.8	19.5
<i>65-74: No skin cancer, HCTZ single ingredient</i>	31.2	28.5	32.4	31.1	30.0	31.5	30.7	30.5
<i>75-84: No skin cancer, HCTZ single ingredient</i>	33.8	30.9	35.2	33.7	32.7	34.3	33.3	33.1
<i>85+: No skin cancer, HCTZ single ingredient</i>	30.1	28.0	31.5	30.4	29.5	30.8	30.2	29.9
No skin cancer: HCTZ combination								
<i>0-40: No skin cancer, HCTZ combination</i>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>41-64: No skin cancer, HCTZ combination</i>	0.8	0.8	0.9	0.8	0.8	0.9	0.8	0.8
<i>65-74: No skin cancer, HCTZ combination</i>	3.5	3.2	3.7	3.6	3.5	3.7	3.6	3.6
<i>75-84: No skin cancer, HCTZ combination</i>	9.1	8.4	9.7	9.3	9.0	9.6	9.4	9.4
<i>85+: No skin cancer, HCTZ combination</i>	9.9	9.1	10.4	10.3	9.9	10.5	10.4	10.4
<b>Denominators</b>								
<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Limited denominator								
<i>0-40: Skin cancer, limited denominator</i>	8.1	7.7	8.2	8.2	8.2	8.8	7.8	7.3
<i>41-64: Skin cancer, limited denominator</i>	48.3	45.9	50.7	48.5	47.1	49.2	48.2	47.4
<i>65-74: Skin cancer, limited denominator</i>	67.1	61.5	70.3	67.2	65.0	67.9	66.2	66.0
<i>75-84: Skin cancer, limited denominator</i>	71.7	65.6	75.2	71.8	69.4	73.0	70.7	70.6
<i>85+: Skin cancer, limited denominator</i>	61.2	56.7	64.1	61.8	59.9	62.6	61.2	60.7

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Evidence of skin cancer in enrollment history prior to exposure</b>								
Skin cancer: Full denominator								
<i>0-40: Skin cancer, full denominator</i>	35.7	33.1	37.3	35.3	35.1	36.1	35.0	33.8
<i>41-64: Skin cancer, full denominator</i>	140.1	133.0	145.5	140.1	137.2	142.0	138.2	138.1
<i>65-74: Skin cancer, full denominator</i>	201.2	186.7	210.0	201.7	196.9	204.8	200.6	199.6
<i>75-84: Skin cancer, full denominator</i>	252.3	233.7	263.8	253.8	246.9	257.9	251.4	251.3
<i>85+: Skin cancer, full denominator</i>	307.4	289.5	321.2	311.3	305.5	316.4	310.3	310.3
<b>No evidence of skin cancer in enrollment history prior to exposure</b>								
No skin cancer: Limited denominator								
<i>0-40: No skin cancer, limited denominator</i>	3.4	3.2	3.6	3.5	3.4	3.4	3.4	3.3
<i>41-64: No skin cancer, limited denominator</i>	46.9	43.9	49.1	47.2	45.9	47.2	46.2	45.7
<i>65-74: No skin cancer, limited denominator</i>	70.0	64.1	73.1	70.3	67.6	71.1	69.4	68.9
<i>75-84: No skin cancer, limited denominator</i>	73.5	67.5	77.3	73.8	71.5	75.1	73.0	72.9
<i>85+: No skin cancer, limited denominator</i>	61.9	57.5	65.1	62.7	60.8	63.5	62.5	61.7
No skin cancer: Full denominator								
<i>0-40: No skin cancer, full denominator</i>	13.7	12.9	14.4	13.9	13.5	13.9	13.7	13.4
<i>41-64: No skin cancer, full denominator</i>	130.9	123.3	136.7	132.0	128.5	132.2	130.0	128.5
<i>65-74: No skin cancer, full denominator</i>	205.0	190.1	214.2	207.2	200.6	209.4	205.4	204.4
<i>75-84: No skin cancer, full denominator</i>	259.1	241.1	271.1	261.4	254.7	265.8	260.0	259.3
<i>85+: No skin cancer, full denominator</i>	311.0	293.9	326.1	316.2	310.1	321.9	316.5	315.5

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products					
0-40	173	169	170	172	100
41-64	21,786	21,574	21,199	21,160	14,453
65-74	93,980	94,532	93,556	96,967	88,260
75-84	117,203	118,515	118,252	123,575	116,282
85+	47,203	47,260	46,980	48,295	46,123
HCTZ single ingredient/monotherapy					
0-40	91	86	82	85	49
41-64	9,743	9,569	9,598	9,599	6,653
65-74	45,096	45,234	44,734	46,919	43,305
75-84	59,337	59,348	59,606	62,849	59,558
85+	25,868	25,660	25,698	26,407	25,489
HCTZ combination products					
0-40	87	84	89	89	52
41-64	12,147	12,105	11,703	11,660	7,862
65-74	49,185	49,634	49,152	50,433	45,289
75-84	58,296	59,573	59,017	61,161	57,152
85+	21,483	21,758	21,441	22,073	20,794
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products					
0-40	54,967	54,317	53,067	52,239	36,275
41-64	598,061	592,889	576,700	575,164	417,272
65-74	857,763	856,822	843,014	859,966	804,287
75-84	407,864	409,154	407,104	417,831	395,916
85+	112,433	112,285	111,062	111,842	107,350

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ single ingredient/monotherapy					
0-40	27,703	27,236	26,565	26,143	18,840
41-64	276,156	272,702	264,798	267,514	200,196
65-74	410,814	409,333	403,180	415,460	393,757
75-84	203,964	204,118	203,270	210,387	202,264
85+	61,237	60,852	60,380	61,019	59,404
HCTZ combination products					
0-40	87	84	89	89	52
41-64	12,147	12,105	11,703	11,660	7,862
65-74	49,185	49,634	49,152	50,433	45,289
75-84	58,296	59,573	59,017	61,161	57,152
85+	21,483	21,758	21,441	22,073	20,794
<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
0-40	187	180	184	186	107
41-64	23,446	23,277	22,899	22,842	15,679
65-74	102,186	102,699	101,726	105,602	96,139
75-84	129,112	130,524	130,513	136,247	128,396
85+	53,489	53,577	53,368	54,741	52,259
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
0-40	832	825	835	817	571
41-64	67,845	67,655	66,902	67,442	48,398
65-74	311,043	313,176	310,723	321,344	293,572
75-84	460,815	465,605	469,702	486,078	459,193
85+	273,255	275,102	276,005	281,582	268,347

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
0-40	59,731	59,008	57,799	56,901	39,645
41-64	646,055	640,921	623,545	622,667	453,839
65-74	930,723	929,677	915,489	934,352	873,975
75-84	448,813	449,748	448,620	460,418	436,183
85+	126,562	126,387	124,778	125,930	121,032
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
0-40	245,209	242,301	240,293	237,997	168,682
41-64	1,818,910	1,807,033	1,773,015	1,775,155	1,350,365
65-74	2,761,803	2,768,858	2,739,522	2,794,860	2,615,157
75-84	1,601,985	1,609,212	1,606,961	1,644,883	1,561,091
85+	649,305	648,874	643,619	650,140	623,972
<b>Eligible members per month</b>					
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>Evidence of skin cancer in enrollment history</b>					
Enrollees with at least one day of coverage					
0-40	24,855	24,839	24,862	24,856	15,852
41-64	498,496	499,498	501,771	503,363	348,038
65-74	1,588,306	1,593,925	1,597,358	1,598,935	1,527,189
75-84	1,873,495	1,893,562	1,911,858	1,929,927	1,886,744
85+	898,575	903,299	906,884	909,716	886,865

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Enrollees with at least one day of coverage					
0-40	18,658,185	18,653,982	18,672,023	18,685,680	12,389,667
41-64	14,404,269	14,370,666	14,354,660	14,351,353	10,440,823
65-74	13,794,935	13,782,930	13,757,150	13,738,302	13,494,266
75-84	6,313,505	6,339,820	6,363,085	6,395,139	6,377,732
85+	2,097,325	2,092,165	2,084,640	2,079,007	2,073,061
	<b>Number of patients with dispensing per 1,000 eligible members</b>				
	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: HCTZ-containing					
0-40: Skin cancer, HCTZ-containing	7.0	6.8	6.8	6.9	6.3
41-64: Skin cancer, HCTZ-containing	43.7	43.2	42.2	42.0	41.5
65-74: Skin cancer, HCTZ-containing	59.2	59.3	58.6	60.6	57.8
75-84: Skin cancer, HCTZ-containing	62.6	62.6	61.9	64.0	61.6
85+: Skin cancer, HCTZ-containing	52.5	52.3	51.8	53.1	52.0
Skin cancer: HCTZ single ingredient					
0-40: Skin cancer, HCTZ single ingredient	3.7	3.5	3.3	3.4	3.1
41-64: Skin cancer, HCTZ single ingredient	19.5	19.2	19.1	19.1	19.1
65-74: Skin cancer, HCTZ single ingredient	28.4	28.4	28.0	29.3	28.4
75-84: Skin cancer, HCTZ single ingredient	31.7	31.3	31.2	32.6	31.6
85+: Skin cancer, HCTZ single ingredient	28.8	28.4	28.3	29.0	28.7
Skin cancer: HCTZ combination					
0-40: Skin cancer, HCTZ combination	3.5	3.4	3.6	3.6	3.3
41-64: Skin cancer, HCTZ combination	24.4	24.2	23.3	23.2	22.6
65-74: Skin cancer, HCTZ combination	31.0	31.1	30.8	31.5	29.7
75-84: Skin cancer, HCTZ combination	31.1	31.5	30.9	31.7	30.3
85+: Skin cancer, HCTZ combination	23.9	24.1	23.6	24.3	23.4

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: HCTZ-containing					
<i>0-40: No skin cancer, HCTZ-containing</i>	2.9	2.9	2.8	2.8	2.9
<i>41-64: No skin cancer, HCTZ-containing</i>	41.5	41.3	40.2	40.1	40.0
<i>65-74: No skin cancer, HCTZ-containing</i>	62.2	62.2	61.3	62.6	59.6
<i>75-84: No skin cancer, HCTZ-containing</i>	64.6	64.5	64.0	65.3	62.1
<i>85+: No skin cancer, HCTZ-containing</i>	53.6	53.7	53.3	53.8	51.8
No skin cancer: HCTZ single ingredient					
<i>0-40: No skin cancer, HCTZ single ingredient</i>	1.5	1.5	1.4	1.4	1.5
<i>41-64: No skin cancer, HCTZ single ingredient</i>	19.2	19.0	18.4	18.6	19.2
<i>65-74: No skin cancer, HCTZ single ingredient</i>	29.8	29.7	29.3	30.2	29.2
<i>75-84: No skin cancer, HCTZ single ingredient</i>	32.3	32.2	31.9	32.9	31.7
<i>85+: No skin cancer, HCTZ single ingredient</i>	29.2	29.1	29.0	29.4	28.7
No skin cancer: HCTZ combination					
<i>0-40: No skin cancer, HCTZ combination</i>	0.0	0.0	0.0	0.0	0.0
<i>41-64: No skin cancer, HCTZ combination</i>	0.8	0.8	0.8	0.8	0.8
<i>65-74: No skin cancer, HCTZ combination</i>	3.6	3.6	3.6	3.7	3.4
<i>75-84: No skin cancer, HCTZ combination</i>	9.2	9.4	9.3	9.6	9.0
<i>85+: No skin cancer, HCTZ combination</i>	10.2	10.4	10.3	10.6	10.0

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: Limited denominator					
<i>0-40: Skin cancer, limited denominator</i>	7.5	7.2	7.4	7.5	6.7
<i>41-64: Skin cancer, limited denominator</i>	47.0	46.6	45.6	45.4	45.0
<i>65-74: Skin cancer, limited denominator</i>	64.3	64.4	63.7	66.0	63.0
<i>75-84: Skin cancer, limited denominator</i>	68.9	68.9	68.3	70.6	68.1
<i>85+: Skin cancer, limited denominator</i>	59.5	59.3	58.8	60.2	58.9
Skin cancer: Full denominator					
<i>0-40: Skin cancer, full denominator</i>	33.5	33.2	33.6	32.9	36.0
<i>41-64: Skin cancer, full denominator</i>	136.1	135.4	133.3	134.0	139.1
<i>65-74: Skin cancer, full denominator</i>	195.8	196.5	194.5	201.0	192.2
<i>75-84: Skin cancer, full denominator</i>	246.0	245.9	245.7	251.9	243.4
<i>85+: Skin cancer, full denominator</i>	304.1	304.6	304.3	309.5	302.6
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: Limited denominator					
<i>0-40: No skin cancer, limited denominator</i>	3.2	3.2	3.1	3.0	3.2
<i>41-64: No skin cancer, limited denominator</i>	44.9	44.6	43.4	43.4	43.5
<i>65-74: No skin cancer, limited denominator</i>	67.5	67.5	66.5	68.0	64.8
<i>75-84: No skin cancer, limited denominator</i>	71.1	70.9	70.5	72.0	68.4
<i>85+: No skin cancer, limited denominator</i>	60.3	60.4	59.9	60.6	58.4
No skin cancer: Full denominator					
<i>0-40: No skin cancer, full denominator</i>	13.1	13.0	12.9	12.7	13.6
<i>41-64: No skin cancer, full denominator</i>	126.3	125.7	123.5	123.7	129.3
<i>65-74: No skin cancer, full denominator</i>	200.2	200.9	199.1	203.4	193.8
<i>75-84: No skin cancer, full denominator</i>	253.7	253.8	252.5	257.2	244.8
<i>85+: No skin cancer, full denominator</i>	309.6	310.1	308.7	312.7	301.0



Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

	Patients with dispensing per month				
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products					
0-40	115	41	17	20	17
41-64	12,429	5,152	2,312	2,425	2,319
65-74	71,753	75,245	2,523	2,606	2,620
75-84	95,146	102,386	2,314	2,426	2,497
85+	38,282	40,430	930	899	925
HCTZ single ingredient/monotherapy					
0-40	59	31	*****	*****	*****
41-64	5,824	2,593	1,020	1,095	1,050
65-74	35,298	36,814	1,193	1,226	1,258
75-84	49,194	52,873	1,170	1,218	1,197
85+	21,270	22,482	497	489	511
HCTZ combination products					
0-40	57	*****	*****	11	12
41-64	6,657	2,576	1,301	1,335	1,280
65-74	36,728	38,729	1,339	1,395	1,370
75-84	46,264	49,920	1,155	1,215	1,310
85+	17,164	18,094	434	412	416
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ-containing products					
0-40	32,660	14,917	6,958	6,983	6,958
41-64	345,545	170,060	76,099	76,784	75,295
65-74	598,215	609,867	49,321	50,161	48,770
75-84	297,409	311,546	21,298	21,704	20,928
85+	84,485	86,605	4,925	4,996	4,771

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
HCTZ single ingredient/monotherapy					
0-40	17,025	8,214	3,381	3,452	3,423
41-64	165,908	87,016	34,194	34,455	33,722
65-74	295,488	300,310	23,534	23,934	23,295
75-84	152,603	159,678	10,785	10,957	10,712
85+	47,007	47,899	2,739	2,730	2,578
HCTZ combination products					
0-40	57	*****	*****	11	12
41-64	6,657	2,576	1,301	1,335	1,280
65-74	36,728	38,729	1,339	1,395	1,370
75-84	46,264	49,920	1,155	1,215	1,310
85+	17,164	18,094	434	412	416
<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
0-40	122	43	18	23	19
41-64	13,461	5,696	2,472	2,605	2,502
65-74	78,197	81,996	2,702	2,830	2,837
75-84	105,313	113,418	2,529	2,643	2,718
85+	43,607	46,101	1,034	1,032	1,041
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
0-40	498	252	92	96	93
41-64	40,915	21,176	6,621	6,798	6,724
65-74	242,431	251,487	8,046	8,477	8,254
75-84	381,776	403,497	9,105	9,522	9,431
85+	228,784	238,210	5,165	5,260	5,290

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Limited denominator: any HCTZ-containing product, chlorothiazide, bendroflumethiazide, or any thiazide-like diuretic					
0-40	35,680	16,582	7,595	7,623	7,614
41-64	375,208	187,844	81,984	82,774	81,207
65-74	650,917	663,807	53,526	54,364	52,910
75-84	328,837	344,107	23,366	23,803	23,041
85+	95,416	97,798	5,518	5,586	5,334
Full denominator: any HCTZ-containing product, any thiazide diuretic, or any antihypertensive					
0-40	152,065	77,516	35,358	35,961	35,142
41-64	1,105,213	637,318	214,084	217,038	213,685
65-74	1,981,966	2,003,810	156,258	159,414	155,904
75-84	1,198,708	1,235,704	82,602	84,145	81,454
85+	504,203	515,210	27,608	28,136	27,389
<b>Eligible members per month</b>					
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>Evidence of skin cancer in enrollment history</b>					
Enrollees with at least one day of coverage					
0-40	15,337	5,421	3,806	3,844	3,874
41-64	322,764	126,134	62,220	62,964	63,527
65-74	1,389,483	1,299,638	85,827	87,542	89,261
75-84	1,713,740	1,636,868	82,622	84,476	86,238
85+	807,515	763,639	37,342	38,098	38,834

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
Enrollees with at least one day of coverage					
0-40	12,017,639	4,251,080	3,660,095	3,678,318	3,687,719
41-64	9,446,264	4,277,920	2,288,845	2,298,712	2,305,185
65-74	11,279,986	10,384,977	1,315,929	1,319,226	1,323,022
75-84	5,288,011	4,951,524	585,737	588,230	590,998
85+	1,763,116	1,641,680	169,073	169,097	169,087
<b>Number of patients with dispensing per 1,000 eligible members</b>					
	Feb-22	Mar-22	Apr-22	May-22	Jun-22
<b>HCTZ-containing</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: HCTZ-containing					
0-40: Skin cancer, HCTZ-containing	7.5	7.6	4.5	5.2	4.4
41-64: Skin cancer, HCTZ-containing	38.5	40.8	37.2	38.5	36.5
65-74: Skin cancer, HCTZ-containing	51.6	57.9	29.4	29.8	29.4
75-84: Skin cancer, HCTZ-containing	55.5	62.5	28.0	28.7	29.0
85+: Skin cancer, HCTZ-containing	47.4	52.9	24.9	23.6	23.8
Skin cancer: HCTZ single ingredient					
0-40: Skin cancer, HCTZ single ingredient	3.8	5.7	*****	*****	*****
41-64: Skin cancer, HCTZ single ingredient	18.0	20.6	16.4	17.4	16.5
65-74: Skin cancer, HCTZ single ingredient	25.4	28.3	13.9	14.0	14.1
75-84: Skin cancer, HCTZ single ingredient	28.7	32.3	14.2	14.4	13.9
85+: Skin cancer, HCTZ single ingredient	26.3	29.4	13.3	12.8	13.2
Skin cancer: HCTZ combination					
0-40: Skin cancer, HCTZ combination	3.7	*****	*****	2.9	3.1
41-64: Skin cancer, HCTZ combination	20.6	20.4	20.9	21.2	20.1
65-74: Skin cancer, HCTZ combination	26.4	29.8	15.6	15.9	15.3
75-84: Skin cancer, HCTZ combination	27.0	30.5	14.0	14.4	15.2
85+: Skin cancer, HCTZ combination	21.3	23.7	11.6	10.8	10.7

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: HCTZ-containing					
0-40: No skin cancer, HCTZ-containing	2.7	3.5	1.9	1.9	1.9
41-64: No skin cancer, HCTZ-containing	36.6	39.8	33.2	33.4	32.7
65-74: No skin cancer, HCTZ-containing	53.0	58.7	37.5	38.0	36.9
75-84: No skin cancer, HCTZ-containing	56.2	62.9	36.4	36.9	35.4
85+: No skin cancer, HCTZ-containing	47.9	52.8	29.1	29.5	28.2
No skin cancer: HCTZ single ingredient					
0-40: No skin cancer, HCTZ single ingredient	1.4	1.9	0.9	0.9	0.9
41-64: No skin cancer, HCTZ single ingredient	17.6	20.3	14.9	15.0	14.6
65-74: No skin cancer, HCTZ single ingredient	26.2	28.9	17.9	18.1	17.6
75-84: No skin cancer, HCTZ single ingredient	28.9	32.2	18.4	18.6	18.1
85+: No skin cancer, HCTZ single ingredient	26.7	29.2	16.2	16.1	15.2
No skin cancer: HCTZ combination					
0-40: No skin cancer, HCTZ combination	0.0	*****	*****	0.0	0.0
41-64: No skin cancer, HCTZ combination	0.7	349.0	0.6	0.6	0.6
65-74: No skin cancer, HCTZ combination	3.3	3.7	1.0	1.1	1.0
75-84: No skin cancer, HCTZ combination	8.7	10.1	2.0	2.1	2.2
85+: No skin cancer, HCTZ combination	9.7	11.0	2.6	2.4	2.5
<b>Denominators</b>					
<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: Limited denominator					
0-40: Skin cancer, limited denominator	8.0	7.9	4.7	6.0	4.9
41-64: Skin cancer, limited denominator	41.7	45.2	39.7	41.4	39.4
65-74: Skin cancer, limited denominator	56.3	63.1	31.5	32.3	31.8
75-84: Skin cancer, limited denominator	61.5	69.3	30.6	31.3	31.5
85+: Skin cancer, limited denominator	54.0	60.4	27.7	27.1	26.8

Table 9b. Total number of patients dispensed HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month

<b>Evidence of skin cancer in enrollment history prior to exposure</b>					
Skin cancer: Full denominator					
<i>0-40: Skin cancer, full denominator</i>	32.5	46.5	24.2	25.0	24.0
<i>41-64: Skin cancer, full denominator</i>	126.8	167.9	106.4	108.0	105.8
<i>65-74: Skin cancer, full denominator</i>	174.5	193.5	93.7	96.8	92.5
<i>75-84: Skin cancer, full denominator</i>	222.8	246.5	110.2	112.7	109.4
<i>85+: Skin cancer, full denominator</i>	283.3	311.9	138.3	138.1	136.2
<b>No evidence of skin cancer in enrollment history prior to exposure</b>					
No skin cancer: Limited denominator					
<i>0-40: No skin cancer, limited denominator</i>	3.0	3.9	2.1	2.1	2.1
<i>41-64: No skin cancer, limited denominator</i>	39.7	43.9	35.8	36.0	35.2
<i>65-74: No skin cancer, limited denominator</i>	57.7	63.9	40.7	41.2	40.0
<i>75-84: No skin cancer, limited denominator</i>	62.2	69.5	39.9	40.5	39.0
<i>85+: No skin cancer, limited denominator</i>	54.1	59.6	32.6	33.0	31.5
No skin cancer: Full denominator					
<i>0-40: No skin cancer, full denominator</i>	12.7	18.2	9.7	9.8	9.5
<i>41-64: No skin cancer, full denominator</i>	117.0	149.0	93.5	94.4	92.7
<i>65-74: No skin cancer, full denominator</i>	175.7	193.0	118.7	120.8	117.8
<i>75-84: No skin cancer, full denominator</i>	226.7	249.6	141.0	143.0	137.8
<i>85+: No skin cancer, full denominator</i>	286.0	313.8	163.3	166.4	162.0

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Figure 9. Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month




Figure 9 (Continued). Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month








Figure 9 (Continued). Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month





Figure 9 (Continued). Proportional use of HCTZ-containing and non-HCTZ-containing products in the Sentinel Distributed Database from January 1, 2017 - June 30, 2022, by history of skin cancer, age group (years), and calendar year/month



Appendix A. Query period end dates for each Data Partner		
DP ID	Start Date	End Date <sup>1</sup>
DP01	01/01/2008	06/30/2022
DP02	01/01/2010	03/31/2022
DP03	01/01/2006	02/28/2022
DP04	01/01/2007	01/31/2022
DP05	01/01/2008	12/31/2021

<sup>1</sup>End Date represents the earliest of last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

**Appendix B. List of Generic and brand names of medical products used to define hydrochlorothiazide (HCTZ)-containing products**

Generic name	Brand name
<b>HCTZ single ingredient/monotherapy</b>	
hydrochlorothiazide	hydrochlorothiazide
hydrochlorothiazide	Microzide
<b>ACEI + HCTZ combination product</b>	
acei hctz	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	Lotensin HCT
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
enalapril maleate/hydrochlorothiazide	Vaseretic
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
lisinopril/hydrochlorothiazide	Zestoretic
moexipril HCl/hydrochlorothiazide	moexipril-hydrochlorothiazide
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
<b>ARB + HCTZ combination product</b>	
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
<b>Potassium-sparing diuretic + HCTZ combination product</b>	
amiloride HCl/hydrochlorothiazide	amiloride-hydrochlorothiazide
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
triamterene/hydrochlorothiazide	Dyazide
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid
<b>Beta blocker + HCTZ combination product</b>	
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol succinate/hydrochlorothiazide	metoprolol su-hydrochlorothiaz
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid

**Appendix B. List of Generic and brand names of medical products used to define hydrochlorothiazide (HCTZ)-containing products**

<b>ARB + CCB + HCTZ combination product</b>	
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiaid
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
olmesartan medoxomil/amlodipine besylate/hydrochlorothia	olmesartan-amlodipin-hcthiaid
olmesartan medoxomil/amlodipine besylate/hydrochlorothia	Tribenzor
<b>Direct renin inhibitor + HCTZ combination product</b>	
aliskiren hemifumarate/hydrochlorothiazide	Tekturna HCT
<b>Central alpha 2 agonist + HCTZ combination product</b>	
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide

**Appendix C. List of Generic and brand names of medical products used to define non-hydrochlorothiazide (HCTZ)-containing products**

<b>Generic name</b>	<b>Brand name</b>
<b>Chlorothiazide</b>	
chlorothiazide	chlorothiazide
chlorothiazide	Diuril
<b>Bendroflumethiazide</b>	
nadolol/bendroflumethiazide	Corzide
nadolol/bendroflumethiazide	nadolol-bendroflumethiazide
<b>Thiazide-like diuretics</b>	
chlorthalidone	chlorthalidone
chlorthalidone	Thalitone
indapamide	indapamide
metolazone	metolazone
<b>ACEIs</b>	
amlodipine besylate/benazepril HCl	amlodipine-benazepril
amlodipine besylate/benazepril HCl	Lotrel
benazepril HCl	benazepril
benazepril HCl	benazepril HCl (bulk)
benazepril HCl	Lotensin
captopril	captopril
captopril	captopril (bulk)
enalapril maleate	enalapril maleate
enalapril maleate	enalapril maleate (bulk)
enalapril maleate	Epaned
enalapril maleate	Vasotec
enalaprilat dihydrate	enalaprilat
fosinopril sodium	fosinopril
lisinopril	lisinopril
lisinopril	lisinopril (bulk)
lisinopril	Prinivil
lisinopril	Qbrelis
lisinopril	Zestril
moexipril HCl	moexipril
perindopril arginine/amlodipine besylate	Prestalia
perindopril erbumine	Aceon
perindopril erbumine	perindopril erbumine
quinapril HCl	Accupril
quinapril HCl	quinapril
ramipril	Altace
ramipril	ramipril
trandolapril	Mavik
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil

**Appendix C. List of Generic and brand names of medical products used to define non-hydrochlorothiazide (HCTZ)-containing products**

CCBs	
amlodipine benzoate	Katerzia
amlodipine besylate	amlodipine
amlodipine besylate	amlodipine besylate (bulk)
amlodipine besylate	Norvasc
amlodipine besylate/celecoxib	Consensi
clevidipine butyrate	Cleviprex
diltiazem HCl	Cardizem
diltiazem HCl	Cardizem CD
diltiazem HCl	Cardizem LA
diltiazem HCl	Cartia XT
diltiazem HCl	diltiazem HCl
diltiazem HCl	diltiazem HCl (bulk)
diltiazem HCl	DILT-XR
diltiazem HCl	Matzim LA
diltiazem HCl	Taztia XT
diltiazem HCl	Tiadyt ER
diltiazem HCl	Tiazac
diltiazem HCl in 0.9 % sodium chloride	diltiazem HCl in 0.9% NaCl
diltiazem HCl/dextrose 5 % in water	diltiazem in dextrose 5 %
felodipine	felodipine
isradipine	isradipine
levamlodipine maleate	Conjupri
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in 5 % dextrose in water	nicardipine in 5 % dextrose
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nifedipine	Adalat CC
nifedipine	Afeditab CR
nifedipine	Nifedical XL
nifedipine	nifedipine
nifedipine	nifedipine (bulk)
nifedipine	Procardia
nifedipine	Procardia XL
nifedipine, micronized	nifedipine, micronized (bulk)
nimodipine	nimodipine
nimodipine	nimodipine (bulk)
nimodipine	Nymalize
nisoldipine	nisoldipine
nisoldipine	Sular
verapamil HCl	Calan
verapamil HCl	Calan SR
verapamil HCl	verapamil
verapamil HCl	verapamil (bulk)
verapamil HCl	Verelan
verapamil HCl	Verelan PM



**Appendix C. List of Generic and brand names of medical products used to define non-hydrochlorothiazide (HCTZ)-containing products**

<b>Potassium-sparing diuretics</b>	
amiloride HCl	amiloride
eplerenone	eplerenone
eplerenone	Inspira
spironolactone	Aldactone
spironolactone	CaroSpir
spironolactone	spironolactone
triamterene	Dyrenium
triamterene	triamterene

<b>Loop diuretics</b>	
bumetanide	bumetanide
ethacrynic acid	Edecrin
ethacrynic acid	ethacrynic acid
furosemide	furosemide
furosemide	Lasix
toremide	Demadex
toremide	toremide

**Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes used to define skin cancer**

Code	Description	Code category	Code type
<b>Skin cancer</b>			
173.11	Basal cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.21	Basal cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.31	Basal cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.41	Basal cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.51	Basal cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.61	Basal cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.71	Basal cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.81	Basal cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.91	Basal cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM
173.12	Squamous cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.22	Squamous cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.32	Squamous cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.42	Squamous cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.52	Squamous cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.62	Squamous cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.72	Squamous cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.82	Squamous cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.92	Squamous cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM
C44.712	Basal cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.719	Basal cell carcinoma of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.81	Basal cell carcinoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.91	Basal cell carcinoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.122	Squamous cell carcinoma of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.129	Squamous cell carcinoma of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.320	Squamous cell carcinoma of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.321	Squamous cell carcinoma of skin of nose	Diagnosis	ICD-10-CM
C44.329	Squamous cell carcinoma of skin of other parts of face	Diagnosis	ICD-10-CM
C44.42	Squamous cell carcinoma of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.520	Squamous cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C44.521	Squamous cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C44.529	Squamous cell carcinoma of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM

C44.729 Squamous cell carcinoma of skin of left lower limb, including hip  
C44.82 Squamous cell carcinoma of overlapping sites of skin  
C44.92 Squamous cell carcinoma of skin, unspecified

Diagnosis ICD-10-CM  
Diagnosis ICD-10-CM  
Diagnosis ICD-10-CM

**Appendix E. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).

**Run:** r01  
**Query period:** 1/1/2017 - most recent available data  
**Coverage requirement:** Medical and Drug Coverage  
**Pre-index enrollment requirement:** 0 days  
**Enrollment gap:** 45 days  
**Age groups:** 0-40, 41-64, 65-74, 75-84, 85+ years  
**Stratifications:** Calendar year\*Month  
 Age group  
 Age group\*Calendar year\*Month  
 Sex  
 Sex\*Calendar year\*Month  
 Race  
 Race\*Calendar year\*Month  
 Age group\*Race\*Calendar year\*Month

**Exposure**

Scenario	Group	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Treatment episode gap	Exposure episode extension
1	hctz_containing_all	Prevalent: Any HCTZ-containing product, any strength (monotherapy or HCTZ combination products)	All valid exposures during the query period	0	N/A	0 days	0 days
2	hctz_containing_06	Prevalent: Any HCTZ-containing product, 6.25 mg (monotherapy or HCTZ combination products)	All valid exposures during the query period	0	N/A	0 days	0 days

<b>Appendix E. Specifications Defining Parameters for this Request</b>							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
3	hctz_containing_12	Prevalent: Any HCTZ-containing product, 12.5 mg (monotherapy or HCTZ combination products)	All valid exposures during the query period	0	N/A	0 days	0 days
4	hctz_containing_15	Prevalent: Any HCTZ-containing product, 15 mg (monotherapy or HCTZ combination products)	All valid exposures during the query period	0	N/A	0 days	0 days
5	hctz_containing_25	Prevalent: Any HCTZ-containing product, 25 mg (monotherapy or HCTZ combination products)	All valid exposures during the query period	0	N/A	0 days	0 days
6	hctz_containing_50	Prevalent: Any HCTZ-containing product, 50 mg (monotherapy or HCTZ combination products)	All valid exposures during the query period	0	N/A	0 days	0 days
7	hctz_mono_all	Prevalent: HCTZ monotherapy, any strength	All valid exposures during the query period	0	N/A	0 days	0 days
8	hctz_mono_06	Prevalent: HCTZ monotherapy, 6.25 mg	All valid exposures during the query period	0	N/A	0 days	0 days
9	hctz_mono_12	Prevalent: HCTZ monotherapy, 12.5 mg	All valid exposures during the query period	0	N/A	0 days	0 days
10	hctz_mono_15	Prevalent: HCTZ monotherapy, 15 mg	All valid exposures during the query period	0	N/A	0 days	0 days
11	hctz_mono_25	Prevalent: HCTZ monotherapy, 25 mg	All valid exposures during the query period	0	N/A	0 days	0 days
12	hctz_mono_50	Prevalent: HCTZ monotherapy, 50 mg	All valid exposures during the query period	0	N/A	0 days	0 days

<b>Appendix E. Specifications Defining Parameters for this Request</b>							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
13	hctz_combo_all	Prevalent: HCTZ combination products, any strength	All valid exposures during the query period	0	N/A	0 days	0 days
14	hctz_combo_06	Prevalent: HCTZ combination products, 6.25 mg	All valid exposures during the query period	0	N/A	0 days	0 days
15	hctz_combo_12	Prevalent: HCTZ combination products, 12.5 mg	All valid exposures during the query period	0	N/A	0 days	0 days
16	hctz_combo_15	Prevalent: HCTZ combination products, 15 mg	All valid exposures during the query period	0	N/A	0 days	0 days
17	hctz_combo_25	Prevalent: HCTZ combination products, 25 mg	All valid exposures during the query period	0	N/A	0 days	0 days
18	hctz_combo_50	Prevalent: HCTZ combination products, 50 mg	All valid exposures during the query period	0	N/A	0 days	0 days
19	hctz_acei_combo	Prevalent: ACEI + HCTZ, any strength (Lisinopril, Benazepril, Enalapril, Quinapril, Fosinopril, Moexipril, Captopril)	All valid exposures during the query period	0	N/A	0 days	0 days
20	hctz_arb_combo	Prevalent: ARB + HCTZ, any strength (Losartan, Valsartan, Olmesartan, Irbesartan, Telmisartan, Candesartan)	All valid exposures during the query period	0	N/A	0 days	0 days
21	hctz_potass_combo	Prevalent: Potassium-sparing diuretics + HCTZ, any strength (Triameterene, Spironolactone, Amiloride)	All valid exposures during the query period	0	N/A	0 days	0 days
22	hctz_beta_combo	Prevalent: Beta blockers + HCTZ, any strength (Bisporolol, Metoprolol, Propranolol)	All valid exposures during the query period	0	N/A	0 days	0 days

<b>Appendix E. Specifications Defining Parameters for this Request</b>							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
23	hctz_arb_ccb_combo	Prevalent: ARB + CCB + HCTZ, any strength (Olmesartan + Amlodipine, Valsartan + Amlodipine)	All valid exposures during the query period	0	N/A	0 days	0 days
24	hctz_direct	Prevalent: Direct renin inhibitors + HCTZ, any strength (Aliskiren)	All valid exposures during the query period	0	N/A	0 days	0 days
25	hctz_central	Prevalent: Central alpha 2 agonist + HCTZ, any strength (Methyldopa)	All valid exposures during the query period	0	N/A	0 days	0 days
26	other_thiazide_plus	Prevalent: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics (non-HCTZ combination) (Chlorthalidone, Metolazone, Indapamide)	All valid exposures during the query period	0	N/A	0 days	0 days
27	other_chloro	Prevalent: Chlorothiazide	All valid exposures during the query period	0	N/A	0 days	0 days
28	other_bendro	Prevalent: Bendroflumethiazide	All valid exposures during the query period	0	N/A	0 days	0 days
29	other_thiazide	Prevalent: Thiazide-like diuretics (non-HCTZ combination) (Chlorthalidone, Metolazone, Indapamide)	All valid exposures during the query period	0	N/A	0 days	0 days
30	other_acei	Prevalent: ACEIs (non-HCTZ combination)	All valid exposures during the query period	0	N/A	0 days	0 days
31	other_ccb	Prevalent: CCBs (non-HCTZ combination)	All valid exposures during the query period	0	N/A	0 days	0 days
32	other_potass	Prevalent: Potassium-sparing diuretics (non-HCTZ combination) (Spironolactone, Eplerenone, Amiloride, Triamterene)	All valid exposures during the query period	0	N/A	0 days	0 days

Appendix E. Specifications Defining Parameters for this Request							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
33	other_loop	Prevalent: Loop diuretics (Bumetanide, Ethacrynic acid, Furosemide, Torsemide)	All valid exposures during the query period	0	N/A	0 days	0 days
34	denom_limited	Prevalent <b>denominator</b> : Any HCTZ-containing product, any strength, Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics <i>(aggregate of scenarios 1 and 26)</i>	All valid exposures during the query period	0	N/A	0 days	0 days
35	denom_all	Prevalent <b>denominator</b> : Any HCTZ-containing products, any thiazide diuretics, any diuretics, or any antihypertensives <i>(aggregate of scenarios 1, 26, 30, 31, 32, and 33)</i>	All valid exposures during the query period	0	N/A	0 days	0 days
ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.							
NDC codes are checked against First Data Bank's FDB MedKnowledge®.							



<b>Appendix E. Specifications Defining Parameters for this Request (Continued)</b>									
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).									
Scenario	Group	Exposure							
		Minimum exposure episode duration	Minimum days supplied	Maximum exposure episode duration	Forced days code supply value	Stockpiling	Care setting	Censor treatment episode at evidence of:	Strength
1	hctz_containing_all	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
2	hctz_containing_06	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	6.25 mg
3	hctz_containing_12	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	12.5 mg
4	hctz_containing_15	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	15 mg
5	hctz_containing_25	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	25 mg
6	hctz_containing_50	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	50 mg
7	hctz_mono_all	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
8	hctz_mono_06	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	6.25 mg

<b>Appendix E. Specifications Defining Parameters for this Request (Continued)</b>									
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).									
9	hctz_mono_12	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	12.5 mg
10	hctz_mono_15	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	15 mg
11	hctz_mono_25	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	25 mg
12	hctz_mono_50	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	50 mg
13	hctz_combo_all	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
14	hctz_combo_06	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	6.25 mg
15	hctz_combo_12	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	12.5 mg
16	hctz_combo_15	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	15 mg
17	hctz_combo_25	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	25 mg
18	hctz_combo_50	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	50 mg

<b>Appendix E. Specifications Defining Parameters for this Request (Continued)</b>									
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).									
19	hctz_acei_combo	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
20	hctz_arb_combo	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
21	hctz_potass_combo	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
22	hctz_beta_combo	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
23	hctz_arb_ccb_combo	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
24	hctz_direct	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
25	hctz_central	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
26	other_thiazide_plus	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
27	other_chloro	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
28	other_bendro	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength

<b>Appendix E. Specifications Defining Parameters for this Request (Continued)</b>									
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).									
29	other_thiazide	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
30	other_acei	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
31	other_ccb	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
32	other_potass	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
33	other_loop	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
34	denom_limited	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
35	denom_all	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360. NDC codes are checked against First Data Bank's FDB MedKnowledge®.									

**Appendix F. Specifications Defining Parameters for this Request, Part II**

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).

**Run:** r02  
**Query period:** 1/1/2017 - most recent available data  
**Coverage requirement:** Medical and Drug Coverage  
**Pre-index enrollment requirement:** 0 days  
**Enrollment gap:** 45 days  
**Age groups:** 0-40, 41-64, 65-74, 75-84, 85+ years  
**Stratifications:** Calendar year\*Month  
 Age group  
 Age group\*Calendar year\*Month  
 Sex  
 Sex\*Calendar year\*Month  
 Race  
 Race\*Calendar year\*Month  
 Age group\*Race\*Calendar year\*Month

**Exposure**

Scenario	Group	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Treatment episode gap	Exposure episode extension
1	hctz_containing_hx	Prevalent: Any HCTZ-containing product, any strength (monotherapy or HCTZ combination products); History of skin cancer prior to dispensing	All valid exposures during the query period	0	N/A	0 days	0 days
2	hctz_containing_no	Prevalent: Any HCTZ-containing product, any strength (monotherapy or HCTZ combination products); No history of skin cancer prior to dispensing	All valid exposures during the query period	0	N/A	0 days	0 days

<b>Appendix F. Specifications Defining Parameters for this Request, Part II</b>							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
3	hctz_mono_hx	Prevalent: HCTZ monotherapy, any strength; History of skin cancer prior to dispensing	All valid exposures during the query period	0	N/A	0 days	0 days
4	hctz_mono_no	Prevalent: HCTZ monotherapy, any strength; No history of skin cancer prior to dispensing	All valid exposures during the query period	0	N/A	0 days	0 days
5	hctz_combo_hx	Prevalent: HCTZ combination products, any strength; History of skin cancer prior to dispensing	All valid exposures during the query period	0	N/A	0 days	0 days
6	hctz_combo_no	Prevalent: HCTZ combination products, any strength; No history of skin cancer prior to dispensing	All valid exposures during the query period	0	N/A	0 days	0 days
7	hctz_acei_combo_hx	Prevalent: ACEI + HCTZ, any strength (Lisinopril, Benazepril, Enalapril, Quinapril, Fosinopril, Moexipril, Captopril)	All valid exposures during the query period	0	N/A	0 days	0 days
8	hctz_acei_combo_no	Prevalent: ACEI + HCTZ, any strength (Lisinopril, Benazepril, Enalapril, Quinapril, Fosinopril, Moexipril, Captopril)	All valid exposures during the query period	0	N/A	0 days	0 days
9	hctz_arb_combo_hx	Prevalent: ARB + HCTZ, any strength (Losartan, Valsartan, Olmesartan, Irbesartan, Telmisartan, Candesartan)	All valid exposures during the query period	0	N/A	0 days	0 days
10	hctz_arb_combo_no	Prevalent: ARB + HCTZ, any strength (Losartan, Valsartan, Olmesartan, Irbesartan, Telmisartan, Candesartan)	All valid exposures during the query period	0	N/A	0 days	0 days
11	hctz_potass_combo_hx	Prevalent: Potassium-sparing diuretics + HCTZ, any strength (Triameterene, Spironolactone, Amiloride)	All valid exposures during the query period	0	N/A	0 days	0 days
12	hctz_potass_combo_no	Prevalent: Potassium-sparing diuretics + HCTZ, any strength (Triameterene, Spironolactone, Amiloride)	All valid exposures during the query period	0	N/A	0 days	0 days

<b>Appendix F. Specifications Defining Parameters for this Request, Part II</b>							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
13	hctz_beta_combo_hx	Prevalent: Beta blockers + HCTZ, any strength (Bisporolol, Metoprolol, Propranolol)	All valid exposures during the query period	0	N/A	0 days	0 days
14	hctz_beta_combo_no	Prevalent: Beta blockers + HCTZ, any strength (Bisporolol, Metoprolol, Propranolol)	All valid exposures during the query period	0	N/A	0 days	0 days
15	hctz_arb_ccb_combo_hx	Prevalent: ARB + CCB + HCTZ, any strength (Olmesartan + Amlodipine, Valsartan + Amlodipine)	All valid exposures during the query period	0	N/A	0 days	0 days
16	hctz_arb_ccb_combo_no	Prevalent: ARB + CCB + HCTZ, any strength (Olmesartan + Amlodipine, Valsartan + Amlodipine)	All valid exposures during the query period	0	N/A	0 days	0 days
17	hctz_direct_hx	Prevalent: Direct renin inhibitors + HCTZ, any strength (Aliskiren)	All valid exposures during the query period	0	N/A	0 days	0 days
18	hctz_direct_no	Prevalent: Direct renin inhibitors + HCTZ, any strength (Aliskiren)	All valid exposures during the query period	0	N/A	0 days	0 days
19	hctz_central_hx	Prevalent: Central alpha 2 agonist + HCTZ, any strength (Methyldopa)	All valid exposures during the query period	0	N/A	0 days	0 days
20	hctz_central_no	Prevalent: Central alpha 2 agonist + HCTZ, any strength (Methyldopa)	All valid exposures during the query period	0	N/A	0 days	0 days
21	other_thiazide_plus_hx	Prevalent: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics (non-HCTZ combination) (Chlorthalidone, Metolazone, Indapamide)	All valid exposures during the query period	0	N/A	0 days	0 days

<b>Appendix F. Specifications Defining Parameters for this Request, Part II</b>							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
22	other_thiazide_plus_no	Prevalent: Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics (non-HCTZ combination) (Chlorthalidone, Metolazone, Indapamide)	All valid exposures during the query period	0	N/A	0 days	0 days
23	other_chloro_hx	Prevalent: Chlorothiazide	All valid exposures during the query period	0	N/A	0 days	0 days
24	other_chloro_no	Prevalent: Chlorothiazide	All valid exposures during the query period	0	N/A	0 days	0 days
25	other_bendro_hx	Prevalent: Bendroflumethiazide	All valid exposures during the query period	0	N/A	0 days	0 days
26	other_bendro_no	Prevalent: Bendroflumethiazide	All valid exposures during the query period	0	N/A	0 days	0 days
27	other_thiazide_hx	Prevalent: Thiazide-like diuretics (non-HCTZ combination) (Chlorthalidone, Metolazone, Indapamide)	All valid exposures during the query period	0	N/A	0 days	0 days
28	other_thiazide_no	Prevalent: Thiazide-like diuretics (non-HCTZ combination) (Chlorthalidone, Metolazone, Indapamide)	All valid exposures during the query period	0	N/A	0 days	0 days
29	other_acei_hx	Prevalent: ACEIs (non-HCTZ combination)	All valid exposures during the query period	0	N/A	0 days	0 days
30	other_acei_no	Prevalent: ACEIs (non-HCTZ combination)	All valid exposures during the query period	0	N/A	0 days	0 days
31	other_ccb_hx	Prevalent: CCBs (non-HCTZ combination)	All valid exposures during the query period	0	N/A	0 days	0 days



Appendix F. Specifications Defining Parameters for this Request, Part II							
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).							
32	other_ccb_no	Prevalent: CCBs (non-HCTZ combination)	All valid exposures during the query period	0	N/A	0 days	0 days
33	other_potass_hx	Prevalent: Potassium-sparing diuretics (non-HCTZ combination) (Spironolactone, Eplerenone, Amiloride, Triamterene)	All valid exposures during the query period	0	N/A	0 days	0 days
34	other_potass_no	Prevalent: Potassium-sparing diuretics (non-HCTZ combination) (Spironolactone, Eplerenone, Amiloride, Triamterene)	All valid exposures during the query period	0	N/A	0 days	0 days
35	other_loop_hx	Prevalent: Loop diuretics (Bumetanide, Ethacrynic acid, Furosemide, Torsemide)	All valid exposures during the query period	0	N/A	0 days	0 days
36	other_loop_no	Prevalent: Loop diuretics (Bumetanide, Ethacrynic acid, Furosemide, Torsemide)	All valid exposures during the query period	0	N/A	0 days	0 days
37	denom_limited_hx	Prevalent <b>denominator</b> : Any HCTZ-containing product, any strength, Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics <i>(aggregate of scenarios 1 and 26)</i>	All valid exposures during the query period	0	N/A	0 days	0 days
38	denom_limited_no	Prevalent <b>denominator</b> : Any HCTZ-containing product, any strength, Chlorothiazide, Bendroflumethiazide, or Thiazide-like diuretics <i>(aggregate of scenarios 1 and 26)</i>	All valid exposures during the query period	0	N/A	0 days	0 days
39	denom_all_hx	Prevalent <b>denominator</b> : Any HCTZ-containing products, any thiazide diuretics, any diuretics, or any antihypertensives <i>(aggregate of scenarios 1, 26, 30, 31, 32, and 33)</i>	All valid exposures during the query period	0	N/A	0 days	0 days

**Appendix F. Specifications Defining Parameters for this Request, Part II**

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).

40	denom_all_no	Prevalent <b>denominator</b> : Any HCTZ-containing products, any thiazide diuretics, any diuretics, or any antihypertensives <i>(aggregate of scenarios 1, 26, 30, 31, 32, and 33)</i>	All valid exposures during the query period	0	N/A	0 days	0 days
----	--------------	---	---	---	-----	--------	--------

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

**Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)**

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).

Scenario	Group	Exposure				Stockpiling	Care setting	Censor treatment episode at evidence of:	Strength
		Minimum exposure episode duration	Minimum days supplied	Maximum exposure episode duration	Forced days code supply value				
1	hctz_containing_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
2	hctz_containing_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
3	hctz_mono_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
4	hctz_mono_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
5	hctz_combo_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
6	hctz_combo_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
7	hctz_acei_combo_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength

**Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)**

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).

8	hctz_acei_combo_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
9	hctz_arb_combo_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
10	hctz_arb_combo_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
11	hctz_potass_combo_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
12	hctz_potass_combo_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
13	hctz_beta_combo_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
14	hctz_beta_combo_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
15	hctz_arb_ccb_combo_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
16	hctz_arb_ccb_combo_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
17	hctz_direct_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength

**Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)**

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).

18	hctz_direct_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
19	hctz_central_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
20	hctz_central_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
21	other_thiazide_plus_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
22	other_thiazide_plus_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
23	other_chloro_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
24	other_chloro_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
25	other_bendro_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
26	other_bendro_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
27	other_thiazide_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength

<b>Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)</b>									
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).									
28	other_thiazide_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
29	other_acei_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
30	other_acei_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
31	other_ccb_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
32	other_ccb_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
33	other_potass_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
34	other_potass_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
35	other_loop_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
36	other_loop_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
37	denom_limited_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength

**Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)**

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).

38	denom_limited_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength
39	denom_all_hx	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date	Any strength
40	denom_all_no	1 day	1 day	N/A	1	Each NDC has its own individual stockgroup	Outpatient pharmacy dispensing	Death; DP end date; Skin cancer code	Any strength

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

<b>Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)</b>				
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).				
<b>Inclusion/Exclusion Criteria</b>				
<b>Scenario</b>	<b>Group</b>	<b>Inclusion / Exclusion</b>	<b>Criteria</b>	<b>Evaluation period</b>
1	hctz_containing_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
2	hctz_containing_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
3	hctz_mono_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
4	hctz_mono_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
5	hctz_combo_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
6	hctz_combo_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
7	hctz_acei_combo_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
8	hctz_acei_combo_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
9	hctz_arb_combo_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
10	hctz_arb_combo_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
11	hctz_potass_combo_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
12	hctz_potass_combo_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)



<b>Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)</b>				
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).				
13	hctz_beta_combo_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
14	hctz_beta_combo_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
15	hctz_arb_ccb_combo_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
16	hctz_arb_ccb_combo_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
17	hctz_direct_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
18	hctz_direct_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
19	hctz_central_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
20	hctz_central_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
21	other_thiazide_plus_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
22	other_thiazide_plus_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
23	other_chloro_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
24	other_chloro_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
25	other_bendro_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
26	other_bendro_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
27	other_thiazide_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)

<b>Appendix F. Specifications Defining Parameters for this Request, Part II (Continued)</b>				
The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v12.0.0 to estimate the prevalence of hydrochlorothiazide and understand the impact of labeling changes on August 8, 2020 in the Sentinel Distributed Database (SDD).				
28	other_thiazide_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
29	other_acei_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
30	other_acei_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
31	other_ccb_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
32	other_ccb_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
33	other_potass_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
34	other_potass_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
35	other_loop_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
36	other_loop_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
37	denom_limited_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
38	denom_limited_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
39	denom_all_hx	<b>Inclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
40	denom_all_no	<b>Exclusion</b>	Evidence of skin cancer	(Enrollment history, day 0 index date)
ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360. NDC codes are checked against First Data Bank's FDB MedKnowledge®.				